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Abstract 
The effectiveness of antiretroviral therapy (ART) has led to greatly improved prognosis 
for people living with HIV, such that they now have a similar life expectancy to the 
general population. However, these improvements over time have not necessarily 
been seen equally among all demographic groups. The aim of this thesis was to 
investigate the differences in virological response to ART, treatment adherence, and 
late HIV diagnosis by gender and sexual orientation among people with HIV in the UK, 
and assess whether any differences have narrowed in more recent years. Additional 
analyses explored whether socio-economic factors could explain the observed 
differences in outcome across gender/sexual orientation groups.  
The analyses were based on data from two observational UK studies: the Royal Free 
HIV Cohort Study and the Antiretrovirals Sexual Transmission Risk and Attitudes 
(ASTRA) questionnaire study.  
Results showed that, among individuals on ART, women and men who have sex with 
women (MSW) had a higher prevalence of detectable viral load and lower CD4 counts 
than men who have sex with men (MSM). Similarly, for initial response to first-line 
ART, virological outcomes were less favourable for women and MSW, compared to 
MSM even in the most recent years, and there was no evidence that these differences 
in outcome were narrowing over time. Socio-economic disadvantage (financial 
hardship; non-employment; renting; unstable housing status; non-university education) 
was strongly associated with higher prevalence of ART non-adherence and poorer 
virological outcomes. Socio-economic status explained much of the disparities in 
treatment outcomes between MSM and women, but less between MSW and MSM. A 
considerably higher prevalence of late diagnosis was seen among women and MSW 
compared to MSM.  
In conclusion, this thesis identified ongoing disparities in HIV outcomes between 
gender/sexual orientation groups. Clinical management strategies should focus on 
demographic and socio-economic groups at risk of poorer treatment outcomes. 
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 Introduction 
This chapter provides background information on the natural history of Human 
Immunodeficiency Virus (HIV), antiretroviral drugs (ARVs) used to treat HIV, the 
stages in the care continuum, policies and recommendations for HIV screening and 
treatment in the UK, and details of the current epidemic in the UK. In addition, this 
chapter introduces the relationship between gender/sexual orientation, socio-economic 
status (SES), and HIV outcomes. 
 Natural history of HIV in the absence of treatment  
 The life cycle of HIV virions  
HIV is a retrovirus: a family of enveloped viruses that replicate in the host cells. More 
specifically it belongs to the subgroup of lentiviruses or ‘slow viruses’1;2 named 
because of the long period between infection and the onset of serious symptoms3. 
Once HIV is transmitted, the virus targets and binds to CD4 T-cells. These cells play a 
vital part in the co-ordination of the human immune system4. New viral particles are 
produced within the cell and are then ready to infect further cells, with a single cell able 
to produce thousands of infectious HIV particles3. Although the exact mechanisms are 
still not fully understood, through this process, HIV weakens and destroys CD4 T-cells 
and reduces the ability of the body to replace them5;6. 
 The natural history of HIV infection 
Transmission 
HIV spreads between individuals via the exchange of bodily fluids including blood, 
semen, pre-seminal fluid, rectal fluids, vaginal fluids and breast milk. The main 
transmission routes are: through condom-less sex between men or between men and 
women7, and more rarely through oral sex8; through intravenous drug use (IDU) using 
contaminated needles9; by mother to child transmission (MTCT) or vertical 
transmission during pregnancy, birth, or breast feeding10; or receiving contaminated 
blood products11.  
Sexual transmission is the most common route of HIV infection worldwide12. The most 
important factor associated with the risk of sexual transmission of HIV is the sexual 
partner’s HIV-RNA levels – the number of copies of the viral particles (of HIV genetic 
material) found in each millilitre of plasma. This quantity is also known as the viral load 
(VL). The higher an individual’s VL, the higher the probability of transmission13;14. The 
risk of infection through sexual intercourse is also dependent on: the sexual partner, 
sexual act, use of preventative methods such as condoms7, the presence of other 
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sexually transmitted infections such as the Herpes simplex virus-2 (HSV-2)15, genetic 
susceptibility16, and stage of infection of sexual partner17. For transmission via 
heterosexual sex, the probability of infection per sexual act is as low as one in a 
thousand for female-male exposure even in the presence of detectable viraemia18;19, 
with male-to-female infection twice as likely as female-to-male infection per sexual 
act3;20. In high-income settings, men who have sex with men (MSM) are often the 
group with the highest reported risk for HIV infection21. MSM receptive of anal 
intercourse are at a higher risk of infection per sexual act with a HIV-positive partner 
compared with being the insertive partner7.  
Laboratory markers of HIV 
Two surrogate laboratory markers are primarily used to monitor HIV progression: CD4 
cell count and VL (described in Section 1.1.2.1 ). The normal range for the CD4 count 
in a healthy individual without HIV is 500-1600 cells/µL22;23, with values around 100 
cells/µL higher for women than for men on average22.  
Pathogenesis of HIV infection 
In the absence of treatment, the course of HIV infection in an individual can be divided 
into three main stages: primary (or acute) infection, asymptomatic infection and 
symptomatic infection/AIDS24;25. During primary infection, which lasts for approximately 
12 weeks after infection, 70-90% of individuals will experience a seroconversion 
illness26;27. However, the symptoms commonly experienced, such as fever, malaise, 
night sweats and lymphadenopathy, are frequently confused with general ‘flu-like’ 
symptoms28. These symptoms generally last days to a week27. During this phase, the 
VL can reach levels up to 10 million copies/µL before declining to a more stable level 
of around 10000-100000 copies/mL, which is sometimes termed the viral “set point”29. 
High levels of viraemia and mucosal shedding mean that the risk of onwards 
transmission is at its highest during this time17;30. Meanwhile, the CD4 cell count 
rapidly declines before recovering slightly to a level below that seen prior to infection6.  
Following primary infection is a period of clinical latency. Although it is highly variable 
from individual to individual, it typically lasts around 10 years31;32. During this phase, 
there is steady but small increase over time in the VL, with a rate of increase between 
0.08 and 0.11 log copies/mL per year33-35. The CD4 count continues to steadily 
decline, on average between 1.2 and 1.7 cells/µL per year on the square root 
scale33;36, but this is highly variable between individuals. In this latent phase, a person 
living with HIV is generally asymptomatic and so individuals are likely to remain 
unaware of their HIV status unless they are tested.  
27 
 
The end of this clinically latent stage is marked by the onset of constitutional 
symptoms. This usually occurs when the CD4 count declines to approximately 200 
cells/µL. Here, the immune system cannot prevent opportunistic infections (OIs) and 
lymphomas from occurring due to the now low levels of CD4 cells. During this late 
phase of HIV, the VL also increases dramatically. Once an individual experiences an 
OI listed in Table 1.137, the individual is considered to be at an advanced stage of HIV, 
acquired immunodeficiency syndrome (AIDS). Once a person has reached this stage, 
in the absence of treatment, at some point they would inevitably die from their 
condition. 
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Table 1.1: World Health Organisation (WHO) clinical stage 4: AIDS-defining conditions  
Clinical conditions Further details 
HIV wasting syndrome  >10% of body weight 
associated with either chronic 
diarrhoea or chronic weakness 
and fever for ≥1 month 
Pneumocystis pneumonia  
Recurrent severe bacterial pneumonia >1 month 
Chronic herpes simplex infection Orolabial, genital, anorectal, 
visceral at any site 
Candidiasis/candida Oesophagus, trachea, bronchi, 
lungs 
Extra pulmonary tuberculosis  
Kaposi sarcoma  
Cytomegalovirus infection  
Central nervous system toxoplasmosis  
HIV encephalopathy  
Cryptococcosis, extra pulmonary  Including meningitis 
Disseminated non-tuberculosis mycobacteria infection  
Progressive multifocal leukoencephalopathy  
Chronic cryptosporidiosis With diarrhoea 
Chronic isosporiasis  
Disseminated mycosis  
Recurrent non-typhoidal Salmonella bacteraemia  
Lymphoma Cerebral, B-cell non-Hodgkin 
Invasive cervical carcinoma  
Atypical disseminated leishmaniosis  
Symptomatic HIV-associated nephropathy  
Symptomatic HIV-associated cardiomyopathy  
Reactivation of American trypanosomiasis  
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 Antiretroviral drugs for the treatment of HIV 
HIV is treated with antiretroviral drugs (ARVs) and the treatment regimen is referred to 
as antiretroviral therapy (ART). There are currently five main classes of ARV that act 
at different points in the HIV lifecycle:  
 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs)38 
 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)38 
 Protease Inhibitors (PIs)38 
 Entry/Fusion Inhibitors39 
 Integrase Strand Transfer Inhibitors (InSTIs)40;41. 
 Brief history of HIV treatment 
The first ARV was the NRTI zidovudine (AZT), which was approved for the treatment 
of HIV in the US by the Food and Drug Agency (FDA) in 1987 following lower rates of 
OI and death compared with placebo in clinical trials42. In this period of monotherapy, 
the life-prolonging effects were only around 6-18 months43, there were many serious 
adverse reactions (partly due to the very high doses used)44, and studies reported the 
rapid emergence of drug-resistant mutations45. AZT was the only approved treatment 
for HIV until 1991 when didanosine (ddl) and zalcitabine (ddC) were licenced46;47. To 
overcome the development of drug resistance, combinations of two (both from the 
NRTI class at this time) were recommended, known as dual therapy.  
The FDA approved the first PI, saquinavir, in 1995, which allowed for combination 
antiretroviral therapy (cART) for the first time, also known as highly active antiretroviral 
therapy (HAART). cART is typically defined as a treatment regimen containing at least 
three ARVs, which were initially two NRTIs and a PI. This is now commonly 
considered a regimen consisting of two NRTIs (the “backbone”) alongside a third drug 
from the PI, NNRTI or InSTI classes. cART has been recommended for treatment of 
HIV since 1996 when it was shown to be superior to mono or dual therapy48-52. 
Ritonavir (RTV)-boosted PIs combine a low dose of RTV at sub-therapeutic levels with 
a second PI to achieve higher sustained levels of the second PI. These regimens were 
used from around 200053, increasing the efficacy of the PI and allowing for less 
frequent dosing54. The introduction of cART revolutionised HIV treatment, and since 
1996 there has been a sustained decrease in both morbidity and mortality55;56. The 
projected life expectancy for HIV infected individuals now approaches that of the 
general population in high-income countries57 and HIV is often considered as a 
chronic, manageable condition rather than a terminal infection55;58-60.  
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When cART was first introduced, individuals were taking up to 10 tablets every eight 
hours61-63. Alongside this very high pill-burden, individuals had strict dietary restrictions 
and suffered serious toxicities. Over time, with the introduction of new ARVs and 
changes to the dosing schedules for some of the existing regimens, the number of 
doses required per day and thus the number of pills was reduced. In 2006, atripla, the 
first combination pill for one pill once a day was approved64. Since then other single 
tablet regimens have been introduced including eviplera, stribild and triumeq. With the 
introduction of a wider choice of ARVs, treatment tolerability has improved. The main 
ARVs and co-formulations in current use are in Table 1.265. 
As discussed above, early mono/dual NRTI regimens had inferior efficacy compared to 
cART. However, recent studies of modern, PI-based mono or dual ARV regimens 
have suggested they may have reasonable efficacy to cART for maintaining virological 
suppression, among individuals who have already achieved virological suppression66-72 
and as such may be a reasonable treatment option for specific groups73. Furthermore, 
there is evidence that these regimens are more cost-effective68;74;75 and that NRTI-
sparing regimens may avoid some of the NRTI-associated side effects (Table 
1.2)70;76;77.  
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Table 1.2: FDA approved HIV medicines 
 Drug 
Class 
Drug name 
(acronym) 
FDA 
Approval 
date 
Recomme
nded 
current 
dosing 
Common side 
effects 
NRTIs Zidovudine (AZT, 
ZDV) 
March 1987 1 BD Nausea, vomiting, 
fatigue, anaemia, 
lipoatrophy, muscle 
pain 
Didanosine (ddl) a October 
1991  
1 OD Peripheral 
neuropathy, lactic 
acidosis, pancreatitis 
Stavudine (d4T) a June 1994 1 BD Peripheral 
neuropathy, 
lipoatrophy, lactic 
acidosis 
Lamivudine (3TC) November 
1995 
1 or 2 OD Peripheral 
neuropathy, hair loss 
Combivir (3TC/AZT) a September 
1997 
1 BD (See individual 
components) 
Abacavir (ABC) December 
1998 
2 OD Hypersensitivity 
Trizivir 
(ABC/3TC/AZT) a 
November 
2000 
1 BD (See individual 
components) 
Tenofovir disoproxil 
fumarate (TDF) 
October 
2001 
1 OD Kidney function, 
reduced bone 
mineral density 
Emtricitabine (FTC) July 2003 1 OD  
Kivexa (ABC/3TC) August 
2004 
1 OD (See individual 
components) 
Truvada (FTC/TDF) August 
2004 
1 OD (See individual 
components) 
Tenofovir alafenamide April 2016 Only 
available in 
formulation 
 
Descovy (FTC/TAF) April 2016 1 OD  
NNRTIs Nevirapine (NVP) June 1996 1 OD or 1 
BD 
Rash, liver problems 
Delavirdine (DLV) a April 1997 4 TTD Rash, headache, 
nausea, diarrhoea, 
excessive tiredness 
Efavirenz (EFV) September 
1998 
1 OD Sleep disturbance, 
mood changes, rash, 
liver problems, lipid 
changes, kidney 
problems 
Etravirine (ETR) January 
2008 
1 or 2 BD Rash, nausea, liver 
problems 
Rilpivirine (RPV) May 2011 1 OD Depressive 
disorders, rash, 
nausea, liver 
problems 
PIs Saquinavir (SQV) a b December 
1995 
2 BD Lipid changes, 
lipodystrophy, 
diarrhoea, heart 
rhythm problems, 
liver problems 
Ritonavir (RTV) c March 1996 Depends 
on PI that it 
is boosting 
Nausea, vomiting, 
lipid changes 
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 Drug 
Class 
Drug name 
(acronym) 
FDA 
Approval 
date 
Recomme
nded 
current 
dosing 
Common side 
effects 
Indinavir (IDV) a March 1996 2 BD Urine crystals, kidney 
stones, hair loss, dry 
skin, frozen shoulder, 
jaundice, lipid 
changes, diarrhoea, 
lipodystrophy 
Nelfinavir (NFV) a March 1997 5 BD Diarrhoea, lipid 
changes 
Lopinavir/ ritonavir 
(LPV/RTV or LPV/r) b 
September 
2000 
2 BD Nausea, diarrhoea, 
lipodystrophy, lipid 
changes, heart 
disease 
Atazanavir (ATV) June 2003 2 OD Nausea, diarrhoea, 
lipodystrophy, 
jaundice 
Fosamprenavir (FPV) b October 
2003 
1 BD Nausea, diarrhoea, 
rash, lipid changes, 
lipodystrophy 
Tipranavir (TPV) a b June 2005 2 BD Nausea, tiredness, 
diarrhoea, 
lipodystrophy, lipid 
changes 
Darunavir (DRV) b June 2006 1 OD Nausea, diarrhoea, 
rash, lipodystrophy, 
lipid changes 
Atazanavir/ cobicistat 
(ATV/COBI) 
January 
2015 
1 or 2 OD (See individual 
components) 
Darunavir/ cobicistat 
(DRV/COBI) 
January 
2015 
1 OD (See individual 
components) 
Fusion 
inhibitors 
Enfuvirtide (T-20) a March 2003 1 injection 
BD 
Injection site 
reaction, bacterial 
pneumonia, allergy 
Entry 
inhibitors 
Maraviroc (MVC) August 
2007 
1 OD Rash, muscle and 
joint pain, dizziness, 
may affect heart 
InSTIs Raltegravir (RAL) October 
2007 
1 BD Nausea, rash, 
diarrhoea, headache 
Dolutegravir (DTG) August 
2013  
1 OD Sleep disturbance, 
mood changes 
Elvitegravir (EVG) b September 
2014 
1 OD  
Pharmaco-
kinetic 
Enhancers 
Cobicistat (COBI) c September 
2014 
1 OD  
Complete 
regimen d 
Atripla (EFV/FTC/TDF) July 2006 1 OD  
Eviplera 
(FTC/RPV/TDF) 
August 
2011 
1 OD  
Stribild 
(EVG/COBI/FTC/TDF) 
August 
2012 
1 OD  
Triumeq 
(ABC/DTG/3TC) 
August 
2014 
1 OD  
Genvoya 
(EVG/COBI/FTC/TAF) 
November 
2015 
1 OD  
Odefse 
(FTC/RPV/TAF) 
March 2016 1 OD  
 a Withdrawn or no longer recommended in the UK; b need to be boosted with RTV; c now only 
used to boost drug levels of other drugs; d see the individual drugs in formulation for side 
effects; OD= once daily; BD= twice daily; TTD= three times daily. 
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 Surrogate markers for ART response 
Lower CD4 counts and higher VLs are strongly associated with increased risk of AIDS 
and death78-83, particularly the CD4 count. Therefore, these are commonly used as 
surrogate clinical markers for response to ART.  
The main marker of ART response is suppression of VL to levels below that which is 
quantifiable. The defined limit for virological suppression varies depending upon the 
lower limit of assay used. Since approximately 1999, the lower limits of VL assays 
have commonly been 40 or 50 copies/mL, though the most sensitive assays are 
currently able to measure as low as one copy/mL. Sometimes a single or confirmed VL 
<200 copies/mL is used as a marker of response to ART, in accordance with 
recommendations in the US to allow for variation between VL assays84.  
Once levels of viral replication have been suppressed, immune reconstitution usually 
occurs, with a corresponding increase in CD4 cell counts. The pattern most commonly 
seen is a rapid increase in the CD4 count in the first months of ART85. This is followed 
by a steady increase of approximately 50 to 100 cells/µL per year until a stable level is 
reached86. In the long-term, for many HIV-positive individuals, this level is above 500 
cells/µL (i.e. represents a return to levels in the normal range)87;88. These 
improvements in CD4 cell counts have been shown to be a very good surrogate 
marker for immunological function, and therefore also for clinical response89.  
 Stages in the continuum of care and policies and 
recommendations in order to achieve them 
The continuum of care for HIV is a model describing the stages involved in the 
diagnosis and management of HIV, and includes a timely diagnosis, retention in care, 
receipt of appropriate antiretroviral treatment and achievement of a good treatment 
response. There are a number of stages across the care spectrum at which individuals 
can be ‘lost’ from the health system: testing for HIV, linkage to care, retention in care, 
initiation of treatment, and adherence to treatment. 
Several bodies produce guidelines for HIV care. The World Health Organisation 
(WHO) makes worldwide recommendations on healthcare, including for treatment of 
HIV. The European AIDS Clinical Society (EACS) produce European guidelines for the 
treatment of HIV-infected adults. The British HIV Association (BHIVA) is a national 
advisory body on all aspects of HIV care. Clinical treatment guidelines for the UK have 
been written by BHIVA since the early 1990’s, and these include guidance on when to 
initiate ART and with which ARVs. The guidelines are accredited by the National 
Institute for Health and Clinical Excellence (NICE)90. 
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 Diagnosis  
CD4 counts are useful markers of stage of HIV infection at the time of diagnosis. A 
timely HIV diagnosis is important for slowing the progression of HIV91;92 and therefore 
improving prognosis93-99, reducing onwards transmission100;101 and reducing costs to 
health services102;103. Although several definitions have been proposed, late diagnosis 
is now generally defined by consensus as diagnosis with CD4 count <350 cells/µL and 
very late diagnosis as a CD4 count <200 cells/µL104. Individuals with delayed diagnosis 
continue to have a 10-fold increased risk of death in the year following diagnosis105. 
Even in high-income countries, late diagnosis of HIV remains prevalent106-114. Of 
concern, late diagnosis means that ART will necessarily be initiated at a CD4 <350 
cells/µL. It is worth noting that time of diagnosis is not the same as time of infection. In 
fact, individuals may have a long time between infection and diagnosis for many 
reasons, including lack of symptoms, low perceived risk, fear of stigma, fear of positive 
result, and lack of health education. 
Testing and screening policies in the UK 
Prior to 2001, HIV tests in the UK were primarily provided upon request of the 
individual in a genitourinary medicine (GUM) clinic. The National Strategy for Sexual 
Health and HIV then recommended that GUM clinics should offer an HIV test to 
everyone on an opt-out basis115, and most now use this strategy. In antenatal settings, 
prior to 2000, the level of HIV testing was health-care worker dependent, however, the 
introduction of a universal opt-out system resulted in a vast improvement in antenatal 
testing rates and a large reduction in the proportion of undiagnosed HIV infections at 
delivery116. In the most recent BHIVA guidelines, published in 2008, universal HIV 
testing is recommended in: GUM or sexual health clinics, antenatal services, 
termination of pregnancy services, drug dependency programmes, and healthcare 
services for those diagnosed with tuberculosis, hepatitis B, hepatitis C and 
lymphoma117. A HIV test should also be considered for all individuals registering at a 
general practice and all general medical admissions where diagnosed HIV prevalence 
in the local population exceeds two in 1000 population. HIV testing is recommended to 
be routinely performed among blood donors, dialysis patients, and organ transplant 
donors and recipients117. 
In terms of testing frequency, repeat HIV tests are required for individuals who have 
tested HIV negative but where a possible exposure has occurred within the window 
period117. BHIVA guidelines recommend that MSM and PWID test for HIV annually, or 
more frequently if they are likely to be in primary infection or are still having high-risk 
exposures. Women attending antenatal clinics should be re-offered an HIV test on two 
additional occasions during pregnancy if it is declined upon booking. 
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In April 2013, the management of HIV prevention services, transferred from the NHS 
to local authorities. The London HIV Prevention Programme (LHPP) is a joint 
commissioning of key HIV prevention services by all 33 London councils118. This is a 
significant challenge since HIV prevalence exceeds two in 1000 population in 32 of 33 
London boroughs, so these are therefore considered high prevalence areas. The 
LHPP aims to increase the frequency of HIV testing, promote consistent condom use 
and safer sexual behaviours, in pursuit of which they have gained funding for condom 
distribution and for London-wide testing campaigns. 
Rapid (point-of-care) HIV testing involves an HIV test which can be conducted in a 
doctor’s office or community setting and does not need to be sent to a laboratory to get 
the results. Test results can usually be given in 20-30 minutes which is their major 
benefit over general HIV tests. However, BHIVA recommend that all positive results 
must be confirmed by serological tests as there will be false positives, particularly in 
lower prevalence environments117. This is because rapid HIV tests have been found to 
have a lower sensitivity and specificity119. Postal and self-testing allow the individual 
the privacy and convenience of testing for HIV from home. While the individual can 
conduct both of these types of tests, postal tests need to be sent off to a laboratory to 
be tested whereas the individual can read self-test results themselves within 15-20 
minutes. Postal tests have always been legal in the UK, but self-testing kits became 
legal in the UK in April 2014. Rapid testing, postal testing, and self-testing are all ways 
in which HIV testing has become more easily accessible over time, which studies have 
shown to be associated with reduced HIV transmission and an increase in retention in 
care120-123. 
 Initiation of ART 
As is the case for many chronic conditions, for PLWH worldwide, poor access to 
healthcare and treatment is a significant problem. In settings without universal free 
access to care there may be financial barriers to accessing ART124. Other barriers to 
starting ART include lack of health literacy, perceptions of discrimination, fear, 
language barriers and lack of trust in the healthcare system. 
When to start 
Lower CD4 count and higher VL at the time of initiating ART are strongly predictive of 
longer time to achieving virological suppression125-128, lower short-term CD4 counts127, 
lower likelihood of CD4 counts returning to normal levels129, and faster progression to 
AIDS and death130;131. Even among those with a timely diagnosis, delayed HIV 
treatment initiation is associated with poorer health outcomes132.  
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Recommendations of when to start by the WHO, EACS, and BHIVA have varied 
considerably over time. Regardless of CD4 count, individuals have been 
recommended to initiate ART upon onset of clinical symptoms. However, for 
asymptomatic individuals, CD4 count has generally been the determining factor for 
when to initiate treatment. Until 2015 EACS and BHIVA both recommended starting 
ART before the CD4 count fell below 350 cells/µL133 and WHO recommended starting 
when the CD4 count is below 500 cells/µL134. However, the Strategic Timing of 
Antiretroviral Therapy (START) randomised controlled trial (RCT) demonstrated that 
starting ART with a CD4 count of above 500 cells/µL is superior with respect to clinical 
endpoints than waiting for the CD4 count to reach 350 cells/µL135. Following these 
results, WHO, EACS and BHIVA have all since removed the CD4 threshold for 
recommending when to initiate ART136;137. This is called the “test and treat” strategy, 
because individuals are now recommended to start ART immediately or as soon as 
they are ready138;139. 
Initiating ART in primary infection was recommended to occur only within the setting of 
clinical trials for a number of years in the UK133;140-143. Studies have shown that starting 
treatment in primary infection can improve immune control144, however, long-term 
adherence, potential toxicity and development of resistance were additional 
considerations that meant that treatment was recommended to be deferred124;129-132. 
More recently, studies have shown improvements in long-term immunological and 
virological outcomes among those initiating ART in primary infection145. Since 2015 
initiation of treatment as soon as possible has been recommended by BHIVA for 
individuals in primary HIV infection136. 
What to start 
The choice of which ARVs should be included in an individual’s first-line regimen is 
dependent upon possible side effects, potential for drug interactions, drug resistance, 
health of the individual, convenience and cost. The recommendations of which ARVs 
to include in first-line regimens have changed over time so the most commonly used 
regimens have also changed over time.  
In 2000, BHIVA recommended that ART-naïve individuals start cART containing two 
NRTIs and either a PI, an NNRTI, or a third NRTI140. In the guidelines published in 
2003 however, triple NRTI regimens and regimens including PIs not boosted with 
Ritonavir were no longer recommended141. A regimen composed of two NRTIs and an 
InSTI was first recommended in BHIVA guidelines in 2012 when Raltegravir was 
included as a preferred third agent133. In the 2015 guidelines, BHIVA recommended 
that ART-naïve individuals start cART containing two NRTIs (preferred: TDF FTC; 
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alternative: ABC 3TC) and either a RTV-boosted PI (ATV/r or DRV/r), an NNRTI 
(preferred: RPV; alternative: EFV), or an InSTI (DTG, RAL, or EVG/COBI)136. 
Efavirenz was changed from a preferred NNRTI option in the 2012 guidelines to an 
alternative option in the 2015 guidelines, since other ARVs, including Dolutegravir, 
have demonstrated superiority146. This was mainly due to higher rates of 
discontinuation among individuals on Efavirenz due to adverse events147;148. The 
recommendations of what regimen to start initial HIV treatment with vary depending on 
factors including diagnosis of Hepatitis B or C (HBV or HCV), other chronic conditions, 
and pregnancy. 
Treatment as prevention 
Treatment as Prevention (TasP) is the term used to describe interventions used to 
reduce the rate of transmission of HIV. The idea of this method is to reduce an 
individual’s VL to levels at which they are less likely to be infectious – since VL is the 
most important factor in risk of HIV transmission as mentioned in Section 1.1.2.1 The 
results of the HPTN 052 and PARTNER studies provided evidence that individuals 
with a suppressed VL had a very low risk of transmitting HIV through sexual 
intercourse (anal or vaginal)149;150. The new recommendation to treat all individuals 
newly diagnosed with HIV with ART as soon as possible (see Section 1.3.2.1 ) both 
aims to improve the individual’s prognosis and to reduce the risk of onwards 
transmission. Prevention of mother-to-child transmission (PMTCT), post-exposure 
prophylaxis (PEP) and pre-exposure prophylaxis (PrEP) are also methods which use 
ART to prevent transmission. 
PMTCT is the treatment of a women with ARVs during and after pregnancy, 
regardless of whether they would usually have been recommended to initiate ART, 
with the aim of preventing vertical transmission to their child. PMTCT has been used 
since the mid-1990s and has been found to reduce the risk of transmission to the child 
by up to 95%151. As a result, vertical transmission in the UK has substantially declined 
over time152. 
PEP is a short course of ARVs given to individuals who have had recent exposure to 
HIV. PEP has been used for health-care workers occupationally exposed to HIV 
infection since 1998153. More recently, PEP has been used to treat individuals who 
may have had exposure to HIV in a single event (e.g. unprotected sex)154. To be 
effective PEP must be taken as soon as possible after the exposure and most 
guidelines recommend that it is taken within 48 hours. The first UK guidelines on PEP 
were published in 2006, these stated that PEP was recommended for individuals who: 
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had had anal or vaginal sex with an HIV positive individual, or had receptive anal sex 
with a person of unknown HIV status but from a group or area of high prevalence155.  
PrEP is the use of ARVs by HIV negative individuals to prevent HIV infection prior to 
potential exposures156. Studies have shown that when adhered to as prescribed, the 
risk of infection when using PrEP is near-zero157;158. Initially it was only recommended 
for key affected populations, such as MSM or PWID, but in 2015 WHO recommended 
that PrEP be offered as a choice to all individuals at high-risk of HIV infection (e.g. 
partners of PLWH)159. In 2016, BHIVA recommended that PrEP be offered to: (i) MSM, 
trans men and trans women who are engaging in condomless anal sex; (ii) HIV-
negative partners who are in serodifferent heterosexual and same-sex relationships 
with a HIV-positive partner whose viral replication is not suppressed; and (iii) other 
heterosexuals considered to be at high risk160. Although, PrEP can be accessed under 
the NHS in Scotland and Wales, this is not yet the case in England, except for for 
participants in the IMPACT trial161. 
 Response to ART 
Despite the hugely successful impact of ART on the prognosis for PLWH, there is yet 
no cure. The Strategies for Management of Antiretroviral Therapy (SMART) study 
published in 2006 found that episodic ART guided by CD4 count significantly 
increased the risk of opportunistic infections or any-cause mortality compared to 
continuous ART162. Furthermore, despite being the purpose of the CD4 count-guided 
treatment interruptions, the risk of ART-associated adverse events (see Section 
1.3.3.1 ) was not reduced in the SMART study. Thus, ART is a lifelong commitment, 
as it is generally not recommended to take treatment interruption or ‘holidays.’ 
Successful long-term virological suppression on ART is therefore critical163-170. The 
most common reasons for treatment failure are drug toxicities, drug-resistance, and 
ART non-adherence, all of which are closely linked171-174.  
Drug toxicities 
Owing to the success of cART in improving life expectancy57, PLWH are taking ARVs 
for a longer period of time, and therefore they potentially have to deal with side effects 
of ARVs (Table 1.2) in the long-term. Side effects, otherwise known as adverse effects 
or toxicities, are not uncommon with ARVs. Use of certain ARVs has been shown to 
be associated with cumulative long-term toxicities such as cardiovascular disease 
(diseases of the heart and circulation)175-181, nephrotoxicity (kidney toxicity)182-185, and 
lactic acidosis (inadequate clearance of lactic acid from the blood)186-188. Early 
treatment regimens came with a lot of associated toxicity, however, through the 
introduction of new, more tolerable ARVs there has been a reduction in incidence of 
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some toxicities, such as lipodystrophy (fat loss or redistribution). Toxicities may make 
it difficult for individuals to take their treatment and they may need to change their ART 
regimen174;189;190. 
Drug resistance 
HIV is a member of the retrovirus family, which inherently have a high mutation rate 
due to the lack of “proof-reading” ability191;192. Wild type virus, which is susceptible to 
all antiretroviral drugs, is usually the dominant type as it has the highest replicative 
capacity. However, other virus types are preferentially selected, despite having lower 
viral fitness in some situations. Drug resistant virus refers to HIV strains that contain 
mutations that confer resistance to antiretroviral drugs, which in turn leads to the 
replication of HIV even in the presence of ART. Antiretroviral drug resistance most 
commonly occurs amongst people with incomplete virological suppression on ART, for 
example during periods of moderate adherence193. Although each antiretroviral has its 
own specific resistance profile, there are a number of mutations that historically 
conferred resistance to a whole drug class194;195. This in turn can lead to a higher cost 
or less effective second/third-line regimens and transmission of drug-resistant strains 
of HIV. However, the risk of exhaustion of treatment options due to resistance has 
decreased over time with the introduction of more ARVs which have higher thresholds 
before resistance occurs, and improved resistance profiles which remain active even 
in the presence of mutations that would have previously conferred class-wide 
resistance196. In high income countries, the prevalence of transmitted HIV drug 
resistance has stabilised in recent years197;198.  
ART non-adherence 
Non-adherence to ART has emerged as the major determinant for treatment 
success199. Non-adherence covers three areas: dose non-adherence (missing ART 
doses), schedule non-adherence (not taking doses at the correct time) and instruction 
non-adherence (not taking doses under the correct conditions e.g. with food). Non-
adherence may occur due to individual choice (for example due to high levels of 
toxicity or life events), lack of comprehension of treatment schedule, or forgetting. 
Non-adherence to ART is a significant predictor of virological non-suppression and 
treatment failure171;173;199;200. Poor adherence can also lead to the development of drug 
resistance201-203 and the subsequent increased risk of onward transmission202;204.  
Adherence to ART can be measured in a number of ways: self-report, Medical Event 
Monitoring Systems (MEMS) caps (counting the number of times a pill bottle is 
opened), pill-count (number of pills left is counted), prescription coverage (time 
covered by prescription), clinician report, or a combination of these. Self-report is the 
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most commonly used measure since it is the easiest to obtain and least costly 
measure. Despite the frequent use of self-report to define adherence, the lack of 
standardisation of questions (with regard to how many missed doses count as poor 
adherence and over what time period they consider) means that even among studies 
using self-reported adherence measures it is difficult to make comparisons between 
them205. The main disadvantage of self-reported variables is that they may be more 
subject to error and bias. For example, individuals may not remember all missed 
doses, particularly over longer periods, or may tend to over-estimate adherence due to 
social desirability bias – the tendency of respondents to answer questions in a manner 
that they believe will be viewed favourably by others. It is difficult to accurately capture 
adherence to treatment by any one measure206;207, however, collecting multiple 
measures may be impractical in a clinical setting.  
 
 The current HIV epidemic in the UK 
 The number of people living with HIV in the UK 
In the UK in 2015, there was a rate of new diagnosis of 11.4 per 100000 people208. Of 
the countries in Western Europe, the UK has the highest rate of HIV per head 
population, with the exception of Luxembourg209. In 2015 there were an estimated 
101200 PLWH in the UK (95% credible interval (CrI): 97500, 105700), of whom, 18100 
(95% CrI: 10200, 17800) or 13% (95% CrI: 10%, 17%) were estimated to be unaware 
of their HIV status208. 
 Demographics of people living with HIV in the UK 
HIV prevalence in the UK 
In 2015, the overall HIV prevalence was estimated to be 1.6 per 1000 population (95% 
CrI: 1.5, 1.6) among all ages and 2.1 per 1000 population (95% CrI: 2.0, 2.2) among 
individuals aged 15-74 years (Figure 1.1)208. When considered in men and women 
separately, the prevalence was 2.3 per 1000 (95% CrI: 2.2, 2.5) among men and 0.98 
per 1000 (95% CrI: 0.95, 1.02) among women208. Women account for about a third of 
individuals infected with HIV in the UK210. MSM and black African heterosexuals are 
disproportionally affected by HIV: in 2015 the prevalence per 1000 population was 
58.7 (95% CrI: 51.2, 88.0) for MSM, 22.2 (95% CrI: 21.3, 23.6) for black African men 
and 42.6 (95% CrI: 41.0, 44.3) for black African women208. 
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Figure 1.1: Estimated number of people living with HIV of all ages (diagnosed and 
undiagnosed) using the MPES model: UK, 2015 
 
 
It has been acknowledged that, similar to other chronic conditions, socio-economic 
deprivation is associated with a greater likelihood of being infected with HIV211. In 
London in 2013, it was estimated that the HIV prevalence among adults aged 15-59 
years was 7.4 per 1000 population in the most deprived areas compared to 2.4 in the 
least deprived areas (Figure 1.2105). 
Figure 1.2: Prevalence of adults aged 15-59 years diagnosed HIV infection by index of 
multiple deprivation (IMD): England, 2013 
 
MPES=Multi-Parameter Evidence System 
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New HIV diagnoses in the UK 
Of a total of 6095 people diagnosed with HIV in the UK in 2015, 3320 (54%) men 
acquired HIV through sex with men, 1010 (15%) men acquired HIV through 
heterosexual sex, 1350 (22%) women acquired HIV through heterosexual sex, and 
210 (3%) acquired HIV through IDU (Figure 1.3)208.  
Figure 1.3: New HIV diagnoses by exposure group: UK 2015 
 
 
 
 
 
 
 
 
 
Over time, there has been a resurgence in transmission among MSM212;213, who 
represented over half of all new diagnoses in 2015. The high levels of new HIV 
diagnoses among MSM are a result of both increased levels of HIV testing and 
ongoing high rates of transmission208. However, there is some indication from very 
recent data that the rate of transmission amongst MSM may be declining, perhaps due 
to PrEP, TasP and other behavioural changes214. The number of new diagnoses 
among heterosexuals has almost halved in the last decade (4340 in 2006 vs. 2360 in 
2015), mainly due to fewer reports among African-born men and women, reflecting 
changing migration patterns208. Since the inception of the needle exchange program, 
transmission by IDU has decreased and remained at low numbers215;216, although 
there was a notable increase between 2014 and 2015 (160 vs. 210) associated with 
an HIV outbreak among people who inject drugs (PWID) in Glasgow208. Similarly 
MTCT has been decreasing due to routine antenatal testing217-219 and effective 
interventions such as avoidance of breastfeeding220. Although in the early stages of 
the epidemic, a number of people were infected by exposure to infected blood 
products, since 1985 blood has been screened for HIV in the US, Canada, and 
Europe3, and therefore acquisition of HIV via this route is extremely rare. Overall, new 
* Gay/bisexual men also includes gay/bisexual men who have injected drugs 
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diagnoses in the UK are declining, however, the beneficial impact of HIV treatment 
contributes to the continuing rise in the number of PLWH105. 
Late HIV diagnoses in the UK 
Late diagnosis of HIV remains a challenge in the UK, with 39% of people newly 
diagnosed with HIV in 2015 having a CD4 count <350 cells/µL and 22% with a CD4 
count <200 cells/µL208. Figure 1.4 shows that in 2015, a greater proportion of women 
compared to men, older individuals, individuals of black ethnicity, heterosexual men 
and women compared to gay/bisexual men, and individuals living outside of London 
were diagnosed late208. The proportion of individuals diagnosed late had declined from 
56% in 2006 to 39% in 2015 and had declined across all HIV exposure groups, 
however, the decline was largest among heterosexual women (from 64% to 49%), 
mainly due to the antenatal screening programme and changing migration patterns208. 
Figure 1.5 shows that the one-year mortality rate among individuals diagnosed with a 
CD4 count <350 cells/µL was 31.5 per 1000 compared to 3.6 per 1000 among 
individuals diagnosed with a CD4 count ≥350 cells/µL208. Mortality rates were highest 
among men compared to women, individuals over 50 years old, individuals of other 
ethnicity compared to white or black ethnicity, and PWID (Figure 1.5). 
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Figure 1.4: Proportion of adults diagnosed late (CD4 count <350 cells/µL within three 
months of diagnosis) by demographic factors: UK, 2015 
         
Figure 1.5: One-year mortality rates among adults newly diagnosed with HIV by CD4 
count at diagnosis: UK, 2014 
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 The UK HIV care continuum: comparison to UNAIDS targets 
In 2014, UNAIDS introduced the “90-90-90” targets in terms of the HIV care 
continuum221. They proposed that by 2020: 90% of PLWH will be diagnosed, 90% of 
people HIV-diagnosed will be on sustained ART, and 90% of those receiving ART will 
have a suppressed VL. If these targets are achieved, then 81% of all PLWH will be on 
treatment and 73% will have an undetectable VL. Meeting this target would both 
improve the prognosis for PLWH and, modelling studies have suggested, potentially 
end the epidemic spread of HIV by 2030221.  
Among the estimated number of people living with HIV in the UK in 2015, 87% were 
HIV-diagnosed, 83% were on treatment and 78% were virologically suppressed208. 
Figure 1.6 shows these percentages by the blue bars, and the blue arrows denote the 
percentage of individuals at the stage before the arrow which have reached the 
subsequent stage (e.g. 94% of individuals on ART were virologically suppressed). The 
red bars in Figure 1.6 show the three UNAIDS targets. The UK has not yet reached 
the first UNAIDS target, having 90% of people living with HIV diagnosed, however, the 
second two targets have already been met and surpassed. Despite the progress 
towards meeting the 90:90:90 targets to date, the persisting high levels of HIV 
transmission and late diagnosis remain a concern in the UK208.  
Figure 1.6: UK HIV care continuum 2015: progress against UNAIDS 90:90:90 targets 
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 Sex, gender and sexual orientation: differences in health 
outcomes and HIV outcomes in particular 
 Sex, gender, sexual orientation and health inequalities 
There is evidence that men and women have differing health outcomes via biological 
mechanisms, including susceptibility to a number of conditions, from migraines to 
multiple sclerosis222-226, and pharmacokinetic differences (because of differing 
gastrointestinal functioning, BMI, metabolism etc.)227-230. At a global level, women have 
a higher life expectancy than men, however, on average women have less years of 
“healthy life”231. This differs greatly by country; in those with less social discrimination, 
women’s life expectancy is higher232. This difference in life expectancy is therefore 
unlikely to be because of biological sex alone but also differences in lifestyle and 
behavioural factors between men and women. Health inequalities reflect both 
biological sex differences and socially constructed gender differences and their 
interaction233. Some examples of where gender plays a role in health outcomes 
include: greater reporting of anxiety and depression among women despite no 
evidence that they are constitutionally more susceptible234, masculine stereotyping 
making men more reluctant to access healthcare235, women being less likely to receive 
social support and hence experiencing poorer positive coping236, and men’s greater 
partaking in risky behaviours such as smoking237.  
Differences in health outcomes by sexual orientation are not generally considered, 
except in the case of sexually transmitted infections (STIs) and mental health. Among 
men, reported STI acquisition has been found to be associated with increasing 
numbers of male sexual partners238. Men who self-identify as gay or bisexual are at 
six-fold increased risk of an STI diagnosis compared to self-identifying heterosexual 
men239. Among women however, studies have reported that self-identifying bisexual 
women have the highest risk of an STI diagnosis, followed by heterosexual women, 
and then lesbian women240. Multiple studies have also found differences by sexual 
orientation in the prevalence of mental health problems, i.e. MSM have been found to 
be at increased risk of mental health problems compared to men who have sex with 
women (MSW)241-244. 
 Biological sex differences in HIV-related outcomes 
Studies have previously considered whether there are biological differences in HIV-
related outcomes by sex. There is evidence that women are more likely to acquire HIV 
per heterosexual act3;20, they are more likely to be diagnosed during routine testing 
mainly due to routine opt-out antenatal testing217-219;245, they have a higher CD4 count 
on average before HIV infection22;246-249 and at seroconversion250-252, and are at 
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increased risk of adverse reactions to ARVs253 compared to men. There is also 
evidence of differences in pharmacokinetics and pharmacodynamics for ARVs254. 
More recently, there has been a greater focus on behavioural gender based 
differences in HIV-related outcomes.  
 Non-biological gender differences in HIV-related outcomes 
HIV has similarities to several diseases, disorders and conditions, for example 
rheumatoid arthritis, asthma, and diabetes, in that they require long-term treatment 
adherence to avoid disease progression and ultimately mortality255. Several studies of 
rheumatoid arthritis256-259, asthma260-263, and diabetes264-266 have observed poorer 
prognosis and increased risk of morbidity among women compared to men. Thus, it is 
possible that gender disparities would also be apparent for HIV treatment response. 
HIV differs to these conditions in that: infection is mainly acquired through sexual 
intercourse or intravenous drug use (IDU)7;9; individuals are infected at any age rather 
than predominantly among older individuals267; it disproportionately affects certain 
socio-demographic groups such as migrants and MSM; and the stigma attached and 
thus possible difficulties with disclosure255;267;268. Therefore, gender may affect 
responses to treatment differently for HIV. 
In many studies investigating gender effects in HIV prognosis, MSW have been 
grouped with MSM and compared to women. This approach does not consider the 
differences between these two male groups. MSW are more often migrants than 
MSM269;270, and more often have poorer SES271. Additionally, although there is some 
evidence that MSM are at increased risk of sexually transmitted infections (STIs)272;273 
and mental health problems274-276, particularly men who self-identify as gay or 
bisexual277, this group has been found to be more likely to test for HIV compared to 
self-identifying heterosexual men278. This means that MSM and MSW may have very 
different health profiles. This separation of men into whether they have sex with men 
or women would not be a reasonable consideration for women, since sexual HIV 
transmission between women is very rare. 
One could consider comparing MSM with a single group of heterosexual men and 
women; however, there are also a number of reasons to consider women separately. 
There are known gender differences in utilisation of healthcare services and reporting 
of symptoms for other common diseases279;280 which could also be apparent for HIV 
and lead to differences in response to treatment. Pregnancy affects the timing for ART 
initiation and which regimen is started281, which may in turn affect subsequent 
response to ART282. Similarly, as women are more often the primary caregiver for 
children, the effect of having children is more likely to affect HIV-related outcomes and 
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adherence of women compared to men. However, in HIV-positive populations in high-
income settings MSW often have greater similarities with respect to culture, 
demographics and SES with women than with MSM283. This suggests that, when 
assessing HIV-related outcomes, there are essentially three separate gender/sexual 
orientation groups that should be considered, rather than binary gender (see Chapter 
2 for a full review of the literature). 
 
 Socio-economic status: differences in health outcomes and 
HIV outcomes in particular 
SES is the position of individuals in society, based on a combination of occupational, 
financial and educational criteria. Less frequently, housing status, literacy or cultural 
characteristics may be used as indicators of SES284. Alternatively some studies 
consider neighbourhood-level measures using area-based deprivation as a marker for 
individual-level SES285. Individuals with higher SES might be thought of as having 
greater access to desired resources such as material goods, money, friendship 
networks, and educational opportunities. The terms “socio-economically 
disadvantaged” and “socio-economically deprived” are commonly used to describe 
individuals with limited access to these resources. 
 Socio-economic status and health inequalities 
SES encompasses a range of indicators that have been identified as key to 
inequalities in health286-288. SES is a determinant of health predominantly through three 
pathways: access to healthcare, environmental exposures and health behaviour289. 
The extent that SES affects incidence and prognosis of ill health and chronic diseases 
is likely to differ between different healthcare settings. Although some settings, such 
as the US, have a reliance on ability to pay for healthcare and treatment, the UK has a 
national healthcare system so that access to healthcare and treatment is universally 
free at the point of care. However, ability to pay is by no means the only barrier to 
good health among individuals of lower SES: other barriers may include poorer health 
literacy (ability to read and comprehend medical information)290-295, riskier or less 
healthy lifestyle296-301, and fewer resources to facilitate access to healthcare (e.g. 
transport)302. There is evidence of an association between socio-economic 
disadvantage and poorer health across diverse health outcomes, ranging from the 
incidence of relatively minor illnesses such as headaches303;304, to chronic conditions 
such as diabetes305-307.  
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Despite universal healthcare coverage in the UK, various aspects of healthcare 
including longer hospital waiting times and longer wait for referral308;309, and reduced 
access to health screening310, healthcare311 and needed surgery312 have been found to 
be associated with poorer SES. Socio-economic factors such as social deprivation, 
lower income and education, have also been found to be associated with delayed 
diagnosis and poorer prognosis for a number of diseases, including cancer and 
chronic conditions such as diabetes and cardiovascular disease305;313-318. 
 Socio-economic differences in HIV-related outcomes  
As shown in Section 1.4.2.1 , there is a higher prevalence of HIV diagnoses in the 
most socio-economically deprived areas of the UK compared to the least deprived 
areas, particularly in London. Socio-economic disadvantage has been found to be 
associated with riskier sexual behaviours319-322, which may partially explain the 
disproportionate amount of individuals of lower SES infected with HIV7. The 
demographic correlates of SES may also contribute to the association between SES 
and HIV prevalence. 
 Correlation between socio-economic and demographic factors 
The HIV-positive population in the UK is made up of distinct demographic groups. For 
example, the majority of women and heterosexual men living with HIV are of black 
African ethnicity, whereas among MSM most individuals are of white ethnicity208. This 
means that studies considering gender differences in HIV outcomes are often likely 
concurrently examining differences by gender, ethnicity, culture and socio-economic 
background. The correlation between SES, ethnicity and route of transmission in 
particular means that the studies aiming to look at one of these factors are often 
comparing all at once. Therefore, when evaluating differences between demographic 
groups, it is important to consider these other factors, including SES. The extent to 
which differences in prognosis between demographic sub-groups can be explained by 
SES requires investigation. 
 
 Summary 
In the UK, treatment outcomes are improving such that HIV is now considered a 
chronic but manageable condition. However, improvements may not have been 
experienced equally throughout the HIV-positive population. Disparities may occur 
between different demographic and socio-economic groups at various stages of the 
care continuum, including diagnosis and response to treatment. The specific aims and 
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objectives of this thesis are displayed in Chapter 3, following a literature review in 
Chapter 2.  
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 Literature review: gender/sexual orientation, 
socio-economic status and HIV treatment 
outcomes  
 Objectives 
In this chapter, I address three questions among people with HIV and prescribed ART 
in high-income settings: (i) what evidence is there for an association between 
gender/sexual orientation and response to ART? (ii) what evidence is there for an 
association between SES and response to ART?; (iii) is there any evidence that 
observed differences in treatment responses according to gender/sexual orientation 
can be explained by differences in socio-economic circumstances, and vice versa? 
Three outcome measures are considered: (i) virological response (ii) immunological 
response (as measured by CD4 count) and (iii) ART non-adherence. As this thesis 
focusses on the UK setting, I only consider studies conducted in high-income 
countries, as they are likely to have similarities to the UK that mean that the results will 
be generalisable to some extent. 
 
 Methods 
 Overview  
In Section 1.6.3 I showed that there were three main groups when considering gender 
differences, as it is very difficult to separate gender and sexual orientation as 
explanatory variables in the context of HIV. Thus, I began this chapter by presenting 
the results of my first systematic review, which summarised the literature on the 
association between gender/sexual orientation and ART response. However, since 
many studies have included gender as a covariate rather than gender/sexual 
orientation, I first gave an overview of studies that have considered the association 
between gender and HIV treatment outcomes without further sub-categorisation of the 
male group. 
The effect of SES on ART response was the second focus of this thesis. Therefore, I 
conducted a second systematic review of the association between socio-economic 
factors and response to ART. 
As discussed in Section 1.7.3, in the setting of HIV, demographic factors (particularly 
gender, sexual orientation and ethnicity) and SES are frequently interrelated in high-
income countries323;324. Lower SES is strongly associated with a greater prevalence of 
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HIV infections particularly amongst MSW and women320, thus there will be a wider 
distribution of SES among these individuals compared to MSM136. In order to 
understand the drivers of any potential gender/sexual orientation or SES inequalities in 
ART response, and in turn to help identify potential interventions to reduce them, I 
investigated evidence of the extent to which differences in treatment outcomes by 
gender/sexual orientation can be explained by SES, or vice versa. For this, I 
considered the studies identified by the two systematic reviews that included both 
gender/sexual orientation and SES in multivariable models. 
There are several other potential mediators of the association of gender/sexual 
orientation and SES with treatment outcomes. Therefore, finally, I also looked at any 
other factors considered by any of the studies identified in the literature reviews that 
may explain gender/sexual orientation or SES differences in HIV-treatment outcomes. 
The primary potential mediator I considered was adherence, when it was considered 
as a covariate in models with virological or CD4 count outcomes, rather than as an 
outcome. Due to the highly effective modern ART regimens, treatment adherence is a 
key determinant of HIV treatment success162;173;199;200;325. 
 Identification of relevant studies 
The papers included in this review were identified by a systematic literature search of 
the electronic database PubMed in August 2016. Original research studies (of any 
design and including secondary observational analyses of Randomised Controlled 
Trial [RCT] data) were identified using the search terms shown in Figure 2.1 for the 
gender/sexual orientation review, and in Figure 2.2 for the SES review. Any literature 
reviews or Meta analyses identified by this search were also included in the review 
(although not included in the summary tables). Additional studies were identified by 
searching the websites of the following major observational studies:  
• AIDS Care Cohort to evaluate Exposure to Survival Services (ACCESS) study 
• Agence Nationale se Recherches sur le Sida (ANRS) VESPA study 
• ART Cohort Collaboration (ART-CC) study 
• Antiretrovirals, Sexual Transmission Risk, and Attitudes (ASTRA) study 
• AIDS Therapy Evaluation in the Netherlands (ATHENA) study 
• Canadian Observational Cohort (CANOC) study 
• Collaboration of Observational HIV Epidemiological Research Europe 
(COHERE) study 
• Cohorte de la Red de Investigaciόn en Sida (CoRIS) 
• Danish HIV Cohort Study (DHCS) 
• EuroSIDA 
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• HAART Observational Medical Evaluation and Research (HOMER) study 
• Italian Cohort of Naïve Antiretrovirals (ICoNA) study 
• North American AIDS Cohort Collaboration on Research and Design (NA-
ACCORD) study 
• Swiss HIV Cohort Study (SHCS) 
• UK Collaborative HIV Cohort (CHIC) study. 
The selection criteria for the literature reviews were as follows:  
• Set in high-income counties 
• Has individual-level data 
• More than 100 participants 
• At least some recruitment taking place from 2001 onwards (after the 
introduction of ritonavir (RTV)-boosted PIs) 
• At least some participants prescribed ART 
• Studies with virological and CD4 count outcomes that only report analyses 
adjusted for adherence were excluded since adherence is on the causal 
pathway between either gender/sexual orientation or SES and HIV treatment 
outcomes 
• Written in English.
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 Figure 2.1: Flow diagram of literature search for studies investigating the association 
between gender/sexual orientation and virological ART response, CD4 count ART 
response and ART adherence 
 
 
Geographical breakdown
US: 5 US and Canada: 1 Europe: 10
Europe, Austrailia, 
Canada, Africa: 1
Studies identified as relevant and included in the review
17
Potentially relevant from abstract
149
Studies identified
4753
Pubmed search of termsa:
“HIV” and “antiretroviral” and any of “sexual orientation”, "sexual acquisition", "sexually 
transmitted", "exposure category", "sex interaction", "gender interaction", “transmission 
category”, “sex and transmission risk” with any “virologic”, “virological”, “viral load”, 
“immunologic”, “immunological”, “CD4”, “failure”, “rebound”, “suppression”, “detectable” 
“adherence”, “non-adherence”
a Including MeSH terms. 
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Figure 2.2: Flow diagram of literature search for studies investigating the association 
between socio-economic factors and virological ART response, CD4 count ART 
response and ART adherence 
 
 
 
Geographical breakdown
US: 28 Canada: 6 Europe: 14 Australia: 1
Studies identified as relevant and included in the review
49
Potentially relevant from abstract
154
Potentially releant from title
236
Studies identified
4446
Pubmed search of terms a:
“HIV” and any of “socioeconomic”, “socio-economic”, “antiretroviral”, “ART” with any “virologic”, 
“virological”, “immunologic”, “immunological”, “failure”, “rebound”, “suppression”, “viral load”, 
“CD4”, “education level”, “employment”, “housing”, “occupation”, “deprivation”, “poverty”, 
“income” or “insurance”
a Including MeSH terms. 
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 Definition of gender, gender/sexual orientation and socio-economic 
factors 
For the gender-based section of my literature review, I considered any study which 
met the above selection criteria and which categorised individuals as men and women 
and did not divide these groups further by sexual orientation. 
For the gender/sexual orientation-based systematic literature review, I considered any 
study which met the above selection criteria and which included MSM, MSW, and 
women as distinct groups, although not all three groups had to be included. Studies 
comparing heterosexual men and women were considered as part of this review rather 
than the gender-based review because MSM and MSM were still categorised as 
different groups in these studies, even though MSM were excluded. Although mode of 
HIV acquisition and sexual orientation are separate entities, I included studies that 
used either variable to categorise individuals. I also included studies that additionally 
divided women into two groups: women who have sex with men [WSM] and women 
who have sex with women [WSW]. 
In the SES-based systematic review, the following specific markers of SES were 
considered: education, employment, income/financial status, housing, health 
insurance and neighbourhood SES. The advantages and disadvantages of each of 
these factors as indicators of SES are set out in Figure 2.3 and discussed in the 
relevant subsections of this section269;326;327. 
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Figure 2.3: Advantages and disadvantages of the indicators of SES 
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 Summary of the identified studies 
I summarised the results of the identified studies, according to whether they 
considered virological outcomes, CD4 count outcomes, or ART adherence outcomes. 
Studies were listed according to study design and then by number of participants. I 
presented the reported unadjusted and adjusted risk ratios (RR), odds ratios (OR), 
prevalence ratios (PR), and hazard ratios (HR) for the association between the 
explanatory variable (gender; gender/sexual orientation; or socio-economic factor) and 
the outcome of interest. I standardised all effect size estimates such that: for gender, 
men were the comparison group; for gender/sexual orientation, MSM were the 
comparison group, or MSW were the comparison group when comparing MSW and 
women; for SES, the lowest SES group was compared with the highest. In each 
review of the literature on ART adherence, the effect size estimates were standardised 
such that they were in terms of ART non-adherence rather than adherence. In the 
summary tables, all studies will be referred to only by their acronym (refer to list on 
pages 10-11).  
 
 Review of the literature on gender and HIV treatment 
outcomes 
In this section, I summarised major studies that consider associations between gender 
(as a factor alone not combined with sexual orientation) and response to ART among 
people living with HIV (PLWH). These papers were identified during the systematic 
review of the literature for studies that considered the effect of gender/sexual 
orientation on HIV treatment outcomes, but could not be included since they did not 
split the men up into two groups. Since the studies were still of interest I have added a 
short summary of them here. 
 Virological response to ART: Association with gender 
Numerous studies have considered gender as an explanatory variable, although not 
always as the primary factor of interest, when considering factors associated with 
virological response to HIV treatment. The observational studies reviewed are 
summarised in Table 2.1.  
A meta-analysis of 40 clinical trials found no evidence of a difference in virological 
suppression at 48 weeks from ART initiation between men and women, however, 
particular trials included found that women had poorer virological outcomes328. People 
in trials may not be representative of the general HIV population, and so one may 
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expect a better response rate from individuals enrolled in trials and an underestimation 
of relative differences in treatment response. 
A recent literature review of 65 observational studies considered gender disparities in 
mortality, progression to AIDS, virological and immunological response to ART329, of 
which 68% found no statistically significant difference for any of the outcomes between 
men and women. In particular, they found pooled hazard ratios (women vs. men) of 
0.93 (95% CI 0.85, 1.01) and 0.94 (0.89, 0.99) for virological failure and virological 
suppression, respectively. 
Of 17 observational studies identified by my review, seven similarly found that women 
had a lower rate of virological suppression92;330;331, and a greater risk of virological 
rebound330;332-335 or virological failure335. In another study, the Royal Free HIV Cohort 
study (RFHCS), the setting of some of the analyses in this thesis, a comparable 
percentage of men and women experienced virological failure when those who 
discontinued ART were excluded from the analysis336. However, when treatment 
discontinuations were additionally considered as virological failure, 10% and 14% 
more women than men experienced virological failure at 48 and 96 weeks 
respectively.  
Conversely, three other studies observed a better initial virological response to 
treatment in women than in men, including the Spanish GEEMA study127 and two 
population-based studies of the HIV-positive population of New York128;337. The 
Spanish study, among treatment experienced individuals, found that men had a higher 
VL than women at all time-points following ART initiation127. Among these three 
studies, two were in study populations where individuals had not necessarily started 
ART, and one considered a population in which around 80% had experience of taking 
ARVs prior to ART initiation. Thus, these results may be reflecting differences in timing 
of ART initiation or in pre-ART differences. Furthermore, studies that found that men 
tended to have poorer outcomes had a greater proportion of women in the study 
population – 26-30% vs. 16-24% in studies finding women had poorer outcomes. 
Finally, the six remaining studies found no difference in time to VL <500copies/mL 
following ART initiation335;338, virological suppression in the first 12 months of ART339-
341, and time to virological rebound128;342 by gender. Thus, the literature considering 
differences in virological response to ART according to gender is very mixed. 
Six studies adjusted for mode of HIV acquisition333;335;337;338;340;341. In four of these there 
were no gender differences after adjustment335;338;340;341; however, three of these did 
not present unadjusted results. In the other two studies, there was evidence that 
60 
 
gender differences were attenuated by adjustment for mode of HIV acquisition. In the 
ART Cohort Collaboration (ART-CC) study, the 58% higher rate of rebound among 
women in unadjusted analyses was attenuated to a 14% higher rate333. Additionally in 
a study of the New York HIV-positive population, though in unadjusted analyses 
women tended to have a lower prevalence of VL suppression than men, adjusting for 
mode of HIV acquisition and other baseline factors meant that women had 4% greater 
prevalence of VL suppression337. All of these studies adjusted for several factors 
simultaneously, so it was not possible to conclude whether gender differences were 
explained by differences in mode of HIV acquisition. Adjustment can also be 
problematic in this situation, as generally one of the mode of acquisition groups 
(commonly labelled as MSM, gay/bisexual or historically as homosexual) contains 
exclusively men.  
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Table 2.1: Original research studies considering the association between virological outcomes and gender among people prescribed ART a 
Publication 
Setting, Study years 
and Study Group b 
Study Viral outcome 
definition 
(prevalence) 
Estimate (95% CI) c 
Women vs Men 
Factors adjusted for 
  N % 
Women 
% 
MSM 
 Measure Unadjusted Adjusted  
Cross-sectional 
Torian 2014 AJPH337 
US, 2006-10 
NYC HARS 
87,146  
HIV diagnosed 
30% 
 
36% <400 (59%) PR 0.99 (0.98, 1.00) 1.04 (1.03, 1.06)  HIV acquisition risk, age, 
ethnicity, country of birth, 
AIDS diagnosis 
Longitudinal 
Vandenhende 2015 
AIDS333 
Europe & N America 
1996-2012 
ART-CC 
17,902  
VL<50 in 3-9 
mths of 
initiating ART 
24%  
 
42% Two consecutive >500 
(11%) 
HR  1.58 (1.39, 1.80) 1.14 (0.97, 1.33) HIV acquisition risk, age, 3rd 
ARV, yr ART start, VL & 
CD4 at ART start, CDC 
stage, low level viraemia 
Robertson 2014 AIDS 
Care128 
US 2005-11 
NYC HARS 
12,318  
HIV diagnosed 
26%  
 
42% Time to <400 
 
Subsequent time to 
>1000 
HR 
 
1.17 (1.12, 1.23) 
 
NS 
1.15 (1.10, 1.20) 
 
NS 
Age diagnosis, yr diagnosis, 
time to start ART, CD4 at 
diagnosis  
Althoff, 2010, AIDS338 
US & Canada 1998-
2008 
NA-ACCORD 
12,196  
ART-naïve 
initiating ART 
with VL>500 
17%  
 
29% 
 
Time until <500 OR n/k 0.98 (0.92, 1.05) HIV acquisition risk, age, 
ethnicity, initial ART 
regimen, yr of ART start, VL 
and CD4 at ART start, prior 
AIDS diagnosis, cohort 
Smit, 2013, PLoS 
One341 
Netherlands 1996-
2010 
ATHENA 
10,278  
ART-naïve 
initiating ARTc 
16% 
 
59%  
 
<1,000 within 12 mths 
of ART initiation (95%) 
HR n/k 1.06 (0.98, 1.14) HIV acquisition risk, age, 
region, time, VL & CD4 at 
ART start, ART regimen 
Cescon, 2013, PLoS 
One330 
Canada 2000-11 
CANOC 
5,442  
ART-naïve 
initiating ART 
21% 
 
n/k 2 consecutive <50 
 
Subsequent>1000 
HR 
 
0.72 (0.64,0.81) 
1.68 (1.34, 2.11) 
0.82 (0.72, 0.93) 
1.31 (1.03, 1.66) 
Age, province, third ARV, VL 
& CD4 at ART start, yr of 
ART start, VL testing rate  
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Publication 
Setting, Study years 
and Study Group b 
Study Viral outcome 
definition 
(prevalence) 
Estimate (95% CI) c 
Women vs Men 
Factors adjusted for 
  N % 
Women 
% 
MSM 
 Measure Unadjusted Adjusted  
Cescon, 2011, HIV 
Med92 
Canada 2000-08 
CANOC 
3,555 
ART-naïve 
initiating ART, 
VL≥ 50 
20% 
 
n/k Two consecutive <50  HR 0.74 (0.68, 0.81) 0.86 (0.78, 0.94) Age, province, IDU, third 
ARV, VL and CD4 at ART 
start, prior AIDS diagnosis 
Collazos, 2007, 
AIDS127 
Spain 1998-99 
GEEMA 
2,620  
initiating NFV-
based ART with 
VL>200 
28% 
 
14% <200 at 12 mths after 
ART start 
 % ARV experienced: 
49% vs. 40% 
ARV naïve:  
79% vs. 74% 
n/k  
Moore, 2003, JAIDS335 
Europe 1999-2001 
EuroSIDA 
2,548  
PI and NNRTI 
naïve initiating 
ART 
20% 48% Time to <500 
 
Time to two 
consecutive >500 
 
Failure to reach <500 
by wk 32 
 HR 0.93 (0.84, 1.03) 
 
1.40 (1.18, 1.67)  
 
1.16 (1.03, 1.32) 
0.91 (0.81, 1.03) 
 
1.17 (0.95, 1.44) 
 
1.15 (0.98, 1.33) 
HIV acquisition risk, age, 
ethnicity, geographical 
region, ART history, VL & 
CD4 at ART start, prior 
AIDS 
Nicastri, 2005, AIDS340 
Italy 1996-99 
IATG 
2,460  
PI and NNRTI 
naïve initiating 
PI-based ART, 
VL>500 
28% 
 
15% <500 within 12 mths  
 
Two subsequent 
consecutive >500  
HR n/k 1.04 (0.92, 1.18) 
 
NS 
HIV acquisition risk, age, VL 
& CD4 at ART start, prior 
AIDS 
Saracino, 2016, Clin 
Microbiol Infect342 
Italy 2004-14 
ICoNA 
2,321  
ART-naïve 
initiating ART 
≥6 mths ago 
21%  
 
43% Time to two 
consecutive >200 (3.3 
per 100 pyrs) 
RR n/k 1.15 (0.71, 1.85) Migrant status, employment 
status, first-line regimen 
type, CD4 at enrolment, 
CDC stage 
Geretti, 2008, Antivir 
Ther334 
UK & Germany 1996-
2005 
Two centres 
1,386  
ART-naïve 
initiating ART, 
achieve VL≤ 50 
& no VL>400 in 
1st yr 
21% 
 
n/k 2 consecutive >400 or 
single >400 followed by 
ARV change/end of 
follow-up (26%) 
IRR 1.77 (1.11,2.82) 1.79 (1.12, 2.85) ART regimen and presence 
of low level viraemia in yr 
after virological suppression 
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Publication 
Setting, Study years 
and Study Group b 
Study Viral outcome 
definition 
(prevalence) 
Estimate (95% CI) c 
Women vs Men 
Factors adjusted for 
  N % 
Women 
% 
MSM 
 Measure Unadjusted Adjusted  
Lima, 2010, J Acquir 
Immune Defic Syndr332 
Canada 2000-07 
BC-CfE 
1,305  
ART-naïve 
initiating ART, 
achieve VL≤ 50 
16% 
 
n/k 2 consecutive >400 
(21%) 
% and 
OR 
37% vs. 18% 
p<0.01 
1.68 (1.05, 2.69) Age, IDU, third ARV, nadir 
CD4, VL at ART start, yr of 
ART start, adherence, drug 
resistance, time suppressed 
d 
Multhingham, 2013, 
JAIDS339 
US 2009-10 
All HIV-positive 
residents of San 
Francisco 
862 
HIV diagnosed 
7% 
 
68%  <200 within 1 yr of 
diagnosis (50%) 
 
<200 within 1 yr of 
diagnosis among those 
retained in care (76%) 
% 57% vs. 50% 
 
81% vs. 76% 
n/k  
Castillo, 2004, AIDS 
Care331 
Canada 1997-2002 
BC-CfE 
788 
ART-naïve 
initiating ART 
18% 
 
n/k Time to 2 consecutive 
<500 
HR 0.69 (0.55, 0.86) 0.80 (0.63, 1.01) Age, IDU, VL & CD4 at ART 
start, physician experience, 
pharmacy dispensing site 
Pence, 2008, JAIDS343 
US 2001-02  
CHASE 
474  
on ART, 
VL<400 at 
enrolment 
30% 
 
n/k Time to ≥400  HR n/k 0.92 (0.49, 1.74) Age, ethnicity, insurance, 1st 
line ART, time on regimen, 
alcohol, depression, drug 
use, trauma, recent stress, 
social support, self-efficacy 
 
Smith, 2007, JAIDS336 
UK 1996-2006 
RFHCS 
433  
ART-naïve 
initiating EFV-
based ART 
22% 
 
55% OT: 2 consecutive 
>500 by wk 48  
 
OT: 2 consecutive 
>500 by wk 96  
 
ITT: 2 consecutive 
>500 by wk 48 
 
%  
(95% CI) 
1.3% (0.0, 3.9) vs 
3.8% (1.6, 6.0)  
 
4.4% (0.0,9.3) vs 
5.8% (3.0,8.6) 
 
39% (29, 49) vs  
29% (24, 34) 
 
n/k  
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Publication 
Setting, Study years 
and Study Group b 
Study Viral outcome 
definition 
(prevalence) 
Estimate (95% CI) c 
Women vs Men 
Factors adjusted for 
  N % 
Women 
% 
MSM 
 Measure Unadjusted Adjusted  
ITT: 2 consecutive 
>500 by wk 96 
57% (46, 68) vs  
43% (38, 49) 
Red= VL outcomes of men were better than those of women; Green= VL outcomes of women were better than that of men; bold= estimates with an associated 
P-value<0.05. 
a Studies ordered by study size within each category (cross-sectional and longitudinal); b refer to list of relevant study acronyms on pages 10-11 for full study 
names; c estimates are standardised such that men are the reference group; d adjusted for adherence which is on the causal pathway; n/k=not known; NS= non-
significant association but no specific estimates given; yr=year; mth=month; wk=week; pyrs=person years; PI=Protease Inhibitor; NNRTI=Non-Nucleoside 
Reverse Transcriptase Inhibitor; EFV=efavirenz; OT=on treatment analysis; ITT=intent-to-treat analysis; CD4=CD4 cell count; IDU=injection drug use; 
HCV=hepatitis C virus; CI=Confidence Interval; OR=Odds Ratio; PR=Prevalence Ratio; HR=Hazard Ratio; RR=Risk Ratio; IRR= Incidence Rate Ratio. 
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 Immunological response to ART 
I identified fewer studies (seven) comparing immunological response to ART (as 
measured by changes in the CD4 count) between genders (Table 2.2). One study was 
conducted in the USA, and six were conducted in Western Europe. A global review 
identified four observational studies with a pooled risk ratio for immunological failure of 
0.83 for women compared to men329. Four of the seven studies found improved 
immunological outcomes for women127;338;341;344. In contrast, only one reported any 
evidence of improved CD4 count response among men compared to women at 12 
weeks after ART initiation, and this difference was not statistically significant (p=0.24) 
and did not persist in the longer-term336. This study had the highest proportion of men 
reporting sex between men as the likely route of HIV acquisition (71%). The two 
remaining studies found no evidence of differences in immunological response 
between men and women, however, these contained the smallest number of 
participants and so they may have had less power to detect gender differences335;340. 
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Table 2.2: Original research studies considering the association between CD4 outcomes and gender among people prescribed ART a 
Publication 
Setting, date and study 
b 
Study characteristics CD4 count 
outcome definition 
Estimate (95% CI) c d 
Women vs Men 
Factors adjusted for 
  n % 
Women 
% 
MSM 
 Measure Unadjusted Adjusted  
Althoff, 2010, AIDS338 
US and Canada 1998-
2008 
NA-ACCORD 
12,196  
ART-naïve 
initiating ART 
with VL>500 
17% 
 
n/k Time to 100 
increase 
HR n/k 1.13 (1.05, 
1.21) 
HIV acquisition risk, age, 
ethnicity, initial ART 
regimen, yr ART of start, 
VL and CD4 at ART start, 
prior AIDS diagnosis, 
cohort 
Smit, 2013, PLoS One341 
Netherlands 1996-2010 
ATHENA 
10,278  
ART-naïve 
initiating ART d 
16% 
 
59% 
 
Increase by 150 in 
first yr (70%) 
HR n/k 1.26 (1.14, 
1.38) 
Mode of HIV acquisition, 
age, region, time, VL and 
CD4 at ART start, ART 
regimen 
Kesselring, 2010, Antivir 
Ther344 
Netherlands 1996-2009 
ATHENA 
6,057  
ART-naïve 
initiating ART 
with VL <400 by 
9 mths, exclude 
if 2 VL≥400 or 
>30d not on 
ART 
19% 
 
56% Change 0 to 6 mths 
 
Change 6 mths to 3 
yrs 
Mean 
difference 
 
+26, p<.0001 
 
+35, p<.0001 
 
n/k  
Collazos, 2007, AIDS127 
Spain 1998-99 
GEEMA 
2,620  
initiating 
nelfinavir 
regimen with 
VL>200 
28% 
 
14% Change at 1 yr  
 
Median ARV experienced: 
+91 vs. +81, p=0.1 
ARV naïve: +212 vs. 
+147 p=0.002 
n/k  
Moore, 2003, JAIDS335 
Europe 1999-2001 
EuroSIDA 
2,548  
PI and NNRTI 
naïve initiating 
ART 
20% 48% Time to 100 
increase 
HR 
 
0.96  
(0.86, 1.70) 
1.02 (0.88, 
1.14) 
 
HIV acquisition risk, age, 
ethnicity, geographical 
region, treatment history, 
VL and CD4 at ART start, 
prior AIDS diagnosis  
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Publication 
Setting, date and study 
b 
Study characteristics CD4 count 
outcome definition 
Estimate (95% CI) c d 
Women vs Men 
Factors adjusted for 
  n % 
Women 
% 
MSM 
 Measure Unadjusted Adjusted  
Nicastri, 2005, AIDS340 
Italy 1996-99 
IATG 
2,460 PI and 
NNRTI naïve 
initiated PI-
based ART with 
VL>500 
28% 
 
15% 
 
1 yr  
 
 
2 yrs 
 
 
3 yrs 
 
 
4 yrs 
Median 
(IQR) 
336 (219-528) vs. 
313 (181-488) 
 
414 (252-590) vs. 
375 (226-569) 
 
437 (282-630) vs. 
407 (250-613) 
 
465 (277-632) vs. 
430 (267-651) 
n/k  
Smith, 2007, JAIDS336 
UK 1996-2006 
RFHCS 
433  
ART-naïve 
initiated EFV 
containing 
regimen 
22% 
 
55% 
 
Change at 12 wks  
 
 
 
Change at 48 wks  
 
 
Change at 120 wks 
Median 
(IQR) 
+87 (+44, +54) vs. 
+104 (+53, +173), 
p=0.24 
 
+166 (+89, +239) vs. 
+176 (+93, +263) 
 
+303 (+171, +414) 
vs. +249 (+124, 
+375), p=0.33 
n/k  
  
 
 
  
Red= CD4 count outcomes of men were better than those of women; Green= CD4 count outcomes of women were better than that of men; bold= estimates with 
an associated P-value<0.05. 
a Studies ordered by study size within each category (cross-sectional and longitudinal); b refer to list of relevant study acronyms on pages 10-11 for full study 
names; c estimates are standardised such that men are the reference group; d CD4 count estimates in cells/µL; n/k=not known; yrs=years; mths=months; 
wks=weeks; PI=Protease Inhibitor; NNRTI=Non-Nucleoside Reverse Transcriptase Inhibitor; EFV=efavirenz; CD4=CD4 cell count; CI=Confidence Interval; 
HR=Hazard Ratio; IQR=Interquartile Range. 
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 ART non-adherence 
In a previous literature review of 44 observational studies, in high-income or upper-
middle income countries, published between 2000 and 2011, 30 found poorer 
adherence to ART among women than men, though only nine of these reached 
statistical significance345. Only one found lower adherence among men compared to 
women. The authors noted that all studies which used a cut-off of 100% or ≥95% 
adherence as constituting “good” adherence found women had a lower mean 
adherence than men, but studies using cut offs of ≥90% or ≥80% found that women 
had a higher mean adherence.  
A summary of studies of the association between gender and ART adherence are 
displayed in Table 2.3. Five cross-sectional observational studies were considered 
(one from Switzerland and four from USA/Canada). All studied individuals on ART, 
regardless of length of exposure, and had a self-reported adherence outcome. All 
found that women had higher odds of self-reported ART non-adherence compared to 
men, with adjusted odds ratios varying from 1.14 to 1.68346-350.  
There were also five longitudinal observational studies, with far more mixed findings 
than the cross-sectional studies. Three, from the USA, had objective endpoints of 
prescription refill351 and MEMS352;353 and each found lower adherence in women than in 
men. One Spanish study127 considered self-reported adherence and found no 
evidence of differences between genders. The population studied in this case included 
the highest number of IDU and lower number of MSM of any of the studies considered. 
Finally, a large study of over 6000 participants from the SHCS considered changes in 
adherence354. Women had 10% greater odds of worsening adherence and 16% 
greater odds of improving adherence compared to men in adjusted analyses. This 
study was inconclusive about the effect of gender on changes in adherence. However, 
this was not the focus of the study, so unadjusted results were not reported and the 
adjusted model included a large number of variables.  
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Table 2.3: Original research studies considering the association between adherence to ART and gender among people prescribed ART a 
Publication 
Setting, date and study 
b  
Study Non-adherence outcome 
definition 
OR (95% CI) Women vs Men c d Factors adjusted for 
 n % 
Women 
% 
MSM 
Self-
report 
Definition 
(prevalence) 
Unadjusted Adjusted  
Cross-sectional 
Glass, 2006, JAIDS346 
Switzerland 2003 
SHCS 
3,607 on 
ART ≥6 
mths 
29% 
 
n/k Yes Missed ≥1 dose last 
4 wks (31%) 
1.20 (1.03, 1.41) 1.14 (0.95, 1.45) 
 
Age, ethnicity, living alone, 
education, time on ART, current 
IDU, psychiatric treatment, 
lipodystrophy, number previous 
regimens, dose frequency, 
current regimen 
Missed ≥2 doses last 
4 wks (15%) 
1.23 (1.01, 1.49) 
 
1.11 (0.88, 1.39) 
 
<95% last 4 wks (7%) 1.28 (0.98, 1.69) 1.02 (0.74, 1.39) 
Beer, 2012, Open AIDS 
J347 
US 2007-08 
MMP 
3,307  
on ART 
25% 
 
n/k Yes <100% dose last 48 
hrs (13%) 
1.55 (1.24, 1.92) 1.36 (1.07, 1.74) 
 
Age, ethnicity, education, public 
assistance, depression, crack 
use, homelessness, 
amphetamine use, binge drinking, 
time on ART, dose frequency, 
time since diagnosis, knew VL, 
resistance discussed 
<100% schedule last 
48 hrs (27%) 
1.66 (1.40, 1.97) 1.46 (1.20, 1.76) 
<100% instruction 
last 48 hrs (30%) 
NS NS 
Raboud, 2011, AIDS 
Behav348 
Canada 
2007-09  
OCS 
779  
on ART 
15% 
 
69% Yes <100% last 4 dys 
(15%) 
1.45 (0.88, 2.44) N/A N/A 
O'Neil, 2012, J Int Assoc 
Physicians AIDS Care349  
Canada 2007-10 
LISA 
556  
on ART  
27% 
 
n/k No Prescription refill 
<95% 1 yr (44%) 
n/k 1.68 (1.07, 2.64) Age, ethnicity, education, income, 
housing stability, IDU, history of 
incarceration, depressive 
symptoms, illicit drug use, 
methadone treatment, ART 
frequency, medication, memory 
aids, in assisted therapy program 
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Publication 
Setting, date and study 
b  
Study Non-adherence outcome 
definition 
OR (95% CI) Women vs Men c d Factors adjusted for 
 n % 
Women 
% 
MSM 
Self-
report 
Definition 
(prevalence) 
Unadjusted Adjusted  
Kyser, 2011, AIDS 
Care350 
US 2004-06 
SUN 
528  
on ART 
22% 
 
56% Yes <100% last 3 dys 
(16%) 
1.68 (1.00, 2.82) 1.21 (0.53, 2.79) Ethnicity, education, employment, 
time since HIV diagnosis, suicidal 
ideation, mental and physical 
health scores, alcohol use, 
marijuana use, cocaine use, 
tobacco use, exercise 
Longitudinal 
Glass, 2010, JAIDS354 
Switzerland 2003-09 
SHCS 
6,709 on 
ART 
30% 
 
38% Yes 100% to <100% last 
4 wks 2 
measurements 6 
mths apart (17%) 
 
<100% to 100% last 
4 wks 2 
measurements 6 
mths apart (18%) 
n/k 
 
 
1.10 (0.98, 1.23) 
 
 
 
 
1.16 (0.97, 1.39) 
 
Age, ethnicity, education, living 
alone, stable partnership, IDU, 
drug maintenance program, 
alcohol, smoking, started riskier 
sex, psychiatric treatment, 
released from prison, 
hospitalised, co-medication, time 
living with HIV, change in ART, 
regimen frequency, time on ART, 
lipodystrophy, change in 
physician, adherence at first visit 
Silverberg, 2009, J Gen 
Intern Med351 
US 1996-2005 
KPNC 
 
4,686 
initiating 
ART 
10 % 
 
64% No Prescription refill 
difference in mean 
over 2 yrs since ART 
initiation 
n/k 
 
-4.2% (-7.2%, -
1.2%), p=0.006 
Mode of HIV acquisition, age, 
ethnicity, insurance, 
neighbourhood SES, yr ART 
initiation, VL and CD4 at ART 
start, ART experience, ART 
regimen, HCV, depression, 
comorbidities 
Collazos, 2007, AIDS127 
Spain 1998-99 
GEEMA 
2,620 
initiating 
NFV-
based 
ART with 
VL>200 
28% 
 
14% Yes <100% last 3 mths 
(at 3, 6, 9 mths after 
ART initiation) 
n/k but no 
association 
(p=0.1 to p=0.9) 
n/k  
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Publication 
Setting, date and study 
b  
Study Non-adherence outcome 
definition 
OR (95% CI) Women vs Men c d Factors adjusted for 
 n % 
Women 
% 
MSM 
Self-
report 
Definition 
(prevalence) 
Unadjusted Adjusted  
Simoni, 2012, JAIDS353 
US 1997-2009  
MACH14 
1,809 on 
ART 
33% 
 
n/k No MEMS mean over 4-
wk periods  
 
65% vs. 69% 0.96 (0.83, 1.11) Age, ethnicity, site, education, 
income, substance use, 
depression 
Berg, 2004, J Gen Intern 
Med352 
US 1998-2001 
HERO 
113 
current/ 
former 
opioid 
users 
43% 
 
n/k No MEMS median 
across study period  
46% (18%-77%) 
vs 
73% (30%-93%), 
p=0.04 
n/k  
  
Red= adherence outcomes of men were better than those of women; Green= adherence outcomes of women were better than that of men; bold= estimates 
with an associated P-value<0.05. 
a Studies ordered by study size within each category (cross-sectional and longitudinal); b refer to list of relevant study acronyms on pages 10-11 for full study 
names; c estimates are standardised such that men are the reference group; d standardised such that non-adherence is the outcome; OR=Odds Ratio; 
CI=Confidence Interval; n/k=not known; NS= non-significant association but no specific estimates given; N/A=not applicable; yr/s=year/s; mths=months; 
wks=weeks; dys=days; hrs=hours; NFV=nelfinavir; MEMS=Medical Event Monitoring System; CD4=CD4 cell count; IDU=injection drug use; HCV=hepatitis C 
virus. 
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 Review of the literature on gender/sexual orientation and 
HIV treatment outcomes 
This section of my literature review evaluated studies that have considered the 
association of HIV treatment outcomes with gender/sexual orientation, as a combined 
variable. 
 Virological response to ART 
Fifteen studies considered the association between gender/sexual orientation and 
virological response to ART126;355-368, of which four were cross-sectional and 11 
longitudinal. The results of these studies are summarised in Table 2.4.  
MSW vs MSM 
When focusing on the comparison between the two male groups, eight of nine studies 
which considered the outcome of virological suppression found that MSW had a lower 
prevalence355;356, lower adjusted odds (aOR varying between 0.54 to 0.80357-359), or 
lower adjusted rate (aHR=0.83-0.91360-362) of virological suppression compared to 
MSM. The US-based HIV Outpatient Study (HOPS) did not find a difference in time to 
virological suppression between MSW and MSM despite a higher prevalence of late 
diagnosis among MSW363. There are a number of potential explanations for the 
difference of the HOPS results to the rest of the literature. Since only individuals who 
were linked to care and enrolled in the HOPS within six months of diagnosis were 
included, it may have resulted in the inclusion of individuals with more favourable 
virological outcomes. HOPS was the study with the fewest number of participants 
(N=926), although the differences were not so imprecise that this could explain the 
difference. In contrast to the other studies, HOPS adjusted for insurance status and 
private vs. public clinic, thus it is possible that these differences could have explained 
the differences between MSW and MSM in this study. 
Of four studies which considered virological non-suppression/failure, three found 
poorer virological response to ART among MSW compared to MSM362;364;365. Two of 
these were in the RFHCS, the setting of some chapters in this thesis and one in the 
French Agence Nationale se Recherches sur le Sida (ANRS) study. On the other 
hand, in the Collaboration of Observational HIV Epidemiological Research Europe 
(CASCADE) study, there was no evidence of a difference in the rate of initial 
virological non-suppression/ rebound366. This study included a particularly high 
proportion of MSM compared to the other studies (74%) and a small proportion of 
MSW (11%), and was a seroconverters cohort. In addition, the study population 
included individuals in low-income countries (sub-Saharan Africa) as well as high-
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income countries, and associations of gender/sexual orientation may not have been 
generalisable between high- and low-income countries.  
In the SHCS, latent class analysis was used to allocate individuals into seven groups 
by highest membership probability357. Older MSW and single heterosexual migrants 
had aORs of 0.54 and 0.58 for VL suppression after six months of ART compared to 
MSM, respectively. However, when those who acquired HIV through heterosexual sex 
were considered as a single group, they had a more attenuated aOR of 0.72 
compared to MSM. The results of this study provide some support for analysing 
groups with demographic factors in mind rather than solely by mode of HIV acquisition. 
Women vs MSM 
Of eight studies which considered initial virological suppression as an outcome, five 
found evidence of a lower prevalence355;356, odds358;359, or rate361 among women 
compared to MSM. These studies took place in both US-based355;356 and 
European358;359;361 observational cohorts. On the other hand, in the North American 
AIDS Cohort Collaboration on Research and Design (NA-ACCORD)360 study, the 
RFHCS362, and HOPS363 there was no evidence of a difference. Previous studies have 
observed more frequent VL monitoring among men330;369;370 or MSM371 compared to 
women or heterosexuals, respectively; therefore, since all three studies used time-to-
event analyses, the results are potentially subject to bias. Additionally, two of these 
studies restricted participation to individuals who had a timely ART initiation/linkage to 
care360;363 which may have resulted in selection bias, and hence accounted for any 
differences.  
Two of three studies considering endpoints of virological failure found women had 
poorer outcomes compared to MSM: in the RFHCS362 (aHR=3.3 and 4.7) and the 
ANRS study (aOR=6.9 among migrant women vs. MSM)364. Similarly to the 
comparison between MSW and MSM, the CASCADE study did not find any evidence 
of a difference between initial virological non-suppression/rebound in women and 
MSM366. 
Women vs MSW 
All six studies comparing virological suppression outcomes between women and MSW 
found little evidence of a difference between women and MSW. In three studies there 
was no difference in the odds or prevalence of virological suppression355;361;368 and, 
though in two further studies there were differences in unadjusted analyses (in 
opposite directions), these were attenuated by adjustment for baseline factors126;367. 
The remaining study from the RFHCS showed weak evidence of a higher rate of 
virological suppression among women362. 
74 
 
Two UK-based studies additionally considered an outcome of virological 
failure/rebound and found some evidence of a greater rate of VL failure among women 
compared to MSW362;367. Adjustment for baseline factors (including demographics, VL 
and CD4 count at ART initiation) substantially attenuated any associations. However, 
when pregnant women were excluded from the UK CHIC study, men had a 33% 
higher rate of virological rebound than the remaining women367. This and other studies 
have shown that part of the reason for a higher prevalence of rebounds among women 
are the greater ART discontinuations among postpartum women and poorer ART 
adherence in pregnancy372.
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Table 2.4: Original research studies considering the association between virological outcomes and gender/sexual orientation among people prescribed ART a b 
Publication 
Setting, date 
and study c 
Study 
characteristics 
Viral outcome 
definition 
(prevalence) 
Prevalence of 
gender/sexual 
orientation groups 
Main results: 
Estimate (95% CI) d 
Factors adjusted for 
   Group % Measure Unadjusted Adjusted  
Cross-sectional         
Hall 2013, JAMA 
Intern Med355 
US 2009 
MMP and NHSS 
378906 
prescribed ART 
in US in 2009 
Most recent <200 
(78%) 
MSM 
MSW 
WSM 
PWID 
52% 
9% 
18% 
16% 
% 82% 
74% 
74% 
- 
n/k  
Cohen 2014, 
JAIDS356 
US 2010 
NHSS 
42363  
≥1 CD4 or VL in 
2010 with any 
further tests <3 
mths apart 
Most recent <200 
(48% of engaged 
in care; 74% of 
retained in 
continuous care) 
MSM 
MSW 
WSM 
PWID 
Other 
51% 
7% 
17% 
23% 
2% 
PR 1.00 
0.94 (0.93, 0.95) 
0.92 (0.91, 0.92) 
- 
- 
n/k  
D’Almeida, 2016, 
Antivir Ther359 
France 2011-12 
ANRS-VESPA2 
1246  
on ART ≥12 
mths 
<50 for at least 6 
mths (78%) 
MSM 
non-African MSW 
non-African WSM 
MSW from SSA 
WSM from SSA 
PWID 
35% 
15% 
11% 
12% 
24% 
3% 
OR 1.00 
1.0 (0.6, 1.5) 
0.8 (0.4, 1.4) 
0.5 (0.3, 0.9) 
0.7 (0.5, 1.1) 
- 
1.00 
1.2 (0.6, 2.1) 
1.7 (0.9, 3.4) 
0.8 (0.4, 1.7) 
1.0 (0.5, 2.0) 
- 
Employment status, material 
deprivation, education, health 
literacy, social network, late 
ART initiation, HIV-related 
discrimination, ART 
adherence e 
Dray-Spira 2007, 
AIDS364 
France 2002-03 
ANRS-VESPA 
896  
on ART ≥6 mths 
Detectable and 
CD4<200 (3.4%) 
MSM 
French MSW 
French WSM 
migrant MSW 
migrant WSM 
PWID 
38% 
17% 
10% 
11% 
11% 
12% 
% and 
OR 
1.4% 
4.1% 
0.9% 
6.7% 
4.1% 
- 
1.00 
2.75 (0.68, 11.1) 
0.63 (0.07, 6.09) 
8.23 (1.77, 38.3) 
6.91 (1.03, 46.3) 
- 
Age, pre 1996 diagnosis, 
time on ART, AIDS at ART 
start, HCV, VL & CD4 at ART 
start, depressive symptoms, 
current drug use, HIV care 
interruption, ART adherence e 
Longitudinal         
Hanna 2013, 
CID360 
US and Canada 
2001-09 
NA-ACCORD 
5329  
ART-naïve, 
initiating ART 
within 6 mths of 
eligibility 
Time to <500 
within 12 mths of 
ART start (55% in 
2001, 81% in 
2009) 
MSM 
MSW 
Women 
PWID 
 
43% 
20% 
22% 
15% 
HR n/k 1.00 
0.91 (0.84, 0.99) 
0.99 (0.91, 1.08) 
- 
Age at eligibility, ethnicity, 
eligibility criteria, 
psychosocial barriers, yr 
eligibility, province residence, 
VL at eligibility 
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Publication 
Setting, date 
and study c 
Study 
characteristics 
Viral outcome 
definition 
(prevalence) 
Prevalence of 
gender/sexual 
orientation groups 
Main results: 
Estimate (95% CI) d 
Factors adjusted for 
   Group % Measure Unadjusted Adjusted  
Zugna 2012, 
Antivir Ther366 
Canada, 
Australia, 
Europe, Africa 
2011 CASCADE 
4337  
ART-naïve, on 
ART ≥90 dys  
>500 six mths 
after ART start or 
<500 at 6 mths 
followed by two 
>1000 (10%) 
MSM 
MSW 
Women 
Other  
74% 
11% 
13% 
1% 
HR n/k 1.00 
0.91 (0.65, 1.27) 
1.07 (0.80, 1.43) 
- 
Age, ART regimen, VL and 
CD4 at ART start, started 
ART within yr of 
seroconversion, yr ART start 
Rosin, 2014, HIV 
Med126 
Switzerland 
1998-2011 SHCS 
3,925  
ART-naïve 
initiating ART 
<50 at 1 yr (77%) MSW 
Women  
 
50% 
50% 
OR 1.00 
0.83 (0.72, 0.96) 
1.00 
0.87 (0.73, 1.04) 
Age, ethnicity, IDU, 
education, time, VL and CD4 
at ART start, previous AIDS, 
HCV 
Barber, 2011, 
Antivir Ther367 
UK 1998-2007  
UK CHIC 
3,666  
ART-naïve 
initiating ART 
Time to <50  
 
 
Time to two 
subsequent >500 
 
<50 at 6 mths 
 
 
<50 at 12 mths 
MSW 
Women 
 
MSW 
Women 
 
MSW 
Women 
 
MSW 
Women 
41% 
59% 
HR 
 
 
HR 
 
 
OR 
 
 
OR 
1.00 
1.12 (1.04, 1.22) 
 
1.00  
1.30 (1.08, 1.59) 
 
1.00  
0.95 (0.81, 1.12) 
 
1.00  
0.81 (0.68, 0.96) 
1.00 
1.06 (0.97, 1.16) 
 
1.00 
0.85 (0.68, 1.08) 
 
1.00 
1.09 (0.88, 1.32) 
 
1.00 
0.94 (0.76, 1.18) 
Age, ethnicity, ART regimen 
type, yr ART start, VL and 
CD4 at ART start, previous 
AIDS diagnosis 
Costagliola, 
2012,  
Lancet Infect 
Dis358 
Europe 2000-09 
COHERE 
2,476 started 
ART, previously 
had TCVF f 
<50 after TCVF e 
(17% in 2000, 
49% in 2008) 
MSM 
MSW 
Women 
PWID 
28% 
21% 
26% 
14% 
OR 1.00  
0.77 (0.66, 0.91) 
0.67 (0.57, 0.78) 
- 
1.00  
0.77 (0.64, 0.93) 
0.63 (0.52, 0.75) 
- 
Age, VL and CD4 at TCVF f, 
AIDS diagnosis, previous 
VL<50, drug failures before 
TCVF f 
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Publication 
Setting, date 
and study c 
Study 
characteristics 
Viral outcome 
definition 
(prevalence) 
Prevalence of 
gender/sexual 
orientation groups 
Main results: 
Estimate (95% CI) d 
Factors adjusted for 
   Group % Measure Unadjusted Adjusted  
Fardet 2006, HIV 
Med361 
France 1997-
2001  
ANRS 
2,225 
prescribed ART, 
started ART 
with VL>500 
Time to <500 
 
MSM 
MSW 
WSM 
PWID 
Other 
 
WSM 
MSW 
32% 
20% 
26% 
10% 
12% 
HR n/k 1.00  
0.86 (0.73, 0.98) 
0.89 (0.75, 0.98) 
- 
- 
 
1.00 
1.04 (0.89, 1.21) 
Age, ART type, VL and CD4 
at ART start, period of ART 
start 
Lampe 2007, 
Arch Intern 
Med365 
UK 1999-2004 
RFHCS 
1,698  
On ART 
 
>50 in yr (36.9% 
in 1999- 14.5% in 
2004) 
 
 
 
>50 received 
ART for ≥24 wks 
(31.2% in 1999 – 
10.1% in 2004) 
MSM 
White MSW 
White women 
Non-white MSW 
Non-white women 
 
MSM 
White MSW 
White women 
Non-white MSW 
Non-white women 
63% 
4% 
5% 
10% 
17% 
RR n/k 1.00  
n/k 
n/k 
1.35 (1.15, 1.59) 
n/k 
 
1.00 
n/k 
n/k 
1.42 (1.14, 1.82) 
n/k  
Age, calendar period, time 
since first clinic visit 
 
Keiser 2013, 
AIDS Behav357 
Switzerland 
2000-08 
SHCS 
1,180  
ART-naïve 
initiating ART, 
≥6 mths follow-
up 
<50 6 mths after 
ART initiation 
(75.3%) 
older MSM 
young MSM 
MSW and WSM 
Older MSW 
PWID 
Single migrants 
Migrant women in 
partnership 
 
MSM (all) 
Heterosexual (all) 
35% 
4% 
20% 
10% 
13% 
10% 
9% 
OR 1.00  
2.11 (0.73, 6.12) 
0.79 (0.55, 1.15) 
0.69 (0.44, 1.08) 
- 
0.50 (0.31, 0.82) 
0.82 (0.50, 1.35) 
 
 
1.00  
0.70 (0.52, 0.94) 
1.00  
2.52 (0.84, 7.56) 
0.80 (0.54, 1.18) 
0.54 (0.32, 0.93) 
- 
0.58 (0.34, 0.99) 
0.97 (0.56, 1.66) 
 
 
1.00  
0.72 (0.50, 1.03) 
Age, ART type, VL and CD4 
at ART start, HIV stage 
 
 
 
 
 
 
 
Additionally adjusted for 
gender 
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Publication 
Setting, date 
and study c 
Study 
characteristics 
Viral outcome 
definition 
(prevalence) 
Prevalence of 
gender/sexual 
orientation groups 
Main results: 
Estimate (95% CI) d 
Factors adjusted for 
   Group % Measure Unadjusted Adjusted  
Saunders 2015, 
HIV Med362 
UK 2006-12 
RFHCS 
1,086  
ART-naïve 
initiating ART 
Time to <50 
 
 
 
 
 
 
Time to two 
consecutive >200 
after >6 mths 
ART (censored at 
discontinuation) 
 
 
Time to two 
consecutive >200 
after >6 mths 
ART 
MSM 
MSW 
Women  
 
MSW 
Women 
 
MSM 
MSW 
Women 
 
MSW 
Women 
 
MSM 
MSW 
Women 
 
MSW 
Women 
52% 
19% 
29% 
HR 1.00  
0.91 (0.77, 1.08) 
1.04 (0.91, 1.20) 
 
1.00 
1.14 (0.95, 1.37) 
 
1.00  
2.03 (1.12, 3.69) 
3.13 (1.92, 5.10) 
 
1.00 
1.54 (0.88, 2.70) 
 
1.00 
1.58 (0.99, 2.52) 
2.98 (2.09, 4.25) 
 
1.00 
1.89 (1.20, 2.94) 
1.00  
0.83 (0.67, 1.03) 
0.95 (0.78, 1.17) 
 
1.00 
1.15 (0.93, 1.41) 
 
1.00  
3.64 (1.69, 7.83) 
4.74 (2.29, 9.84) 
 
1.00 
1.30 (0.70, 2.44) 
 
1.00 
2.32 (1.28, 4.22) 
3.28 (1.91, 5.64) 
 
1.00 
1.41 (0.86, 2.33) 
Age, ethnicity, ART 
backbone, pre-ART VL and 
CD4, yr starting ART, time 
from diagnosis to ART start 
Novak 2015, 
JAIDS363 
US 2000-13 
HOPS 
926  
ART-naïve 
initiating ART 
Time to first <500 MSM  
MSW  
Women 
Other 
53% 
17% 
23% 
8% 
HR 1.00  
0.9 (0.7, 1.1) 
0.8 (0.7, 1.0) 
- 
1.00  
1.1 (0.8, 1.3) 
1.0 (0.8, 1.2) 
- 
Age, ethnicity, IDU, 
insurance, private or public 
clinic, date diagnosis, VL and 
CD4 at ART start 
Thorsteinsson, 
2012, BMC Infect 
Dis368 
Denmark 1997-
2009 
DHCS 
908  
initiating ART 
<500 at 1 yr 
 
 
<500 at 3 yrs 
 
 
<500 at 6 yrs 
MSW 
Women 
 
MSW 
Women 
 
MSW 
48% 
52% 
%  
and  
OR 
92% 
83% 
 
87% 
82% 
 
87% 
1.00 
0.81 (0.47, 1.39) 
 
1.00 
1.09 (0.62, 1.89) 
 
1.00 
Age, ethnicity, period of ART 
initiation, previous AIDS 
diagnosis 
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Publication 
Setting, date 
and study c 
Study 
characteristics 
Viral outcome 
definition 
(prevalence) 
Prevalence of 
gender/sexual 
orientation groups 
Main results: 
Estimate (95% CI) d 
Factors adjusted for 
   Group % Measure Unadjusted Adjusted  
Women  83% 1.15 (0.54, 2.44) 
  
 
 
 
 
 
Blue= MSM had improved virological outcomes than other gender/sexual orientation group; Red= MSW had improved virological outcomes than other 
gender/sexual orientation group; Green= Women had improved virological outcomes than other gender/sexual orientation group; bold= estimates with an 
associated P-value<0.05. 
a Studies recruited not entirely before 2001, with sample size >100; b studies ordered by study size within each category (cross-sectional and longitudinal); c refer to 
list of relevant study acronyms on pages 10-11 for full study names; d estimates are standardised such that the MSM is the reference group; e adjusted for 
adherence which is on the causal pathway; f TCVF=Triple class virological failure: VL>500 despite ≥4 months continuous ART use to at least 1 PI, 1 NNRTI and 2 
NRTI; MSM= men who have sex with men; MSW= men who have sex with women; WSM= women who have sex with men; PWID= people who inject drugs; 
n/k=not known; yr/s=year/s; mths=months; wks=weeks; IDU= injection drug use; HCV=hepatitis C virus; CI=Confidence Interval; PR=Prevalence Ratio; OR=Odds 
Ratio; HR=Hazard Ratio; RR=Risk Ratio.  
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 Immunological response to ART 
My literature review identified seven studies investigating the association between 
gender/sexual orientation and CD4 count response to ART126;361;362;364;365;367;368. All 
seven were longitudinal studies that took place in European settings (Table 2.5). 
MSW vs MSM 
There was evidence of a poorer CD4 count response to ART among MSW compared 
to MSM in three of four studies which included MSM361;364;365, whereas the remaining 
study found this in the shorter term but not the longer-term362. In a cross-sectional UK 
study, black African MSW had 2.4 times the adjusted risk of a CD4 count <200 
cells/µL compared to MSM among individuals in care365. Though the proportion of 
white MSW with low CD4 count was consistently above that of MSM, there was no 
direct comparison of MSM and white MSW made. The results of another UK-based 
study found differences between MSM and MSW at 12 months but not at 24 
months362, potentially reflecting the lower pre-ART CD4 counts among MSW. 
Women vs MSM 
All three studies comparing the CD4 count response on ART of women and MSM 
found that women had poorer outcomes361;362;364. Dray-Spira et al. found that migrant 
women had over twice the odds of failure to increase CD4 count by 100 cells/µL 
compared to MSM, even after adjustment for adherence to ART364. However, the 
outcomes of non-migrant women and MSM were similar. In another French study, 
similarly, there was evidence that heterosexual women took longer to see an increase 
in CD4 count of 100 cells/µL361. In a UK-based study, women had smaller median 
changes in CD4 count one and two years after ART initiation compared to MSM, 
suggesting that differences extend at least into the medium term.  
Women vs MSW 
Six studies looked at differences in CD4 count response between women and MSW, 
of which all six were in Europe – five amongst those initiating ART and one amongst 
those on ART for at least six months. Three found poorer responses among 
MSW126;364;367, two found no differences361;368, and one found mixed results362. The 
study with mixed results was the RFHCS, which found that MSW had smaller 
increases in CD4 count at 12 months after ART initiation compared to women, but 
larger increases in CD4 count at 24 months362. This was despite similar median CD4 
counts at ART initiation in these groups. Two studies from the same French cohort 
which had the same outcome of CD4 count increases >100 cells/µL, had conflicting 
results. In one, a greater proportion of MSW migrants and non-migrants had an 
absence of an 100 cells/µL CD4 count increase compared to migrant and non-migrant 
81 
 
women respectively364; however, others, which did not divide the population into 
migrants and non-migrants, found no evidence of differences between the groups361. 
These studies also had other differences that could account for the disparate results. 
The study that did not find differences between MSM and women: included individuals 
initiating ART rather than those on ART for at least six months; adjusted for calendar 
time; and did not adjust for ART adherence, AIDS at ART initiation, HCV diagnosis, 
drug use, depressive symptoms, or HIV care interruptions.  
 
82 
 
Table 2.5: Original research studies considering the association between CD4 outcomes and gender/sexual orientation among people prescribed ART a b 
Publication 
Setting, date and 
study c 
Study CD4 count 
outcome 
definition 
Prevalence of 
Gender/sexual 
orientation groups 
Main results: 
Estimate (95% CI) d 
Factors adjusted for 
   Group % Measure Unadjusted Adjusted  
Longitudinal          
Barber, 2011, 
Antivir Ther367 
UK 1998-2007 
UK CHIC 
3,666 
ART-
naïve 
initiating 
ART  
6 mths  
 
 
Change at 6 mths  
 
 
1 yr 
 
 
Change at 1 yr 
MSW 
Women 
 
MSW 
Women 
 
MSW 
Women 
 
MSW 
Women 
41% 
59% 
Median (IQR)  
and  
mean 
difference 
230 (140-330) 
272 (170-397)p=0.0001 
 
108 (52-170), 
118 (54-192) p=0.003 
 
279 (179-380) 
310 (211-429)p=0.0001 
 
150 (80-231) 
160 (81-248) p=0.16 
n/k 
 
 
0.0 
+14.6 (+4.5, +24.6) 
 
n/k 
 
 
0.0 
+12.1 (-0.2, +24.4) 
Age, ethnicity, ART 
regimen type, yr ART 
start, VL and CD4 at 
ART start, previous 
AIDS  
Rosin, 2014, HIV 
Med126 
Switzerland 1998-
2011 
SHCS 
3,925 
ART-
naïve 
initiating 
ART  
Change at 1 yr MSW 
women 
50% 
50% 
Median (95% 
CI) 
and  
mean 
difference 
(95% CI) 
140 (64, 247) 
170 (78, 269)  
0.0 
+17 (+5, +29) 
Age, ethnicity, IDU, 
education, time, VL 
and CD4 at ART 
start, previous AIDS, 
HCV  
Fardet 2006, HIV 
Med361 
France 1997-2001  
ANRS 
2,491 
started 
ART 
during 
follow-up 
Time to increase 
≥100  
 
MSM 
MSW 
WSM 
PWID 
other 
 
Women vs MSW 
32% 
20% 
26% 
10% 
12% 
HR n/k 1.00 
0.86 (0.76, 1.00) 
0.83 (0.73, 0.95) 
- 
- 
 
0.97 (0.83,1.12) 
Age, type of ART, VL 
and CD4 at study 
initiation, time 
Lampe 2007, Arch 
Intern Med365 
UK 
1999-2004 
2,386  
clinic 
populatio
n 
Percent with 
<200 in calendar 
yr 
MSM 
White MSW 
White women 
non-white MSW 
63% 
4% 
5% 
10% 
RR n/k 1.00 
n/k  
n/k 
2.38 (2.00, 2.94) 
Age, calendar period, 
time since first clinic 
visit 
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Publication 
Setting, date and 
study c 
Study CD4 count 
outcome 
definition 
Prevalence of 
Gender/sexual 
orientation groups 
Main results: 
Estimate (95% CI) d 
Factors adjusted for 
   Group % Measure Unadjusted Adjusted  
RFHCS non-white women 17% n/k 
Saunders 2015, 
HIV med362 
UK 
2006-12 
RFHCS 
1,086 
ART-
naïve 
initiating 
ART  
Change at 1 yr 
 
 
 
Change at 2 yrs 
MSM 
MSW 
Women  
 
MSM 
MSW 
Women 
52% 
19% 
29% 
Median (IQR) 222 (113, 332) 
174 (83, 294) 
190 (108, 270)p<.0001 
 
278 (153, 407) 
274 (152, 408) 
266 (155, 378)p<.0001 
N/A N/A 
Thorsteinsson, 
2012, BMC Infect 
Dis368 
Denmark 
1997-2009 
DHCS 
908 
initiating 
ART 
1 yr 
 
 
3 yrs 
 
 
6 yrs 
MSW 
Women 
 
MSW 
Women 
 
MSW 
Women 
48% 
52% 
Median 360 (220-510)  
330 (210-457) 
 
469 (318-656) 
459 (316-600)  
 
582 (382-793) 
530 (380-696) 
p=0.9 
 
 
p=0.9 
 
p=0.9 
Age, ethnicity, period 
of ART initiation, 
previous AIDS 
diagnosis 
Dray-Spira 2007, 
AIDS364 
France 
2002-03 
ANRS-VESPA 
896  
on ART 
for ≥6 
mths 
Absence of ≥100 
increase between 
ART initiation and 
data collection 
MSM  
French MSW 
French WSM 
migrant MSW 
migrant WSM 
PWID  
38% 
17% 
10% 
11% 
11% 
12% 
%  
and  
OR 
16.4% 
10.6% 
13.4% 
27.4% 
37.5% 
- 
1.00 
0.73 (0.39, 1.33) 
0.93 (0.45, 1.91) 
2.27 (1.14, 4.56) 
2.19 (1.17, 4.08) 
- 
Age, VL & CD4 at 
ART start, drug use, 
HCV, time on ART, 
diagnosis pre 1996, 
depression, HIV care 
interruptions, ART 
adherence e 
  
 
 
Blue= MSM had improved CD4 outcomes than other gender/sexual orientation group; Red= MSW had improved CD4 outcomes than other gender/sexual 
orientation group; Green= Women had improved CD4 outcomes than other gender/sexual orientation group; bold= estimates with an associated P-
value<0.05. 
a Studies recruited not entirely before 2001, with sample size >100; b studies ordered by study size; c refer to list of relevant study acronyms on pages 10-11 
for full study names; d estimates are standardised such that the MSM is the reference group; e adjusted for adherence which is on the causal pathway; MSM= 
men who have sex with men; MSW= men who have sex with women; WSM= women who have sex with men; PWID= people who inject drugs; yr/s=year/s; 
mths=months; HCV=hepatitis C virus; CI=Confidence Interval; OR=Odds Ratio; HR=Hazard Ratio; RR=Risk Ratio. 
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 ART non-adherence 
Seven studies examined the association between gender/sexual orientation and 
adherence to ART, four of which were cross-sectional and three longitudinal. The 
results of these are summarised in Table 2.6. 
MSW vs MSM 
Of seven studies which considered differences in ART adherence between MSW and 
MSM, two found poorer ART adherence among MSW357;373, while the remaining five 
found no evidence of differences164;271;374-376.  
In all four cross-sectional studies, ART non-adherence was defined by self-report. 
Three considered at least one measure which included schedule and/or instruction 
non-adherence in addition to missed doses164;374;375. A UK-based cross-sectional study 
found similar proportions of MSM and MSW reported ART non-adherence when 
doses, schedule and instructions were considered (56% and 54% respectively) and 
similar proportions of these groups self-reported at least two doses missed in the last 
week (8% and 12% respectively)164. None of the four studies found a substantially 
increased prevalence of non-adherence in MSW compared to MSM. 
There were three longitudinal studies, two of which were from the US and considered 
an outcome measured using MEMS caps. The remaining study was based in 
Switzerland and considered self-reported adherence. One of the US-based studies 
found MSW had 15% lower adjusted adherence scores than MSM373, while the other 
found no difference271. The study which found an association used the data from 
participants of a US-based RCT (where the intervention was not associated with 
improved adherence377). Given this cohort only included individuals currently using 
ART with a recent detectable VL the results are unlikely to be generalisable. The 
Swiss study was the only one to specifically consider previously naïve individuals 
starting ART. They found that heterosexuals had 59% increased odds of reporting 
ART non-adherence in the last four weeks, and single heterosexual migrants were 
three times more likely to report ART non-adherence compared to older MSM357. 
Adjustment for factors at ART initiation did not account for these differences.  
Women vs MSM 
Women had poorer adherence to ART than MSM in four of seven studies164;357;374-
376239;331, with the other three finding no association. One164 of four374-376 cross-sectional 
studies considering self-reported non-adherence found an association. 
All three longitudinal studies found that women had poorer adherence than MSM. One 
of two studies considering ART non-adherence measured by MEMS caps found that 
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women had 2.2% lower ART coverage over one month compared to MSM in 
unadjusted analyses373. However, following adjustment for demographic factors 
(including gender), SES, symptoms, and ART regimen, women had 3.8% higher ART 
coverage than MSM. This was likely the result of collinearity from gender being 
included in the model. In the other study, average adherence over one month was 
76% among MSM and 74% among WSM271. However, a separate group of WSW had 
only 71% mean adherence. This study indicates that perhaps there may be differences 
in ART adherence by sexual orientation among women, but this study did not have a 
large enough sample of HIV-positive WSW to formally test this.  
Women vs MSW 
Of five studies considering differences in ART non-adherence between women and 
MSW (four cross-sectional and one longitudinal) just one cross-sectional study found a 
greater prevalence of self-reported ART non-adherence among women376, and the 
remaining four found no differences (three considered self-reported 
adherence116;309;310, and one MEMS caps271). The study finding differences between 
the groups looked at self-reported adherence over a period of three days376, whereas 
the other cross-sectional studies considered adherence over the period of a 
week164;374;375. Different measures of adherence may capture differing ART taking 
behaviours. In addition, the studies which did not find differences in adherence differed 
in several ways from the study which found women had poorer adherence: they were 
European studies rather than US-based; they considered combinations of dose, 
schedule and instruction adherence, rather than solely dose adherence; they had 
fewer study participants; and they considered less recent data. 
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Table 2.6: Original research studies considering the association between ART adherence outcomes and gender/sexual orientation among people prescribed ART ab 
Publication, 
Setting, date 
and study c 
Sample 
size 
Non-adherence outcome Prevalence of 
gender/sexual 
orientation groups 
Main results d e 
Estimate (95% CI) 
Factors adjusted for 
  Self-
report 
Definition 
(prevalence) 
Group % Measur
e 
Unadjusted Adjusted  
Cross-sectional 
Beer, 2014, AIDS 
Educ Prev376 
US 2009-10 
MMP 
3,606  
on ART  
Yes <100% last 3 dys MSM 
MSW 
WSM 
Other 
48% 
24% 
25% 
3% 
%  
 
14% (12%, 16%) 
12% (9%, 15%) 
18% (15%, 20%) 
p=0.0038 
n/k  
Peretti-Watel 
2006, Soc Sci 
Med375 
France 2003 
ANRS-VESPA 
1,809  
on ART, 
diagnosed 
≥1 yr 
Yes <100% dose or 
schedule last wk 
(42%) 
MSM 
MSW 
WSM 
44% 
34% 
23% 
% 41.5%  
40.8% 
44.9% 
p=0.40 
n/k  
Sherr 2008, AIDS 
Care374 
UK 2005-06 
5 centres 
502  
on ART 
Yes 100% dose but 
<100% schedule or 
instruction last wk 
(36.1%) 
<100% schedule 
dose, or instruction 
last wk (22.4%)  
MSM 
MSW 
WSM 
 
MSM 
MSW 
WSM 
64% 
12% 
23% 
% 35.9% 
35.1% 
37.6% 
 
20.9%  
21.1% 
21.1% 
n/k  
Sherr 2010, AIDS 
Care164 
UK 2005-06 
5 centres 
486  
on ART 
Yes <100%, schedule 
dose or instruction 
last wk (57.2%)  
 
≥1 dose missed last 
wk (21.0%)  
 
 
≥2 doses missed last 
wk (10.1%) 
MSM 
MSW 
WSM 
 
MSM 
MSW 
WSM  
 
MSM 
MSW 
WSM 
67% 
12% 
21% 
% 56.4% 
54.4% 
59.4%; p=0.80 
 
20.9% 
19.3% 
21.8%; p=0.93 
 
8.4% 
12.3% 
13.9%; p=0.24 
n/k  
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Publication, 
Setting, date 
and study c 
Sample 
size 
Non-adherence outcome Prevalence of 
gender/sexual 
orientation groups 
Main results d e 
Estimate (95% CI) 
Factors adjusted for 
  Self-
report 
Definition 
(prevalence) 
Group % Measur
e 
Unadjusted Adjusted  
Longitudinal 
Keiser 2013, 
AIDS Behav357 
Switzerland 
2000-08 
SHCS 
1,485  
ART-naïve 
initiating 
ART 
Yes <100% last 4 wks older MSM 
young MSM 
MSW and WSM 
older MSW 
PWID 
single migrants 
migrant women in 
partnership 
 
MSM (all) 
Heterosexual (all) 
35% 
4% 
20% 
10% 
13% 
10% 
9% 
OR 1.00 
2.00 (0.89, 4.55) 
1.69 (1.11, 2.56) 
0.90 (0.49, 1.67) 
- 
2.94 (1.75, 5.00) 
1.30 (0.70, 2.38) 
 
 
1.00 
1.59 (1.11, 2.22) 
1.00 
2.00 (0.88, 4.55) 
1.79 (1.16, 2.78) 
0.93 (0.50, 1.72) 
- 
3.23 (1.85, 5.56) 
1.30 (0.70, 2.44) 
 
 
1.00 
1.61 (1.14, 2.27) 
Age, type of ART 
regimen, VL and CD4 at 
study enrolment, stage of 
disease 
 
 
 
 
 
Additionally adjusted for 
gender 
Remien 2014, 
AIDS Behav271 
US 1997-2009 
MACH14 
459  
on ART  
No MEMS: Mean 
coverage over 1 mth 
(mean=0.75 
SD=0.28) 
MSM 
MSW 
WSM 
WSW 
34% 
29% 
16% 
5% 
Mean 
(SD) 
0.76 (0.28) 
0.75 (0.29) 
0.74 (0.25) 
0.71 (0.28) 
n/k  
Genberg 2013, 
AIDS patient care 
STDs373 
US 2002-05 
RCT (two 
centres) 
137  
on ART, 
detectable 
VL at most 
recent 
clinic visit 
No MEMS: % time 
covered by ART in 
30 dys after study 
visit 
Women 
M/WSM 
M/WSW 
 
MSW vs MSM 
Women vs MSM 
22% 
58% 
13% 
Mean 
differen
ce (SE) 
 
 
 
 
-19.0 (6.4) 
-2.2 (6.4) 
 
 
 
 
-14.8 (8.0)  
3.8 (7.1) 
Gender, age, ethnicity 
time, education, marital 
status, employment, ART 
type, depression, mental 
score, physical score, 
stage of change f 
  
 
Blue= MSM had better ART adherence than other gender/sexual orientation group; Red= MSW had better ART adherence than other gender/sexual orientation 
group; Green= Women had better ART adherence than other gender/sexual orientation group; bold= estimates with an associated P-value<0.05. 
a Studies recruited not entirely before 2001, with sample size >100; b studies ordered by study size within each category (cross-sectional and longitudinal); c refer 
to list of relevant study acronyms on pages 10-11 for full study names; d estimates are standardised such that the MSM is the reference group; e standardised 
such that non-adherence is the outcome; f stage of change= model for changing behaviour; MSM= men who have sex with men; MSW= men who have sex with 
women; WSM= women who have sex with men; WSW= women who have sex with women; PWID= people who inject drugs; n/k=not known; mth=month; 
wk/s=week/s; dys=days; CI=Confidence Interval; SE=Standard Error; SD=Standard Deviation; OR=Odds Ratio; MEMS=Medical Event Monitoring System;  
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 Discussion – Association between treatment outcomes and 
gender/sexual orientation 
This review found improved ART responses among MSM compared to MSW in 10/12 
studies of virological response to ART and 4/4 studies of CD4 count outcomes. 
Likewise, MSM had improved virological and CD4 count outcomes compared to 
women in 6/11 and 3/3 studies, respectively. No studies found that MSM had a poorer 
response. While some observed differences are relatively small360, others found 
relative risks in the range of 2-3362;364;365. There was less agreement when comparing 
MSW and women126;362;367. One study found that women had poorer virological 
responses to ART after adjustment, and five found no difference. In contrast, three 
studies found they had improved CD4 count responses, and three found no difference. 
There were no obvious reasons for these differences, although adjustment for baseline 
factors frequently attenuated the differences observed in unadjusted analyses126;367. 
This highlights the important role of other factors, such as ethnicity, migrant status, 
having children, and SES. This last point will be further explored in Chapter 8. 
There were more mixed findings when considering the outcome of adherence. It is 
feasible that the observed gender/sexual orientation differences in treatment response 
were not a result of differences in adherence to ART, and other factors were playing a 
role such as drug resistance and pharmacokinetics. However, the only study, which 
considered both virological, and adherence outcomes found that MSM had 
consistently improved outcomes. Furthermore, only one studied adherence among 
individuals initiating first-line ART and found differences between the three groups357. It 
is possible that initial adherence to ART could differ but be similar in the longer term; 
further study of adherence levels amongst those initiating ART and according to time 
spent on ART is required. Reasons for any differences between groups could include: 
younger age, alcohol abuse, financial difficulty and unsatisfactory housing375. The 
ANRS study suggested that predictors might also be context-specific: food privation, 
migrant status and discriminatory behaviour from relatives were only predictive of non-
adherence among heterosexual individuals; and duration since diagnosis, suicide 
attempts and IDU only among MSW. Thus, different interventions may be required in 
different gender/sexual orientation groups. Finally, it is possible that any observed 
differences between gender/sexual orientation groups could relate to different 
perceptions of adherence and social desirability bias  
Treatment modification, i.e. switching or discontinuing ARVs or the entire ART 
regimen, was a suggested option for individuals with incomplete virological 
suppression (treatment failure)378, or drug toxicities. However, it may also indicate 
compliance issues. Discontinuing ART for any period of time could lead to virological 
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rebound, drug resistance and/or progression to AIDS and death162. Studies have 
reported higher rates of treatment switches during the first year of treatment362 and 
higher rates of complete ART discontinuation300;321 among women compared to men, 
even when pregnant women have been excluded126. In the RFHCS, toxicity and 
treatment choice were common reasons given for switching regimen among all 
gender/sexual orientation groups but treatment failure and pregnancy-related reasons 
were more common for MSW and women, respectively362. Similarly, an Italian study189 
and a Dutch study341 found women were at a higher risk of toxicity-related outcomes. 
Even in studies where men and women have similar rates of discontinuation, women 
are more likely to report adherence difficulties as their reason for stopping 
treatment379. 
Ethnicity is an important consideration alongside gender/sexual orientation, since they 
are usually highly correlated in HIV-positive populations. Four of 15, 2/7 and 1/7 
studies with virological, CD4 count and adherence outcomes respectively considered 
ethnicity/migrant status and gender/sexual orientation as a combined variable; an 
additional six, three and one provided estimates adjusted for ethnicity. Adjustment can 
help to identify the extent to which any differences in ART-response between 
gender/sexual orientation groups operate through ethnicity. However, if, as one would 
expect, ethnicity is very highly correlated with gender/sexual orientation, it may not be 
possible to distinguish between the effects of gender/sexual orientation and ethnicity.  
Few studies provided information on pregnancy. The characteristics of HIV-positive 
pregnant women are different to those of men and non-pregnant women on ART, due 
to different recommended ART regimens50;281, closer monitoring51;290, earlier HIV 
diagnosis due to opt-out antenatal testing and immediate ART start regardless of 
current CD4 count217-219. Four studies explicitly performed sensitivity analyses 
excluding pregnant women and three then found no differences in virological outcome 
compared to men330;380;381. In contrast, although the primary analysis of the UK CHIC 
study found no difference between women and MSW, the latter group were at a higher 
risk of virological rebound after excluding pregnant women367. Furthermore, women 
may experience higher levels of virological rebound372, or historically may completely 
discontinue ART if they only initiated treatment for prevention of mother-to-child 
transmission282. Prior studies have also shown that caring for two or more children can 
have a negative impact on ART response for women382, likely due to difficulty in 
adhering to ART with greater care-giving responsibilities382;383. 
My review had a few limitations. Since gender refers to the social or cultural 
categorisation of men and women, it is conceivable that differences in treatment 
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response between the gender/sexual orientation groups may not be generalisable 
across social or cultural settings. Gender/sexual orientation was not the primary 
covariate of interest in many studies, thus only solely unadjusted or adjusted results 
were available. Inconsistent outcome definitions, particularly for adherence384;385, 
across studies make it difficult to make direct comparisons of associations or to 
combine them into a pooled estimate. In one study, individuals were not necessarily all 
on ART and a small proportion were on fewer than three ARVs, although the CD4 
count of untreated individuals and the percentage receiving fewer than three ARVs did 
not vary between gender/sexual orientation groups365. 
Publication bias was likely to be a concern because studies finding no association, or 
an unexpected inverse association, may have been less likely to publish or to note 
their findings in their publication. There is evidence that, in the general population, 
women are more likely to self-report poorer health, particularly women of black 
ethnicity386. Differences in adherence between the groups could be a result of 
differences in reporting bias. Selection bias could be induced by studies using MEMS 
caps since pillboxes may not have been able to be used by all individuals387 and/or 
flexibility and privacy of pill-taking may have been compromised388. There may be 
some unmeasured confounding present due to observational study designs. 
Thus, my review suggests that it is still unknown whether there are gender/sexual 
orientation disparities in adherence and response to ART. There are also several 
understudied areas, for example European studies considering gender/sexual 
orientation disparities. In addition, of the studies identified by this review, only one from 
the RFHCS (the same database I have analysed in my thesis) considered differences 
between MSM, MSW and women in virological rebound in addition to virological 
suppression362. Three had a study period which ended over 10 years ago361;364;365, and 
although one study found similar reductions in prevalence of ART non-response over 
calendar time in each gender/sexual orientation group365, there are no recent studies. 
These trends may have changed in recent years following the advances in ART 
regimens and increased awareness of the importance of ART adherence. Additional 
study of trends over time would provide insight into whether current strategies are 
sufficient to lead to reduction or elimination of inequalities in ART response by 
gender/sexual orientation in the near future. Although adherence is likely to be a key 
determinant of differences in virological response to ART, only one study observed 
both outcomes357 and two considered virological response adjusted for ART 
adherence359;364. Satisfying this gap in the literature would likely give insight into 
possible adherence interventions to reduce disparities by gender/sexual orientation in 
ART response. 
91 
 
 Review of the literature on socio-economic status and HIV 
treatment outcomes 
This chapter has so far focused on the differences in HIV treatment outcomes and 
ART adherence by gender and sexual orientation. This section assesses socio-
economic differences in virological outcomes, CD4 count responses and in ART 
adherence. To my knowledge, there is no recent systematic review of this topic. Socio-
economic factors are structural factors, i.e. those characterised by social institutions 
such as family, education, religion, and economic and political institutions. Both 
structural389-392 and behavioural393-397 factors have been shown to play a role in 
shaping health inequalities. Prior studies have suggested that structural factors are the 
most important determinants of health398, as they operate both independently and 
through their influence on lifestyle399. Social structural factors (higher income, working 
full-time, caring for a family and social support) have been found to be more important 
determinants of women’s health than men’s, and behavioural factors (smoking and 
alcohol consumption) were more important for men398.  
 Virological and immunological response to ART 
Seventeen studies looked at the association between SES and virological response 
(Table 2.7). Seven studies considered SES and CD4 count response (Table 2.8). 
 Education 
Educational achievement was the most frequently available measure of SES in large 
observational studies, categorised as either highest level of education attained (for 
example ‘university degree’) or number of years in education. Since number of years 
of education does not contain any information on qualifications achieved, highest level 
of education may be a better measure. However, qualifications could be difficult to 
compare between settings, e.g. A-level in the UK with the baccalaureate in France.  
Four cross-sectional studies359;400-402 and five longitudinal studies126;403-406 considered 
the association between education and virological non-suppression among ART-
treated individuals. Of these, four found lower education level was associated with 
lower odds of VL suppression (aOR=0.2-0.6)359;402;403;405, two found weak evidence of 
this association (aOR=0.9 in both)126;401, and two found no association404;406. The 
remaining study, the Veterans Aging Cohort Study (VACS), found weak evidence that 
lower education was associated with improved virological response400. The individuals 
included in this study tended to be of an older age (median age 49 years) and only 2% 
were women, compared to the other studies that all had a lower mean or median (33-
48) age and higher percentages (14-32%) of women. Two of the studies which found 
either weak evidence or no evidence of an association were conducted among specific 
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subgroups: among food insecure individuals401 and in a cohort of PWID404, groups in 
which there may be less variation in educational level. Importantly, one of these 
studies only reported analyses adjusted for other socio-economic factors, and so 
collinearity may have accounted for the lack of association401. 
Two studies found no evidence of an association between educational attainment and 
virological rebound among those with virological suppression on ART407;408. Another 
found no statistically significant association between education and change in VL over 
time409; with all estimates close to one. One potential explanation for the disparate 
findings for VL rebound compared to VL suppression may relate to the fact that those 
who achieve initial virological suppression may be less affected by the mechanisms 
acting against maintaining virological suppression, such as non-adherence. 
One cross-sectional study and five longitudinal studies considered education and CD4 
count response to ART (Table 2.8). Two found that lower educational attainment was 
associated with poorer response403;405 and four reported no association126;400;406;409, 
although they did not provide further information. Three studies that found no 
association considered absolute changes in CD4 count126;406;409 and the other 
considered whether CD4 count was <200 cells/µL at the time of the study among 
individuals on ART400. In contrast, the two studies that found lower odds of CD4 
response to ART among those with lower educational attainment, both defined the 
outcome as CD4 increases of less than 50 or 100 cells/µL after six months of first-line 
ART403;405. 
 Employment 
Employment may be used as a measure of SES as a binary (employed vs. not 
employed) or categorical variable (e.g. full- or part-time status and/or reasons for non-
employment, such as retirement, illness). Use of a binary categorisation could lead to 
loss of information, such as how those who are unemployed due to inability to work 
differ from others. Type of occupation is also sometimes used instead of employment 
status. 
Of the six studies identified which considered the association between employment 
status and virological suppression/non-suppression, four were cross-sectional359;400-402 
and two were longitudinal342;404. Three studies found that unemployment was 
associated with poorer virological response to ART in adjusted analyses342;359;401, one 
found this association in unadjusted analyses only (OR=1.85)402, and two found no 
evidence of an association400;404, with estimates close to one. No studies found that 
unemployment was associated with improved response to ART. The French ANRS 
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study also considered the association between occupation and six months of 
sustained virological suppression among individuals on ART359. The greatest 
difference was between the tradesperson and executive groups (OR=0.6), but, likely 
due to lack of numbers in each group, there were relatively wide confidence intervals. 
One additional study found that unemployed individuals had smaller improvements in 
VL following ART initiation than employed individuals409. 
Across the studies considered, the prevalence of unemployment ranged from 13% to 
95%. The studies with the lower prevalence of unemployment found it had the greatest 
effect on virological outcome342;359. The distribution of employment status in the study 
populations is likely to affect their ability to detect any differences between groups. In 
addition, one of the studies which did not find an association between employment and 
virological non-suppression was among PWID, a group in which other factors might 
have dominated in determining response to ART404. Three of the four US-based 
studies found non-employment was associated with poorer VL outcome401;402;409. It 
might be expected that stronger adverse effects of non-employment on ART response 
would be apparent in a setting without a nationalised health system, where an 
individual’s employment status is likely to be strongly associated with health insurance 
status, and therefore potentially access to care and treatment.  
Two studies were identified that assessed CD4 count outcomes, one of which was 
cross-sectional400 and the other longitudinal409. Both of these US-based studies found 
that unemployment was associated with poorer immunological response to ART.  
 Income/financial status 
Income might be regarded as a desirable indicator of SES since it is a direct measure 
of material living standards and ability to access resources. Some studies consider 
absolute income as a categorical variable, while others consider the extremes of 
financial status, such as financial insecurity or hardship. Studies considering income 
level may use either individual or household income. The latter may be more reflective 
of living standards. 
Of the three studies investigating the association between income and virological non-
suppression or change in VL, two cross-sectional400;401 and one longitudinal409, none 
found an association. However, in another study solely among women, the Women’s 
Interagency HIV study (WIHS), lower income was associated with an 80% higher 
adjusted rate of rebound408. All four of the studies investigating income as a covariate 
were based in the US. One may expect that income would be an important factor in 
more than one of these studies since they were all in a setting without universal free 
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access to care. However, the participants of these studies were those who had access 
to ART in the first place, thus they represented a subset of low income PLWH. 
In addition to the studies looking at income level, four cross-sectional studies 
considered deprivation measures. Three of these studies considered the association 
between food insecurity as a marker of deprivation and virological non-
suppression400;401;410, and the other study considered the association of material 
deprivation defined using the EU-SILC questionnaire411 with sustained virological 
suppression359. Three studies found evidence of an association between greater 
deprivation and poorer virological response at least in unadjusted analyses (OR=1.4-
1.7)359;400;410, and the other study only displayed adjusted associations401. In adjusted 
analyses, all four included other socio-economic factors in the model, so 
associations/lack of association between deprivation and VL response in these models 
could be affected by collinearity. In the VACS, food deprivation was associated with 
37% higher adjusted odds of VL >500 copies/mL, despite adjustment for other socio-
economic factors and despite finding no differences in this outcome by absolute 
income400.  
All three studies of immunological ART response and income/deprivation found an 
association between poorer financial status, measured by lower monthly income 
(OR=1.4 or 24 cells/µL lower improvement)400;409 and food insecurity (OR=1.5-
1.6)400;410, and poorer CD4 count response in unadjusted analyses.  
 Housing 
There is a relatively high prevalence of HIV among homeless individuals in some 
countries412, thus housing status may be an important factor to consider for HIV 
treatment outcomes. A number of studies have categorised housing status as 
homeless or housed. Others use housing stability and consider types of housing 
situation such as homeowner, renting, or living with relatives. 
Poorer housing status was associated with VL non-suppression in all three of the 
studies which assessed this (two cross-sectional (OR=1.4-2.4)400;402, one longitudinal 
(time to suppression HR=0.6)404) in unadjusted analyses. The longitudinal AIDS Care 
Cohort to evaluate Exposure to Survival Services (ACCESS) study also found 40% 
lower adjusted rate of suppression among homeless individuals404. However, both of 
the cross-sectional studies included multiple socio-economic factors in multivariate 
analyses; therefore, again collinearity may have been an issue400;402.  
One further study in the ACCESS cohort considered VL rebound and found no 
evidence of an association, with an unadjusted HR of 0.9 comparing unstable housing 
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to stable housing407. On the other hand, a qualitative study of 27 individuals with 
histories of illegal drug use from the same cohort identified changes in housing status 
and neighbourhood of residence were associated with virological rebound413. Perhaps 
the disruption from changes in circumstances and greater distances from usual health 
care providers may have been influential for VL response rather than housing status. 
In the only study that assessed immunological outcomes and homelessness, VACS, 
recently homeless individuals on ART had twice the odds of having a CD4 count ≤200 
cells/µL compared housed individuals400.  
Health insurance 
In settings where healthcare and treatment are not free at the point of use, health 
insurance, like income, can act as a direct marker of SES. Insurance may be 
considered as a binary variable, or as three levels: none, public and private insurance.  
Three longitudinal US-based studies considered the association between health 
insurance status and virological ART response343;363;408. In unadjusted analyses (in 
studies where this was available) a lower rate of virological suppression (HR=0.8)363 
and a higher rate of virological rebound (HR=1.6)408 were observed among those with 
public compared to private insurance. However, there was evidence that uninsured 
individuals had 0.7 times the rate of rebound compared to privately insured individuals. 
In adjusted analyses there was no evidence that virological response differed between 
individuals with public or private insurance363;408, but adjustment reversed the 
association between none vs. private insurance, such that those with no insurance had 
46% increased rate of rebound408. In the Community Health And Safety Evaluation 
(CHASE) study there was no evidence of an association between insurance and 
virological rebound, however, it reported adjusted analyses only (aHR=1.3)343. 
Neighbourhood SES 
Neighbourhood SES differs from all other SES measures considered, as it is not an 
individual-level factor. There is mixed evidence for the use of neighbourhood-level 
data as a proxy for individual-level SES285;414. The most important disadvantage of 
these measures is that, by definition, inferences for an individual are made based on 
group data. There is a high risk of misrepresenting an individual’s SES in settings 
where large variations in socio-economic circumstance exist within “neighbourhoods.” 
In the SHCS, among individuals initiating ART, those in the lowest quintile of a national 
index of socio-economic position had 44% lower odds of VL suppression after six 
months compared to the highest quintile415, in a model adjusted for demographic 
factors. 
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Table 2.7: Original research studies considering the association between virological outcomes and socio-economic factors among people prescribed ART a b 
Publication 
Setting, date and study 
c  
Sample size Outcome: 
Viral 
response 
Measures of SES OR (95% CI) 
Yes vs No d 
Factors adjusted for 
  Definition Marker Preva
lence 
Unadjusted Adjusted  
Cross-sectional 
Wang, 2011, J Gen 
Intern Med400  
US 
2002-08 
VACS 
1,911 
receiving 
ART 
>500 study 
enrolment 
(39%) 
Education <high school 
 
Non-employed 
 
Annual income<$25,000 
 
Food insecurity 
 
Homeless in last 4 wks 
 
Food insecurity 
7% 
 
74% 
 
74% 
 
24% 
 
10% 
0.68 (0.45, 1.08) 
 
1.11 (0.90, 1.37) 
 
1.09 (0.89, 1.36) 
 
1.49 (1.17, 1.81) 
 
1.41 (1.03, 1.94) 
0.75 (0.47, 1.19) 
 
- 
 
- 
 
1.37 (1.09, 1.73) 
 
1.15 (0.82, 1.63) 
 
1.32 (1.05, 1.68) 
Age, ethnicity, 
relationship status, 
recent 
homelessness/food 
insecure, cocaine use, 
depression score 
 
 
 
 
 
Additionally adjusted for 
ART adherence e 
D’Almeida, 2016, Antivir 
Ther359 
France 
2011 
ANRS- VESPA2 
1,246  
ART-naïve, 
on ART ≥1 
yr 
<50 for >6 
mths at time 
of survey 
(78%) 
Education<primary 
 
 
Unemployed 
 
Manual worker 
 
 
Material deprivation 
21% 
 
 
14% 
 
24% 
 
 
30% 
=0.6 (0.3, 1.0)  
(vs >2 yrs university) 
 
0.5 (0.3, 0.8) 
 
0.8 (0.4, 1.3)  
(vs executive) 
 
0.6 (0.4, 0.8) 
0.4 (0.2, 0.9)  
(vs >2 yrs university) 
 
0.6 (0.3, 1.0) 
 
1.5 (0.8, 2.9)  
(vs executive) 
 
1.0 (0.7, 1.9) 
Gender/sexual 
orientation, age, other 
SES factors, HBV, HCV, 
health literacy, social 
network, CD4 at ART 
start, time on ART, 
depressive symptoms, 
CVD, anxiety symptoms, 
ART adherence, HIV 
discrimination e 
Kalichman, 2015, J 
Community Health410 
US 2012 
Single centre 
521 
prescribed 
ART 
Most recent 
detectable 
(16%) 
food insecurity last mth 38 1.4 (0.80, 2.61) 1.3 Housing, transportation, 
neighbourhood poverty, 
living in an area without 
a supermarket 
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Publication 
Setting, date and study 
c  
Sample size Outcome: 
Viral 
response 
Measures of SES OR (95% CI) 
Yes vs No d 
Factors adjusted for 
  Definition Marker Preva
lence 
Unadjusted Adjusted  
Kalichman, 2015, Infect 
Dis Ther401 
US 2013-14 
Multi-centre 
418  
food 
insecure on 
ART 
Most recent 
>200 (23%) 
 
Yrs of education 
 
 
Non-employed 
 
Annual income<$10,000 
 
Food insecurity factors 
- 
 
 
87% 
 
68% 
 
- 
n/k 0.89 (0.76, 1.03) 
/year longer 
 
1.39 (1.05, 1.85)  
 
1.10 (0.74, 1.64) 
 
1.08 (0.93, 1.25) 
/additional factor 
Yrs since diagnosis, 
alcohol and drug use, 
side-effects, medication 
necessity and concern 
beliefs, ART food 
requirements, other SES 
factors 
Shacham, 2010, AIDS 
Pat Care STDS402 
US 2007 
Single centre 
370  
on ART 
>400 (11%) 
 
Education ≤ high school e 
 
Unemployed 
 
Homeless 
49% 
 
59% 
 
8% 
3.23 (1.58, 6.58) 
 
1.85 (1.11, 3.85) 
 
2.42 (1.45, 8.46)  
2.32 (1.08, 5.00) 
 
NS 
 
NS 
Gender, age, 
employment status, PI- 
or NNRTI-based ART 
Longitudinal 
Rosin, 2014, HIV Med126 
Switzerland 1998-2011 
SHCS 
3,925  
ART-naïve 
initiating 
ART 
heterosexual  
<50 at 12 
mths (77%) 
 
Length of education<9 
yrs 
12% 0.80 (0.69, 0.93) 
 
0.89 (0.75, 1.07) Gender, age, ethnicity, 
IDU, prior-AIDS, HCV, 
VL and CD4 at ART 
start, ART regimen, time 
Gueler, 2015, AIDS415 
Switzerland 2000-13 
SHCS 
2,694  
ART-naïve 
initiating 
ART 
<50 at 6 mths  
 
Lowest neighbourhood 
SES quintile 
23% n/k 0.66 (0.49, 0.88)  
(vs. highest 
quintile) 
 
Gender, age 
Saracino 2016, Clin 
Microbiol Infect342 
Italy 
2004-14 
ICoNA 
2,321  
ART-naïve 
initiating 
ART >6 
mths ago 
Time to two 
consecutive 
>200 (3.3 /100 
person yrs) 
Education ≤primary 
 
Unemployed 
6% 
 
13% 
n/k - 
 
2.09 (1.31, 3.32) z 
Gender, migrant status, 
CD4 at enrolment, CDC 
stage at enrolment, initial 
ART regimen 
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Publication 
Setting, date and study 
c  
Sample size Outcome: 
Viral 
response 
Measures of SES OR (95% CI) 
Yes vs No d 
Factors adjusted for 
  Definition Marker Preva
lence 
Unadjusted Adjusted  
Sobrino-Vegas, 2012, 
Antivir ther405 
Spain 2004-09 
CoRIS 
1,903 
ART-naïve 
initiating 
ART 
<50 at 6 mths 
(76%)  
 
<50 at 1 yr 
(80%) 
Education ≤primary 
 
Education ≤primary 
45% 0.51 (0.37, 0.68) 
 
0.53 (0.41, 0.69) 
0.56 (0.38, 0.82) 
 
0.75 (0.55, 1.03) 
Mode of HIV acquisition, 
gender, age, VL and 
CD4 at ART start 
Legarth, 2014, AIDS406 
Denmark 1998- 2009 
DHCS 
1,178  
ART-naïve 
initiating 
ART  
Time to <500 
  
Low education from 
attainment register 
29% NS n/k  
Novak 2015, JAIDS363 
US 2000-13 
HOPS 
926  
ART-naïve 
initiating 
ART 
Time to <500 Public insurance 
 
 
46% 0.8 (0.7, 1.0) x 0.9 (0.8, 1.1) x Gender/sexual 
orientation, age, 
ethnicity, IDU, 
private/public clinic, date 
diagnosis, VL and CD4 
at ART start 
McFall, 2013, JAIDS408 
US 2006-11  
WIHS 
887  
women on 
ART, 
confirmed 
VL<80, in 
care >3 yrs 
Time to >200 Education <high school  
 
Annual income ≤$24,000 
 
Non home owner 
 
Public insurance 
 
 
No insurance 
37% 
 
68% 
 
12% 
 
 
 
 
16% 
1.16 (0.92, 1.49) x 
  
1.75 (1.30, 2.36) x 
(vs. ≥$36,001) 
 
 
1.59 (1.22, 2.08) x 
(vs. private) 
 
0.71 (0.54, 0.94) x 
(vs. public) 
1.80 (1.19, 2.72) x 
 
- 
 
- 
 
0.83 (0.57, 1.22)x  
(vs private) 
 
1.46 (0.98, 2.16)x  
(vs public) 
Age, CD4 at previous 
visit, previous AIDS 
diagnoses, time since 
ART initiation, VL>200 
prior to study, clinic 
Pence, 2008, JAIDS343 
US 2001-02 
CHASE 
474  
on ART, 
VL<400 at 
enrolment 
Time to ≥400  No insurance 
 
 
21% n/a 1.25 (0.67, 2.38) x 
(Public/none vs. 
private) 
Gender, age, ethnicity, 
time on ART regimen, 
first-line ART, 
depression, alcohol, drug 
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Publication 
Setting, date and study 
c  
Sample size Outcome: 
Viral 
response 
Measures of SES OR (95% CI) 
Yes vs No d 
Factors adjusted for 
  Definition Marker Preva
lence 
Unadjusted Adjusted  
use, trauma, recent 
stress, social support, 
self-efficacy 
Zaragoza-Macias, 2010, 
AIDS Res Hum 
Retroviruses403 
US 2003-05 
Single centre 
 
287 ART-
naïve 
initiating 
ART  
<400 wk 24 
(73%)  
 
<400 wk 48 
(72%)  
 
Education <high school  
 
 
Education <high school  
 
  
29% n/k 
 
 
n/k 
1.69 (0.29, 10.00) 
 
 
0.20 (0.04, 0.90) 
Gender, age, ethnicity, 
ART regimen, VL and 
CD4 at ART start, ART 
adherence e 
Milloy, 2012, JAIDS407 
Canada 1996-2009 
ACCESS 
277  
PWID 
on/initiating 
ART, 2 
consecutive 
VL<500/<50 
Second of two 
VL>1000 
(45%) 
 
Education <high school  
 
Unstable housing 
n/k 1.04 (0.88, 1.24) x 
 
0.90 (0.76, 1.06)  
n/k 
 
 
Milloy, 2012, AIDS 
Patient Care STDS404 
Canada 1996-2009 
ACCESS 
247  
PWID ART-
naïve 
initiating 
ART 
Time until 
<500 (57% ≥1 
VL 
suppression) 
Education <high school  
 
Non-employed; 
 
>1 episode 
homelessness 
 
>1 episode 
homelessness 
39% 
 
95% 
 
42% 
0.89 (0.76, 1.05) x 
 
1.11 (0.84, 1.47) x 
 
0.56 (0.40, 0.78) x 
- 
 
- 
 
0.60 (0.43, 0.84) x 
 
 
0.79 (0.56, 1.11) x 
 
Age, recent 
incarceration, yr ART 
start, VL at ART start 
 
 
 
 
 
Additional adjustment for 
ART adherence e 
Simoni, 2013, AIDS 
care409 
US 2003-07 
Single centre RCT 
224  
ART-naïve/ 
restarting/ 
switching 
Trajectory 0 to 
3 mths after 
ART start 
 
 
Education ≤high school 
 
Non-employed 
 
Income<$552/mth 
21% 
 
80% 
 
~50% 
-0.39 log copies/mLy 
 
+0.07 log copies/mLy 
 
+0.14 log copies/mLy  
N/A N/A 
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Publication 
Setting, date and study 
c  
Sample size Outcome: 
Viral 
response 
Measures of SES OR (95% CI) 
Yes vs No d 
Factors adjusted for 
  Definition Marker Preva
lence 
Unadjusted Adjusted  
new ART 
regimen  
 
Trajectory 3 to 
9 mths after 
ART start 
 
 
Education ≤high school 
 
Non-employed 
 
Income<$552/mth 
 
+0.48 log copies/mLy  
 
-0.32 log copies/mLy 
 
-0.08 log copies/mLy 
 Red= virological outcomes of higher SES group were better than those of lower SES group, Green= virological outcomes of lower SES group were better than 
that of higher SES group; bold= estimates with an associated P-value<0.05. 
a Studies recruited not entirely before 2001, with sample size >100; b studies ordered by study size within each category (cross-sectional and longitudinal); c refer 
to list of relevant study acronyms on pages 10-11 for full study names; d estimates are standardised such that the lower SES group is compared with the higher 
one; e adjusted for adherence which is on the causal pathway; x hazard ratio rather than odds ratio presented; y mean difference rather than odds ratio presented; 
z risk ratio rather than odds ratio presented;  SR= self-reported; NS= non-significant association if estimates not given; n/k=not known; N/A=not applicable; 
yr/s=year/s; mth/s=month/s; wk/s=weeks; CI=Confidence Interval; OR=Odds Ratio; PWID= people who inject drugs; IDU= injection drug use; HCV=Hepatitis C 
virus; HBV=Hepatitis B virus; CVD=Cardiovascular disease. 
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Table 2.8: Original research studies considering the association between CD4 outcomes and socio-economic factors among people prescribed ART a b 
Publication 
Setting, date and study 
c 
Study  CD4 count 
outcome definition 
(cells/mm3) 
Prevalence of socio-economic 
groups 
Estimate (95% CI) d Factors adjusted for 
   Group % Unadjusted Adjusted  
Cross-sectional        
Wang, 2011, J Gen 
Intern Med400  
US 2002-08 
VACS 
1,860 
receiving 
ART 
≤200 (24%) Education<high school 
 
 
Non-employed 
 
Annual income<$25,000 
 
Food insecure in past 4 wks 
 
Homeless in past 4 wks 
 
 
Non-employed 
 
Homeless in past 4 wks 
6% 
 
 
74% 
 
74% 
 
24% 
 
10% 
1.01 (0.60, 1.69)  
(vs college graduate) 
 
1.82 (1.37, 2.38) 
 
1.39 (1.08, 1.82) 
 
1.45 (1.14, 1.86) 
 
2.00 (1.45, 2.57) 
 
 
- 
 
 
1.75 (1.30, 2.38) 
 
1.09 (0.80, 1.45) 
 
1.13 (0.86, 1.47) 
 
1.66 (1.15, 2.38) 
 
 
1.72 (1.28, 2.38) 
 
1.63 (1.13, 2.34) 
Age, ethnicity, 
relationship status, 
other SES factors, 
binge alcohol use, 
Cocaine use, opioid 
use, depression 
score 
 
 
 
 
 
 
 
Additionally adjusted 
for ART adherence e 
Kalichman 2015, J 
Community Health410 
US 2012 
Single centre 
521 
prescribed 
ART 
Most recent <500 
(54%) 
 
Food insecure in last mth 38% 1.6 (1.04, 2.62) 1.4 Housing, 
transportation, 
neighbourhood 
poverty, food desert 
Longitudinal        
Rosin, 2014, HIV Med126 
Switzerland 
1998-2011 
SHCS 
3,925 
heterosexu
als  
ART-naïve 
initiating 
ART  
Median increase 
from ART initiation to 
1 yr 
Length of education <9 yrs 12% n/k NS Gender, age, 
ethnicity, IDU, prior 
AIDS, HCV, VL and 
CD4 at ART start, 
ART type, calendar 
period 
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Publication 
Setting, date and study 
c 
Study  CD4 count 
outcome definition 
(cells/mm3) 
Prevalence of socio-economic 
groups 
Estimate (95% CI) d Factors adjusted for 
   Group % Unadjusted Adjusted  
Sobrino-Vegas, 2012, 
Antivir ther405 
Spain 
2004-09 
CoRIS 
1,903 
previously 
ART-naïve 
initiating 
ART 
>50 increase in 0-6 
mths (82%)  
 
>50 increase in 6-12 
mths (74%) 
Education ≤ primary 45% 0.56 (0.41, 0.76)  
 
 
0.42 (0.30, 0.59) 
0.71 (0.50, 1.00)  
 
 
0.57 (0.40, 0.82) 
Mode of HIV 
acquisition, gender, 
age, VL and CD4 at 
ART start 
Legarth, 2014, AIDS406 
Denmark 
1998-2009 
DHCS 
1,178 
previously 
ART-naïve 
initiating 
ART  
Median increase at 
12 wk intervals 
Low Education from 
attainment register 
29% NS n/k  
Zaragoza-Macias, 2010, 
AIDS Res Hum 
Retroviruses403  
US 2003-05 
Single centre 
287 
previously 
ART-naïve 
initiating 
ART 
Increase>100 by wk 
24 (56%)  
 
Increase>100 by wk 
48 (72%) 
Education <high school 
 
 
Education <high school 
29% n/k 
 
 
n/k 
0.20 (0.04, 0.99) 
 
 
0.65 (0.13, 3.23) 
Gender, age, 
ethnicity, ART 
regimen, VL and CD4 
at ART start, 
adherence e 
Simoni, 2013, AIDS 
care409 
US 2003-07 
Single centre RCT 
224 ART-
naïve/ 
restarting/ 
switching 
new ART 
regimen 
CD4 trajectory over 
9 mths from ART 
initiation 
 
Education ≤high school 
 
Unemployed 
 
Income <$552/mth 
21% 
 
80% 
 
~50
% 
-4 cells/µL p=0.16 y 
 
-30 cells/µL y 
p=0.003  
 
-24 cells/µL y 
p=0.003 
N/A N/A 
  
 
 
Red= CD4 outcomes of higher SES group were better than those of lower SES group, Green= CD4 outcomes of lower SES group were better than that of 
higher SES group; bold= estimates with an associated P-value<0.05. 
a Studies recruited not entirely before 2001, with sample size >100; b studies ordered by study size within each category (cross-sectional and longitudinal); c 
refer to list of relevant study acronyms on pages 10-11 for full study names; d estimates are standardised such that the lower SES group is compared with the 
higher one; e adjusted for adherence which is on the causal pathway; y mean difference rather than estimate and 95% CI; SR= self-reported; RCT= 
Randomised Controlled Trial; IDU= intravenous drug use; HCV= Hepatitis C; NS= non-significant association if estimates not given; n/k=not known; N/A=not 
applicable; yr/s=year/s; mth/s=month/s; wk/s=weeks; CI=Confidence Interval; OR=Odds Ratio; PR=Prevalence Ratio; HR=Hazard Ratio. 
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 ART non-adherence 
In general, the findings for an association between poorer levels of SES markers and 
increased risk of ART non-adherence were more mixed than those seen for VL and 
CD4 outcomes (Table 2.9, where a red result indicates poorer adherence among 
those of lower SES and green indicates the opposite association). 
 Education 
Again, the most common marker of SES available was educational level for which, out 
of 25 studies: 11 found that lower educational attainment was associated with non-
adherence346-349;353;354;374;402;416-418; 11 did not find evidence of an 
association164;350;373;401;419-425; two found weak evidence of better adherence among 
individuals with lower educational attainment426;427; and one UK study found that, 
among women, having below university level education was associated with 75% 
lower odds of ART non-adherence428. 
In the UK study, which found an inverse association between education and non-
adherence in the subgroup of women compared to the subgroup of men, the authors 
suggest that this could potentially be explained by less trust of health-care 
professionals among highly educated women428. However, there was little evidence of 
why highly educated women would be more mistrustful than highly educated men in 
the literature. Two other UK-based studies did not find an association between 
adherence and education164;374, however, they did not consider men and women 
separately. In these studies the definition of adherence was also more stringent – 
<100% dose, schedule and instruction adherence was defined as non-adherence – 
and as such different lifestyle factors may have been more important in explaining 
non-adherence than education. In studies considering these three aspects of non-
adherence separately, less education was not associated with dose non-adherence, 
but instead with greater odds of self-reported instruction418 or schedule347 non-
adherence. This suggests that lower levels of education may have been associated 
with greater difficulties in taking ART at the scheduled times or as instructed, but not 
necessarily with missing doses altogether. 
Although there were mixed findings for whether education was associated with non-
adherence using most adherence measures, unannounced telephone pill-count 
consistently found no association between education and adherence401;419;420. This 
may have been due to more accurate measurement of adherence, but the possibility 
that expecting pill-counts may act as a facilitator to adherence should not be 
discounted429. 
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Employment 
When considering unemployment, out of 17 studies, three found it was associated with 
increased non-adherence350;373;430 (two cross-sectional studies one longitudinal), while 
14 found no statistically significant association164;348;352;374;401;402;417;420;423;425-427;431;432. 
Indeed, though no significant association was found, one of these 14 studies found 
some suggestion that the unemployed had lower odds of non-adherence427. 
In the only longitudinal study to find an association between employment and ART 
adherence, its participants had been recruited for a clinical trial due to prior evidence 
of non-adherence, therefore the results were unlikely to be generalisable373. Though 
the intervention, of an adherence form given to clinicians before routine appointments, 
was not found to affect adherence overall, it is possible that it had an impact on those 
who were employed more than those not employed. 
 Income/financial status 
Nine of 16 studies found that lower income/higher poverty was associated with greater 
ART non-adherence347;349;375;410;420;426;432-434, whereas the remaining seven found no 
evidence of an association348;352;353;401;416;417;421, and none found an association with 
lower non-adherence. A greater proportion of the studies which looked at a poverty 
related measure compared to absolute income found an association with non-
adherence (5/7 vs. 4/11 where some studies considered both poverty and income 
outcomes). 
In a study of individuals with low health literacy, although income and adherence were 
not associated (OR=0.99), poverty related stress was associated ART non-adherence 
(OR=1.37), a relationship which remained even in multivariate analyses 
(aOR=1.39)420. This implies that the negative material and psychosocial effects of very 
low income were associated with ART adherence even if income itself was not435. In 
studies where food insecurity or food and housing insecurity combined were 
considered, they were associated with non-adherence to ART375;410;433. The results of 
these studies provide further support that the physical effect of poverty is strongly 
linked to poor adherence.  
 Housing 
Poorer housing status was associated with greater non-adherence in nine 
studies347;349;352;375;416;426;430;433;436, and no association in the remaining six 
studies348;373;402;417;421;424.  
In a cross-sectional study of data from an RCT of individuals who were homeless or at 
severe risk of homelessness (which had investigated the effects of providing rental 
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assistance) 424 and three other studies of RCT data, no association was found 
between housing status and self-reported adherence417;424 or adherence measured by 
MEMS caps373;421. It is possible that there is a systematic difference between those 
who agree to participate in clinical trials and those who do not.  
Health insurance 
Three of the four US-based studies of the association between insurance and non-
adherence found either no insurance424;426 or public insurance351 was associated with 
greater non-adherence, but the remaining study found no association between 
adherence measured by MEMS caps and insurance373.  
In Estonia, heath care is financed by a mandatory health insurance system. In a cross-
sectional study, uninsured individuals had 3.67 times the odds of non-adherence 
compared to insured individuals, however, there were only nine uninsured participants 
so there was a very wide confidence interval for this finding427.  
 Neighbourhood SES 
Finally, two US-based studies considered neighbourhood-level SES, of which one 
found that higher neighbourhood poverty was associated with lower non-adherence to 
ART416, and the other found no association351. In the former, the outcome studied was 
missed doses of ARVs for diversion-related reasons (selling or trading drugs), among 
a study population of active substance users416. However, in this same study, higher 
perceived neighbourhood disorder was strongly related to increased diversion-related 
non-adherence (p<0.001). This indicates that perhaps how individuals perceived the 
SES of their neighbourhood is more strongly related to their adherence to treatment 
than the actual status of the neighbourhood they lived in.  
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Table 2.9: Original research studies considering the association between ART non-adherence and socio-economic factors among people prescribed 
ART a b 
Publication, 
Setting, date 
and study c 
Sample size Non-adherence 
outcome 
Prevalence of SES groups OR (95% CI) or 
Prevalence: Yes vs. No d e 
Adjusted for in 
addition to gender 
& age 
  Self-
report 
Definition (%) Marker Prevalence Unadjusted Adjusted  
Cross-sectional 
SHAS436 
US 2000-03 
 
5,404  
on ART 
 
Yes <100% in last 48 
hrs (18%) 
 
Homeless 5% 2.17 (1.54, 3.13) 1.92 (1.18, 3.03) HIV acquisition risk, 
CD4, ethnicity, 
marital status, 
education, drug & 
alcohol use, 
employment, recent 
health status, 
income 
SHCS346 
Switzerland 
2003 
 
3,607  
on ART ≥6 
mths 
Yes Miss≥1 dose in 
last 4 wks (31%) 
Education length ≤9 yrs 26% 1.25 (1.06, 1.49) 1.11 (0.93, 1.33) Ethnicity, living 
alone, IDU, dose 
frequency, 
psychiatric 
treatment, time on 
ART, previous 
regimens, 
lipodystrophy, 
current regimen 
Miss≥2 doses in 
last 4 wks (15%) 
Education length ≤9 yrs  1.37 (1.11, 1.69) 
 
1.15 (0.91, 1.45) 
 
<95% in last 4 
wks (7%) 
Education length ≤9 yrs  1.76 (1.33, 2.32) 1.42 (1.04, 1.94) 
MMP347 
US 2007-08 
 
3,307  
on ART 
Yes <100% dose last 
48 hrs (13%) 
Education <high school 
 
Homeless in last yr 
 
Public assistance in last 
yr 
22% 
 
7% 
 
50% 
NS 
 
1.71 (1.22, 2.41) 
 
1.46 (1.19-1.79) 
- 
 
NS 
 
1.31 (1.05-1.65) 
Ethnicity, other SES 
factors, depression, 
crack use, 
amphetamine use, 
binge drinking, time 
on ART, time since 
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Publication, 
Setting, date 
and study c 
Sample size Non-adherence 
outcome 
Prevalence of SES groups OR (95% CI) or 
Prevalence: Yes vs. No d e 
Adjusted for in 
addition to gender 
& age 
  Self-
report 
Definition (%) Marker Prevalence Unadjusted Adjusted  
<100% schedule 
last 48 hrs (27%) 
Education <high school  
 
Homeless in last yr 
 
Public assistance in last 
yr 
 1.56 (1.32, 1.89) 
 
1.69 (1.28, 2.24) 
 
1.47 (1.26, 1.72) 
1.28 (1.05, 1.56) 
 
1.43 (1.05, 1.95) 
 
1.35 (1.14, 1.60) 
diagnosis, dose 
frequency, knew VL, 
resistance discussed 
 
 
<100% 
instruction last 48 
hrs (30%) 
Education <high school  
 
Homeless in last yr  
 
Public assistance in last 
yr 
 NS 
 
1.38 (0.98,1.94) 
 
NS 
- 
 
NS 
 
- 
ANRS-
VESPA375 
France 
2003 
 
1,809  
on ART  
Yes Dose or schedule 
<100% in last 7 
dys (27%) 
Difficult household 
financial situation 
 
 
Household food privation 
in last 4 wks 
 
 
Unsatisfactory housing 
conditions 
MSM: 19% 
MSW: 33% 
Women: 
33% 
 
MSM: 6% 
MSW: 13% 
Women: 
17% 
 
MSM: 7% 
MSW: 18% 
Women: 
20% 
50% v 40% p=0.03 
50% v 36% p<0.01 
52% v 41% p=0.03 
 
52% v 41% p=0.13 
65% v 37% p<0.01 
56% v 43% p=0.04 
 
58% v 40% p=0.01 
56% v 38% p<0.01 
56% v 42% p=0.02 
NS 
NS 
NS 
 
NS 
2.35 (1.49, 3.71) 
NS 
 
NS 
NS 
NS 
[subsets of] migrant 
status, IDU, 
discrimination, time 
HIV-diagnosed, 
perceived adverse 
effects of ART, 
alcohol use, suicide 
attempts, other SES 
factors h 
 
HIV Futures 
6423 
Australia 2008-
09 
820  
on ART 
Yes <100% in last 2 
dys (39%) 
 
Highest education level 
 
Employment 
 
n/k p<0.2 
 
p>0.2 
 
p>0.1 Drug & alcohol use, 
smoking, health, 
STIs, mental health, 
disclosure, attitude, 
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Publication, 
Setting, date 
and study c 
Sample size Non-adherence 
outcome 
Prevalence of SES groups OR (95% CI) or 
Prevalence: Yes vs. No d e 
Adjusted for in 
addition to gender 
& age 
  Self-
report 
Definition (%) Marker Prevalence Unadjusted Adjusted  
 Income p>0.2 support, ART 
frequency, 
discrimination, type 
of regimen, time on 
ART, symptoms, 
ADEs, latest CD4, 
urbanicity h 
OCS348 
Canada 2007-
09 
779 on ART Yes <100% in last 4 
dys (15%) 
Education <high school  
 
Unemployed 
 
Household income 
<$40,000/yr 
 
Currently homeless 
32%  
 
57% 
 
39% 
 
 
<1% 
2.44 (1.38, 4.17) 
 
p=1.0 
 
p=0.2 
 
 
p=0.2 
NS 
 
- 
 
- 
 
 
- 
HIV acquisition 
mode, ethnicity, 
region of birth, ART 
type, ART 
frequency, alcohol, 
depressive 
symptoms, general 
health, social 
support, stress, 
coping h 
Multi-centre 
RCT424 
US 2004-05 
644 on ART  Yes <100% in last 2 
dys (22%) 
 
 
Education <high school 
  
Homeless/unstable 
housing 
 
Medically uninsured 
n/k 24% v 21% p=0.6 
 
21% v 31% p=0.3 
 
 
34% v 20% p=0.06 
1.20 (0.63, 2.29) 
 
- 
 
 
- 
Ethnicity, problems 
accessing care, 
alcohol 
 
 
 
<90% in last 7 
dys (19%) 
 
Education <high school  
  
Homeless/unstable 
housing 
 
Medically uninsured 
 17% v 20% p=0.3 
 
17% v 20% p=0.74 
 
 
26% v 16% p=0.2 
0.81 (0.41, 1.60) 
 
- 
 
 
2.43 (1.04, 5.69) 
Ethnicity, other SES 
factors, alcohol, drug 
use 
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Publication, 
Setting, date 
and study c 
Sample size Non-adherence 
outcome 
Prevalence of SES groups OR (95% CI) or 
Prevalence: Yes vs. No d e 
Adjusted for in 
addition to gender 
& age 
  Self-
report 
Definition (%) Marker Prevalence Unadjusted Adjusted  
Multicentre 
RCT: 
INSPIRE417 
US 2001-03 
 
636 PWID, 
on ART 
Yes <90% on 
previous day 
(25%)  
Education<high school  
 
Unemployed 
 
Annual income < $10,000 
 
Homeless 
44% 
 
95% 
 
87% 
 
28% 
1.66 (1.16, 2.39) 
 
NS 
 
NS 
 
NS 
1.57 (1.03, 2.41) 
 
- 
 
- 
 
- 
Ethnicity, drug use 
behaviours, 
depression, attitudes 
to medication, 
baseline VL and 
CD4 
LISA349  
Canada 2007-
10 
556 on ART  No Prescription refill 
<95% last yr 
(44%) 
 
Education <high school  
 
 
 
Annual income < 
$15,000/yr 
 
 
Homeless/unstable 
housing 
40% 
 
 
 
59% 
 
 
 
31% 
31% of adherent 
vs. 52% non-
adherent; p<0.001 
 
50% of adherent 
vs. 72% non-
adherent; p<0.001 
 
25% of adherent 
vs. 61% non-
adherent; p<0.001 
NS 
 
 
 
NS 
 
 
 
2.13 (1.39, 3.23) 
Ethnicity, other SES 
factors, 
incarceration, 
depressive 
symptoms, drug use, 
IDU, methadone 
treatment, ART 
frequency, 
medication memory 
aids, in assisted 
therapy program 
SUN350 
US 2004-06 
528 on ART Yes <100% in last 3 
dys (16%) 
Education <high school  
 
Unemployed 
22% 
 
41% 
1.86 (0.98, 3.54) 
 
2.59 (1.53, 4.37) 
1.39 (0.65, 2.95) 
 
1.86 (0.99, 3.48) 
Ethnicity, time since 
HIV diagnosis, 
smoking, alcohol 
marijuana & cocaine 
use, mental & 
physical health, 
aerobic exercise, 
suicidal ideation, 
other SES factors i 
Single 
centre410 
US 2012 
521 
prescribed 
ART 
Yes <85% in last mth 
(25%) 
 
Food insecurity in last 
mth 
38% 2.0 (1.33, 3.23) 
 
2.0; p<0.01 Housing, 
transportation, 
neighbourhood 
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Publication, 
Setting, date 
and study c 
Sample size Non-adherence 
outcome 
Prevalence of SES groups OR (95% CI) or 
Prevalence: Yes vs. No d e 
Adjusted for in 
addition to gender 
& age 
  Self-
report 
Definition (%) Marker Prevalence Unadjusted Adjusted  
 poverty, living in an 
area without a desert 
Single 
centre433 
US 2010-2012 
503  
on ART 
active 
substance 
users 
Yes <95% in last wk 
(46%) 
 
Combined food and 
housing insecurity 
43% 53% v 41% p<0.01 Standardised 
β=-0.95 (-0.122, -
0.002) p=0.044 
Depression, anxiety, 
trauma, 
dependence, 
treatment access, 
mths in care, ARV 
diversion f j 
Single 
centre416 
US 2010-12 
503  
on ART 
active 
substance 
users 
Yes  <100% in last wk 
diversion-related f 
(30%) 
Education <high school  
 
Income < $1,000/mth 
 
Housing in past 90 dys: 
In public housing 
Stay with friend/relative 
Homeless 
 
Perceived disorder in 
neighbourhood  
 
Neighbourhood % below 
poverty level 
44% 
 
81% 
 
 
23% 
13% 
39% 
 
1.52 (1.03, 2.22) 
 
0.96 (0.59, 1.56) 
 
 
- 
2.41 (1.33, 4.39) 
1.97 (1.34, 2.90) 
 
1.03 (1.01, 1.05) 
 
 
0.98 (0.96, 0.99) 
- 
 
- 
 
 
- 
- 
1.72 (1.13, 2.63) 
 
1.01 (0.99, 1.03) 
 
 
- 
ethnicity, income, 
substance 
dependence, 
homelessness, 
individuals 
selling/trading ARVs 
in personal network 
 
 
5 centres374 
UK 2005-06 
502  
on ART 
Yes <100% in last wk 
dose schedule 
and instruction 
(58%) 
Education <university 
 
Non-employed  
 
54% 
 
47% 
n/k 0.54 p=0.03 
 
NS 
 
5 centres164 
UK 2005-06 
 
486  
on ART 
Yes <100% dose 
schedule and 
instruction in last 
wk (51%) 
Education <university 
 
Non-employed 
 
53% 
 
42% 
57% v 58% p=0.73 
 
55% v 58% p=0.63 
n/k  
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Publication, 
Setting, date 
and study c 
Sample size Non-adherence 
outcome 
Prevalence of SES groups OR (95% CI) or 
Prevalence: Yes vs. No d e 
Adjusted for in 
addition to gender 
& age 
  Self-
report 
Definition (%) Marker Prevalence Unadjusted Adjusted  
<100% dose in 
last wk (20%) 
 
Education <university 
 
Non-employed 
 22% v 21% p=0.84 
 
21% v 21% p=0.84 
 
≥2 doses missed 
in last wk (7%)  
 
Education <university 
 
Non-employed 
 12% v 8% p=0.24 
 
10% v 10% p=0.52 
 
CHS HIV 
Wave 4 Patient 
study431 
US 2007 
 
461 
on ART 
  
Yes <100% average 
wk (46%) 
non-employed 56% Employed: 44% 
adherent vs. 44% 
non-adherent 
p=0.88 
1.12 (0.69, 1.83) Ethnicity, insurance, 
cost manageability, 
drug use, ART 
satisfaction, daily pill 
count, comorbidities 
Single 
centre402 
US 2007 
 
370  
on ART 
Yes <95% in last 4 
dys (25%) 
 
Education<high school  
 
Unemployed 
 
Homeless 
49% 
 
59% 
 
8%  
33% v 23% p<0.05 
 
NS 
 
NS 
n/k  
RCT425 
US 2007-09 
326  
on ART 
Yes <100% in last 4 
dys (40%) 
Education <high school 
 
 
Employment: 
Employed 
Non-employed (health 
related) 
Non-employed (non-
health related) 
41% 
 
 
 
21% 
65%  
 
14% 
0.95 (0.79, 1.16) 
 
 
 
1.00 
1.01 (0.78, 1.29) 
 
1.06 (0.88, 1.27) 
n/k  
Multi-centre 
RCT422 
US 2004-09 
 
192 
previously 
ART-
naïve/ART 
No MEMS over 7 dys Education <high school 
 
22% r=0.092 No causal 
pathways 
between 
education, coping 
and adherence 
Coping 
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Publication, 
Setting, date 
and study c 
Sample size Non-adherence 
outcome 
Prevalence of SES groups OR (95% CI) or 
Prevalence: Yes vs. No d e 
Adjusted for in 
addition to gender 
& age 
  Self-
report 
Definition (%) Marker Prevalence Unadjusted Adjusted  
switch/ non-
adherent 
Project Gold418  
US 2010-11 
180  
On ART 
MSM >50 yrs 
Yes  <100% dose in 
last 4 dys (20%) 
 
<100% schedule 
in last 4 dys 
(48%)  
 
<100% 
instruction in last 
4 dys (24%)  
 
<100% dose last 
weekend (18%) 
Education <university 67% 1.14 (0.52, 2.50) 
 
 
1.75 (0.93, 3.33) 
 
 
2.33 (0.98, 5.55) 
 
 
 
1.15 (0.51, 2.63) 
0.99 (0.44, 2.22) 
 
 
1.61 (0.82, 3.13) 
 
 
1.85 (0.75, 4.55) 
 
 
 
0.97 (0.41, 2.27) 
HIV-related stigma h 
 
 
Depression, HIV-
related stigma, 
sexual compulsivity h 
 
Depression, HIV-
related stigma, body 
distress, sexual 
compulsivity h 
 
sexual compulsivity h 
5 centres428 
UK 2005-06 
 
170  
on ART 
heterosexual 
Yes <100% dose 
schedule & 
instruction in last 
wk (56%) 
Education <university Men: 61% 
Women: 
67% 
3.18 (1.02, 9.86) 
0.25 (0.09, 0.66) 
 
2.64 (0.63, 10.9) 
0.26 (0.09, 0.76) 
 
Ethnicity, UK birth, 
disclosure, 
symptoms h 
Single 
centre427 
Estonia 2010 
 
144 
on ART 
Yes  <100% last 3 dys 
(12%) 
 
Length education<9 yrs 
 
Unemployed (receiving 
benefits) 
 
Medically uninsured 
30% 
 
73% 
0.43 (0.08, 1.67) 
 
0.55 (0.14, 2.16) 
 
 
3.67 (0.73, 15.46) 
0.36 (0.08, 1.23) 
 
0.50 (0.14, 1.91) 
 
 
4.41 (1.03, 17.2) 
Insurance, SR health 
j 
Single 
centre430 
Spain 
 
143 on ART Both Self-report or 
prescription refill 
<100% (33%) 
Employment; 
 
Housing 
n/k n/k 
 
Both 
independent 
predictors of 
good adherence 
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Publication, 
Setting, date 
and study c 
Sample size Non-adherence 
outcome 
Prevalence of SES groups OR (95% CI) or 
Prevalence: Yes vs. No d e 
Adjusted for in 
addition to gender 
& age 
  Self-
report 
Definition (%) Marker Prevalence Unadjusted Adjusted  
Single 
centre426 
US 2006 
 
132  
on ART 
Both Self-report, 
detectable VL 
without 
resistance, lack 
of prescription 
refill or clinician 
report <100% last 
wk (26%) 
Education<high school 
 
 
 
Unemployed 
 
 
 
Living in someone else’s 
house 
 
 
Annual income≤$10,000 
 
 
 
Medically Uninsured 
28% 
 
 
 
55% 
  
 
 
31% 
 
 
 
42% 
 
 
 
13% 
33% of adherent 
vs. 15% non-
adherent p=0.09 
 
54% of adherent 
vs. 64% non-
adherent p=0.14 
 
26% of adherent 
vs. 53% non-
adherent p=0.01 
 
40% of adherent 
vs. 61% non-
adherent p=0.05 
 
10% of adherent 
vs. 25% non-
adherent p=0.02 
n/k  
Single 
centre432 
US 
 
116  
on ART 
Yes <95% last mth 
(39%) 
 
Unemployed 
 
Annual income <$10,000 
62% 
 
63% 
Non-employed: 
59% of adherent 
vs. 67% non-
adherent 
 
<$850/mth income: 
52% of adherent 
vs. 62% non-
adherent 
n/k  
Longitudinal         
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Publication, 
Setting, date 
and study c 
Sample size Non-adherence 
outcome 
Prevalence of SES groups OR (95% CI) or 
Prevalence: Yes vs. No d e 
Adjusted for in 
addition to gender 
& age 
  Self-
report 
Definition (%) Marker Prevalence Unadjusted Adjusted  
SHCS354 
Switzerland 
2003-09 
6,709  
on ART 
Yes 100% to <100% 
last 4 wks 2 
measurements 6 
mths apart (17%) 
“Basic” education 27% n/k 1.16 (1.03, 1.31) Ethnicity, living 
alone, ended stable 
partnership, started 
IDU, started drug 
maintenance 
program, alcohol, 
smoking, risky sex, 
psychiatric 
treatment, prison 
release, 
hospitalised, time 
living with ART, co-
medication, ART 
change, regimen 
frequency change, 
time on ART, 
lipodystrophy, 
physician change, 
adherence at first 
visit 
<100% to 100% 
last 4 wks 2 
measurements 6 
mths apart (18%) 
“Basic” education  n/k 0.82 (0.68, 0.99) 
KPNC351 
US 1996-2005 
 
4,686 
initiating ART 
No Mean 
prescription refill 
mean over 2 yrs 
since ART 
initiation 
Public insurance 
 
 
Live in area with >25% 
individuals<high school 
education 
 
Live in area with>20% 
below poverty line 
11% 
 
 
23% 
 
 
 
16% 
n/k −4.8% (−7.7, 
−2.0) p<0.001 
 
-1.3% (−3.4, 0.8) 
p=0.21 
 
 
-0.8% (−3.2, 1.6) 
p=0.52 
HIV acquisition risk, 
ethnicity, yr ART 
start, baseline VL 
and CD4, ART 
experience, ART 
regimen, HCV, 
Depression, 
comorbidities, other 
SES factors 
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Publication, 
Setting, date 
and study c 
Sample size Non-adherence 
outcome 
Prevalence of SES groups OR (95% CI) or 
Prevalence: Yes vs. No d e 
Adjusted for in 
addition to gender 
& age 
  Self-
report 
Definition (%) Marker Prevalence Unadjusted Adjusted  
MACH14353 
US 1997-2009 
 
1,809  
on ART 
No MEMS mean 
over 4-wk periods  
Education<high school  
 
Annual household 
income<$10,000` 
23% 
 
59% 
n/k 1.24 (1.06, 1.44) 
 
1.06 (0.93, 1.20) 
Ethnicity, site, other 
SES factor, 
substance use, 
depression 
MACS434 
US 2003-09 
 
712  
on ART 
MSM 
Yes Score from 1-4 
(1=high and 4 
=low) since last 
visit 
Annual income<$20,000 19% n/k <$20,000: 
mean=1.81 
 
>$20,000: 
mean=1.73 
p<0.0001 
Ethnicity, sex with 
women, recent 
seroconversion h 
Multi-centre401 
US 2013-14 
 
418  
on ART 
food insecure 
No Unannounced 
telephone pill 
count <85% 
measured 3 
times in 6 wks 
(43%) 
 
 
Number yrs of education;  
 
 
Non-employed 
 
Annual income<$10,000 
 
Number food insecurity 
indicators 
 
 
 
87% 
 
68% 
n/k 0.97 (0.86, 1.10) 
/additional yr 
 
1.05 (0.84, 1.32) 
 
1.19 (0.88, 1.62) 
 
1.02 (0.91, 1.16) 
/additional 
indicator 
Yrs HIV diagnosed, 
alcohol, drug use, 
side-effects, 
medication necessity 
and concern beliefs, 
ART regimen food 
requirements, other 
SES factors j 
Project 
MOTIV8 multi-
centre RCT421 
US 2004-09 
 
204  
ART-naïve/ 
adherence 
problems/ 
No MEMS <90% 
over 30 dys 
before yr 1 visit 
(41%) 
Education<high school 
 
Include≤$1,000/mth 
 
Insecure housing 
23% 
 
63% 
 
35% 
46% v 33% p=0.11 
 
45% v 35% p=0.19 
 
45% v 39% p=0.45 
n/k  
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Publication, 
Setting, date 
and study c 
Sample size Non-adherence 
outcome 
Prevalence of SES groups OR (95% CI) or 
Prevalence: Yes vs. No d e 
Adjusted for in 
addition to gender 
& age 
  Self-
report 
Definition (%) Marker Prevalence Unadjusted Adjusted  
switching 
ART 
MEMS <90% 
over 30 dys 
before yr 2 visit 
(44%) 
Education<high school 
 
Include≤$1,000/mth 
 
Insecure housing 
 53% v 37% p=0.16 
 
48% v 38% p=0.21 
 
50% v 41% p=0.30 
 
Multi-centre420 
US 2008-09 
 
188  
on ART  
with poor 
health 
literacy 
No Unannounced 
telephone pill-
count <85% over 
a mth (67%) 
 
Yrs of education 
 
 
Non-employed 
 
Annual Income  
 
High poverty-related 
stress 
 
 
 
96% 
 
70% 
 
n/k 
1.00 (0.85, 1.18) 
/yr fewer 
 
1.15 (0.84, 1.59) 
 
0.99 (0.64, 1.52) 
 
1.37 (1.16, 1.61) 
 
 
 
 
 
 
 
1.39 (1.12, 1.69) 
Social stressors, 
stress severity, 
depression, 
internalised stigma, 
drug use j 
Multi-centre419  
US 
 
145  
on ART 
No Unannounced 
telephone pill-
count <85% over 
a mth (75%) 
Yrs of education n/k n/k 1.20 (0.95, 1.49) 
/yr fewer 
Yrs HIV diagnosed, 
symptoms, 
depression, stigma, 
social support, 
alcohol, literacy h 
Two centre 
RCT373 
US 2002-05 
 
137  
on ART with 
detectable 
VL 
No MEMS change in 
30 dys following 
each study visit 
Education<primary level 
 
Non-employed 
 
 
 
Homeless  
5% 
 
 
66% 
 
 
6% 
NS 
 
 
Difference=-11.5 
p<0.05 
 
NS 
- 
 
 
Difference =-7.8 
p>0.05 
 
- 
HIV acquisition risk, 
ethnicity, education, 
marital status, ART 
type, physical & 
mental scores, 
depressive 
symptoms, stage of 
change g 
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Publication, 
Setting, date 
and study c 
Sample size Non-adherence 
outcome 
Prevalence of SES groups OR (95% CI) or 
Prevalence: Yes vs. No d e 
Adjusted for in 
addition to gender 
& age 
  Self-
report 
Definition (%) Marker Prevalence Unadjusted Adjusted  
HERO352 
US 1998-2001 
 
113 
prescribed 
ART current/ 
former opioid 
users  
No MEMS median 
over study period 
Unemployed 
 
Receive public 
assistance 
 
No long term housing 
86% 
 
9% 
 
55% 
NS 
 
NS 
 
42% v75% p=.003 
n/k  
  
 
 
 
Red= higher SES group were less likely to be non-adherent to ART than lower SES group; Green= higher SES group were more likely to be non-adherent to 
ART than lower SES group; bold= estimates with associated p-values of <0.05. 
a Studies recruited not entirely before 2001, with sample size >100; b studies ordered by study size within each category (cross-sectional and longitudinal); c refer 
to list of relevant study acronyms on pages 10-11 for full study names; d estimates are standardised such that the lower SES group is compared with the higher 
one; e standardised such that non-adherence is the outcome; f ARV diversion is the selling or trading of ARVs; g stage of change= model for changing behaviour; 
h not adjusted for gender; I not adjusted for age; j not adjusted for gender or age; SR= self-reported; MEMS=Medical Event Monitoring System; IDU= injection 
drug use; HCV=Hepatitis C virus; RCT= Randomised Controlled Trial; ADE=AIDS Defining Event; NS=not significant association but estimates not given; 
n/k=not known; N/A=not applicable; yr/s=year/s; mth/s=month/s; wk/s=weeks; CI=Confidence Interval; OR=Odds Ratio. 
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 Discussion - Association between SES and ART-related outcomes 
This review provides substantial evidence of an adverse effect of lower SES on 
virological and immunological outcomes among individuals prescribed ART. In 
particular, 12 of the 17 (71%) studies across various high-income settings have 
demonstrated a negative effect of lower SES on VL outcomes. In some studies this 
effect was strong342;359;402;403;405, suggesting lower SES may be one of the most 
important predictors of treatment success. Few of the studies reviewed identified that 
those in lower socio-economic groups had better treatment outcomes.  
There exists considerable evidence of socio-economic disparities in prognosis318;437-440 
and adherence to treatment441-443 for a number of other chronic conditions. The finding 
of the present chapter, that HIV-diagnosed people with lower SES were often more 
likely to have poorer treatment outcomes, was consistent with similar results for other 
conditions, and adds to the existing evidence of the adverse impact of social 
disadvantage on health outcomes444-447.  
Each individual socio-economic factor portrays a different aspect of SES. Identification 
of the most important measure may provide some insight into potential mechanisms of 
action448. However, there was considerable multi-collinearity between the indicators 
which may make simultaneous investigation problematic449. It can be difficult to 
interpret results from multivariable models that include more than one socio-economic 
factor401;402;410, particularly when the unadjusted associations between these factors 
and ART response are not presented401. 
Few of the studies identified as assessing the association between SES and VL 
outcome were in European settings (only six of 17); however, they seemed equally as 
likely to find an adverse effect of lower SES as studies in the US, a setting without free 
access to healthcare. This indicated that the main factors for this specific question on 
ART response go beyond those related to healthcare system. In a review of socio-
economic inequalities in mortality and morbidity in 22 European countries, there was 
no evidence of systematically smaller socio-economic inequalities in health in Northern 
Europe compared to other areas of Europe, despite increased welfare support and 
lower prevalence of poverty286. This adds weight to the idea that socio-economic 
disparities in health are not solely a result of inability to pay for treatment. Therefore, 
greater understanding of the effect of socio-economic factors on HIV treatment 
outcomes in a setting with universal healthcare also has implications for settings 
without this.  
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The findings of this review have a number of potential caveats. Previously, substantial 
differences in the magnitude of socio-economic inequalities in health across European 
settings have been found286. Thus, the presence or magnitude of the association 
between SES and ART outcomes cannot be assumed generalisable across countries 
and healthcare settings. Due to differing definitions of SES, ART response outcomes 
and non-adherence across studies it is difficult to directly compare associations. 
Furthermore, the extent of the variation in social circumstances in the study sample 
may influence the magnitude of observed associations. Confounding could also be an 
issue, as several of the reviewed studies were not designed to specifically examine the 
effects of socio-economic factors themselves; this was particularly prevalent among 
the studies which looked at adherence outcomes. Some studies reported on the 
effects of SES among generally low SES populations, for example among food 
insecure individuals, however, a number of studies both in low SES populations and in 
more varied SES populations found consistent results. All studies that were reviewed, 
except one406, excluded individuals with missing values from VL or CD4 endpoints or 
censored follow-up at the last available measurement. If lower SES is associated with 
poorer retention in care450;451, then these studies may underestimate socio-economic 
effects.  
Of the six European studies of SES and VL identified, three considered education as 
the sole SES indicator, one solely considered employment status, and one only 
considered neighbourhood-level SES. Thus only one European study considered 
multiple markers of SES359. Education may be problematic as a marker of SES as it 
does not necessarily capture current resources or living conditions (for example SES 
of migrants in the country of migration). Likewise, neighbourhood-level SES is not 
necessarily a reliable marker of an individual’s situation. At present, there is little 
information from studies in Europe on the effect of poverty and adverse social 
circumstances on HIV treatment outcomes. Other gaps in the literature include studies 
that test specific hypotheses about the mechanisms through which SES affects health 
outcomes and adherence. Moreover, quantitative and qualitative research is needed to 
better understand these precise mechanisms and to inform intervention approaches. A 
review of the literature on the effect of SES on other points in the care continuum 
would also be valuable. My review highlights the need for routine assessment and 
documentation of socio-economic factors in the clinic setting, to identify, and in turn 
give support to, those at greater risk of ART non-adherence and poorer ART 
response.  
This literature review adds evidence of socio-economic disparities in HIV treatment 
outcomes to the disparities already identified by gender/sexual orientation. 
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Furthermore, it suggests gaps in the current literature that require analysis to gain 
understanding of the associations between SES and ART response. 
 
 Review of potential mediators for any gender/sexual 
orientation and SES differences in HIV-treatment outcomes 
In the literature reviews in Sections 2.4 and 2.5, associations of HIV treatment 
response with gender/sexual orientation and socio-economic disadvantage were 
identified respectively. Here, I will summarise studies that have included both types of 
factors in multivariable models to assess the extent to which any associations are 
attenuated (Section 2.6.1). Then I shall consider other proposed mechanisms through 
which gender/sexual orientation and SES may affect ART outcomes (Section 2.6.2). 
The method of identifying potential mediating factors by looking at the effect of 
adjustment for these factors has its limitations. It is difficult to gain an understanding of 
which factors attenuate associations between the outcome and explanatory variable of 
interest when multiple covariates are adjusted for simultaneously. Additionally, if 
unadjusted analyses are not presented, then it is not possible to investigate the 
mediating role of the factors included in adjusted analyses343;364;401. Adding covariates 
to the model sequentially would allow analysis of the extent to which these factors 
account for any associations.  
 The interaction between gender/sexual orientation and SES 
The prevalence of socio-economic disadvantage differed by gender/sexual orientation 
groups in several European studies357;364;375. In the French ANRS study, heterosexual 
migrants were more likely to have precarious housing conditions, to report financial 
difficulties and food privation, to report social isolation and to be single parents than 
MSM364. Likewise, in the SHCS only 13% and 40% of the single heterosexual migrants 
and older MSW, respectively, had paid work as their main source of income, 
compared to 90% of MSM357. Therefore, virological response differences between 
these groups could partially result from SES inequalities. However, these studies did 
not adjust their measures of the association between gender/sexual orientation and 
virological response for these socio-economic factors so it was not possible to assess 
their interaction. 
Gender/sexual orientation and socio-economic factors were jointly considered in four 
studies. Unadjusted analyses of the SHCS126 found women had lower odds of VL 
suppression compared to MSW and a higher proportion in the lowest education 
category. Adjustment for educational attainment, among other factors, only reduced 
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the OR of virological suppression by 4%, although this no longer reached statistical 
significance (p=0.13). In contrast, the CoRIS405 study focused on SES. The ORs of VL 
suppression among individuals in the low education group at six and 12 months of 
ART were attenuated by 18% and 55%, respectively after adjustment for 
gender/sexual orientation. In the HOPS363 and ANRS359 studies, univariable 
associations of both gender/sexual orientation and socio-economic factors with 
virological suppression were attenuated towards one in multivariable analyses.  
There was also some evidence of the ability of SES to explain gender disparities in 
other areas of health such as mental health452, and that women’s greater exposure to 
stress and life events453 or lower incomes454 were substantial contributors to poorer 
health among women.  
It is difficult to make any firm conclusions about whether SES acts as a mediator for 
gender/sexual orientation on response to ART since it was not the focus of any study 
identified by my literature reviews and only the four described above had any 
information I could use to address this question. 
 Potential mediators of the association of gender/sexual orientation 
or SES with virological and immunological outcomes 
ART non-adherence 
Until this point, ART non-adherence has been considered as an outcome. However, 
adherence to ART is key in achieving the outcome of virological suppression170;455. 
Furthermore, there was some evidence from my literature reviews of differences in 
non-adherence by gender/sexual orientation and SES. Thus it is likely that adherence 
is on the causal pathway between SES/gender/sexual orientation and HIV treatment 
outcomes199;456.  
Only two studies of the association between gender/sexual orientation and treatment 
outcomes, both from the ANRS cohort, looked at the effect of adjusting for adherence. 
Dray Spira et al. found that, despite poorer adherence to ART among heterosexual 
migrants, adjustment for adherence, among other factors, did not account for VL or 
CD4 count outcome differences between heterosexual migrants and MSM364. On the 
other hand, D’Almeida et al. found that associations were attenuated, but did not 
completely disappear. However, many other factors had also been adjusted for, 
including SES359.  
Although the RFHCS did not measure ART adherence, they considered rates of 
complete ART discontinuation362. A model that did not censor follow-up at ART 
discontinuation, found women had 41% higher hazard of virological rebound compared 
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to MSW. In an alternative analysis that did censor follow-up at ART discontinuation, 
this was attenuated to 30%. Thus, higher rates of complete ART discontinuation 
among women (15% vs. 9% among MSW in the first 12 months of ART) may explain 
at least some of the observed VL outcome differences.  
Four studies examined the extent to which non-adherence explained the associations 
between SES and ART response. In the VACS, food insecurity was associated with 
37% higher odds of virological non-suppression in analyses adjusted for demographic, 
lifestyle and other SES factors400. Further adjustment for self-reported adherence 
attenuated associations to some extent, however, food insecure individuals still had 
32% greater odds of non-suppression. In the ACCESS study of PWID, homelessness 
was associated with 67% higher adjusted rates of VL non-suppression compared to 
housed individuals in a model adjusted for age, recent incarceration, year of ART 
initiation and baseline VL404. However, homelessness was no longer associated with 
VL non-suppression after additional adjustment for ART adherence (attenuated by an 
additional 19%).  
The remaining two studies adjusted for adherence in the same stage as other factors 
(including baseline HIV factors such as VL and ART regimen, demographic factors 
and other socio-economic factors) and so it was not possible to isolate the effect of 
adjustment for non-adherence. Nonetheless, in a single-centre US-based study403, and 
the ANRS study359, there were still substantially lower odds of virological suppression 
for individuals with poorer education and/or employment status after adjustment. In 
contrast, in the latter study, associations between deprivation and lower odds of 
sustained VL suppression were attenuated to one in multivariable analyses. 
Calendar Time 
Over time, inequalities in treatment response by gender or SES may be reduced by 
improvements in the efficacy and tolerability of ARVs, earlier HIV diagnosis, and 
improved knowledge of the importance of adherence. Only two of the identified 
studies, both from the RFHCS, considered changes over time. Lampe et al. showed 
that the prevalence of VL >50 copies/mL decreased between 1999 and 2004, but the 
relative differences between gender/sexual orientation groups remained of the same 
magnitude across all time periods365. An earlier study found more rapid reductions 
over time among MSM compared to MSW and women in the risk of VL >200 
copies/mL after six months of ART457. Follow-up in both of these studies ended over 
ten years ago, and therefore it would be of interest to see whether differences over 
time are narrowing in more recent years.  
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Delayed diagnosis and initiation of treatment 
Late diagnosis and late initiation of treatment are often difficult to disentangle when 
looking at their effect on treatment response, since individuals diagnosed with a low 
CD4 count are inevitably going to initiate ART late. Late diagnosis is considered here 
in the context of an explanatory factor for ART response. Differences in late diagnosis 
as an outcome by gender/sexual orientation and SES will be fully discussed in Chapter 
9.  
Being diagnosed and/or starting treatment with a low CD4 count has been shown to 
have a negative impact on HIV progression, particularly immunological response to 
ART135;458-462. Prior studies have shown that women may delay ART initiation more 
frequently than men463. Three studies (two French and one Swiss) found that although 
MSM had a higher median CD4 count at ART initiation than MSW and women, 
adjustment for this (amongst other factors) did not account for gender/sexual 
orientation differences in virological or immunological response357;361;364. An American 
study of individuals initiating ART within six months of eligibility (CD4 count <350 
cells/µL or AIDS-defining condition) found no difference in time to virological 
suppression between women and MSM360. This could suggest that associations were 
not present among individuals initiating ART with a higher CD4 count. However, the 
study only provided estimates adjusted for demographic and eligibility-related factors, 
so one or more of these might have already accounted for any potential differences.  
Socio-economically disadvantaged individuals may initiate treatment at a later stage 
for a range of reasons including competing priorities, lower health literacy and less 
knowledge about ART. Neighbourhood unemployment levels were associated with 
delayed access to treatment in a study of HIV-related deaths in Canada464. However, 
this study was not in the context of the impact of late treatment initiation on ART 
responses. The SHCS126 and CoRIS studies405 found that adjustment for CD4 count 
and VL at ART initiation, along with demographic factors, attenuated the effect size of 
associations between virological response and educational attainment.  
ART regimen 
There is a wide choice of efficacious ART regimens in high-income settings in the 
modern ART era. Despite this, residual differences in efficacy465-469, differential 
adherence patterns468;470;471 related to side-effects472;473, food requirements, dietary 
restrictions, pill burden, and dose frequency could affect virological response 
according to the specific ART regimen used. Thus, ART regimen could act as a 
confounder if there are also differences in prescribing patterns between gender/sexual 
orientation or socio-economic groups.  
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Different ART regimens require differing levels of adherence in order to maintain 
virological suppression474;475. In particular, NNRTI-based regimens require lower levels 
of adherence than un-boosted PI-based regimens384, but greater levels of adherence 
than the forgiving RTV-boosted PI-based regimens192. There is also evidence of higher 
odds of women choosing PI-based regimens over NNRTI-based (OR=1.25)476, likely 
due to EFV being contra-indicated during pregnancy. Thus, women may require lower 
levels of adherence to ART to maintain virological suppression. It will be interesting to 
monitor this in future years as use of other ARVs, particularly integrase inhibitors, 
increases. Even when men and women were prescribed the same regimen, previous 
studies have shown that prevalence of side effects can differ477-479. This may be 
related to women on average having a lower weight, but receiving the same dose as 
men. So even if prescribed the same regimen women may have greater difficulties in 
adhering to treatment than men. 
Some studies have indicated that food requirements for taking ART may have been a 
barrier to adherence to treatment for socio-economically disadvantaged individuals401. 
Thus, through adherence, certain ART regimens may be detrimental to treatment for 
these groups in particular.  
Healthcare 
In general, women are more likely than men to access healthcare in high income 
settings480;481. Women may make greater use of healthcare services because they 
have a greater number of chronic conditions, burden of symptoms or need for 
treatment480. Alternatively, there is evidence of differences in health seeking 
behaviour235;279;482. Women and men have different healthcare needs, for example 
attendance at clinics for contraception, pregnancy and menopause may mean that 
women attend healthcare settings more frequently and therefore may have better 
retention in HIV care if co-located. However despite this, in HIV483 and several other 
health areas481;484;485, there is evidence that women may not have had access to or the 
same quality of treatment as men. 
In settings without universal free access to healthcare, an individual’s ability to freely 
access HIV facilities is likely to provide an advantage in terms of maintaining 
engagement with medical care and achieving a good treatment response, particularly 
for individuals with lower incomes486. In all settings, inequalities in availability of 
resources, such as transport, may lead to inequalities in access of optimal healthcare 
resources487. Studies have also shown that it is possible that healthcare provider bias 
will affect the care that socio-economically disadvantaged individuals receive in 
various areas of health488-490.  
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Mental health and lifestyle factors  
Depression and substance dependence are associated with poorer response to 
ART402;491. The effect of mental health, and drug or alcohol use on VL outcome would 
likely act at least partially through poorer adherence492-494, although studies have also 
identified a direct biological effect of depression on immune response495.  
A meta-analysis of 10 studies concluded that development of depression was not 
associated with sexual orientation among PLWH496. However, several studies have 
reported greater levels of depressive symptoms among women compared to men in 
the HIV-positive population497-499. In a US-based study of RCT data, a model adjusted 
for depressive symptoms, among other factors, attenuated the difference in adherence 
between MSM and women373. Amongst women, particularly those of black African 
ethnicity, depressive symptoms were strongly associated with greater rate of 
virological failure408. Interventions such as mental health care may improve adherence 
to ART among women, while treatment for illegal drug use has been positively 
associated with adherence in men500.  
Substance use and mental health problems are generally more prevalent among 
socio-economically disadvantaged individuals501-504. In the UK-based Antiretrovirals, 
Sexual Transmission Risk and Attitudes (ASTRA) study, depressive symptoms were 
associated with poorer virological response to treatment and strongly with adverse 
socio-economic circumstances505. Three studies found no association between socio-
economic deprivation and virological response to ART in analyses adjusted for factors 
including substance use and/or depression343;359;401. 
Ethnicity and migration 
Although not mediating factors for the association between gender/sexual orientation 
and virological response to ART, ethnicity and migration are intrinsically linked to 
gender/sexual orientation among PLWH. Three European, longitudinal studies 
previously identified considered an explanatory variable that combined gender/sexual 
orientation with other demographic factors357;364;365. They identified differences in 
virological response between MSM (of unspecified ethnicity/migrant status) and 
heterosexual non-migrant groups, but not to the same extent as those found between 
MSM and heterosexual migrants357;364;365. These results suggest differences in 
virological responses by migrant status may drive at least some of the differences 
between heterosexual and MSM groups. 
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 Thesis rationale, aims, and objectives 
 Rationale 
Saunders et al. in 2013 considered gender/sexual orientation differences in response 
to first-line treatment among HIV-positive individuals attending the Royal Free 
Hospital, London, UK362. The authors concluded that worse virological outcomes for 
women persist and suggested that a potential factor influencing this difference may be 
socio-economic status, although no data were available to test this hypothesis. As a 
result of this study, the motivation for my thesis was to assess differences in virological 
response to cART between MSM, non-MSM men and women in recent years, and to 
investigate whether socio-economic factors may contribute to such differences. 
In the era of effective ART, which nonetheless requires life-long adherence to 
treatment162, the literature reviews conducted in Chapter 2 highlighted poorer HIV 
treatment outcomes among MSW and women compared to MSM, and among 
individuals with socio-economic disadvantage. With respect to SES, few studies have 
been performed in settings with universal free access to care (none in the UK), and 
these generally only consider education status. In the HIV setting, gender/sexual 
orientation and SES may be fundamentally linked, but further study is required into 
their joint effects. The literature reviews from the previous chapter identified several 
research gaps including: (i) changes over calendar time in virological and CD4 count 
response to ART by gender/sexual orientation; (ii) differences in VL and CD4 count 
response to ART by SES in a UK setting; and (iii) the mediating effect of SES on 
differences in ART response by gender/sexual orientation. 
It is important to study socio-demographic variation at specific points in the continuum 
of care, and to assess whether such disparities have persisted in more recent years. 
My thesis focuses on the three specific areas of the care continuum outlined in blue in 
Figure 3.1506. Primarily the focus will be on treatment adherence and response to 
treatment for the reasons discussed above, but I will also consider HIV diagnosis. 
Individuals in high-risk groups for acquiring HIV, such as MSM and PWID, may be less 
likely to be diagnosed late than individuals not in high-risk groups since they are 
perceived by themselves and by health-care professionals as in greater need for 
frequent HIV testing. Therefore, it is of interest to assess whether there are gender/ 
sexual orientation disparities in access to a timely HIV diagnosis and what the reasons 
for any differences may be. A literature review for studies considering late diagnosis 
and gender/sexual orientation is included in Chapter 9. 
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Figure 3.1: Process for treatment success with steps from the treatment cascade  
 
 Aims and objectives 
In this thesis there were four main aims:  
1. To build an understanding of the existence of inequalities in virological 
response to ART by gender/sexual orientation and SES in the UK; 
2. To evaluate whether these gender/sexual orientation differences have 
narrowed in more recent years; 
3. To observe whether SES disparities contribute to any gender/sexual orientation 
differences in virological response; 
4. To identify the relationship of gender/sexual orientation and SES with late HIV 
diagnosis in the UK. 
In order to address these aims, the objectives of this thesis were: 
 To assess the trends over calendar time in VL and CD4 count by 
gender/sexual orientation among a whole UK-clinic population (Chapter 5); 
 To assess the trends over calendar time in initial virological response to 
treatment by gender/sexual orientation (Chapter 6);  
 To evaluate the association between socio-economic disadvantage, by several 
markers, and virological response to ART (Chapter 7); 
 To evaluate the ability of socio-economic factors to attenuate associations 
between gender/sexual orientation and virological response to ART (Chapter 
8); 
 To assess the differences in late diagnosis by gender/sexual orientation and 
SES (Chapter 9 - the literature review for this is included in the chapter itself). 
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 My contribution 
I played a major part in developing all of the research questions for this thesis in 
discussion with my PhD supervisors, and I decided upon the specific aims of each 
chapter that were to be addressed. I conducted all of the literature reviews that were 
presented in Chapter 2. For the data collected from the patient registration forms (used 
in Chapter 9), I was the first to analyse data from this source, and so cleaned the data 
and decided upon the best way to classify variables. I planned and conducted the 
analyses, including deriving additional required variables from those that existed 
currently in the data sets. I wrote programs to perform multiple imputation. I prepared 
all of the tables and figures presented in the results chapters of this thesis. I wrote up 
the results of each of the five analysis chapters and interpreted the results accordingly. 
I also considered and summarised the strengths and limitations of my work and the 
clinical implications. 
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 Data collection and methods 
 Introduction 
This chapter will describe the data sources and statistical methods used throughout 
this thesis. The analyses presented in this thesis are based on two UK-based 
observational studies: The Royal Free HIV Cohort Study (RFHCS) and the 
Antiretrovirals, Sexual Transmission Risk and Attitudes (ASTRA) questionnaire study. 
Information on these data sources will include details of the study design; a summary 
of the study population; a description of the data collection methods and procedures; 
and definitions of the variables included. In terms of the statistical methods used, this 
chapter will include background information on each method and considerations that 
need to be made when using these methods. 
 
 The Royal Free HIV Cohort Study 
 Source of the data 
The Ian Charleston Day Centre (ICDC) is an HIV-outpatient clinic at the Royal Free 
Hospital, London, UK. Professor Margaret Johnson helped to set up the ICDC in 1989, 
which was the first open access HIV clinic in the UK507. The ICDC provides a National 
Health Service (NHS) trust-funded multidisciplinary service for people living with HIV 
(PLWH). Currently there are over 3000 PLWH attending the ICDC. 
At the ICDC there are specific services for women in the form of a weekly Women’s 
HIV clinic. This involves a number of HIV clinicians predominantly seeing women on 
Wednesdays, and the following services are also provided on a Wednesday: 
Gynaecology advice available weekly, including everything from smears, contraception 
advice and HRT; sexual health screening, a monthly colposcopy service; antenatal 
clinics/MDTs and breast awareness clinics508. Immediate peer support does not 
coincide but there is psychology support available and access on site peer support the 
following day or referrals to peer support externally. 
 Study design 
The RFHCS is an observational database based on data collected at the ICDC on 
HIV-diagnosed individuals attending the clinic. Although the clinic opened in 1989, the 
RFHCS was not set up until 1994. For the period 1991 to 1994, a retrospective chart 
review was conducted by Professor Amanda Mocroft to extract information on all 
individuals seen in that time. From 1994 to the present day, data have been collected 
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prospectively on all individuals that have ever attended the clinic with a full notes 
review conducted annually. The database is used to address questions related to 
treatment, prognosis and clinical management of HIV in the UK. In this thesis, the 
dataset used provides information up until March 2015 (the administrative censoring 
date).  
 Study population 
Six thousand four hundred and twenty-three individuals have met the inclusion criteria 
for the RFHCS and are currently included in the database. Inclusion criteria are being 
HIV positive, having attended the ICDC on at least one occasion as an outpatient, and 
aged ≥16 years old at the first visit. Individuals were excluded if they acquired HIV 
through vertical transmission or through receipt of blood products, since these are 
quite distinct populations compared to individuals with HIV transmission through other 
routes, specifically in terms of: a greater number of years since HIV infection, likely 
limited therapeutic options early in infection509, greater likelihood of being ARV-
experienced at cART initiation, and a greater risk of co-infection with Hepatitis C 
(HCV) in the case of individuals infected through blood products510.  
 Data collection 
Patient registration forms 
At an individual’s first visit to the ICDC, a full clinical and social history is taken. This is 
collected on a patient registration report form (Appendix I.), which is manually 
completed by clinic staff for the purposes of routine care, and subsequently digitised 
and included in the RFHCS database. The latest version of the registration form was 
introduced in April 2011 and differed from previous versions of the form, in that it 
additionally included data on socio-economic factors, and encounters with healthcare 
providers in the year prior to HIV diagnosis, information that my analyses in Chapter 9 
of this thesis are the first to have used. A summary of the data collected by the patient 
registration form that are relevant to this thesis are shown in Table 4.1.  
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Table 4.1: Data fields collected on the patient registration form 
Variable category Variable 
Identifier Hospital number 
Visit details Date of visit 
Demographic factors Date of birth 
Sex 
Ethnicity 
Clinical details Most recent CD4 count 
Most recent VL measurement 
Presentation details Ever negative HIV antibody test 
Date of last negative antibody test 
Date of first positive antibody test 
Who prompted first positive antibody test 
Presenting with seroconversion illness 
Risk behaviour Most likely reasons for HIV infection 
Country of infection 
Self-defined sexual orientation 
Ever injected drugs 
Sexual risk behaviour in last 3 months 
Medical History Ever diagnosed with AIDS 
Current opportunistic infections (OI) 
AIDS-defining conditions 
Social circumstance factors Current partner 
Children 
Socio-economic factors Current housing  
Current employment 
University education 
Lifestyle factors Current smoking status 
Alcohol use 
Recreational drug use 
Encounters with UK healthcare providers 
in year prior to HIV diagnosis 
Number of primary care visits 
Number of emergency department visits 
Number of genitourinary clinic visits 
Offered HIV test prior to first positive test 
Clinic visit form  
On all subsequent visits to the ICDC, the clinician completes a clinic visit form 
(Appendix II.). This form is also manually completed and subsequently digitised. The 
data collected by this form that are relevant to this thesis are shown in Table 4.2. 
Table 4.2: Data collected by the routine clinic follow-up form 
Variable category Variable 
Identifier Hospital Number  
Visit details Visit date 
Clinical details Non-AIDS diagnoses 
New AIDS diagnoses 
Antiretroviral drug (ARV) 
prescription details 
ARVs prescribed 
ARV start and stop dates 
Reasons for stopping an ARV 
Additional information Free text section 
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Prescription data 
Prescription data are collected by the ICDC pharmacy. This data represents the 
prescriptions issued by the pharmacy rather than prescriptions collected. It includes 
both the drugs prescribed and the duration for which they were prescribed. 
Routine laboratory data 
Data are collected on T-lymphocyte cell counts (including CD4 cell count), and HIV 
RNA VL. The T-lymphocyte cell counts are measured using standard flow cytometry 
techniques511. Plasma HIV-1 RNA VL has been measured by several commercially 
available methods that have changed over time. When VL testing was first introduced 
in 1996, monitoring was performed using COBAS AMPLICOR HIV-1 MONITOR test 
1.0 (Roche Diagnostics, Roche Products Ltd., Welwyn Garden City). Improvements 
were then made, by the addition of non-B subtype primers; so that the COBAS 
AMPLICOR HIV-1 MONITOR test 1.5 (Roche Diagnostics) was able to capture non-B 
subtypes in addition to B subtypes. Improvements in the sensitivity of assays were 
made to enable lower limits of detection. While the first tests used in the Royal Free 
had a lower limit of detection of 400 copies/mL, since 1998 most routinely used tests 
have had lower limits of detection of 40 or 50 copies/mL. More recently at the Royal 
Free, the COBAS TaqMan (Roche Diagnostics) assay has been used. This assay was 
accepted for use after formal tests in the laboratory found that the TaqMan and 
AMPLICOR assays were strongly and linearly correlated and thus considered 
equivalent512. Other assays used at the Royal Free include the LCx (Abbott) and 
RealTime (Abbott). Again, studies have found a high degree of agreement between 
these assays513;514. 
 Compilation of the research database 
The research database utilises the information held in the clinic database. Annually, a 
trained research assistant, Clinton Chaloner, conducts a 100% notes audit of the clinic 
database. He extracts additional information from the text section of the routine clinic 
follow-up form and the paper notes, corrects any mistakes, and updates any 
information that has changed since the last notes audit. The information collected by 
the note review includes: start and stop dates for each individual ARV; reasons for 
stopping any ARV; hospital in-patient admissions and discharges with reasons; date 
and type of AIDS-defining events; date and type of non-AIDS events; known transfers 
out of the ICDC with centre transferred to if known. If an individual has transferred to 
the Royal Free hospital from another HIV outpatient clinic, and if the individual gives 
their consent, then details of previous HIV-related medical history (including laboratory 
test results) is requested and included in the database wherever possible. This method 
of notes review means that the database provides a high level of accuracy. In 
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particular, information that is more complete is available on treatment changes, 
discontinuations and adherence – with reported ARV interruptions of any length noted 
in the database, even those as short as 2-3 days. The prescription data and routine 
laboratory data are transferred electronically from the relevant departments. Sam 
Hutchinson, who completes Coding Causes of Death in HIV (CoDe) forms on 
individuals in the database who have died, collects data on deaths in the cohort. This 
is part of the CoDe project which aims to provide a standardized method for coding the 
underlying cause of death in PLWH515. The RFHCS data is manually entered into the 
database and the database is securely transferred to Fiona Lampe and Colette Smith 
in the UCL Research Department of Infection and Population Health.  
Data management 
Additional data cleaning steps are then performed to detect and correct inaccurate 
entries, by checking variable ranges and crosschecking for discrepancies. For 
example, the sequences of dates (e.g. ensuring drug start dates precede stop dates 
and that no events occur on a date after the recorded date of death) are investigated. 
Implausible data are also double-checked, such as checking the antiretroviral 
treatment information of those receiving mono or dual therapy regimens or five or 
more ARVs simultaneously in the modern era. Incomplete variables are also 
completed through other available information where possible: for example, if the 
gender of a current partner has been completed on the patient registration form, but 
there is no response to whether the individual has a current partner, then this can be 
completed as an affirmative response. Finally, searches are made to identify 
individuals with duplicate hospital numbers, including checking the data of individuals 
with similar names and dates of birth and asking staff to report any that they identify on 
an ad hoc basis. Identified potential errors and discrepancies are checked against the 
paper-based data collection forms. 
As I was the first person to use the data from the revised patient registration forms, I 
played a key role in data cleaning, formatting and the generation of new variables 
using the methods described above. 
 Ethics 
At the time of writing of the thesis, analysis of data from the RFHCS was covered by a 
letter of approval from the Chairman of the Royal Free Ethics committee. 
 
 Antiretrovirals, Sexual Transmission Risk and Attitudes 
(ASTRA) questionnaire study 
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The ASTRA study was designed in 2010 in order to examine sexual risk behaviours 
and attitudes among people diagnosed with HIV and under care in the UK. The main 
aims of the study included: 
 To assess the association of ARV use, current VL suppression, demographic 
and socio-economic factors, transmission risk beliefs, and other factors, with 
high-risk sexual behaviour 
 To assess the association of questionnaire assessed factors (demographic, 
socio-economic, symptoms, quality of life, lifestyle and HIV-related factors), 
with attitudes to starting immediate ART among those who were ART-naïve 
 To investigate the association of questionnaire assessed factors (demographic, 
socio-economic, symptoms, quality of life, lifestyle, HIV-related) with laboratory 
and clinical outcomes 
The methods and participant characteristics have previously been published516, 
however, in this section I have summarised the main methods of the ASTRA study. 
 Study design 
ASTRA is an observational, cross-sectional self-administered questionnaire study 
conducted in eight UK NHS HIV outpatient clinics from February 2011 to December 
2012, with an additional longitudinal component. The eight centres were Royal Sussex 
County Hospital (Brighton), East Sussex Sexual Health Service (Eastbourne), 
Homerton University Hospital (London), Mortimer Market Centre (London), Newham 
University Hospital (London), North Manchester General Hospital (Manchester), Royal 
Free Hospital (London) and Whipps Cross University Hospital (London). All 
participants completed a study questionnaire, and the latest values of CD4 count and 
VL were recorded by study personnel in a study log for all participants. For consenting 
participants, linked routine clinical data was provided by each centre using this study 
log, which contained both the study and clinic numbers. This included clinical data 
from both before the time of the questionnaire and the time after the questionnaire up 
until the data was processed to provide to study personnel. Linked data are currently 
available for six clinics (Brighton, Eastbourne, Homerton, Mortimer Market, Newham, 
Royal Free) which were collated from 2013 onwards. At the time of this thesis, data 
was provided up until April 2014 for Brighton, January 2015 for Eastbourne, March 
2013 for Homerton, December 2013 for Mortimer Market, October 2015 for Newham, 
and May 2014 for the Royal Free. 
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Prior to main study recruitment, a pilot study was conducted at several of the study 
sites, after which minor changes were made to the questionnaire and information 
sheet. 
 Study population 
PLWH aged ≥18 years and attending one of the eight centres for outpatient care were 
eligible for inclusion in the study. Individuals were excluded if they were unable to 
complete the questionnaire in English or French due to language or cognitive 
difficulties, or because they were too ill or distressed to participate. 
 Recruitment 
Within selected recruitment sessions, consecutive individuals attending the HIV 
outpatient clinics were invited to participate, either while waiting for, or after, their 
routine clinic appointment. Recruitment took place in each centre over at least a six-
month period, as the majority of individuals under care would have been expected to 
attend the centre over this period. Individuals who were approached and asked to 
participate were provided with an information sheet about the study (Appendix III.). 
Those who agreed to participation were asked to sign a consent form (Appendix IV.). 
This form included an additional optional consent to linkage of questionnaire 
responses with available routine clinical data.  
 Data collection 
The questionnaire was self-administered in the waiting room either before or after the 
participant’s outpatient appointment. In each clinic, a private space was also available 
to complete the questionnaire, if the participant preferred this. Participants were asked 
to seal completed questionnaires in the envelope provided and leave in a labelled box 
in the clinic. Completed questionnaires were stored securely in the clinic and 
periodically transferred back to the research centre. Although participants were asked 
to complete the questionnaire in clinic on the day of recruitment to the study, if this 
was not possible, they could take away a paper questionnaire and post it back using a 
pre-paid envelope.  
There was a separate version of the questionnaire for men (Appendix V.) and women 
(Appendix VI). The main differences were that only women were asked to record the 
ages of any children, the HIV status of these children, and whether they were currently 
pregnant. Men were asked about sexual intercourse with men and women separately, 
whereas women were only asked about sexual intercourse with men. A French version 
of the questionnaire was also available if desired.  
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Identifiable information such as names and clinic identification numbers were not 
included on the questionnaire, but instead a unique study number was pre-assigned 
and completed on the first page by the study recruiter, prior to questionnaire 
completion by the participant. Participants were reassured of the confidentiality of their 
questionnaire responses, and in particular, that their answers would not be seen by 
clinic staff or included in their clinic notes.  
Study nurses at each of the sites completed a study log for each person approached 
and asked to participate. Information included the date, study number, clinic number 
(not provided to research team), consent to participate, and additionally, for those who 
consented to participate: consent to linkage with clinical data, latest VL and CD4 count 
and the date that they were measured. The latest value was defined as the last value 
available to (communicated to) the participant at the time that the questionnaire was 
issued. 
For consenting participants, each study centre used the clinic number in the study log 
to link the study number to their routine clinical data. Periodically the routine clinical 
data was securely transferred to the research centre using only the pseudonymised 
study number for the purposes of confidentiality.  
Questionnaires were sent for digitisation to an external data entry company where 
data were entered twice. Further data checks were performed at the research centre.  
Table 4.3 lists the variables collected by the questionnaire that were relevant to this 
thesis. Table 4.4 lists the routine clinic data provided by clinics for consenting 
participants that were relevant to this thesis (Appendix VII.).
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Table 4.3: Summary of information collected by the ASTRA questionnaire 
Variable 
category 
Variable Response options 
Identifier Study number  
Clinic Brighton/Eastbourne/ 
Homerton/Manchester/ Mortimer 
Market/Newham /Royal Free/Whipps 
Cross 
Demographic 
factors 
Month and year of birth  
Sexual orientation Homosexual/heterosexual 
/bisexual/other 
Ethnicity White/black African/other 
Socio-economic 
factors 
Financial hardship - able to 
afford basic needs? 
Always/mostly/sometimes/ no 
Employed Yes/no 
Housing status Homeowner/renting/ unstable or other 
University education Yes/no 
Social 
circumstances 
Country of birth UK/non-UK 
Time in the UK UK-born/>5 years/≤5 years 
English reading fluency UK-born/fluent/not fluent 
Current partner Yes/no 
Children Yes/no 
Supportive network (modified 
Duke UNC Functional Social 
Support Questionnaire 
[FSSQ]) 
Most/medium/least 
Lifestyle factors Current smoking status Smoker/non-smoker 
Evidence of alcohol 
dependency (CAGE score) 
Yes/no 
Recreational drug use in the 
last 3 months 
Yes/no 
Symptom Major symptoms of 
depression (PHQ-9) 
Yes/no 
Major or other symptoms of 
depression (PHQ-9) 
Yes/no 
HIV-related 
factors 
Month and year of first 
positive antibody test 
 
Most recent CD4 count  
Most recent VL a  
Most likely reasons for HIV 
infection 
 
ART use Ever on ART Yes/no 
Month and year ART initiated  
Started ART because ill Yes/no 
Ever changed ART because 
of VL failure 
Yes/no 
Currently on ART Yes/no 
Frequency of taking ART  
ART adherence Number of doses missed in 
the last 2 weeks 
 
Reasons for non-adherence 
in last 2 weeks 
 
Missed treatment for ≥2 
consecutive days in the last 3 
months 
Yes/no 
 
a For those who ever started ART only 
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Table 4.4: Summary of information collected from linkage to patient notes 
Variable category Variable 
Demographic factors Month and year of birth 
HIV-related factors HIV exposure category 
Clinical details Date of first HIV clinic visit 
Date of first positive HIV test result 
VL test results a 
VL test dates a 
CD4 count test results a  
CD4 count test dates a 
ADE or other clinical diagnoses a 
Date of ADE or other clinical diagnoses a 
Date of death 
ART prescription details ART drugs prescribed 
Date ART drugs prescribed 
 
 Response rates 
An estimated 12566 individuals were seen in the participating clinics during the 
recruitment period. Of these, 5112 were approached about participating in the ASTRA 
study and met the eligibility criteria. Of these, 4200/5112 consented to participate and 
3258/5112 completed the questionnaire, which gives a response rate of 64% (see flow 
chart in Figure 4.1). In the six clinics with linked clinic data currently available, 3203 
participants agreed to linkage between their questionnaire and clinical data; of those 
who completed the questionnaire 2575 agreed to linkage with clinical data (2575/4285; 
which is an overall response rate of 60% for longitudinal analyses in the clinics with 
available data). 
 
 
a All available, before and after the date of the questionnaire; ADE = AIDS defining event. 
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Figure 4.1:  Flowchart of ASTRA study participation
Seen in one of eight clinics 
during recruitment period
N=12566
Approached to participate
N=5112
Consented to participate
N=4200
Completed the questionnaire
N=3258
Consented to linkage with clinical 
data and clinic data available
N=2575
2575 included in 
longitudinal 
analysis
3258 included in 
cross-sectional 
analysis
Did not consent to linked data
N=274
Clinic data unavailable
N=409
Did not complete the questionnaire
N=942
Did not consent
N=912
Not approached to participate or did 
not meet criteria
N=7454
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 Data management 
Clinic identifiers or contact details were not transferred to the study management 
centre so that participants were identified only through the pseudonymised study 
number. All data from the study are stored only on encrypted password protected 
drives, thus responses are kept confidential.  
Participants of the study did not necessarily complete all parts of the questionnaire. In 
order to have as much complete data as possible, information from clinical records 
were used to complete any missing information when permission for linkage to routine 
clinical notes was given and when this information was available. For example missing 
values for month and year of age, month and year of HIV diagnosis, and ART status 
information from clinic records was used where possible. For questions with free text 
answers, these were manually coded into categories as described in Section 4.4.2.  
In ASTRA among those on ART, there were 15 individuals with missing data for the 
adherence question on doses missed in the last two days, and 14 with missing data on 
whether they had missed two consecutive days of ART in the past three months. For 
each of these variables, individuals with missing data were included in the adherent 
category on the basis that there is no indication of non-adherence given. 
 Ethics 
Ethical approval for the ASTRA study was obtained via the North West London REC 2 
research ethics committee (ref 10/H0720/70). 
 
 Summary of data used and main variables of interest 
In Sections 4.2 and 4.3 I described the data sources for this thesis: the RFHCS 
database, including the Royal Free hospital patient registration forms, and the ASTRA 
study. In this section, I will detail the data used in each results chapter and give details 
of the main variables used. Table 4.5 summarises which data source is used in each 
chapter. 
Table 4.5: Summary of data used throughout the thesis 
Chapter Data source N in dataset N in primary analysis 
5 RFHCS 6423 5910 
6 RFHCS 6423 1615 
7 ASTRA study Cross-sectional: 3258 
Longitudinal: 2983 
Cross-sectional: 2405 
Longitudinal: 1740 
8 ASTRA study Cross-sectional: 3258 
Longitudinal:2983 
Cross-sectional: 2405 
Longitudinal: 1740 
9 RFHCS (Royal Free 
Hospital patient 
registration forms) 
888 417 
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In all chapters, the definitions of ART and cART are consistent. ART was defined as a 
regimen including at least one ARV, whereas cART was defined as a regimen of at 
least three ARVs (see Section 1.2.1). 
As a result of the focused research aims of my thesis (Chapter 3), I used only the 
variables that were needed to address these specific aims. For example, disclosure of 
HIV status collected by the ASTRA questionnaire was not included in this thesis since 
Daskalopoulou et al had already examined this and there was no evidence of 
disclosure being associated with non-adherence or virological suppression517. Study 
centre was also not included because of confounding with both gender/sexual 
orientation and SES; therefore adjusting for it would have removed some of the 
gender/sexual orientation or socio-economic effects that I wished to measure. 
Furthermore, given post-code data was collected in the patient registration forms, it 
would have been possible to use area-based measures of SES in addition to the 
individual-level variables, however, the results from the literature review in Chapter 2 
suggested that neighbourhood SES was a poorer marker. The variables considered in 
this thesis are outlined in detail below. 
 Derivation of main demographic, socio-economic and lifestyle 
variables used from the RFHCS 
Gender/sexual orientation 
Gender/sexual orientation was defined using gender, and mode of HIV acquisition as a 
proxy for sexual orientation, as sexual orientation is not routinely recorded in the 
RFHCS database. On the patient registration forms the only options for gender/sex 
were male or female. There were fewer than 10 transgender people across the entire 
cohort and these individuals were classified according to the gender that they identify 
as. Thus, the three groups were defined as: (i) men who likely acquired HIV through 
sex with men (MSM), (ii) men who likely acquired HIV through sex with women 
(MSW), and (iii) women who likely acquired HIV through sex with men. Therefore, 
individuals in the RFHCS who did not have a sexual mode of acquisition of HIV were 
unclassified in the gender/sexual orientation variable and excluded.  
Ethnicity 
Ethnicity was self-reported to the clinic using standard Self-Defined Ethnicity Codes 
(SDE) and further classified into a six-category variable: white, black African, black 
Caribbean, Asian, other/mixed, and unknown. 
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New Patient status 
New patient status at any point in time was classified using the time between the date 
of first visit to the ICDC and the date of interest. There were three categories: ≤ six 
months; six to 12 months; and >12 months. 
 Derivation of main demographic, socio-economic and lifestyle 
variables used from the ASTRA study 
Gender/sexual orientation 
Gender/sexual orientation was defined using gender, together with responses to 
questions on sexual orientation and recent sexual behaviour. Given that individuals 
were given either a questionnaire for men or one for women, and this was used to 
determine gender, transgender and non-binary gender was not recorded. MSM were 
defined as men who reported their sexual orientation as gay, homosexual or bisexual 
(or related term), or those who reported having sex with a man in the past three 
months. MSW were defined as men who reported their sexual orientation as 
heterosexual or straight and had not been classified as MSM. Women were defined as 
women of any sexual orientation (therefore this definition differs from the ‘women’ 
category used for the RFHCS, which required sexual transmission of HIV). For a small 
number of cases, for which sexual orientation could not be classified based on the 
above definitions, additional information (likely mode of HIV acquisition according to 
questionnaire or linked clinic data if available) was used to assign a category518. 
Ethnicity 
Ethnicity was defined as a three-category variable: white; black African; other. White 
and black African or black Caribbean were included in the other category. For 
individuals who selected more than one category, classification was made based on 
an individual basis and using responses to country of birth.  
Socio-economic factors 
Financial hardship was derived from the question “Do you have enough money to 
cover your basic needs? (E.g. food, heating)” for which respondents scored 1: “Yes, all 
the time” 2: “Yes, most of the time” 3: “Yes, some of the time,” and 4: “No.” For 
individuals who selected more than one category, they were categorised as the least 
hardship selection; an average of the selections if they were not consecutive. 
Employment status was grouped into two categories for the purposes of this thesis: 
“employed” includes individuals who reported either full- or part-time employment; 
“non-employed” includes everyone else with a response to employment status.  
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Housing status was grouped into three categories: homeowners or owner occupiers; 
renting, which included those who rented privately or from the council or housing 
association; unstable/other which included those living in a hostel, shelter, squat, other 
temporary accommodation, those staying with partners, family or friends, and those 
who were homeless.  
Education was considered as a binary variable: individuals with a university level 
education or higher; and individuals with below university level education. 
Individuals who report “other” to the questions on employment status, housing status 
or education are categorised into the most relevant category based on any comments 
in the free text section.  
Social circumstances factors 
Country of birth was defined according to the question “were you born in the UK?” and, 
if the answer was no, then participants were asked which country they were born in. 
These were grouped into continents since there were too many countries reported to 
allow meaningful statistical analysis, and grouped as UK; Europe non-UK; Africa; 
North America; South America; Asia; Australia; Unknown non-UK.  
Time living in the UK was defined as three categories: born in the UK; living in the UK 
for over five years; and living in the UK for five or fewer years. For English reading 
ability, individuals who are not classified as born in the UK were split into two groups: 
individuals reporting “fluent” reading ability; and then all other individuals with non-
missing data on reading ability. If individuals had missing data for these variables but 
white British ethnicity recorded, then they were included in the UK-born group.  
Supportive network aimed to measure supportive relationships based on a 
modification of the Duke UNC Functional Social Support Questionnaire (FSSQ)519. 
Participants scored from 1: “much less than I would like” to 5: “as much as I would 
like,” on each of the following five items: whether they have people who care what 
happens to them; they receive affection; they get chances to talk to someone they 
trust; they get invited to do things; and they get help when sick. Scores of 5-12 were 
classified as “least support,” 13-24 as “medium support,” and scores of 25 as “most 
support.” 
Current partner was a binary yes/no variable derived from the question “Are you 
currently in an ongoing relationship with a partner (wife/ husband or civil partner or 
girlfriend/ boyfriend)?”  
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Whether individuals currently have children was also considered as a binary yes/no 
variable. Number of children and any children’s ages were not considered since these 
were only collected among women. 
Lifestyle factors 
Current smoking status was a binary variable derived from responses to questions on 
whether the participant is a current smoker, ex-smoker, or they have never smoked. 
Ex-smokers and individuals who have never smoked were defined as a single group 
since the intention was to consider current lifestyle.  
Recreational drug use was defined using binary yes/no responses to the question “in 
the past three months, have you used recreational drugs? (E.g. poppers, cannabis, 
cocaine).” If individuals had a missing response to this question then their response 
was assumed to be a “no.”  
Alcohol dependency was defined using the CAGE four question alcohol use 
score520;521. The standard definition based on this score was used, so participants with 
CAGE scores ≥2 were considered to have evidence of alcohol dependency. 
Individuals with a missing response were assumed not alcohol dependent, except if 
the whole of the lifestyle section on the questionnaire was blank, and in this case, the 
response was considered missing.  
Mental health factors 
Depression symptoms were defined using the Patient Health Questionnaire nine item 
scale (PHQ-9) depression inventory522. This is a self-administered questionnaire 
validated for use in primary care to screen for depression. The standard definitions of 
“major depression” and “major or other depression” based on criteria were used. Major 
depressive symptoms was defined by an affirmative response to at least five symptom 
questions, defined as “being bothered or distressed” by the symptom on ‘more than 
half the days’ or ‘almost every day’ in the last two weeks. For the symptom “thoughts 
that you would be better off dead” an affirmative response also included the category 
“some of the days”. In addition, in order to fulfil the definition the participant was 
required to have an affirmative response to at least one of two specific symptoms: 
“little interest or pleasure in doing things” or “feeling down, depressed or hopeless.” 
Major or other depressive symptoms was defined by an affirmative response ≥2 
symptom questions as defined above, which included an affirmative response to one 
of the two aforementioned symptoms. 
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 Derivation of main demographic, socio-economic and lifestyle 
variables used from the RFHCS patient registration data 
Gender/sexual orientation 
Gender/sexual orientation was defined using self-reported sexual orientation. Men who 
reported heterosexual sexual orientation were categorised as MSW. All other men 
were categorised as MSM, so this group also included a small number of men who 
have sex with both men and women. The third category was women of any sexual 
orientation. There were not separate groups for bisexual men and bisexual or lesbian 
women since there were too few individuals in these categories. 
Ethnicity 
Ethnicity was defined as a three-category variable: white, black African, and other.  
Socio-economic and social circumstances factors 
Employment, housing status, and education were defined in the same way as for the 
ASTRA study. Current partner and children were again defined as binary yes/no 
variables. 
 HIV risk factors 
Reported recent sexual activity was defined using yes/no responses to whether the 
individual had had any sexual activity in the three months prior to their first visit to the 
ICDC. Individuals without a response recorded were categorised as “no.”  
The risk factor ever injected drugs was also defined using yes/no responses, and 
similarly, individuals without a response were categorised as “no.” 
Country of infection was considered as a binary variable where individuals were 
classified as likely infected in the UK or likely infected outside the UK.  
 
 Statistical methods 
This section gives an overview of the statistical methods used throughout this thesis. 
Specific detail of the methods for each analysis are supplied in the methods section of 
the relevant chapter. SAS version 9.3523 was used for all analyses with the exception 
of multiple imputation analyses which were conducted in Stata version 13524.  
 Descriptive statistics 
Provision of summary statistics is important in order to give an overview of the study 
population. They are particularly valuable for cohort studies since, unlike clinical trials, 
individuals are not randomised and thus there are likely to be differences between the 
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groups studied. For categorical variables, the total number of individuals (N) and 
percentage (%) in each category are reported. For continuous normally distributed 
variables the mean and standard deviation are reported, or, in the case of skewed 
distributions, then the median and interquartile range (IQR) are reported. 
Incidence is defined as the probability of an event occurring over a given period of time 
(e.g. diagnoses, deaths, virological rebound). Prevalence is defined as the number of 
people with a particular condition or factor at a given time. Related concepts are risks, 
odds, and rates. Incidence risk is the probability that an event will occur by a certain 
time. Incidence rate is the frequency with which an event occurs in a defined 
population relative to the person-time at risk. Odds describe the ratio of the probability 
that an event will occur to the probability that an event will not occur.  
 Effect measures 
Effect measures are used to quantify differences between groups and in order to 
interpret and understand associations. Effect size of an association is commonly 
measured by a risk ratio (RR) (also known as relative risk), odds ratio (OR), rate ratio, 
hazard ratio (HR), or prevalence ratio (PR). These are all relative effect measures that 
express the frequency of an outcome or dependent variable in one group relative to 
that in another group (see Appendix VIII.). 
For each of these effect measures, a value of greater than one indicates an increased 
risk of the outcome occurring, while less than one indicates a decreased risk of the 
outcome occurring. If the confidence interval does not include one, then this indicates 
a statistically significant difference between groups. 
Comparison of the effect measures 
RR is an intuitive measure that is easier to interpret than an OR, although ORs are 
approximately equal to a RR if the outcome is relatively rare (usually taken as an 
incidence of below 10%). In cases when the outcome is not rare however, ORs may 
be falsely interpreted as RRs and thus may exaggerate associations525. On the other 
hand, the main advantage of ORs is that they are not dependent on the prevalence of 
an event, whereas RRs are525.  
PRs are easy to understand as a comparative measure of prevalence. They can be 
interpreted in a similar way as the RR, since both can be seen as probabilities – PRs 
provide information on the relative frequency of an event at a set time and RRs on the 
relative frequency of an event over a period of follow-up.  
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In longitudinal analyses where follow-up data is considered, individuals may not be 
followed for equal lengths of time for many reasons, for example late study entry, lost 
to follow-up (LTFU), death, cure, etc. Using RR or OR will be misleading if there are a 
large number of individuals with varying lengths of follow-up so rate ratios would be a 
more appropriate measure.  
 Associations between variables 
Pearson’s Chi squared test was used to make comparisons between the groups of a 
categorical variable, however, if any expected cell count is less than five, then Fisher’s 
exact test was used. For ordinal categorical variables, the Cochran-Armitage test for 
trend was used. Wilcoxon-Mann-Whitney tests were used for continuous variables, as 
they were not normally distributed. All tests performed are two-sided. A P-valueless 
than 0.05 was considered an indication of a statistically significant difference. 
 Statistical models 
The choice of which statistical method to use depends on the type of dependent 
variable (or outcome or response) being considered. The two main statistical models 
used in this thesis are the modified Poisson regression model, and the Cox 
proportional hazards regression model. 
Regression analyses 
Regression analysis is a statistical process for estimating the relationships between a 
dependent variable and one or more independent variables (covariates, explanatory 
variables or predictors). A family of regression models exist called generalised linear 
models (GLMs), where the dependent variable is assumed to follow an exponential 
family distribution with its mean equal to some linear function of the independent 
variables (see Appendix IX.). Some examples of GLMs are linear (Appendix X.), 
logistic (Appendix XI.), Poisson, and cox proportional hazards, with the simplest being 
linear regression. 
Poisson regression and modified Poisson regression 
Count data is constrained to the range of positive integers only. The Poisson 
distribution is more appropriate for such data than the normal distribution (used in 
linear regression), since a Poisson-distributed variable can only take integer values 
and the mean is positive. Poisson regression is described in Appendix XII. in more 
detail. 
Poisson regression was used in this thesis in two contexts. The first is for binary 
dependent variables. Although the dependent variable in a Poisson regression is 
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usually a count, it can also be used in a modified format to model a binary dependent 
variable (i.e. situations in which the count can only take the values zero or one). Here, 
the Poisson model is estimating the probability of an event occurring, rather than the 
odds of an event occurring as done in logistic regression. Therefore, associations with 
explanatory variables are estimated using RRs. As RRs are intuitive to understand, I 
have chosen to use this method in my thesis instead of the more traditional logistic 
regression, which would have produced less easily interpretable ORs. 
As mentioned in the previous paragraph, a modification is required for Poisson 
regression when the dependent variable is binary. A Poisson-distributed variable has 
an equal mean and variance by definition. In contrast, the mean of a binomial-
distributed variable is given by 𝑝 and its variance by p(1 − p). The variance must be 
smaller than the mean, as (1 − p) is a probability and must be ≤1. Thus, the variance 
of a binary dependent variable is overestimated in a Poisson regression. To account 
for this over dispersion, I used the well-established modified Poisson regression model 
proposed by Zou et al.526. In this method, sandwich estimation is used to provide 
robust error variance, which works by defining subjects as if they have repeated 
observations even though only one observation is available. Further details may be 
found in Appendix XIII. and in the paper by Zou et al.526.  
Survival analysis approaches and Cox proportional hazards models 
A standard survival analysis approach was used for time to event data. Although the 
name of survival analysis suggests that the dependent variable should be time to 
death, it need not be death or even a negative event. Thus, dependent variables such 
as time to virological suppression or time to virological rebound can also be analysed 
with this approach. Survival analysis approaches are suitable for data in which the 
time to event is censored for some individuals. Censored data happens when a 
measurement or observation is only partially known. In this thesis, I only have 
situations with right-censored data, although left-censored and interval-censored data 
can occur. Right censoring refers to the situation when a period of follow-up for an 
individual ends before the event of interest; we do not know the time-to-event for this 
individual, only that it had not yet occurred at the last visit. We say that the individual’s 
follow-up is censored as this last visit date.  
In this thesis, I have used Kaplan-Meier methods to calculate unadjusted estimates of 
survival/failure probabilities and compared groups using the log-rank non-parametric 
test. The associations of explanatory variables with time-to-event dependent variables 
were investigated using Cox proportional hazards regression (see Appendix XIV.). 
This model uses the hazard rate (i.e. the instantaneous rate of an event occurring) as 
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its outcome, and so associations between potential risk factors and the outcome are 
quantified using the hazard ratio (HR). The main advantage of this method over 
Poisson regression is that it is semi-parametric: it makes no assumption about the 
shape of the underlying hazard function. In other words, it puts no restrictions on how 
the rate of the event changes over time; it only requires that the ratio of hazards 
between exposure groups remain constant over time. This is known as the 
proportional hazards assumption.  
Generalised estimating equations 
GLMs with Generalised Estimating Equations (GEEs) can be used to model data with 
a clustered dependent variable527;528. In this case, not all observations are independent 
of each other, and a major assumption of GLMs no longer holds (see Appendix IX.). In 
my thesis, I encountered clustered data when including repeated measurements, for 
example when including the virological response of an individual at a number of 
different time-points in the same analysis. Here, responses from the same individual 
(cluster) are likely to group together (be correlated), whereas responses from different 
individuals are likely to be independent. In this situation, standard GLMs may 
underestimate standard errors due to false inflation of information, as it assumes all 
observations are independent and does not account for this correlation between 
responses from the same individual. Inclusion of GEEs in a regression model is a way 
of accounting for this by explicitly specifying the structure of this additional correlation. 
A more detailed explanation of GEEs and different correlation matrices is included in 
Appendix XV. and in a paper by Zeger et al.529. 
Regression models with GEEs estimate mean, or population average, responses. The 
parameters obtained from this model can be interpreted similarly as for a standard 
GLM; for example, ORs are obtained from a logistic regression. However, they now 
refer to the average response in the population. For example, an OR obtained from a 
GLM with GEEs estimates the effect of a unit increase in the independent variable on 
the average response of the population.  
Linear contrasts 
When summarising the association between a categorical variable and a dependent 
variable, one of the categories is usually chosen as the reference. The risk of an event 
in the other categories is then estimated compared to this reference group, for 
example by presenting a RR. However, the choice of reference group is relatively 
arbitrary and can be changed without fundamentally altering an analysis. When 
considering the association of gender/sexual orientation with the outcomes considered 
in this thesis, I wished to present each pairwise comparison rather than choosing a 
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specific reference group. Therefore, I used a linear contrast, which is a linear 
combination of variables whose coefficients add up to zero. This enabled me to define 
pairwise comparisons for MSW vs. MSM, women vs. MSM, and women vs. MSW all 
from the same regression model. 
 Confounding variables, mediating variables, statistical interaction, 
and collinearity 
Confounding variables 
A confounding variable is one which (i) is independently associated with the 
dependent variable; (ii) is associated with the exposure of interest; and (iii) does not lie 
on the causal pathway between the exposure and dependent variable (i.e. it is not a 
result of the exposure and a risk factor for the dependent variable). Though 
confounding is not an issue for randomised studies as condition (ii) cannot hold by 
definition, it is frequently a major issue in observational studies. Confounding can 
either mask or falsely induce an association between the exposure of interest and the 
outcome. For example, consider the association between ART adherence and 
gender/sexual orientation. Here, age is a potential confounder, since men living with 
HIV tend to be older than women are and younger age is a risk factor for poorer ART 
adherence375;530-533 (Figure 4.2). 
Figure 4.2: Illustration of confounding using a causal diagram 
 
Mediating variables 
A mediating (or intermediary) variable is one that is on the causal pathway between an 
exposure and outcome being investigated. In other words, a variable that follows the 
exposure but precedes the outcome in a causal chain. For example, ART adherence 
may be a mediating variable for the association between SES and virological rebound, 
as lower SES status could lead to lower adherence, which in turn leads to a higher risk 
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of virological rebound. Mediating factors represent an indirect effect of the exposure on 
the outcome as represented in Figure 4.3. 
Figure 4.3: Hypothetical illustration of mediating factors using a causal diagram 
 
Statistical interaction  
An interaction between variables occurs when a relationship between two variables is 
modified by at least one other variable, i.e. the strength or direction of an association 
between two variables is different depending on the level of an additional variable. For 
example, there may be large differences in the percent with virological non-
suppression in the different gender/sexual orientation groups in earlier calendar years, 
but these differences may no longer be present in later years; here gender/sexual 
orientation and calendar year interact. This hypothetical example is represented 
graphically in Figure 4.4. 
Figure 4.4: Hypothetical illustration of statistical interaction 
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Collinearity 
Collinearity refers to the situation in which two or more independent variables in a 
multivariate model have a tendency to vary together (i.e. they are highly correlated); 
this is illustrated in Figure 4.5. For example, different markers of SES, such as 
financial hardship and employment, are likely to be highly correlated. When the 
association of one dependent with two or more explanatory variables are considered 
simultaneously, the more highly correlated the variables are, the more difficult it is to 
distinguish how much of the variation in the outcome each is accountable for. The 
consequences are that the estimated coefficients will have large standard errors, 
estimates of effect size may be irregular, and it is difficult to distinguish the effect of the 
individual collinear variables on the outcome.  
Figure 4.5: Illustration of collinearity between variables (X1 X2) a and of variance 
explained b 
 
 
a Overlap between X1 and X2 illustrates the correlation between them; b overlap between the 
outcome and either X1 or X2 represents the proportion of the variance in outcome that can be 
explained by that variable.  
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 Approaches taken in this thesis to account for confounding, 
statistical interaction, and collinearity 
Methods for handling confounding 
In this thesis, I have used one of the most common ways for accounting for 
confounding by using multivariable regression analysis. These models provide 
adjusted estimates of effects (such as RRs, ORs and PRs) which enables one to 
estimate the association between a specific independent variable and a dependent 
variable, holding all other independent variables constant534.  
Methods for handling statistical interaction 
In this thesis, I have used regression models to investigate presence of statistical 
interactions, by adding an interaction term (the product of variables) alongside the 
independent variables. If the hypothesis test for this interaction term reaches statistical 
significance, then it implies that the coefficient the interaction term is different from 
zero. In other words, the effect of one explanatory variable on the dependent variable 
differs according to the value of the second explanatory variable. Thus, the effects of 
each independent variable has to be presented conditional on the level of the second 
independent variable (e.g. multiple estimates of the association between 
gender/sexual orientation should be presented, which will differ according to calendar 
year and vice versa). 
Methods for handling collinearity 
Two common approaches to collinearity in regression models are: (i) combining highly 
correlated explanatory variables into one explanatory variable (or a small number of 
uncorrelated variables); and (ii) only including a subset of the correlated variables in 
the model at any one time. The first situation can be applied by employing methods 
such as principal component analysis (PCA) or partial least squares regression, which 
use orthogonal transformations to convert a set of potentially correlated variables into 
linearly uncorrelated variables. However, as this can lead to explanatory variables that 
are difficult to interpret clinically, I have decided to take the second approach.  
There are two situations that I have encountered in my thesis where collinearity was a 
particular issue. Firstly, there are high levels of collinearity of both ethnicity and clinic 
of recruitment with the covariates of interest; namely gender/sexual orientation and 
SES, throughout the thesis. In the UK, ethnicity is very strongly associated with 
gender/sexual orientation, as for example a large proportion of MSM are of white 
ethnicity, whereas a large proportion of MSW are of black African ethnicity. Thus, 
disentanglement of the effects of gender/sexual orientation and ethnicity is not 
straightforward. In the ASTRA study, the clinic of recruitment is strongly correlated with 
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gender/sexual orientation (e.g. Mortimer Market had a higher proportion of MSM than 
the other clinics), and with socio-economic factors due to the clinic’s geographical 
locations. As gender/sexual orientation and SES are the focus of this thesis, I have 
therefore not included ethnicity and clinic in multivariable models. 
Secondly, in Chapters 7 to 9, I have considered different markers of socio-economic 
status in separate regression models in the majority of cases. The main reason for this 
is because they are highly correlated with each other (see Section 7.4.1), but it is also 
that I am interested in the individual association of each SES marker with virological 
and late diagnosis outcomes, regardless of how much of this effect is independent of 
other SES markers. The one exception to this is in Chapter 8 where I have used 
stepwise regression to select a subset of variables to include in a model. Stepwise 
regression fits regression models using an automatic procedure to select which 
independent variables to include. At each step, a variable is considered for addition to 
or subtraction from the independent variables in the model based on some pre-
specified criterion535. More detail will be given in Section 8.3.5. 
 Handling missing data 
Missing values for dependent and independent variables can cause biased estimates, 
biased standard errors and inefficiency. It is possible to classify types of missing data 
into: Missing Completely At Random (MCAR), Missing At Random (MAR) or Missing 
Not At Random (MNAR). If the probability that data are missing does not depend on 
the values of the observed or missing data, then the data are MCAR. In other words, 
data are MCAR when there is no systematic reason why data are missing, other than 
random chance. In contrast, data being MAR is much more common, and occurs when 
the probability of being missing depends only on observed data. For example, if data 
on SES were more likely to be missing in men than women, and this were the only 
reason (other than chance) for it to be missing, then data on SES would be MAR, 
providing information on gender was also available in the dataset. Finally, MNAR is the 
situation when the probability of being missing depends on both observed and missing 
data. For example, if data on SES were missing depending on the level of SES itself 
(so those of lower SES were less likely to complete the responses to these questions) 
then these data would be MNAR, as it would depend on a factor that was unobserved. 
Figure 4.6 illustrates the different missing data mechanisms. 
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Figure 4.6: Missing data mechanisms a 
  
 
 
There are ways to distinguish whether data are MAR rather than MCAR (for example 
comparing the characteristics of individuals with observed data and individuals with 
missing data). However, there is no statistical way to test whether the data are MNAR 
rather than MAR so it is necessary to make a judgement based on knowledge of the 
situation. 
There are two methods used in this thesis to deal with the issue of missing data: 
Complete-Case analysis (CC) and Multiple Imputation (MI). 
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Complete-case analysis 
Complete-case analysis is a method whereby only individuals with complete data are 
included in the analysis, and individuals with missing values are excluded. This 
method may be employed when few data are missing. Thus omitting cases would not 
severely diminish the analysis population, and would be unlikely to cause significant 
bias. However, note that in multivariable analysis, if an individual has missing 
information on the dependent variable or any of the independent variables being 
considered, then their entire record is necessarily excluded from analysis. Thus, small 
amounts of missing data across a range of variables can lead to large amounts of 
missing data overall. 
Multiple imputation 
Multiple imputation by chained equations (MICE) is a method whereby missing data 
are completed using an iterative process536. Each missing observation is assigned 
(imputed) an initial value using some arbitrary method, for example the mean for that 
variable. These values are then replaced in turn using univariate imputation models, 
i.e. regression of the observed values of that variable on all other observed and 
currently imputed variables. This model may be improved by including auxiliary 
variables – these are variables which are not a part of the analysis model of interest 
but that predict either the incomplete variables or the probability that they are missing. 
It is an iterative process, performed until the dataset is complete with no missing data 
a process which is then repeated to result in a number of imputed datasets (say 𝑚 
datasets). The main analysis is performed on each of the imputed datasets, resulting 
in 𝑚 estimates of the RR/OR/PR. These are then combined into a single overall 
estimate of the association being studied using Rubin’s rules537. 
Before undertaking MI, some details require consideration. The literature suggests that 
𝑚 should be at least equal to the proportion of incomplete cases (so, if 20% of data 
are missing in a dataset, then 20 imputed datasets should be created)536;538. Monte 
Carlo error (MCE) can be used to determine an adequate number of imputations to 
obtain stable results536. MCE reflects the variability in the results across the imputed 
datasets due to using a finite number of imputations. The MCE for the estimates, test 
statistics and the p values need to be sufficiently small in order to make reasonably 
reliable inferences following the imputation of the missing values. The literature 
suggests that the MCE of all estimates should be <10% of the corresponding standard 
error and MCEs of the test statistics should be approximately 0.1536. Secondly, a 
sufficient number of the initial imputations should be discarded such that the estimates 
will be unaffected by the arbitrary method used for the first imputation and the process 
will have converged to produce stable estimates. This is called the burn-in period. It is 
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also important to take into account the potential presence of perfect prediction – there 
is a level of a categorical variable for which the outcome is certain to occur/not occur. 
This calls for a few low weighted observations to be added to the data set so that no 
prediction is perfect (augmented regression), in order to avoid biased results. 
It is possible to account for the bias caused by data being MNAR using MI methods 
with weighted Rubin’s rules. However, this requires knowledge of the nature of the 
missing data and reasons why they are missing. As this is usually difficult to ascertain, 
one needs to make assumptions, which adds uncertainty to the results and are often 
unverifiable.  
Choice of method for handling missing data 
MI is a more efficient analysis method compared to CC because all cases are 
included, thus the estimates of associations are likely to be more precise. This is 
particularly true for situations with a large proportion of missing data539. However, 
when the missing data mechanism is MCAR then CC has been shown to lead to 
unbiased estimates of association and is a much simpler method to use. Under the 
MAR missing data mechanism, MI has negligible bias, whereas CC is biased because 
it ignores systematically missing data. However, there are other situations in which CC 
has negligible bias, such as when the variables in the model are either uncorrelated or 
the correlation between them is small. In data which has missing values for the 
response variable, in general CC would be used because it does not add any value to 
the analysis to include these cases, except when auxiliary variables are available for 
imputation540;541. It is often unclear which of MI or CC are more appropriate for the 
missing data mechanism539, thus it may be helpful to evaluate the results of both 
approaches. 
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 Trends in prevalence of virological non-
suppression according to gender/sexual 
orientation in a UK clinic population 2000-2014 
 Objectives 
 To present descriptive data on the trends over calendar time by gender/sexual 
orientation in demographic factors, ART use, type of ART regimen used, CD4 
count, VL, hospitalisations, AIDS events, and death among a whole UK HIV-
clinic population (the Royal Free HIV Cohort Study) from 2000 to 2014. 
 To assess the trends over calendar time in the prevalence of virological non-
suppression among all cART treated individuals in the clinic population 
 To assess whether any trends of calendar time differed by gender/sexual 
orientation. 
 Introduction 
The composition of the HIV-diagnosed population in the UK has changed over time in 
terms of demographic characteristics210;542. Although the number of new HIV 
diagnoses among heterosexual individuals in the UK is now decreasing, 
heterosexually infected individuals make up a greater proportion of people living with 
HIV (PLWH) and accessing care than MSM543. It is vital to examine changes in the HIV 
epidemic over time in order to understand the demographic make-up and clinical 
characteristics of the HIV-positive population accessing care in the UK. The 
description of an HIV-clinic population presented in this chapter also serves as a 
documentation of the characteristics of the Royal Free HIV Cohort Study (RFHCS) on 
which the subsequent analyses in this chapter and the analyses in Chapters 6 and 9 
were based. This allows additional insights into the generalisability, interpretation and 
implications of the results presented in these chapters. There have been substantial 
improvements in the prognosis for PLWH over time in high-income countries60;543-550. 
This includes evidence of improved virological and immunological responses to ART in 
previous studies of the Royal Free HIV cohort59;365;551. These improvements may be a 
result of: increasingly efficacious and less toxic antiretroviral drugs (ARVs) and 
regimens546-548; a greater number of treatment options; better management of 
toxicities; recommendations not to interrupt treatment162; a greater appreciation of the 
importance of treatment adherence and additional adherence support; guidelines to 
initiate ART at an earlier stage135;552-554; and reductions in late diagnoses543. However, 
such improvements in treatment success may not necessarily have occurred equally 
across the gender/sexual orientation groups. Even in the most recent years, 
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heterosexual men and women have a high prevalence of late diagnosis210;543, and 
treatment disruptions remain more common among women compared to men126;189;362. 
Such factors may influence the success of treatment and contribute to disparities in 
response between MSM, MSW and women. 
Chapter 2 highlighted several studies examining the effects of gender/sexual 
orientation on virological response amongst those initiating ART (see Section 2.4), and 
this question is addressed in the RFHCS in Chapter 6 of this thesis. However, in 
addition to studies focussing on sub-populations such as those starting ART, it is also 
important to study virological status among all people with diagnosed HIV, using entire 
clinic populations, in order to get a more comprehensive picture of the success of 
clinical care and treatment. A number of studies have addressed the wider issue of 
immunological and virological status among representative populations of HIV-
diagnosed individuals under routine care, regardless of time spent on 
ART355;356;359;364;365. All observed a higher probability of virological non-suppression 
among heterosexual individuals on ART compared to MSM. In particular, a previous 
study of the Royal Free HIV cohort from 1999 to 2004 found a decrease in prevalence 
of VL >50 copies/mL over calendar time, but found that on average black African 
heterosexual men had a 30% higher prevalence of non-suppression compared to 
MSM receiving ART for ≥24 weeks365. In addition, there was no evidence that the 
differences between these two groups were narrowing over calendar time. However, 
this study did not directly compare women with either MSM or heterosexual men. 
Furthermore, the results relate to a period more than 10 years ago and may no longer 
be representative of trends or gender/sexual orientation differences in prevalence of 
VL non-suppression. Therefore, it is important to assess whether gender/sexual 
orientation disparities in ART response have narrowed or widened with time in the 
clinic population as a whole.  
 
 Methods 
 Study population 
All individuals in the RFHCS who attended the Ian Charleson Day Centre (ICDC) at 
the Royal Free Hospital (i.e. attending for care) at least once between 1 January 2000 
and 31 December 2014 with a recorded sexual route of HIV acquisition were included. 
January 2000 was chosen as the threshold ART initiation date for inclusion in the 
analysis since ritonavir boosting of PIs was established as an efficacious ART 
component53 and VL assays with a lower limit of detection of 50 copies/mL were in 
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routine use by this time. At the time of the analysis, the last complete year for which 
there had been a clinic notes review was 2014. I excluded individuals who acquired 
HIV through a non-sexual route, e.g. intravenous drug use (IDU), as there was no 
information to use as an indicator of sexual orientation for these individuals. In line with 
the UK HIV-positive population as a whole, only a small proportion (6%) of the cohort 
had a non-sexual or unknown mode of HIV acquisition.  
 Outcomes of interest 
In order to address the first aim of this chapter, trends over time by gender/sexual 
orientation in the following outcomes were considered:  
 Age: for each year as that on the 1st July, this was calculated using date of 
birth.  
 Ethnicity: self-reported and, for the purposes of this analysis, categorised into 
six groups: white, black African, black Caribbean, Asian, mixed/other, and 
unknown for individuals with missing data.  
 ART use: on ART was defined as on at least one ARV at the time of the VL or 
CD4 count measurement closest to the middle of that calendar year. 
 ART regimen: the number of drugs in the regimen, the specific Nucleoside 
Reverse Transcriptase Inhibitors (NRTIs) used, and the ARV drug classes in 
the regimen.  
 CD4 count: using the measurement closest to the middle of that calendar year. 
 VL: using the measurement closest to the middle of that calendar year. 
 Hospitalisations: rate calculated as the frequency of hospitalisations in a 
particular year divided by the total follow-up time and multiplied by 100. 
Multiple hospitalisations per individual were permitted. Events at presentation 
were included, as long as they did not occur more than two weeks before the 
date of first visit to the ICDC. 
 AIDS events: rates were calculated in the same way as for hospitalisations. 
Multiple AIDS events were permitted but repeated re-occurrences of the same 
specific AIDS event that an individual had previously experienced were not 
included. Events at presentation were included, as long as they did not occur 
more than two weeks before the date of first visit to the ICDC. 
 Death: rates were calculated as the number of deaths in a particular year 
divided by the total follow-up time and multiplied by 100.  
In order to address the second and third aims of this chapter, a single outcome of 
virological non-suppression was considered, defined as a VL >50 copies/mL. A cut-off 
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of 50 copies/mL was used primarily because it was the lower limit of detection of the 
VL assays used most frequently over the follow-up period, and also because UK 
guidelines state that achievement of a VL <50 copies/mL is the goal of treatment552. A 
higher cut-off was not used as a recent study suggests even a single VL between 51 
and 199 copies/mL is strongly predictive of subsequent virological rebound555. 
 Inclusion criteria 
To be included in analyses for a particular year, an individual was required to have 
attended HIV services at the Royal Free Hospital for care in that year. Presence of 
either a CD4 count or VL measurement was used as a proxy for clinic attendance, as 
both were routinely measured at each visit over the study period. Individuals could be 
included multiple times if their attendance spanned more than one calendar year, 
however, only one CD4 count and VL measurement per individual per year was 
included. This is because frequency of monitoring may be dependent on the CD4 
count and VL values. For example, individuals with an unsuppressed VL (as per 
current UK recommendations552) or those with advanced disease are likely to be more 
closely monitored. Thus, a single value per year was considered to ensure that these 
groups were not over-represented. The measurement chosen was the one measured 
closest to the mid-point of the year of interest (1st July). 
Different entry criteria were used for analyses with clinical outcomes (AIDS events, 
hospitalisations and death), which took a person-years approach. Here, individuals 
were followed from the date of their first attendance at the Royal Free Hospital, until 
the earliest of 31st December 2014, death, or last clinic visit.  
For the second half of this chapter, formally assessing trends over time in prevalence 
of virological non-suppression, two sub-populations were considered: (i) for each 
calendar year, individuals who attended the clinic in that year and had been on 
continuous cART for at least the six months prior to the date of the VL measurement 
were included (individuals would be excluded if they stopped taking at least three 
ARVs within this period); (ii) for each calendar year, individuals who attended the clinic 
in that year and had ever started cART at least six months previously, regardless of 
any current treatment interruptions or disruptions, were included. The second sub-
population was chosen to reflect the current paradigm, based primarily on the results 
of the SMART study162, that once started, cART should not be discontinued. As such, 
the aim is for all individuals who have ever started cART to have a suppressed VL. As 
the SMART study results were released in 2006, this analysis was restricted to 2006-
14. The six-month window was chosen to allow individuals the potential to achieve 
162 
 
virological suppression; most individuals would be expected to have attained this after 
this length of time367;556-560.  
 Covariates of interest 
The two main covariates of interest were gender/sexual orientation and calendar year. 
Gender/sexual orientation groups MSM, MSW, and women were defined as explained 
in Section 4.4.1.1 . Calendar year was used as a continuous variable (to estimate an 
average trend over time) in each statistical model, and was used as a categorical 
variable in graphical representations. 
 Statistical analyses 
First, the percentage of the clinic population that were MSM, MSW and women in each 
calendar year was presented. Then, for categorical variables, proportions by calendar 
year and gender/sexual orientation were presented graphically. For age, the median, 
interquartile range (IQR) and range for each gender/sexual orientation group in each 
calendar year was displayed using box plots.  
For hospitalisation, AIDS events, and death crude incidence rates per 100 person-
years and corresponding 95% confidence intervals (CIs) were calculated, stratified by 
calendar year of follow-up. CIs were calculated using the exact Poisson method if ≤20 
events occurred, and with a normal approximation otherwise. 
The prevalence of virological non-suppression for each gender/sexual orientation 
group in each year was calculated for the two sub-populations. Modified Poisson 
regression was used to obtain prevalence ratios (PR) for the association of the 
covariates with virological non-suppression. Generalised estimating equations (GEEs) 
were used to account for the repeated observations for each individual. The correlation 
structure selected was autoregressive(1) to allow for stronger correlation between 
nearer time points. The association of the two main covariates of interest, 
gender/sexual orientation and calendar year, with the prevalence of virological non-
suppression was assessed first in a model only including these two explanatory 
variables. A second model additionally adjusted for age (as a continuous variable) and 
new patient status, defined as the time between the date of first visit to the ICDC and 
date of VL measurement. This was categorised into three groups: ≤six months; six to 
12 months; and >12 months. This variable was included because a previous study in 
this cohort suggested that new patient status was an important confounder for the 
association between demographic group and raised VL365.  
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Treatment guidelines on when to start cART50;133;134;136;137;142 and treatment regimens 
prescribed548;561-563 have changed considerably over the study period. As the study 
population includes both those newly starting cART and those on long-term cART, 
CD4 count at cART initiation and cART regimen are likely strongly associated with 
calendar time. Thus, I did not adjust for CD4 count at cART initiation or type of cART 
regimen, as I wished to capture (rather than eliminate) the effect of these factors in the 
assessment of trends, as some of the calendar effects are likely mediated through 
these two factors.  
A test for linearity of the association between calendar year and virological non-
suppression was conducted by including a quadratic term (i.e. adding a squared term 
to the model in addition to the linear term). If this quadratic term suggested a non-
linear association, then the association of calendar time with prevalence of virological 
non-suppression was modelled using a piecewise linear slope, as I felt that this 
parameterisation would be easier to interpret than a quadratic term. The time point(s) 
at which the slope changed gradient were determined by visual examination. If there 
was no evidence that inclusion of a quadratic term improved the model fit, then the 
association between calendar time and virological non-suppression was modelled as a 
single linear slope. 
Differences in the trend over time in virological non-suppression by gender/sexual 
orientation were assessed using tests for interaction.  
The proportion lost to follow-up (LTFU) (including having a substantial period of non-
attendance) was also assessed. An individual was considered LTFU in a particular 
year if they had a recorded VL in that year, had the potential for a further two years of 
follow-up, and had no VL measurement in those subsequent two years. In order to 
capture both temporary and long-term LTFU, individuals were defined as LTFU even if 
they had subsequent VL measurements recorded after a gap of two years. It was only 
possible to calculate this up until 2012 since there were not two subsequent years of 
data available for 2013 and 2014. LTFU was analysed for the two sub-populations 
defined previously in Section 5.3.3, thus the denominators were all those with a VL 
recorded (i.e. attending the clinic) in any one year who (i) were currently on cART; or 
(ii) ever started cART.  
 Sensitivity analyses 
As a sensitivity analysis, all analyses were repeated, re-defining virological non-
suppression as a VL >200 copies/mL. Although attaining virological suppression to 
<50 copies/mL would be considered the initial goal of treatment from a clinical 
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perspective, the reason for considering a threshold of 200 copies/mL was that low 
level viraemia may not be indicative of true virological failure564.  
 
 Results 
 Trends over time in the characteristics of HIV-positive individuals  
The number of individuals attending the Royal Free Hospital with a likely sexual mode 
of HIV acquisition has increased from 1262 in 2000 to 2894 in 2014. There were 
increasing numbers in all three gender/sexual orientation groups, although MSM 
remained the largest group compared to MSW or women (Table 5.1). An increasing 
percentage of individuals attending for care were MSW or women.  
The first column of Table 5.1 displays the denominators for the first results section in 
this chapter, considering the trends in the characteristics of all individuals under care. 
The second and third columns give the denominators for the two study populations 
considered for the virological non-suppression analyses.
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Table 5.1: Number of HIV positive individuals who attended the HIV outpatient clinic at the Royal Free Hospital for care 2000-14 a 
 
 
  
 
 
 
Year Number (%) in attendance b  Number in attendance b currently 
receiving cART c  
Number in attendance b and ever 
received cART c d 
MSM MSW Women Total MSM MSW Women Total MSM MSW Women Total 
2000 848 67% 159 13% 255 20% 1262 451 82 113 646 - - - - 
2001 928 65% 196 14% 296 21% 1420 526 99 131 756 - - - - 
2002 1065 65% 239 14% 346 21% 1650 604 131 183 918 - - - - 
2003 1153 63% 268 15% 421 23% 1842 699 164 221 1084 - - - - 
2004 1241 62% 298 15% 451 23% 1990 778 201 261 1240 - - - - 
2005 1355 62% 319 15% 511 23% 2185 887 220 308 1415 - - - - 
2006 1401 61% 332 15% 553 24% 2286 971 236 349 1556 1047 249 399 1695 
2007 1461 61% 358 15% 586 24% 2405 1017 271 402 1690 1091 280 453 1824 
2008 1508 59% 405 16% 638 25% 2551 1126 297 439 1862 1191 312 502 2005 
2009 1571 60% 412 16% 652 25% 2635 1205 322 488 2015 1274 341 542 2157 
2010 1591 59% 419 16% 671 25% 2681 1284 339 527 2150 1337 350 575 2262 
2011 1615 59% 429 16% 695 25% 2739 1322 353 553 2228 1372 366 601 2339 
2012 1658 59% 441 16% 732 26% 2831 1400 373 598 2371 1450 385 639 2474 
2013 1699 59% 456 16% 745 26% 2900 1452 398 632 2482 1500 411 664 2575 
2014 1695 59% 465 16% 734 25% 2894 1390 384 598 2372 1439 395 619 2453 
a Individuals could be included at more than one time point; b defined as a recorded CD4 count and/or VL measurement in that year; c cART = antiretroviral 
therapy consisting of ≥3 antiretroviral drugs; d this analysis considered the years 2006-2014 only. 
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Demographic characteristics 
The median age of PLWH increased in all three gender/sexual orientation groups from 
2000 to 2014 (Figure 5.1a-c). In 2000 the median age was 37, 38, and 35 years for 
MSM, MSW and women, respectively, rising to 48, 49, and 45 years in 2014. MSW 
had a consistently older median age compared to MSM, and the median age among 
women was consistently lower than that of both male groups. 
Figure 5.2a-c show the distribution of ethnicity among MSM, MSW, and women, 
respectively. Most MSM were of white ethnicity and most MSW and women were of 
black African ethnicity across all years. The proportion of individuals of white ethnicity 
decreased over time in all groups: 86% of the MSM in 2000 were white compared to 
82% in 2014; the corresponding figures were 31% and 26% for MSW and 25% and 
18% for women. The percentage of individuals of other/mixed ethnicity remained small 
but increased in all groups over the study period.
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Figure 5.1: Box plots of age among all individuals attending for care by gender/sexual 
orientation 2000-14 a b 
a): MSM c 
 
b): MSW c 
 
c): Women c 
 
 
0
10
20
30
40
50
60
70
80
90
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Ag
e 
(y
ea
rs
)
Calendar year
0
10
20
30
40
50
60
70
80
90
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Ag
e 
(y
ea
rs
)
Calendar year
0
10
20
30
40
50
60
70
80
90
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Ag
e 
(y
ea
rs
)
Calendar year
a Individuals could be included at more than one time point; b denominators are provided in 
column one of Table 5.1; c the mid-point of the boxes represent the median age in that year at 
the time of CD4 count or VL measurement, the ends of the boxes represent the upper and 
lower quartiles, and the lines represent the range. 
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Figure 5.2: Ethnicity among all individuals attending for care by gender/sexual 
orientation 2000-14 
a): MSM a b 
 
b): MSW  
 
c): Women  
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ART use 
The proportion not on treatment decreased substantially over time from over 35% to 
less than 10% in all groups in 2014 (Figure 5.3a-c). Generally, a slightly lower 
proportion of women were on treatment compared to the male groups throughout the 
study period. Most individuals in each group were on triple ARV regimens (i.e. cART), 
although there has been a slight increase in mono and dual PI-based therapy in recent 
years.
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Figure 5.3: Type of ART regimen received among all individuals attending for care by 
gender/sexual orientation 2000-14 a b 
a) MSM 
 
b) MSW  
 
c) Women 
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a Individuals could be included at more than one time point; b denominators are 
provided in column one of Table 5.1; mono= 1 ARV; double= 2 ARVs; triple= ≥3 
ARVs (cART). 
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The specific ARVs used changed over time, in line with the introduction of new drugs 
and increased knowledge of the most effective regimens (Figures 5.4 and 5.5). 
Guidelines of which ARVs should be prescribed to PLWH changed over time and 
influenced which NRTI backbone and combination of ARV classes were 
used50;133;134;136;137;142.  
The NRTIs used over calendar time are displayed in Figure 5.4a-c. Across all three 
groups there has been a move away from regimens including AZT, ddl, and d4T, since 
these are no longer recommended at least for first-line treatment in the UK73, towards 
TDF and FTC, which is now the preferred NRTI backbone. MSW and women were 
more likely to be using regimens including AZT than MSM in the earlier years. Also in 
the early 2000s, a greater proportion of the male groups were on d4T and 3TC 
compared to women. In the most recent years, the NRTIs used were similar for all 
three groups.
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Figure 5.4: ART regimen NRTI backbone among all individuals attending for care and on 
≥1 ARV by gender/sexual orientation 2000-14 a b 
a) MSM 
 
b) MSW 
 
c) Women 
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column one of Table 5.1; NRTI=Nucleoside reverse transcriptase inhibitors; FTC= 
emtricitabine; TDF= tenofovir; ABC= abacavir; 3TC= lamivudine; d4T= stavudine; ddl= 
didanosine; AZT= zidovudine.  
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Trends over time in the distribution of ARV classes used are displayed in Figure 5.5a-
c. Most individuals were on two NRTIs with either a ritonavir boosted Protease 
Inhibitor (PI) or Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) for all 
gender/sexual orientation groups over all calendar years (i.e. PI-based or NNRTI-
based cART). Before 2004, a lower proportion of women were on a PI-based cART 
and a higher proportion on an NNRTI-based cART compared to both male groups. 
Integrase Strand Transfer Inhibitors (InSTIs) were increasingly used in all three groups 
over calendar time, but use of InSTI-based cART only reached 5% in each group in 
2014. There was an increase in PI-based dual and mono therapy from around 2009 
onward, particularly among MSM. In this period, of the individuals on mono therapy, 
92-100% were on a single PI, and, of those on dual therapy, 87-97% were on a PI-
based regimen with an NNRTI, maraviroc, an InSTI, or an NRTI. The increase in 
prevalence of these regimens in recent years is likely a result of evidence of 
reasonable outcomes of mono and dual therapy regimens for individuals who have 
achieved initial VL suppression67;72;565. 
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Figure 5.5: Distribution of ARV classes in regimen among all attending for care and on 
≥1 ARV by gender/sexual orientation 2000-14 a b 
a) MSM 
 
b) MSW 
 
c) Women 
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inhibitors; PI/r= ritonavir boosted PI; NNRTI= Non-Nucleoside reverse transcriptase 
inhibitor; InSTI= Integrase strand transfer inhibitor. 
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CD4 count  
Figure 5.6 displays the median and IQR for CD4 count over calendar year by 
gender/sexual orientation amongst all individuals under care. The points for each 
gender/sexual orientation group in this figure (and any subsequent scatter plot) are 
plotted at a slight offset on the x-axis so that it is visually clear. It can be seen that 
median CD4 count increased over calendar time for all groups, but that MSW 
consistently had the lowest value across all calendar years, followed by women, and 
then MSM. In 2014, compared to 2000, the median CD4 count was 197 cells/µL higher 
for MSM and 190 cells/µL higher for MSW. Women had the greatest difference of 230 
cells/µL.  
Over time, the percent with a CD4 count ≥500 cells/µL increased in all three 
gender/sexual orientation groups but was consistently highest among MSM (Figure 
5.7). The prevalence of severe immunosuppression fell considerably over time. In 
2000, 16% MSM, 25% MSW and 23% of women had CD4 counts <200 cells/µL. In 
2014, these percentages had fallen to 2%, 9% and 6%, respectively.
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Figure 5.6: Median (IQR) CD4 count among all individuals attending for care by gender/sexual orientation 2000-14 a b c 
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Figure 5.7: Distribution of current CD4 count among all individuals attending for care by gender/sexual orientation 2000-14 a b 
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Viral load 
Over time, the proportion of the individuals attending for care who had a VL ≤50 
copies/mL increased substantially in all three gender/sexual orientation groups (Figure 
5.8). Likewise, the proportion with a VL >10000 copies/mL substantially declined. 
When looking at the differences between gender/sexual orientation groups, there have 
consistently been lower proportions of MSW and women with VL ≤50 copies/mL 
compared to MSM over the 15-year period. In 2014, 86% of MSM, 83% of MSW, and 
83% of women in the complete clinic population had VL ≤50 copies/mL. Trends in VL 
non-suppression among people on cART was considered in Section 5.4.2. 
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Figure 5.8: VL among all individuals attending for care by gender/sexual orientation 2000-14 a b 
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Rates of hospitalisation, AIDS, and death 
The total number of hospitalisations, AIDS events, and deaths and the total person-
years of follow-up by gender/sexual orientation are shown in Table 5.2. The rates of 
hospitalisations, AIDS events and death have substantially decreased over time in all 
gender/sexual orientation groups, as seen in Figure 5.9a-c. 
Throughout the follow-up period, MSW and women had a higher rate of 
hospitalisations compared to MSM. The differences in hospitalisations between MSM 
and the heterosexual groups were consistent between 2000 and 2014, as seen by the 
similar slopes for each group (Figure 5.9a), with the exception of 2012 where the rates 
of hospitalisation in MSM and MSW intersected. In 2014, these were 1.2, 3.5, and 2.9 
per 100 person-years among MSM, MSW, and women, respectively.  
Although MSW and women consistently had a higher rate of new AIDS events 
compared to MSW over the study period (Figure 5.9b). In 2000, the rate of AIDS 
among MSM was 4.3 per 100 person-years, declining to 0.6 in 2014. Similar declines 
were seen for MSW (8.4 to 1.8) and women (5.9 to 1.0).  
Figure 5.9c shows that, although the death rate has decreased among all groups over 
the 15-year period it did so to a lesser extent compared to AIDS events and 
hospitalisation. One would expect that the rate of death among women would be 
consistently below that of both male groups, reflecting the pattern seen in the general 
population566. This should particularly be the case since women attending the ICDC 
had a lower median age than the male groups. However, the rates of death among 
women were only below those of MSW and not MSM. In 2000, the rate of death was 
1.8, 4.4, and 1.9 per 100 person-years for MSM, MSW, and women, respectively. Over 
time, the rates among MSW approached those of MSM and women, and in 2010 the 
death rate in MSW had declined to 0.7 per 100 person-years, and thus reached the 
low rates seen among MSM. In 2014 the rates of death were 1.1, 0.9, and 0.1 for 
MSM, MSW, and women.  
When hospitalisation or AIDS events at presentation (within three months of first visit 
to the ICDC) were excluded, there were substantially reduced rates of these clinical 
events in all gender/sexual orientation groups (Figure 5.10a-b). Furthermore, the 
differences in the rates of these events by gender/sexual orientation were much 
reduced. However, death rates remained largely unchanged by the exclusion of 
deaths in the first three months (Figure 5.10c).
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Table 5.2: Total years of follow-up and number of hospitalisations, AIDS events and death observed by gender/sexual orientation among individuals 
attending for care 2000-14 
Year 
Hospitalisations AIDS events Deaths 
MSM MSW Women MSM MSW Women MSM MSW Women 
PY n PY  N PY n PY n PY n PY n PY n PY n PY n 
2000 861 64 154 21 253 26 862 37 155 13 255 15 881 16 160 7 262 5 
2001 938 51 178 31 287 36 940 24 179 21 288 16 951 8 189 5 295 2 
2002 1041 59 217 29 334 35 1042 37 219 17 335 28 1058 16 226 5 347 4 
2003 1142 66 253 27 392 47 1144 35 254 14 396 25 1160 16 261 6 403 2 
2004 1256 65 278 29 443 44 1257 26 279 18 445 35 1268 11 288 4 461 5 
2005 1350 66 298 33 498 41 1350 25 299 20 502 19 1360 11 310 5 511 4 
2006 1401 57 325 28 550 35 1403 26 326 21 554 22 1414 19 337 8 561 6 
2007 1447 56 353 27 592 32 1449 22 355 16 593 12 1459 19 361 9 598 9 
2008 1528 43 384 28 622 36 1529 18 386 20 625 18 1536 7 393 8 635 8 
2009 1570 41 408 25 653 35 1572 20 408 13 656 14 1582 10 414 7 664 2 
2010 1595 45 418 23 689 37 1598 15 420 7 694 8 1606 12 423 3 699 2 
2011 1633 38 435 25 721 26 1637 13 437 12 721 9 1643 7 444 3 725 6 
2012 1681 44 453 10 733 33 1683 10 454 7 733 18 1688 12 457 4 741 4 
2013 1705 28 457 17 739 21 1706 10 458 8 739 9 1711 10 463 2 744 3 
2014 1687 20 456 16 730 21 1687 10 457 8 732 7 1692 18 461 4 736 1 
Total 20836 743 5066 369 8235 505 20858 328 5085 215 8266 255 21008 192 5185 80 8383 63 
PY=person-years; n=number of events. 
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Figure 5.9: Rate a (95% CI) of clinical events over time by gender/sexual orientation 
a) Hospitalisations 
 
b) AIDS events 
 
c) Death  
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Figure 5.10: Rate a (95% CI) of clinical events over time by gender/sexual orientation 
excluding events within first three months of presentation to the Royal Free Hospital 
a) Hospitalisations 
 
b) AIDS events 
 
c) Death  
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 Trends over time in prevalence of virological non-suppression 
VL among individuals currently receiving continuous cART for at least 
six months  
This section focuses on trends in virological non-suppression on cART. This first sub-
section considers the sub-population described in Section 5.3.3, and focuses on 
individuals currently receiving continuous cART for at least 6 months at the time of the 
VL measurement. The second column of Table 5.1 shows the denominators used for 
these analyses.  
As shown in Figure 5.11, the prevalence of virological non-suppression among 
individuals currently receiving continuous cART fell dramatically between 2000 and 
2014. For all gender/sexual orientation groups, the decline appeared to occur 
predominantly between 2000 and 2006, with only a marginal decline subsequently. 
Among MSM, the prevalence of virological non-suppression fell from 31% in 2000 to 
just 8% in 2014. Likewise, among MSW and women, 39% and 31% had virological 
non-suppression in 2000, respectively, compared to 11% of each group in 2014. A 
greater percentage of MSW had virological non-suppression than MSM in all calendar 
years and a greater percentage of women had virological non-suppression than MSM 
from 2005 onward. Examining the figures visually, the pattern of the reduction in the 
prevalence of virological non-suppression over time (shown by the slope of the line) 
appeared similar in all gender/sexual orientation groups. 
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Figure 5.11: Prevalence of VL >50 copies/mL by gender/sexual orientation among individuals currently receiving continuous cART for at least six 
months 2000-14 a b 
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The results presented in Figure 5.11 suggested a non-linear association between 
calendar time and virological non-suppression. Furthermore, when including a 
quadratic term for calendar year in the model, this was strongly associated with 
virological non-suppression (p<0.0001 in a model including calendar year and 
calendar year squared only) which provided further evidence of a non-linear effect.  
Thus, as described in the methods section, I fitted a piecewise linear slope to 
investigate changes over calendar time in the prevalence of virological non-
suppression. Using Figure 5.11, I decided to allow for a change in the slope at the year 
2006. The results of the piecewise model demonstrated strong evidence for a change 
in slope in 2006: in 2006-14 the change in prevalence per year was 0.84 times that 
seen in 2000-06 (95% CI: 0.81, 0.87; p<0.0001). This corresponded to an 18% relative 
reduction in prevalence of virological non-suppression per year before 2006, and a 2% 
relative reduction in prevalence of virological non-suppression per year after 2006, in a 
model including only gender/sexual orientation and the two calendar year terms (Table 
5.3). After adjustment for age and new patient status, there remained a strong 
downward trend in the prevalence of virological non-suppression per calendar year 
before 2006; however, after 2006 there was no evidence of a decline over time.  
Table 5.3 also shows the associations between gender/sexual orientation and 
virological non-suppression. There were significant differences between each of the 
gender/sexual orientation groups. The prevalence ratio of 1.56 comparing MSW and 
MSM means that MSW had a 56% greater prevalence of virological non-suppression 
compared to MSM across the whole time-period. Similarly, women had 24% greater 
prevalence of virological non-suppression compared to MSM. In addition, there was 
evidence of a 19% lower prevalence of virological non-suppression among women 
compared to MSW. Following additional adjustment for age and new patient status, 
there remained evidence of differences between in prevalence of non-suppression 
between each of the gender/sexual orientation groups, with MSM having the most 
favourable profile and MSW the least favourable. Younger age and less than six 
months since an individual’s first visit to the ICDC compared to >12 months were 
associated with a substantially higher prevalence of virological non-suppression. 
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Table 5.3: Association between gender/sexual orientation, calendar year and VL >50 
copies/mL among individuals currently receiving continuous cART for at least six 
months ab 
 
 
 
Test for interaction between gender/sexual orientation and calendar year 
In all models fitted until now, I have assumed that all three gender/sexual orientation 
groups had the same change over calendar time in terms of the relative prevalence of 
virological non-suppression. This section investigates whether there were different 
slopes for each gender/sexual orientation group. In other words, I am assessed 
whether there were different relative changes over time in three groups, and therefore, 
whether or not the MSW and women were “catching up” or “falling behind” the MSM, 
by experiencing a faster or slower decline over time in the prevalence of virological 
non-suppression. This was achieved by a test for interaction between gender/sexual 
orientation and calendar year. As a result of the findings in the previous paragraph, 
calendar year was considered in the two periods: 2000-06 and 2006-14. The results 
are shown in Table 5.4. Recall that here I am considering the relative changes over 
time in virological non-suppression among the three groups. In the period 2000-06, 
MSM had an adjusted PR of 0.82, corresponding to an 18% reduction in the 
prevalence of virological non-suppression per year later. Among MSW and women, 
these figures were 15% and 13%, respectively. Thus there were greater relative 
improvements over time for MSM than the other two groups before 2006, but the 
Covariates 
 
Model including 
gender/sexual orientation 
and calendar year 
Model additionally 
including age and new 
patient status 
aPR 95% CI P-valuec aPR 95% CI P-valuec 
Gender/ 
sexual 
orientation 
MSW vs. 
MSM 
1.56 1.34, 1.81 <0.0001 1.59 1.37, 1.84 <0.0001 
Women vs. 
MSM 
1.24  1.09, 1.44  1.18  1.03, 1.35  
Women vs. 
MSW 
0.81 0.68, 0.96  0.74 0.63, 0.88  
Calendar 
year 2000-
06 
Per year 0.82 0.80, 0.84 <0.0001 0.84 0.82, 0.86 <0.0001 
Calendar 
year 2006-
14  
Per year 0.98 0.96, 1.00 0.045 1.00 0.98, 1.02 0.96 
Age  Per 10 years - - - 0.81 0.76, 0.86 <0.0001 
New 
patient 
status (time 
since first 
visit to the 
ICDC) 
≤6 months 
vs. >12 
months 
- - - 2.22 1.97, 2.50 <0.0001 
6-12 months 
vs. >12 
months 
- -  1.12 0.95, 1.32  
a PRs compare the relative positions of the slopes for VL >50 copies/mL over time, a slope 
which is assumed to stay the same over the study period; b individuals could be included at 
more than one time point; c likelihood ratio test; aPR= adjusted Prevalence Ratio. 
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differences between the groups were not statistically significant (p=0.15; test for 
interaction). In contrast, there was no evidence of a change in the prevalence of 
virological non-suppression over time among MSM, MSW, or women between 2006 
and 2014, nor that these changes over time were different between the three groups 
(p=0.58; test for interaction). In a model solely including the post-2006 period, similarly 
there was no evidence of differences between the gender/sexual orientation groups 
(p=0.62). 
Table 5.4: Associations of the interaction between gender/sexual orientation and 
calendar year with virological non-suppression among individuals currently receiving 
continuous cART for at least six months a 
 
 
 
 
 
 
 
VL among individuals who ever started cART 
This section considers the second sub-population described in Section 5.3.3of those 
that have ever started cART more than six months previously, regardless of whether 
they interrupted or currently remained on cART. The final column of Table 5.1 shows 
the denominators for the analyses in this section.  
When considering this sub-population, as opposed to those on continuous ART for at 
least six months (Section 5.4.2.1 ), the prevalence of VL >50 copies/mL was between 
1.5% and 7% higher in each year. The difference in prevalence of virological non-
suppression found between these sub-populations decreased over the study period. 
MSW and MSM have a comparable prevalence of virological non-suppression in 2006 
(13% vs. 12% respectively), however, after this date the difference between the 
groups increased, with MSM having a lower prevalence (Figure 5.12). Women had an 
initially higher prevalence of virological non-suppression than MSM in 2006 (19% vs. 
12% respectively), and this gap does not appear to have lessened over time, with 
substantial differences between these groups found in most years. MSW and women 
had a similar prevalence of virological non-suppression from 2008 onward, and in 
2014, 13% of both groups had a VL >50 copies/mL compared to 9% of MSM. 
 aPR b  95% CI P-value for 
interaction c 
Relative change per year later: 
2000-06 
MSM  0.82 0.80, 0.85 0.15 
MSW  0.85 0.80, 0.89  
Women 0.87 0.83, 0.92  
Relative change per year later: 
2006-14 
MSM  0.99 0.96, 1.02 0.58 
MSW  1.01 0.97, 1.05  
Women 1.01 0.97, 1.04  
a Individuals could be included at more than one time point; b adjusted for age and new 
patient status; c likelihood ratio test examining whether there is a difference in change 
over time between the three gender/sexual orientation groups; aPR= adjusted Prevalence 
Ratio. 
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Figure 5.12: Prevalence of VL >50 copies/mL by gender/sexual orientation among individuals ever on cART 2006-14 a b 
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a Individuals could be included at more than one time point; b denominators are provided in column three of Table 5.1; the bars on 
graph represent confidence intervals. 
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In this analysis, only considering 2006 onwards, there was no evidence of a non-linear 
trend between calendar year and VL non-suppression (p=0.72 in a model including 
calendar year and calendar year squared only), a finding which was corroborated by 
visual examination of Figure 5.12. Therefore, I considered calendar year as a 
continuous linear variable in subsequent analyses. 
Table 5.5 shows the PRs for the associations of gender/sexual orientation and 
calendar year with virological non-suppression when assuming the same relative 
change over time in prevalence of non-suppression in all three gender/sexual 
orientation groups. In a model including gender/sexual orientation and calendar year 
only, there were higher prevalence’s of virological non-suppression among MSW and 
women compared to MSM (by 43% and 57% respectively), but no evidence of 
differences between MSW and women. For each year later, there was a 6% lower 
prevalence of virological non-suppression on average. The effects of gender/sexual 
orientation and calendar year were marginally attenuated following additional 
adjustment for age and new patient status.  
Table 5.5: Association between gender/sexual orientation, calendar year and VL >50 
copies/mL among individuals ever on cART a b 
 
  
Test for interaction between gender/sexual orientation and calendar year 
There was weak evidence of different changes over time in the prevalence of non-
suppression between gender/sexual orientation groups when adjusting for age and 
new patient status (p=0.066; test for interaction) (Table 5.6). Both MSM and women 
Covariates 
 
Model including 
gender/sexual orientation 
and calendar year 
Model additionally 
adjusted for age and new 
patient status 
aPR 95% CI P-valuec aPR 95% CI P-valuec 
Gender/ 
sexual 
orientation 
MSW vs. 
MSM 
1.43 1.20, 1.69 <0.0001 1.47 1.24, 1.73 <0.0001 
Women vs. 
MSM 
1.57  1.36, 1.81  1.41 1.23, 1.62  
Women vs. 
MSW 
1.10 0.92, 1.32  0.96  0.80, 1.15  
Calendar 
year 
Per year 0.94 0.93, 0.96 <0.0001 0.96 0.95, 0.98 <0.0001 
Age  Per 10 
years 
- - - 0.72 0.68, 0.77 <0.0001 
New patient 
status (time 
since first 
visit to the 
ICDC) 
≤6 months 
vs. >12 
months 
- - - 1.71 1.47, 1.99 <0.0001 
6-12 
months vs. 
>12 months 
- -  1.03 0.85, 1.25  
a PRs compare the relative positions of the slopes for VL >50 copies/mL over time, a slope 
which is assumed to stay the same over the study period; b individuals could be included 
at more than one time point; c likelihood ratio test;  aPR= adjusted Prevalence Ratio. 
191 
 
had a 5% lower prevalence of virological non-suppression per year on average; 
however, there was no evidence of a reduction in the prevalence of virological non-
suppression over calendar time among MSW. This may reflect the fact that overall 
prevalence of virological non-suppression in this latter group was particularly low at the 
start of the period under consideration, and as such could not decrease substantially 
further. 
Table 5.6: Associations of the interaction between gender/sexual orientation and 
calendar year with virological non-suppression among individuals ever on cART a 
 
 
 
 
 
 Loss to follow-up 
Next, I considered LTFU over time in the three gender/sexual orientation groups in 
both sub-populations used for the non-suppression analysis. For the sub-population 
who had received continuous cART for at least 6 months, the percentage of individuals 
LTFU in each year varied between 2% and 8%, with similar proportions in the three 
groups (Figure 5.13a). Likewise, among individuals who ever received cART there was 
a similar proportion of LTFU in all three gender/sexual orientation groups, so it is 
unlikely to have influenced the differences in virological non-suppression (Figure 
5.13b). 
 aPR b  95% CI P-valuec  
Relative change per year later: 
2006-14 
MSM 0.95 0.93, 0.97 0.066 
MSW 1.00 0.96, 1.04  
Women 0.95 0.93, 0.99  
a Individuals could be included at more than one time point; b adjusted for age and new 
patient status; c likelihood ratio test; aPR= adjusted Prevalence Ratio. 
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Figure 5.13: Proportion lost to follow-up a by gender/sexual orientation 2000-12 b  
a): Among individuals currently receiving continuous cART for at least six months c 
 
b): Among individuals ever on cART d 
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a Lost to follow-up = no VL recorded in the subsequent two years; b individuals could be 
included at more than one time point; c denominators are provided in column two of Table 
5.1; d denominators for this graph are in column three of Table 5.1.  
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 Sensitivity analyses  
In a sensitivity analysis, virological non-suppression was re-defined as a VL 
measurement >200 copies/mL rather than >50 copies/mL. Figure 5.14 and Figure 5.15 
show the prevalence of VL >200 copies/mL over time by gender/sexual orientation 
among the two sub-populations considered: individuals currently receiving continuous 
cART for at least six months and individuals who ever received cART, respectively. 
These results were similar to the main analysis with the exception that there still 
appeared to be a reduction in the prevalence of virological non-suppression post-2006 
in the currently receiving cART sub-population, which was not the case in the main 
analysis.  
Similar to the main analyses, there was evidence of a change in slope at 2006 in the 
analysis of individuals currently receiving continuous cART (PR=0.81 per year later 
2006-14 vs. per year later 2000-06; 95% CI: 0.77, 0.86; p<0.0001), so a piecewise 
regression model was used. There was no evidence of a non-linear association with 
calendar year in the analysis of individuals who ever started cART (p=0.29), so 
calendar year could again be assessed as a single continuous variable.  
Table 5.7 shows adjusted PRs for the association of gender/sexual orientation, 
calendar year, age, and new patient status with virological non-suppression under both 
of these analysis strategies. The results of the sensitivity analyses were similar to 
those of the main analyses, although the effect sizes were generally greater in the 
former.  
The results for tests for interaction between gender/sexual orientation and calendar 
time for both analysis strategies are shown in Table 5.8. These were consistent with 
the main analyses. 
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Figure 5.14: Prevalence of VL >200 copies/mL by gender/sexual orientation among individuals currently receiving continuous cART for at least six 
months 2000-14 a b 
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Figure 5.15: Prevalence of VL >200 copies/mL by gender/sexual orientation among individuals ever on cART 2006-14 a b 
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Table 5.7: Association between gender/sexual orientation, calendar year and VL >200 
copies/mL a 
 
 
 
 Table 5.8: Associations of the interaction between gender/sexual orientation and 
calendar year with VL >200 copies/mL a 
 
 
Covariates Individuals currently 
receiving cART 
Individuals ever started 
cART 
aPR b 95% CI P-
valuec 
aPR b 95% CI P-
valuec 
Gender/ 
sexual 
orientation 
MSW vs. 
MSM 
1.67 1.38, 2.03 <.0001 1.41 1.12, 1.77 <.0001 
Women vs. 
MSM 
1.38 1.17, 1.63  1.70 1.44, 2.01  
Women vs. 
MSW 
0.83 0.66, 1.03  1.20 0.96, 1.52  
Calendar 
year 2000-06 
Per year 0.79 0.77, 0.82 <.0001 - - - 
Calendar 
year 2006-14 
Per year 0.98 0.95, 1.01 0.16 0.94 0.92, 0.96 <.0001 
Age  Per 10 
years 
0.78 0.72, 0.84 <.0001 0.67 0.62, 0.73 <.0001 
New patient 
status (time 
since first 
visit to the 
ICDC) 
≤6 months 
vs. >12 
months 
2.74 2.36, 3.19 <.0001 1.91 1.58, 2.31 <.0001 
6-12 
months vs. 
>12 months 
1.07 0.86, 1.33  0.91 0.70, 1.16  
 Individuals currently 
receiving cART 
Individuals ever started 
cART 
aPR b 95% CI P-
valuec 
aPR b 95% CI P-
valuec 
Relative change per 
year later: 2000-06 
MSM 0.77 0.74, 0.81 0.13 - - - 
MSW 0.82 0.77, 0.87  - -  
Women 0.82 0.77, 0.88  - -  
Relative change per 
year later: 2006-14 
MSM 0.97 0.93, 1.01 0.17 0.91 0.89, 0.94 0.14 
MSW 0.95 0.91, 1.01  0.96 0.91, 1.01  
Women 1.02 0.97, 1.07  0.95 0.92, 0.98  
a Individuals could be included at more than one time point; b model includes gender/sexual 
orientation, calendar year, age, and new patient status; c likelihood ratio test; aPR= 
adjusted Prevalence Ratio. 
a Individuals could be included at more than one time point; b adjusted for age and new 
patient status; c likelihood ratio test; aPR= adjusted Prevalence Ratio. 
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 Discussion 
 Summary of results 
 The demographic composition of the Royal Free HIV cohort changed 
considerably between 2000 and 2014, reflecting the changes seen in the 
UK543. In particular, MSW and women constitute an increasing proportion of the 
cohort.  
 Across all three gender/sexual orientation groups, there was a decreasing 
proportion of individuals of white ethnicity and an increase in median age. In 
terms of ARVs used, the gender/sexual orientation groups were generally 
similar. Considerable increases in the proportion receiving cART were 
observed over time and corresponding decreases in the proportion not on 
treatment (over 90% in all groups were receiving some form of ART by 2014). 
 CD4 count <200 cells/µL and VL >10000 copies/mL were more prevalent for 
MSW and women compared to MSM in most years. However, the prevalence 
of these outcomes decreased considerably in all three groups over time. 
Similarly, the occurrence of clinical events, as measured by the rate of 
hospitalisations, AIDS and death, greatly decreased over time, such that the 
rates of these outcomes are low among all three gender/sexual orientation 
groups. 
 Among cART-treated individuals under care between 2000 and 2014, there 
were substantial declines in the prevalence of virological non-suppression. 
Current treatment is now so successful that, amongst those who remain in 
care, only 9% of individuals currently receiving continuous cART, and 11% of 
individuals who have ever started cART had a VL >50 copies/mL in 2014. 
However, a greater percentage of MSW and women had virological non-
suppression than MSM in most years.  
 There was no evidence that the gender/sexual orientation differences in 
virological non-suppression narrowed in relative terms over time. In fact, while 
there were declines in the prevalence of virological non-suppression over time 
among MSM and women who had ever started cART, there was no evidence 
of declines among MSW. Therefore, if anything, the differences between MSM 
and MSW tended to widen slightly in relative terms over time since 2006.  
 Interpretation of results 
The aging population observed in the present analysis, across all gender/sexual 
orientation groups, was likely primarily a result of the success of cART and 
consequent increases in life expectancy for people living with HIV57;98 (as seen by the 
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lower rates of death over calendar time in Section 5.4.1.5 ). Moreover, there have 
been increases in diagnosis of HIV among older individuals over time567. In terms of 
the decreasing proportion of individuals of white ethnicity over time in the present 
study, this was primarily owing to the observed increase in prevalence of unknown 
ethnicity status. It was unlikely a result of an increase in individuals of non-white 
ethnicity, since in recent years the prevalence of new diagnoses among migrants and 
black-African individuals has been falling in Europe543;568. 
There was little difference between the gender/sexual orientation groups in terms of 
specific NRTI backbones and ARV classes used. This suggests that differences in 
ART regimen are unlikely to explain gender/sexual orientation differences observed in 
virological non-suppression. There was lower PI-use (boosted or un-boosted) among 
women between 2000 and 2004, but usage of this class was similar between 
gender/sexual orientation groups after this time. 
Across the study population, 70% MSM, 52% MSW and 66% women had a CD4 count 
above the lower limit of the normal range (i.e. above 500 cells/µL) by 2014, indicating 
that the majority of individuals in all three groups were generally in good overall health 
with respect to their immunological status by this time. Although the majority of 
individuals had a CD4 count that would be considered to be in the ‘normal range’, 
there are data which show that a higher CD4 count is associated with lower risk of 
AIDS and death even among individuals with a CD4 count >500 cells/µL569. Since CD4 
count was analysed among all individual attending the ICDC, regardless of time since 
HIV diagnosis or whether they had been ART-treated, the lower CD4 counts in the 
heterosexual groups could reflect later HIV diagnosis, delays in ART initiation, or 
poorer CD4 count reconstitution following ART initiation.  
Improvements in virological suppression from 2000 to 2014 at the entire clinic 
population level were likely reflective primarily of the corresponding increases in 
prevalence of ART use (Section 5.4.1.2 ). Additionally there were substantial changes 
in the NRTI regimen backbones used over time away from AZT, ddI and d4T towards 
FTC and TDF476. Use of more efficacious ARVs and ones that can be taken in a single 
combined tablet may also have contributed to the improvements in virological status 
over time.  
Hospitalisation and AIDS rates were higher among MSW and women compared to 
MSM. When individuals hospitalised or with AIDS events at presentation were 
excluded, respectively, the differences in rates between the gender/sexual orientation 
groups were substantially attenuated. This indicates that the still high prevalence of 
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late presentation may be a key driver for the differences in clinical outcomes by 
gender/sexual orientation. It is also possible that these differences in late presentation 
affect the virological trends, however, pre-cART CD4 count is not usually an important 
factor when considering virological response to cART462, and it is likely that this has 
been adjusted for to some extent by adjusting for new patient status. 
In analyses of individuals currently receiving continuous cART, there was a non-linear 
association between calendar year and virological non-suppression. Before 2006, 
there were declines in the prevalence of virological non-suppression over time in all 
three gender/sexual orientation groups. However, since approximately 2006 there was 
no evidence of an improvement in virological non-suppression in any gender/sexual 
orientation groups. It is important to consider whether this means that levels of non-
suppression seen in 2006-14 represent a “best case scenario” beyond which 
improvements are not possible. However, although differences were quite small in 
absolute terms, the higher prevalence of virological non-suppression for MSW and 
women even in the post-2006 period would suggest that improvements in these two 
groups should be possible to achieve the levels seen in MSM. Potential reasons for 
virological non-suppression in the era of highly effective cART should be considered. 
Non-adherence to ART is the most likely reason for virological non-suppression on 
treatment. Although many individuals maintain high levels of adherence to treatment 
and achieve sustained virological suppression, cART is a life-long treatment, and short 
periods of low- or non-adherence and associated viral breakthroughs are likely to 
occur for some individuals570. Even in recent years, a substantial proportion of 
individuals were diagnosed with HIV with a low CD4 count210;543 (thus starting cART at 
a more advanced HIV stage96), which may complicate treatment, compromise 
virological response and result in higher levels of virological non-suppression than may 
be optimally achieved.  
Among individuals who ever started cART, from 2006 onward there was some 
evidence of a decreasing prevalence of virological non-suppression among MSM and 
women, although not among MSW. The fact that there were declines under this 
analysis strategy, but not using the first analysis strategy over the same period, 
indicates that these improvements may be a result of fewer treatment 
disruptions/discontinuations over time571-573, which were excluded in the “currently 
receiving cART” analysis. There was some evidence that the difference in prevalence 
of virological non-suppression between MSW and both MSM and women increased 
between 2006 and 2014, thus perhaps treatment disruptions had not declined as much 
among MSW. There may also be some barriers to virological suppression that affect 
MSW to a greater extent than MSM or women. These may include barriers to 
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engagement with medical care, such as experiences of stigma574;575, factors that could 
impact on adherence to ART, and factors that may potentially impact on virological 
outcomes independently of adherence, such as late diagnosis210;576.  
In addition to differences in virological outcome between MSM and the heterosexual 
groups, women had a 26% lower adjusted PR of VL >50 copies/mL than MSW among 
individuals currently receiving cART. However, this was only found in the main 
analysis in this particular sub-population. Due to the inconsistency of this result under 
different analysis strategies, it should be interpreted with caution.  
Methodologically, this chapter draws attention to the impact of choice of denominator 
on the estimated prevalence of virological non-suppression. In the “currently receiving 
continuous cART” analysis, individuals who had interrupted treatment at the time of 
their VL measurement or at any time during the previous six months were excluded. 
Thus, this provides a “best case scenario”. On the other hand, the analysis of 
individuals who ever started cART may be overly pessimistic, since individuals who 
completely discontinue cART are included in the denominator. The prevalence of 
women initiating cART in pregnancy was not accounted for in this chapter. Therefore, 
although it is not recommended and in recent years has become less frequent, 
discontinuations of treatment after pregnancy may account for some of the greater 
prevalence of virological non-suppression among women who have ever been on 
cART577;578. There are some circumstances, even since the results of the START study 
in 2006162, in which an individual may need to temporarily stop treatment. Reasons 
may include serious side effects or drug toxicities, development of other illnesses 
where concurrent treatment is not possible (drug interactions), and to participate in a 
clinical trial. Therefore, there are advantages and disadvantages to both 
denominators. In the current era, non-adherence to treatment and short-term 
interruptions are the main predictors of poorer virological response199, and as such, 
they are likely mediators for associations between gender/sexual orientation and VL 
non-suppression among cART-treated individuals. Thus the “ever on cART” analysis, 
which allows for the variability in virological response according to differences in 
treatment disruptions, may be the most relevant analysis in this context. However, 
completely discontinuing treatment is different to incomplete adherence with respect to 
resistance development172, thus with respect to separating these adherence patterns, 
the analysis of individuals currently receiving cART offers useful information.  
 Strengths and limitations 
One limitation of a single-centre study is external validity. The setting of the RFHCS is 
an urban HIV treatment centre located within a University hospital with a large patient 
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population and highly experienced HIV clinicians. However, the results from this study 
of a single clinic may still be generalisable within the UK as the study is broadly 
representative with respect to demographics (discussed further in Section 10.2) and 
the use of UK guidelines may mean that care is relatively standardised across centres. 
It could be argued that any disparities in virological suppression according to 
gender/sexual orientation may be greater in treatment centres that are newer, smaller, 
or have less experienced medical teams. Only individuals who had sexual 
transmission as the mode of HIV acquisition recorded were included in the present 
analysis, thus the results are not necessarily generalisable to other settings which 
include a large proportion of individuals who acquired HIV through non-sexual routes, 
such as IDU. Studies in a single clinic also have their advantages. The study 
population is likely to be less heterogeneous in terms of HIV care received, treatment 
prescribed, assays used to measure VL, etc., so the chance of confounding is 
reduced. An advantage of using data from the RFHCS in particular is the potential for 
long-term follow-up of individuals in a routine clinic setting, since the database has 
data on HIV-positive individuals attending for care over the past 24 years. The 100% 
notes review conducted annually (described in Section 4.2.5) also means that the data 
should be have a high degree of accuracy, particularly in terms of data collected on 
ART disruptions. Additionally, the RFHCS has sufficient numbers of women included 
to allow for assessment of gender-based (or in this case gender/sexual orientation-
based) differences, unlike a number of HIV clinical trials579. 
Only those with a recorded VL (and hence were under care) were included in the 
analysis for each year. Thus, neither of the analysis strategies used could account for 
LTFU, and these results may be optimistic estimates of the improvement of virological 
non-suppression over time. However, my investigations suggest that LTFU is unlikely 
to have biased the associations between gender/sexual orientation and virological 
non-suppression, or trends over time, since there were similar proportions of LTFU 
among MSM, MSW and women and over calendar year. Although it is likely that a 
large proportion of the individuals recorded as LTFU may have transferred clinic and 
are thus not truly LTFU, it is unfortunately not easy to differentiate between this and 
true disengagement from care in a single-centre study. Thus, the definition of LTFU 
used only provides a simple measure; however, if all individuals classified as LTFU at 
the Royal Free Hospital were assumed to have an unsuppressed VL, the prevalence 
of virological non-suppression among individuals on cART would be increased by 2-
8% in each year. Engagement and retention in care is very important for an 
individual’s probability of achieving virological suppression580-582. 
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It would have been beneficial to exclude pregnant women in a sensitivity analysis to 
see whether this could explain some of the gender/sexual orientation differences, but 
unfortunately these data are not routinely collected on the RFHCS. Among HIV-
positive women conceiving on cART, the proportion with virological failure declined 
substantially from 34% in 2000–2001 to 3% in 2010–2011 in a study in Western 
Europe382. It is therefore more likely that the inclusion of pregnant women in the 
present analysis had a greater impact on the level of virological non-suppression in the 
earlier years of this analysis. In a previous study in the same setting as the analyses in 
this chapter, 10% of women had initiated ART in pregnancy362. When these women 
were excluded, the risk of virological rebound among women compared to MSM was 
lower. This indicated that starting ART in pregnancy was explaining part of the 
differences between these groups, however, there remained a large relative difference 
between these groups. It is likely that this would have been similarly the case for the 
analyses in this chapter. 
One limitation of the statistical analyses in this chapter was that, since GEEs were 
used which treat longitudinal data as a series of cross-sectional time points, it was only 
possible to consider the population average response as opposed to subject-specific 
response. These models are not concerned with within-person changes. Therefore, 
these results should not be interpreted as “being a man who has sex with men is 
associated with a lower prevalence of virological non-suppression compared to being 
a man who has sex with women” but instead that “the prevalence of virological non-
suppression is lower amongst men who have sex with men compared to men who 
have sex with women.” This is otherwise known as the ecological fallacy. In this way, 
the data provide an overview of the virological status of the HIV-positive population 
over time, rather than providing estimates of likely virological response that one may 
see at an individual level.  
It would have been preferable to have age standardised the death rates, since there 
were age differences between the gender/sexual orientation groups. However, the 
small numbers in the study population who died between 2000 and 2014 made this 
difficult (Table 5.2). Additionally, because of the aging HIV population, age 
categorisations that had a sufficient number of events in each group in earlier years, 
had insufficient numbers in the younger age categories in later years. The crude rates 
presented should be interpreted with caution. 
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 Conclusions 
This chapter provides a description of a clinic population of PLWH accessing care in 
the UK setting, with particular emphasis on differences by gender/ sexual orientation. 
Among PLWH under care between 2000 and 2014, for all gender/sexual orientation 
groups there have similarly been increases in cART use and improvements in 
immunological, virological, and clinical outcomes over time. However, MSM 
consistently have higher CD4 counts and higher proportion with virological 
suppression compared to MSW and women. Among cART-treated individuals, it is 
disappointing to find that MSW and women still have a higher prevalence of virological 
non-suppression than MSM, even in recent years, and no evidence that gender/sexual 
orientation disparities are narrowing over time. Further investigation is required to 
understand why gender/sexual orientation disparities persist and to develop 
interventions that may help a greater proportion of MSW and women to achieve 
sustained virological suppression. 
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 Initial virological responses to cART over 
calendar year of cART initiation – are differences 
by gender/sexual orientation narrowing? 
 Objectives 
 To examine trends over calendar time in risk of virological non-suppression 12 
and 24 months after starting first-line cART in the RFHCS and whether there 
were different for MSM, MSW, and women. 
 To assess whether any differences between the gender/sexual orientation 
groups in risk of virological non-suppression after starting cART were 
narrowing or increasing in more recent years of cART initiation. 
 To evaluate the extent to which a prescription-based measure of adherence 
and treatment disruptions accounted for differences in virological cART 
response.  
 Introduction  
Previous studies in both the US and Europe have shown that the risk of an 
unsuppressed VL between six and 12 months after HIV treatment initiation is falling in 
more recent calendar years360;457;544;583;584. Greater antiretroviral drug (ARV) options, 
simpler and less toxic treatments, treatment initiation at a higher CD4 count, 
improvements in management and support for people starting treatment, and 
increasing understanding of the importance of treatment adherence are all likely to 
have led to improvements in initial virological response. However, this does not 
necessarily mean that these improvements have been experienced equally among all 
demographic groups affected by HIV.  
As discussed in Section 2.4, a number of studies in the US and Europe found women 
and MSW had a poorer initial virological response to cART than MSM357;360-362, while 
one recent study in EuroCoord did not find such differences366. In an observational 
study of individuals starting ART between 1996 and 2002 in European and Canadian 
cohorts457, although there was evidence of greater reductions in percent with 
virological non-suppression over calendar time among MSM compared to MSW and 
women, these trends may not necessarily have continued in more recent years. 
Similarly, a previous study of the Royal Free HIV cohort between 2006 and 2012 found 
that confirmed VL >200 copies/mL at least six months after initiating cART was more 
common among women and MSW compared to MSM362. In the same study, when 
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individuals were not censored at complete ART discontinuation, women were identified 
as also being more likely to have poorer initial virological response compared to MSW. 
However, this study did not consider trends in ART response between these 
gender/sexual orientation groups over calendar time.  
ART adherence is a key factor in achieving virological suppression162-169;585, and 
therefore unequal improvements in adherence between the gender/sexual orientation 
groups may explain disparities in trends over calendar year of ART initiation in VL 
outcomes. Poorer adherence to treatment126;166;376;586-591 and a greater prevalence of 
ART disruptions126;189;362 among women than among men have been reported by 
several studies in high-income countries. Although the previous analysis of the Royal 
Free HIV Cohort Study (RFHCS)362, examined gender/sexual orientation differences in 
ART disruptions, measures of ART adherence were not used. 
 
 Methods  
 Study population 
The analyses in this chapter included individuals in the RFHCS who had a recorded 
sexual mode for HIV acquisition, started cART (≥ three ARVs not including RTV 
boosting) between January 2000 and March 2014 (baseline), aged at least 18 years, 
and were previously ART-naïve. The cut-off of January 2000 was chosen for the same 
reasons as those in Chapter 5 (Section 5.3.1). March 2014 was chosen so all 
participants had the potential for 18 months’ follow-up before the date of administrative 
censoring (September 2015). 
 Outcomes of interest 
Initial virological response to cART 
The primary outcome was virological non-suppression, defined as a single VL >50 
copies/mL. This was examined at two time points: (i) at 12 months after starting cART, 
using the first VL measurement between 12 and 18 months after baseline; (ii) at 24 
months, using the first VL measurement between 24 and 30 months. The reasons for 
defining virological non-suppression using this cut-off were discussed in Chapter 5 
(Section 5.3.2) where this was also an outcome. The rationale for basing the outcome 
on a single binary measure, rather than using a ‘time to event’ approach, was that the 
latter approach may be more sensitive to differences in frequency of VL monitoring 
over calendar time, or between gender/sexual orientation groups. 
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Treatment disruptions 
HIV treatment disruptions within 12 months of cART initiation were also considered. 
Two binary outcomes were defined: cART interruption (yes/no); and cART disruption 
(yes/no). Individuals were classified as having had a cART interruption if they had 
completely discontinued cART for at least seven consecutive days (including those 
who stopped and restarted or who were on “treatment holidays”), and all other 
individuals were classified as no interruption. Individuals were classified as having had 
a cART disruption if they had made any changes to their cART regimen (including 
discontinuing one or more ARVs), since switching regimens can be a maker for current 
regimen failure or adherence difficulties. Individuals who had made a change to their 
ART regimen other than completely discontinuing ART for at least seven days were 
classified as other cART disruptions. Individuals were classified as having had no 
cART disruptions if they were on the same regimen for the entire 12-month period. 
Treatment non-adherence 
An adherence measure was derived from the RFHCS prescription coverage data 
(described in Section 4.2.4.3 ). It was defined by calculating the number of days in a 
set period that an individual was covered by a prescription for at least three ARVs and 
then dividing this by the total number of days in the period, and multiplying by 100. 
This produces an adherence percentage. The period considered was three to 12 
months following cART initiation, since 100% adherence for the first three months was 
required as an inclusion criterion in order to ensure individuals had actually initiated 
cART and were collecting prescriptions (see Section 6.3.3 below). Over this period, I 
considered two definitions of non-adherence as outcomes: (i) <95% adherence, and 
(ii) <80% adherence. These binary variables were chosen as there was evidence of 
their clinical relevance to the percentage of adherence required for virological 
suppression. In 2000, Paterson et al. found that un-boosted protease inhibitors 
required >95% adherence for optimised virological response199. However, recent 
studies of modern ARVs suggest that 80% adherence is sufficient325;384;474;475;592;593. 
Although adherence to one drug has been previously shown to be strongly associated 
with adherence to other drugs in the regimen594, it is possible that adherence may 
differ between drugs. Thus, adherence to a triple ARV regimen (cART) was 
considered as opposed to one ARV. Pharmacy adherence measures have been 
regarded as reasonable methods to assess HIV treatment adherence when other 
resources are unavailable595. 
 Inclusion criteria 
Individuals were required to have: ≥1 VL and CD4 count measurement before cART 
initiation (closest within three months before starting cART and seven days after), so 
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that we could conduct analyses adjusted for baseline VL and CD4 count; and at least 
one follow-up measurement after the date of cART initiation in order to measure the 
virological outcome. 
In addition, analyses in which measures of ART non-adherence were included were 
restricted to people who had: (i) an ARV prescription within a week of the date that 
they initiated cART, and (ii) at least one further ARV prescription between one and 
three months after cART initiation. These criteria were chosen to ensure that 
individuals had started cART at the Royal Free Hospital and were collecting 
prescriptions from the hospital pharmacy rather than elsewhere. 
Individuals were not excluded on the basis of whether they were taking the 
recommended ART regimen or not as I wanted to gain a picture of the complete HIV 
positive population at that time. Although from 2003 unboosted PIs were no longer 
recommended by BHIVA, individuals on such regimens were included in the analysis 
to reflect changes over time. This includes both the time before they were no longer 
recommended and the transition period afterwards to switch individuals onto 
recommended regimens. 
 Covariates of interest 
The main covariates of interest were gender/sexual orientation (defined in Section 
4.4.1 and in the same way as Chapter 5) and calendar year of cART initiation. Year of 
cART initiation was considered as a categorical variable for descriptive purposes in 
initial analyses. It was categorised into seven groups (six groups for 24-month 
outcomes) so that there were sufficient numbers in each group in order to permit 
meaningful patterns to emerge: 2000-01, 2002-03, 2004-05, 2006-07, 2008-09, 2010-
11, and 2012-14 (the final two groups were merged for the 24-month outcomes). It 
was also used as a continuous variable in multivariable statistical models when 
assessment of linear trend over calendar time of cART initiation was the primary 
interest.  
The other baseline covariates considered were:  
 Age (continuous), 
 VL (<10,000; 10,000-99,999; ≥100,000 copies/mL), 
 CD4 count (≥350; 200-349; <200 cells/µL),  
 Initial cART regimen type (NNRTI-based; PI-based; other). 
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Age was considered as that at the date of ART initiation. For baseline VL, baseline 
CD4 count and initial cART regimen, the values taken were those closest to the date 
of ART initiation as long as this date was no later than a week after ART initiation. 
These variables were chosen based on previous evidence in the literature that they 
are predictors of virological response to cART92;131;596-599. In particular, in the previous 
RFHCS analysis described in Section 6.2, with the exception of baseline CD4 count, 
these covariates were found to be associated with virological response457. Baseline 
CD4 count was included in the model for the analyses in this chapter as it may be a 
potential confounder, since up until 2015 the timing of cART initiation was 
recommended to be based upon CD4 count (see Section 1.3.2.1 )133;138;139. 
 Statistical analysis 
For the analyses with virological non-suppression as the outcome, three analysis 
strategies were used:  
 Strategy A: missing=failure 
All individuals who had started cART were included, but individuals with no VL 
measurements between 12-18 months (or 24-30 months for the 24-month time-
point) were considered to have virological non-suppression. 
 Strategy B: missing=excluded  
Only those with at least one recorded VL between 12-18 months (or 24-30 
months for the 24-month time-point) were included. 
 Strategy C: on cART 
Only those who were on cART at the time of the recorded VL were included. 
Strategy B was considered the primary analysis. For the analyses with treatment 
disruptions and treatment non-adherence as outcomes, only strategy B was used. 
The association between gender/sexual orientation and each outcome at 12 and 24 
months (virological non-response; treatment interruption, treatment disruption and 
non-adherence) were summarised using risk ratios (RRs). These were calculated 
using modified Poisson regression (detailed in Section 4.5.4.1 ). Univariable models 
were first used, and then multivariable models that additionally included: calendar year 
of cART initiation; age at baseline; baseline VL; baseline CD4 count; cART regimen at 
baseline. Evidence for differences in the trend over year of cART initiation by 
gender/sexual orientation were then assessed by additionally including interaction 
terms in the model. 
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Among individuals with cART disruptions, the clinician-reported reasons for stopping 
any ARV within 12 months of cART initiation were summarised by gender/sexual 
orientation group. 
In addition to being considered as outcomes, cART non-adherence and cART 
disruptions were also considered as mediators of the association between 
gender/sexual orientation and virological non-suppression (i.e. considered as 
covariates in the analysis with a virological non-suppression outcome). If the effects of 
gender/sexual orientation on virological response act through cART non-adherence or 
disruptions, then the inclusion of either factor in multivariable models would be 
expected to attenuate any observed associations between gender/sexual orientation 
and virological non-suppression to some extent. It is important to appreciate that the 
extent to which any factor has the potential to “explain” variation across gender/sexual 
orientation groups in non-adherence/virological outcomes, is dependent on the validity 
of the factor in capturing what it is intended to measure, and the amount of 
measurement error. Therefore, just as an association between an exposure and an 
outcome may be over or underestimated in the presence of measurement error, the 
amount by which a factor “explains” the association between an exposure and an 
outcome may also be over or underestimated in this situation600;601. By using this 
method, one also assumes that the underlying mechanism of correlation (i.e. how one 
factor affects the other) between the covariates is correctly specified. When 
considered as a mediator, cART adherence was defined as continuous percentage 
coverage due to previous evidence of a dose-response relationship between 
prescription based adherence and virological suppression199;325. cART disruption was 
considered as a three-category variable (interrupted - completely discontinued cART 
for at least seven consecutive days; all other cART disruptions; no disruptions) to 
assess how each distinct behaviour was related to treatment response. 
 Sensitivity analyses 
For the 12-month virological non-suppression analyses, three sensitivity analyses 
were performed. In the first, virological non-suppression was redefined as a single VL 
measurement >200 copies/mL (rationale explained in Section 5.3.6). In the second, 
individuals without a VL or CD4 count measurement in the three months before cART 
initiation. This analysis was conducted since 739 individuals (27% of otherwise eligible 
individuals) were excluded due to these criteria, which could have led to selection bias. 
In the third sensitivity analysis, the outcome of virological non-suppression was 
defined as individuals with a VL >50 copies/mL at 12 months as in the main analysis, 
however using the closest VL to 12 months but between six and 18 months after cART 
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initiation rather than between 12 and 18 months. In the past, individuals with HIV 
receiving ART were recommended to be seen by a physician, and have their VL 
measured, every three to four months. However, once on successful ART, this may be 
extended to six-monthly552;602;603. Thus, individuals doing well on treatment may be less 
likely to have visited in the 12-18 month window and so a wider window of 6-18 
months may be more appropriate. 
 Missing data 
By the inclusion criteria, individuals with missing gender/sexual orientation, age, 
baseline VL, baseline CD4 count, cART regimen type were excluded. Likewise, for the 
analyses that included the measure of cART non-adherence, the population was 
restricted to those with prescription data. Therefore, the individuals included in this 
analysis had no missing data for any of the covariates of interest. As described above, 
in a sensitivity analysis, individuals with missing baseline VL and CD4 count were 
included, except for the models which include baseline VL and CD4 count as 
covariates. This provided some limited information on the potential impact of missing 
data on study results. Furthermore, analysis strategy A categorised individuals with 
missing outcome data as having poorer outcomes, whereas analysis strategies B and 
C exclude individuals with missing data, providing some information on the impact on 
results of missing virological outcome data. 
 
 Results 
 Virological non-suppression at 12 months 
Participant characteristics 
The RFHCS database included 6423 individuals in September 2015. Of these, 2937 
started cART between January 2000 and March 2014, 2757 reported likely acquiring 
HIV sexually, of whom 2753 were over 18 years old at the time of starting cART. 
Further exclusions were as follows: 782 had no baseline VL recorded, or no baseline 
CD4 count, or no VL measurements after cART initiation. This resulted in 1971 
individuals (67% of individuals who started cART between 2000 and 2014) included in 
the analyses. Note that 40 (1%) individuals died before they were able to have a VL 
measurement 12-18 months after cART initiation. These individuals were included in 
analysis strategy A as virologically non-suppressed but were excluded from analyses 
under strategies B and C.  
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For strategy A all 1971 individuals were included in the analyses: 1049 (53%) MSM; 
372 (19%) MSW; 550 (28%) women. For strategy B, a further 356 (18% of those 
included in strategy A) individuals were excluded because they had no VL 
measurement 12-18 months after baseline, resulting in 1615 individuals: 877 (54%) 
MSM; 292 (18%) MSW; 446 (28%) women. Finally, for strategy C, a further 93 
individuals were excluded because they were not on cART at the time of the VL 
measurement. This left 1522 individuals included in analysis C: 837 (55%) MSM; 283 
(19%) MSW; 402 (26%) women.  
The characteristics of the study population by gender/sexual orientation for each 
analysis strategy is displayed in Table 6.1. MSW and women were more likely than 
MSM to be of black African ethnicity. MSW had an older median age than MSM, and 
particularly compared to women. The initial cART regimens started were similar 
between the three gender/sexual orientation groups. A small percentage, <6% for all 
groups, initiated a cART regimen other than ≥2 NRTI’s with either a PI or NNRTI as 
the third ARV (for strategy A: 2.25% raltegravir; 0.05% dolutegravir; 0.15% maraviroc; 
3.40% ≥3 NRTI; 1.07% on a PI and NNRTI). MSM had the highest median baseline 
CD4 count, followed by women and then MSW. However, CD4 count at starting ART 
was low across all groups, and the median CD4 for women and MSW was below 200 
cells/µL. Correspondingly, women and MSW were more likely to have had an ADE or 
CD4 count <200 cells/µL before cART initiation compared to MSM, and a marginally 
higher median VL at baseline than MSM. 
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Table 6.1: Characteristics at the time of cART initiation of individuals included in the analysis of virological response to cART at 12 months after 
initiation 
Factors Strategy A: missing=failure (N=1971) Strategy B: missing=excluded (N=1615) Strategy C: on cART (N=1522) 
MSM  MSW Women MSM MSW Women MSM MSW Women 
 N    % N    % N    % 
Overall 1063 53% 372  19% 554  28% 877  54% 292  18% 446  28% 790  55% 266  19% 374  26% 
Calendar 
year of 
cART 
initiation 
2000-01 122 12% 43 12% 71 13% 99 11% 29 10% 54 12% 94 11% 29 10% 46 11% 
2002-03 156 15% 75 20% 84 15% 133 15% 60 21% 70 16% 124 15% 58 10% 63 16% 
2004-05 151 14% 52 14% 82 15% 139 16% 45 15% 73 16% 131 16% 43 15% 62 15% 
2006-07 156 15% 65 17% 106 19% 128 15% 49 17% 81 18% 120 14% 48 17% 69 17% 
2008-09 176 17% 57 15% 92 17% 156 18% 47 16% 73 16% 152 18% 46 16% 71 18% 
2010-11 150 14% 39 10% 63 11% 132 15% 33 11% 54 12% 128 15% 31 11% 51 13% 
2012-14 138 13% 39 10% 52 9% 90 10% 29 10% 41 9% 88 11% 28 10% 40 10% 
Ethnicity White 856  82% 90  24% 80 15% 715  82% 78  25% 66  15% 682 81% 77 27% 62  15% 
Black African 18  2% 194  52% 353  64% 13  1% 147  51% 289  65% 13  2% 141  50% 255  63% 
Other 96  9% 69  19% 85  15% 81  9% 53  19% 64  14% 77  9% 51  18% 61  15% 
Missing 79  8% 19  5% 32  6% 68  8% 14  5% 27  6% 65  8% 14  5% 24  6% 
cART 
regimen 
base 
NNRTI 536  51% 203  54% 262  48% 433  49% 154  53% 201  45% 418  50% 151  53% 188  47% 
PI 472  45% 155  42% 260  47% 410  47% 127  43% 220  49% 386  46% 123  43% 191  48% 
Other 41  4% 124  4% 28  5% 34  4% 11  4% 25  6% 33  4% 9 3% 23  6% 
Previous ADE 124 12% 110  30% 133  24% 108 12% 85  29% 109  24% 105  13% 82  29% 104  26% 
Previously CD4 ≤200 389  37% 229  62% 325  59% 325  37% 179  61% 254  57% 318  38% 174  61% 248  62% 
 Median (IQR) Median (IQR) Median (IQR) 
Age (years) 38  
(33, 44) 
40  
(34, 47) 
36  
(30, 43) 
38  
(33, 44) 
40  
(34, 47) 
36  
(30, 42) 
38  
(33, 45) 
40  
(34, 47) 
37  
(31, 43) 
Baseline CD4 count 
(cells/µL) 
274  
(169, 400) 
163  
(52, 275) 
194  
(79, 300) 
273 
(170, 407) 
170  
(53, 284) 
202  
(80, 303) 
270  
(167, 392) 
168  
(53, 286) 
188  
(70, 279) 
Baseline VL 
(log copies/mL) 
5.0  
(4.5, 5.5) 
4.9  
(4.4, 5.5) 
4.8  
(4.1, 5.4) 
5.0 
(4.5, 5.5) 
4.9  
(4.4, 5.5) 
4.8  
(4.1, 5.4) 
5.0 (4.5, 
5.5) 
4.9  
(4.3, 5.5) 
4.9  
(4.2, 5.4) 
Results in bold had a P-value of <0.05 when assessed using Chi-squared tests for categorical variables or Wilcoxon-Mann-Whitney tests for continuous 
variables; NNRTI= Non-Nucleoside Reverse Transcriptase Inhibitors; PI= Protease Inhibitors; IQR= interquartile range; ADE= AIDS defining event. 
213 
 
Prevalence of virological non-suppression 12 months after cART 
initiation 
By calendar year of cART initiation 
Using strategy A, 617/1971 (31%) individuals were defined as virologically non-
suppressed at 12 months: 356 (58%) with missing VL; and 261 (42%) with VL >50 
copies/mL (100 individuals with 50-200 copies/mL; 43 with 200-1000 copies/mL; 46 
with 1000-10000 copies/mL; 72 with >10,000 copies/mL). Using strategy B, for which 
individuals with missing VL were excluded, 261/1615 (16%) individuals had virological 
non-suppression at 12 months. Finally using strategy C, for which individuals with a 
missing VL or who were not on cART at the time of the VL measurement were 
excluded, 188/1522 (12%) individuals had virological non-suppression at 12 months. 
The percentage of individuals with virological non-suppression 12 months after cART 
initiation by calendar year for each strategy are shown in . Using strategy A, virological 
non-suppression was neither increasing nor decreasing with more recent year of cART 
initiation. However, those categorised as virologically non-suppressed were dominated 
by individuals lost to follow-up (LTFU) in more recent years. There was a greater 
prevalence of missing VL measurement 12-18 months after cART initiation over 
calendar year of cART initiation (p<0.0001) and a decreasing prevalence of VL >50 
copies/mL (p<0.0001) which offset one another. Under analysis strategies B 
(p<0.0001 Cochran-Armitage test for trend) and C (p=0.0038) the prevalence of 
virological non-suppression was decreasing over calendar year of cART initiation. 
Under strategy B, 25% of individuals had VL >50 copies/mL at 12 months in 2000-01, 
which fell to 11% in 2012-14. 
214 
 
 Figure 6.1: Percentage with virological non-suppression 12-18 months after cART initiation by 
calendar year of cART initiation according to analysis strategy
 
  
By gender/sexual orientation 
A substantially greater percentage of MSW and women had virological non-
suppression compared to MSM under all three analysis strategies (for strategies A, B, 
and C p<0.0001; p<0.0001; p=0.0012 by chi squared test) as shown in Figure 6.2. 
However, this was averaged over all calendar years of cART initiation, which was 
shown to be associated with decreasing prevalence of virological non-suppression.  
Figure 6.2: Percentage with virological non-suppression 12-18 months after cART 
initiation by gender/sexual orientation according to analysis strategy 
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Association between gender/sexual orientation, calendar year of cART 
initiation and virological non-suppression 12-18 months after cART initiation 
Generally, the risk of virological non-suppression at 12 months was lower in more 
recent calendar year of starting cART for all gender/sexual orientation groups and all 
analysis strategies (Figure 6.3A, B and C). A greater percentage of MSW and women 
had virological non-suppression at 12 months compared to MSM at most calendar 
years of cART initiation. Considering strategy B for example, of 182 individuals starting 
cART in 2000-01, 16.2% of MSM, 34.5% of MSW and 37.0% of women had virological 
non-suppression 12 months after cART initiation. For the 160 individuals starting cART 
in 2012-14, these values were 11.1%, 10.3% and 12.2% respectively. 
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Figure 6.3: Percentage with virological non-suppression 12-18 months after cART 
initiation over calendar year of cART initiation stratified by gender/sexual orientation 
A: Strategy A (missing=failure) 
 
B: strategy B (missing=excluded) 
 
C: Strategy C (on cART)  
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The association between gender/sexual orientation and virological non-suppression 
can also be seen in terms of RRs in Table 6.2, Table 6.3 and Table 6.4 for analysis 
strategies A, B and C respectively. Across all three analysis strategies, women and 
MSW had a greater risk of virological non-suppression at 12 months compared to 
MSM. In analyses adjusted for calendar year of cART initiation, age, baseline VL, 
baseline CD4 count, and initial cART regimen, MSW had 1.4-1.6 times higher risk of 
virological non-suppression at 12 months after cART initiation than MSM across the 
three analysis strategies. Similarly, women had 1.4-1.9 times higher adjusted risk of 
virological non-suppression at 12 months compared to MSM. MSW and women 
generally had a similar risk of virological non-suppression. ‘MSW vs MSM’ differences 
were similar in the adjusted compared to unadjusted analysis, whereas ‘women vs 
MSM’ differences tended to be somewhat attenuated. There was an adjusted risk 
reduction of 2-8% per additional calendar year of cART initiation across the three 
analysis strategies. This shows that initial virological response had improved over time 
since 2000, even after accounting for changes in characteristics of people starting 
cART and, broadly, for type of starting regimen.  
Of the other factors included in the multivariable model, higher adjusted risk of 
virological non-suppression was associated with younger age and baseline VL <10000 
copies/mL (Table 6.2 Table 6.3 and Table 6.4). Baseline CD4 count <350 cells/µL was 
associated with higher adjusted risk of virological non-suppression under analysis 
strategy C, but not under the other analysis strategies. Likewise, PI- or other-based 
initial cART regimens were associated with a higher adjusted risk of virological non-
suppression compared to NNRTI-based regimens under strategies B and C, but not A.  
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Table 6.2: Associations of gender/sexual orientation, calendar year of cART initiation 
and other baseline factors with virological non-suppression 12-18 months after cART 
initiation – Strategy A (missing=failure) 
Factor a Unadjusted Adjusted 
RR 95% CI P-value b aRR c 95% CI P-value 
Gender/ sexual orientation 
MSW vs. MSM 1.33 1.12, 1.58 <.0001 1.35 1.13, 1.60 0.0001 
Women vs. MSM 1.43 1.23, 1.65  1.35 1.16, 1.58  
Women vs. MSW 1.07 0.90, 1.28  1.01 0.84, 1.20  
Calendar year of cART initiation 
Per year 0.98 0.96, 0.99 0.010 0.98 0.96, 1.00 0.053 
Age 
Per 10 years 0.85 0.79, 0.92 <.0001 0.86 0.80, 0.93 0.0001 
Baseline VL (copies/ mL) 
<10000 1  0.0007 1  0.029 
10000-99999 0.73 0.61, 0.88  0.78 0.64, 0.93  
≥100000 0.82 0.70, 0.98  0.87 0.72, 1.05  
Baseline CD4 count (cells/µL) 
≥350 1  0.55 1  0.91 
200-350 1.02 0.86, 1.22  0.96 0.81, 1.15  
<200 1.09 0.92, 1.29  0.97 0.81, 1.16  
Type of initial cART regimen 
NNRTI 1  0.77 1  0.73 
PI 0.99 0.87, 1.13  0.98 0.86, 1.12  
Other 1.12 0.82, 1.52  1.12 0.83, 1.51  
 a Each factor considered in separate univariable models then all factors in a single 
multivariable model; b likelihood ratio test; c adjusted for all factors listed in the table; 
denominators are provided in Table 6.1; RR= risk ratio; aRR= adjusted risk ratio; NNRTI= 
Non-Nucleoside Reverse Transcriptase Inhibitors; PI= Protease Inhibitors. 
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Table 6.3: Associations of gender/sexual orientation, calendar year of cART initiation 
and other baseline factors with virological non-suppression 12-18 months after cART 
initiation – Strategy B (missing=excluded) 
Factor a Unadjusted Adjusted 
RR 95% CI P-value b aRR c 95% CI P-value b 
Gender/ sexual orientation 
MSW vs. MSM 1.45 1.06, 1.96 <.0001 1.60 1.17, 2.20 <.0001 
Women vs. MSM 1.93 1.51, 2.47  1.87 1.45, 2.43  
Women vs. MSW 1.34 0.99, 1.80  1.17 0.86, 1.58  
Calendar year of cART initiation 
Per year 0.93 0.90, 0.96 <.0001 0.92 0.89, 0.95 <.0001 
Age 
Per 10 years 0.77 0.67, 0.88 <.0001 0.84 0.74, 0.96 0.0095 
Baseline VL (copies/ mL) 
<10000 1  0.0024 1  0.0028 
10000-99999 0.62 0.44, 0.86  0.67 0.48, 0.92  
≥100000 0.90 0.67, 1.22  1.00 0.73, 1.37  
Baseline CD4 count (cells/µL) 
≥350 1  0.96 1  0.093 
200-350 0.97 0.72, 1.29  0.83 0.63, 1.11  
<200 1.00 0.76, 1.32  0.71 0.53, 0.96  
Type of initial cART regimen 
NNRTI 1  0.0009 1  0.0005 
PI 1.51 1.19, 1.91  1.52 1.21, 1.91  
Other 1.80 1.13, 2.88  1.73 1.10, 2.73  
 
a Each factor considered in separate univariable models then all factors in a single 
multivariable model; b likelihood ratio test; c adjusted for all factors listed in the table; 
denominators are provided in Table 6.1; RR= risk ratio; aRR= adjusted risk ratio; NNRTI= 
Non-Nucleoside Reverse Transcriptase Inhibitors; PI= Protease Inhibitors. 
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Table 6.4: Associations of gender/sexual orientation, calendar year of cART initiation 
and other baseline factors with virological non-suppression 12-18 months after cART 
initiation – Strategy C (on cART) 
 
 
 
 
 
 
 
 
 
 
Factor a Unadjusted Adjusted 
RR 95% CI P-value b aRR c 95% CI P-value b 
Gender/ sexual orientation 
MSW vs. MSM 1.63 1.16, 2.29 0.0016 1.60 1.13, 2.26 0.011 
Women vs. MSM 1.67 1.23, 2.26  1.50 1.09, 2.08  
Women vs. MSW 1.02 0.72, 1.46  0.94 0.66, 1.34  
Calendar year of cART initiation 
Per year 0.93 0.90, 0.97 0.0004 0.95 0.91, 0.99 0.014 
Age 
Per 10 years 0.86 0.74, 1.01 0.061 0.90 0.76, 1.05 0.16 
Baseline VL (copies/ mL) 
<10000 1  <.0001 1  0.0003 
10000-99999 0.64 0.40, 1.01  0.65 0.41, 1.02  
≥100000 1.28 0.86, 1.91  1.23 0.80, 1.88  
Baseline CD4 count (cells/µL) 
≥350 1  <.0001 1  0.043 
200-350 1.86 1.20, 2.89  1.66 1.07, 2.58  
<200 2.22 1.46, 3.37  1.56 0.99, 2.47  
Type of initial cART regimen 
NNRTI 1  0.019 1  0.0041 
PI 1.42 1.08, 1.88  1.51 1.15, 1.98  
Other 1.84 1.06, 3.20  1.96 1.14, 3.37  
a Each factor considered in separate univariable models then all factors in a single 
multivariable model; b likelihood ratio test; c adjusted for all factors listed in the table; 
denominators are provided in Table 6.1; RR= risk ratio; aRR= adjusted risk ratio; NNRTI= 
Non-Nucleoside Reverse Transcriptase Inhibitors; PI= Protease Inhibitors. 
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Interaction between gender/sexual orientation and calendar year of cART 
initiation 
To evaluate whether the trend of lower risk of virological non-suppression with more 
recent calendar year was different between the gender/sexual orientation groups, 
models including interaction terms were assessed. These results are displayed in 
Table 6.5. The adjusted RRs in this table represent the estimated slope for virological 
non-suppression over calendar year of cART initiation, within each gender/sexual 
orientation group. Considering strategy B for example, MSM had, on average, a 7% 
lower risk of virological non-suppression per more recent year that cART was initiated. 
In comparison, this was 10% and 7% lower risk per year for MSW and women, 
respectively. Although this trend estimate was greatest among MSW, there was no 
statistically significant difference between the groups (p=0.72). Thus, there was no 
evidence that the differences between the gender/sexual orientation groups in 
virological non-suppression risk were narrowing or widening. This concurred with 
results for analysis strategy C. However, there was evidence that the differences 
between the groups were narrowing under analysis strategy A: 5% and 4% reduced 
risk per calendar year more recently cART was initiated among MSW and women, 
respectively, and no reduction among MSM. The differences using this strategy likely 
reflected differences in LTFU in the year group 2012-2015. When the individuals 
initiating ART in these years were excluded there was no evidence of an interaction 
(p=0.53).  
Table 6.5: Associations of the interaction between gender/sexual orientation and 
calendar year of cART initiation with virological non-suppression 12-18 months after 
cART initiation, according to analysis strategy 
 
 
 
 
 
  Strategy A 
(missing=failure) 
Strategy B 
(missing=excluded) 
Strategy C (on 
cART) 
aRR 
a  
95% 
CI 
P-
valueb 
aRR 
a  
95% 
CI 
P-
valueb 
aRR 
a  
95% 
CI 
P-
valueb 
Relative 
change 
per 
calendar 
year of 
cART 
initiation 
MSM 1.01  0.98, 
1.03 
0.041 0.93  0.88, 
0.97 
0.72 0.97  0.92, 
1.03 
0.19 
MSW 0.95 0.92, 
0.99 
 0.90 0.83, 
0.97 
 0.89 0.81, 
0.97 
 
Women  0.96 0.94, 
0.99 
 0.93  0.88, 
0.98 
 0.96  0.90, 
1.03 
 
a Adjusted for age, baseline VL and CD4 count, initial cART regimen; b likelihood ratio test 
for interaction term; aRR= adjusted risk ratio. 
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 Virological non-suppression 24-30 months after cART initiation 
Participant characteristics 
Of the 1971 individuals in the 12 month analysis, I excluded a further 100 people that 
started cART between March 2013 and March 2014 to ensure that all individuals in 
this analysis had the potential for 30 months follow-up. This resulted in 1871 
individuals (67% of all individuals who started cART between 2000 and 2013) included 
in the analyses of virological non-suppression at 24 months.  
For analysis strategy A, all 1871 were included: 989 (53%) MSM; 356 (19%) MSW; 
526 (28%) women. In strategy B, a further 461 were excluded because they had no VL 
measurement 24-30 months after baseline, which resulted in 1410 individuals: 775 
(55%) MSM; 257 (18%) MSW; 378 (27%) women. Finally, for strategy C, a further 99 
were excluded because they were not on cART at the time of the VL measurement 24-
30 months after baseline, which left 1311 individuals included: 722 (55%) MSM; 247 
(19%) MSW; 342 (26%) women. The characteristics of the study population by 
gender/sexual orientation are displayed in Table 6.6 and were similar to those in the 
12-month analyses.
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Table 6.6: Characteristics of individuals included in the analysis of virological non-suppression 24-30 months after cART initiation 
 
Factors Strategy A: missing=failure 
(N=1871) 
Strategy B: missing=excluded 
(N=1410) 
Strategy C: on cART (N=1311) 
MSM  MSW Women MSM MSW Women MSM MSW Women 
 N    % N    % N    % 
Overall 989  53% 356  19% 526  28% 775  55% 257  18% 378  27% 722  55% 247  19% 342  26% 
Calendar year of 
cART initiation 
2000-01 122 12% 45 13% 71 14% 93 12% 35 14% 47 12% 84 12% 33 13% 41 12% 
2002-03 156 16% 75 21% 84 16% 134 17% 53 21% 67 18% 123 17% 52 21% 59 17% 
2004-05 151 15% 52 15% 82 16% 122 16% 34 13% 64 17% 110 15% 32 13% 55 16% 
2006-07 156 16% 65 18% 106 20% 127 16% 47 18% 77 20% 121 17% 46 19% 72 21% 
2008-09 176 18% 57 16% 92 17% 144 19% 47 18% 69 18% 135 19% 44 18% 64 19% 
2010-13 228 23% 62 17% 91 17% 155 20% 41 16% 54 14% 149 21% 40 16% 51 15% 
Ethnicity White 809  82% 84  24% 70  13% 628  81% 65  25% 54  14% 582 81% 62  25% 51  15% 
Black 
African 
17  2% 189  53% 342  65% 11  1% 131  51% 246  65% 10  1% 127  51% 220  64% 
Other 89  9% 64  18% 82  16% 74  10% 48  19% 59  16% 70  10% 45  18% 54  16% 
Missing 74  7% 19  5% 32  6% 62  8% 13  5% 19  5% 60  8% 13  5% 17  5% 
cART regimen base NNRTI 507  51% 194  54% 247  47% 394  51% 145  56% 174  46% 379  52% 139  56% 164 48% 
PI 446  45% 150  42% 253  48% 356  46% 104  40% 185  49% 321  44% 102  41% 159  46% 
Other 36  4% 12  3% 26  5% 25  3% 8  3% 19  5% 22  3% 6 2% 19  6% 
Previous ADE  121  12% 104  29% 128  24% 97  13% 74  29% 96  25% 96  13% 70  28% 92  27% 
Previously CD4≤200  380  38% 222  62% 313  60% 295  38% 157  61% 229  61% 285  39% 150  61% 221  65% 
 Median (IQR) Median (IQR) Median (IQR) 
Age Years  38 (33, 44) 40 (34, 46) 36 (30, 42) 38 (33, 44) 40 (34, 47) 36 (30, 42) 38 (33, 
45) 
40 (34, 
47) 
36 (31, 
42) 
Baseline CD4 count Cells/µL 269 
(165, 388) 
158  
(52, 268) 
194  
(80, 292) 
269  
(167, 390) 
160  
(55, 268) 
193  
(75, 291) 
261  
(163, 382) 
160  
(53, 281) 
185  
(71, 266) 
Baseline VL Log 
copies/mL 
5.0  
(4.5, 5.5) 
4.9  
(4.4, 5.5) 
4.8  
(4.1, 5.4) 
5.0  
(4.5, 5.5) 
5.0 
(4.4, 5.5) 
4.8  
(4.1, 5.4) 
5.0  
(4.5, 5.5) 
4.9  
(4.3, 5.5) 
4.8  
(4.2, 5.4) 
Results in bold had a P-value of <0.05 when assessed using Chi-squared tests for categorical variables or Wilcoxon-Mann-Whitney tests for continuous 
variables; NNRTI= Non-Nucleoside Reverse Transcriptase Inhibitors; PI= Protease Inhibitors; IQR= interquartile range; ADE= AIDS defining event. 
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Percentage with virological non-suppression 24-30 months after cART 
initiation 
Using strategy A, 678/1871 (36%) individuals had virological non-suppression at 24 
months (461 with a missing VL, 217 with VL >50 copies/mL). In comparison, 217/1410 
(15%) individuals had virological non-suppression at 24 months using strategy B, and 
149/1311 (11%) individuals using strategy C. 
Gender/sexual orientation, calendar year of cART initiation and 
virological non-suppression 24-30 months after cART initiation 
As with virological non-suppression at 12 months, the risk of virological non-
suppression at 24 months after cART initiation decreased in more recent years among 
all three groups (Figure 6.4a, b and c). A higher percentage of women and MSW than 
MSM had virological non-suppression at 24 months after cART initiation across all 
time points and for each of the analysis strategies. The prevalence of virological non-
suppression among MSW intersected with that among women at various points, 
showing the similarity in virological response between these two groups. Under 
analysis strategy B, of those starting cART in 2000-01, 23% of MSM, 34% of MSW 
and 43% of women had a VL >50 copies/mL at 24 months. For those starting cART in 
2010-13, these values were 6%, 10% and 15% respectively. 
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Figure 6.4: The percentage of individuals with virological non-suppression at 24-30 
months after cART initiation over calendar year of cART initiation and stratified by 
gender/sexual orientation using analysis strategy A (missing=failure) 
A: Strategy A (missing=failure) 
 
B: Strategy B (missing=excluded) 
 
C: Strategy C (on cART) 
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Denominators are provided in Table 6.6; the bars on graph represent confidence intervals. 
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Unadjusted and adjusted RRs for the association of gender/sexual orientation with 
virological non-suppression at 24 months after cART initiation are displayed in Table 
6.7, Table 6.8 and Table 6.9. MSW and women were at a greater risk of virological 
non-suppression compared to MSM across all three strategies. Compared to MSM, 
the adjusted RRs were 1.4-2.0 for MSW and 1.4-1.9 for women. MSW and women had 
a similar risk of virological non-suppression. Calendar year of cART initiation was not 
associated with virological non-suppression at 24 months for analysis strategy A. 
However, for analysis strategies B and C for every year more recently that cART was 
initiated, individuals were, on average, at a 11% and 7% reduced adjusted risk of 
virological non-suppression at 24 months, respectively. For the other variables 
included in multivariable analyses, the associations with virological non-suppression 
were similar to those in the 12-month analysis. 
Table 6.7: Associations of gender/sexual orientation, calendar year of cART initiation 
and other factors at baseline with virological non-suppression 24-30 months after cART 
initiation - Strategy A (missing=failure) 
 
 
 
 
 
 
 
 
 
 
 
 
Factor a Unadjusted Adjusted 
RR 95% CI P-value b aRR c 95% CI P-value b 
Gender/ sexual orientation 
MSW vs. MSM 1.32 1.13, 1.55 <.0001 1.35  1.15, 1.59 <.0001 
Women vs. MSM 1.44  1.26, 1.65  1.39  1.21, 1.60  
Women vs. MSW 1.09  0.93, 1.28  1.03 0.88, 1.21  
Calendar year of cART initiation 
Per year 0.99 0.87, 1.01 0.19 0.99  0.98, 1.01 0.53 
Age 
Per 10 years 0.85  0.81, 0.93 <.0001 0.88  0.82, 0.94 0.0002 
Baseline VL (copies/ mL) 
<10000 1  0.15 1   0.41 
10000-99999 0.73  0.70, 1.00  0.90 0.76, 1.07  
≥100000 0.82  0.76, 1.06  0.96 0.81, 1.15  
Baseline CD4 count (cells/µL) 
≥350 1  0.31 1  0.60 
200-350 0.97  0.82, 1.14  0.92 0.78, 1.09  
<200 1.07 0.92, 1.25  0.98 0.83, 1.15  
Type of initial cART regimen 
NNRTI 1  0.42 1  0.53 
PI 1.07 0.95, 1.21  1.05  0.93, 1.19  
Other 1.16 0.87, 1.55  1.15  0.86, 1.55  
a Each factor considered in separate univariable models then all factors in a single 
multivariable model; b likelihood ratio test; c adjusted for all factors listed in the table; 
denominators are provided in Table 6.6; RR= risk ratio; aRR= adjusted risk ratio; NNRTI= 
Non-Nucleoside Reverse Transcriptase Inhibitors; PI= Protease Inhibitors. 
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Table 6.8: Associations of gender/sexual orientation, calendar year of cART initiation 
and other factors at baseline with virological non-suppression 24-30 months after cART 
initiation - Strategy B (missing=excluded) 
 
 
 
 
 
 
 
 
 
 
 
 
Factor a Unadjusted Adjusted 
RR 95% CI P-value b aRR c 95% CI P-value b 
Gender/ sexual orientation 
MSW vs. MSM 1.54  1.11, 2.15 <.0001 1.63  1.17, 2.27 <.0001 
Women vs. MSM 1.96 1.49, 2.57  1.90  1.43, 2.51  
Women vs. MSW 1.27 0.92, 1.76  1.16  0.84, 1.61  
Calendar year of cART initiation 
Per year 0.89 0.86, 0.92 <.0001 0.89 0.86, 0.93 <.0001 
Age 
Per 10 years 0.73 0.63, 0.86 <.0001 0.81 0.70, 0.93 0.0022 
Baseline VL (copies/ mL) 
<10000 1  0.19 1  0.44 
10000-99999 0.84 0.57, 1.24  0.87 0.60, 1.25  
≥100000 1.08 0.75, 1.55  1.03 0.71, 1.48  
Baseline CD4 count (cells/µL) 
≥350 1  0.018 1  0.035 
200-350 0.74 0.52, 1.04  0.63 0.45, 0.88  
<200 1.11 0.83, 1.50  0.75 0.55, 1.02  
Type of initial cART regimen 
NNRTI 1  0.12 1  0.082 
PI 1.30 1.01, 1.67  1.32 1.04, 1.69  
Other 1.14 0.59, 2.22  1.12 0.59, 2.14  
a Each factor considered in separate univariable models then all factors in a single 
multivariable model; b likelihood ratio test; c adjusted for all factors listed in the table; 
denominators are provided in Table 6.6; RR= risk ratio; aRR= adjusted risk ratio; NNRTI= 
Non-Nucleoside Reverse Transcriptase Inhibitors; PI= Protease Inhibitors. 
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Table 6.9: Associations of gender/sexual orientation, calendar year of cART initiation 
and other factors at baseline with virological non-suppression 24-30 months after cART 
initiation - Strategy C (on cART) 
 
 
 
 
 
 
 
 
 
 
 
Interaction between gender/sexual orientation and calendar year of cART 
initiation 
Table 6.10 shows the tests for interaction between calendar time and gender/sexual 
orientation. Among all gender/sexual orientation groups, there was evidence of 
reductions in risk of virological non-suppression 24 months after cART initiation under 
strategy B; however, there was no evidence of an increasing trend under strategy A, 
and only among MSM under strategy C. However, there was no evidence of 
differences in relative change in virological non-suppression per calendar year of 
cART initiation by gender/sexual orientation in any of the three analysis strategies. 
 
 
 
Factor a Unadjusted Adjusted 
RR 95% CI P-value b aRR c 95% CI P-value b 
Gender/ sexual orientation 
MSW vs. MSM 2.13  1.45, 3.11 <.0001 1.98  1.34, 2.91 0.0004 
Women vs. MSM 2.07  1.46, 2.95  1.83  1.28, 2.61  
Women vs. MSW 0.98 0.67, 1.42  0.92 0.63, 1.35  
Calendar year of cART initiation 
Per year 0.90 0.86, 0.94 <.0001 0.93 0.88, 0.97 0.0023 
Age 
Per 10 years 0.81  0.67, 0.97 0.019 0.85  0.71, 1.02 0.064 
Baseline VL (copies/ mL) 
<10000 1  0.0040 1  0.049 
10000-99999 1.07  0.60, 1.91  1.03  0.58, 1.82  
≥100000 1.78  1.04, 3.04  1.53  0.88, 2.67  
Baseline CD4 count (cells/µL) 
≥350 1  <.0001 1  0.067 
200-350 1.60  0.93, 2.76  1.32  0.76, 2.29  
<200 2.77  1.68, 4.55  1.71  1.01, 2.89  
Type of initial cART regimen 
NNRTI 1  0.70 1  0.47 
PI 1.14  0.84, 1.55  1.21  0.89, 1.65  
Other 0.99  0.42, 2.34  1.06  0.45, 2.49  
a Each factor considered in separate univariable models then all factors in a single 
multivariable model; b likelihood ratio test; c adjusted for all factors listed in the table; 
denominators are provided in Table 6.6; RR= risk ratio; aRR= adjusted risk ratio; NNRTI= 
Non-Nucleoside Reverse Transcriptase Inhibitors; PI= Protease Inhibitors. 
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Table 6.10: Associations of the interaction between gender/sexual orientation and 
calendar year of cART initiation with virological non-suppression at 24 months 
 
 
 Treatment disruptions 
The prevalence of treatment disruptions was considered among the 2753 individuals 
who had initiated cART between January 2000 and March 2014 aged over 18 years 
with sexually acquired HIV. Over the first 12 months of cART: 297 (11%) interrupted 
cART (stopped all ARV drugs for over seven consecutive days); 672 (24%) had other 
disruptions (of the individuals who had not interrupted cART); and the remaining 1784 
(65%) had no cART disruptions (on the same cART regimen for the 12-month period).  
Both cART interruption and cART disruption were associated with a greater 
prevalence of virological non-suppression. Among individuals who interrupted cART 
within 12 months of cART initiation, 70% had virological non-suppression compared to 
13% of those who did not stop (p<0.0001). In addition, 30% of individuals who did not 
interrupt but disrupted treatment had virological non-suppression compared to 11% of 
those who had no disruptions (p<0.0001).  
 Prevalence of cART disruptions during the first 12 months of cART 
initiation by calendar year of cART initiation and gender/sexual orientation 
In Figure 6.5 the percentage of MSM, MSW and women who interrupted cART, who 
had other cART disruptions, or who had no treatment disruptions are shown over 
calendar year of cART initiation. The percentage who interrupted their cART regimen 
before 12 months tended to decrease with more recent year of cART initiation in all 
gender/sexual orientation groups. However, there remained a consistently higher 
percentage of women who had interrupted cART compared to MSM (2000-01: 22% vs. 
10%; 2012-14: 9% vs. 2%), while differences between MSW and MSM tended to be 
smaller.
  Strategy A 
(missing=failure) 
Strategy B 
(missing=excluded) 
Strategy C (on 
cART) 
aRR 
a 
95% 
CI 
P-
valueb 
aRR 
a  
95% 
CI 
P-
valueb 
aRR 
a  
95% 
CI 
P-
valueb 
Relative 
change 
per 
calendar 
year of 
cART 
initiation 
MSM 1.00  0.98, 
1.03 
0.51 0.87  0.82, 
0.93 
0.36 0.90  0.83, 
0.98 
0.56 
MSW 0.98  0.94, 
1.01 
 0.88 0.81, 
0.96 
 0.92  0.84, 
1.01 
 
Women  0.99  0.97, 
1.02 
 0.93 0.87, 
0.99 
 0.96  0.88, 
1.04 
 
a Adjusted for age, baseline VL and CD4 count, initial cART regimen; b likelihood ratio test; 
aRR= adjusted risk ratio. 
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Figure 6.5: The percentage with any cART disruptions during the first 12 months of cART initiation by gender/sexual orientation over calendar year of 
cART initiation 
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 The associations of gender-sexual orientation and calendar year of cART 
initiation with cART interruptions and disruptions during the first 12 months of cART 
initiation 
A higher risk of cART interruption was seen among MSW compared to MSM, and among 
women compared to either MSM or MSW in both unadjusted and adjusted analyses (Table 
6.11). Earlier calendar years of cART initiation, younger age, lower baseline VL, and higher 
baseline CD4 count were associated with higher risk of cART interruption. There was no 
evidence of an association with initial cART regimen.  
Also shown in Table 6.11 are associations with either form of treatment disruption: cART 
interruptions or cART switches within 12 months of initiation. Women had an increased risk 
of treatment disruption compared to either MSW or MSM, although there were no differences 
between MSW and MSM. The risk of any treatment disruption decreased over calendar year 
of cART initiation, but the effect size was smaller than that seen when considering cART 
interruption as an outcome alone. The associations between the other covariates and cART 
disruption were similar to the cART interruption analysis, except that baseline VL ≥100000 
copies/mL compared to <10000 copies/mL, and PI- and other-based initial regimen 
compared to NNRTI-based were associated with a higher risk of cART disruption.
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Table 6.11: Associations of gender/sexual orientation, calendar year of cART initiation and other factors at baseline with cART interruption a or cART 
disruption b during the first 12 months of cART initiation 
 Factors c cART interruption cART disruption 
RR  95% CI P-valued aRR 
e 
95% CI P-valued RR  95% CI P-valued aRR e 95% CI P-valued 
Gender/ sexual orientation 
MSW vs. MSM 1.66  1.22, 2.24 <.0001 1.78  1.31, 2.42 <.0001 1.04  0.91, 1.20 <.0001 1.08  0.93, 1.24 <.0001 
Women vs. MSM 2.43  1.91, 3.10  2.36  1.83, 3.03  1.33  1.19, 1.49  1.34  1.20, 1.51  
Women vs. MSW 1.47  1.11, 1.94  1.32 1.00, 1.75  1.28  1.11, 1.48  1.25 1.08, 1.45  
Calendar year of cART initiation 
Per year 0.91  0.88, 0.93 <.0001 0.90  0.88, 0.93 <.0001 0.97  0.96, 0.98 <.0001 0.97 0.96, 0.98 <.0001 
Age 
Per 10 years 0.77  0.67, 0.88 <.0001 0.86  0.76, 0.98 0.017 0.92  0.87, 0.98 0.0055 0.95  0.90, 1.01 0.079 
Baseline VL (copies/mL) 
<10000  1  0.0054 1  0.065 1  0.0057 1  0.0080 
10000-99999  0.74  0.57, 0.95  0.85  0.65, 1.09  0.90  0.79, 1.03  0.96  0.83, 1.09  
≥100000  0.66  0.51, 0.85  0.74  0.57, 0.95  1.10  0.98, 1.24  1.15  1.02, 1.30  
Baseline CD4 count (cells/µL) 
≥350  1  0.0004 1  <.0001 1  0.0005 1  0.0001 
200-350  0.56  0.41, 0.77  0.46  0.34, 0.63  0.78  0.67, 0.90  0.73  0.63, 0.84  
<200 0.87  0.68, 1.12  0.57  0.44, 0.74  0.97  0.85, 1.09  0.83  0.73, 0.95  
Type of initial cART regimen 
NNRTI 1  0.90 1  0.69 1  0.022 1  0.015 
PI 1.05  0.84, 1.31  1.10  0.88, 1.36  1.11  1.00, 1.23  1.11  1.00, 1.23  
Other 1.07  0.65, 1.76  1.11  0.67, 1.84  1.31 1.07, 1.61  1.35  1.10, 1.66  
a cART interruption= stopping all ARVs for greater than seven consecutive days; b cART disruption= stopping all ARVs for greater than seven consecutive days 
or switching cART regimen for reasons other than simplification;  c each factor considered in separate univariable models then all factors in a single 
multivariable model;  d likelihood ratio test; e adjusted for all factors listed in the table; RR= Risk Ratio; aRR= adjusted Risk Ratio; NNRTI= Non-Nucleoside 
Reverse Transcriptase Inhibitors; PI= Protease Inhibitors. 
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Test for interaction between gender/sexual orientation and calendar year 
of cART initiation 
There was an estimated average 14% reduction in the risk of interrupting cART within 
the first 12 months per year later of cART initiation among MSM, compared to 9% and 
6% among MSW and women, respectively (Table 6.12). A test for interaction 
suggested the trend was greater among MSM compared to MSW, and particularly 
compared to women (p=0.029). This indicates that, while in more recent years of cART 
initiation all three groups were less likely to discontinue their cART regimen, the 
reduction in risk over time was greatest for MSM. A similar pattern was apparent for 
risk of cART disruptions, although trends were considerably weaker in all 
gender/sexual orientation groups (Table 6.12). 
Table 6.12: Associations of the interaction between gender/sexual orientation and 
calendar year of cART initiation with cART interruptions and disruptions during the first 
12 months of cART initiation 
  
 
 cART disruptions during the first 12 months of cART initiation as a 
mediating factor for associations between gender/sexual orientation and 
virological non-suppression at 12 months 
An analysis considering virological non-suppression at 12 months as the outcome and 
cART disruptions (cART interruptions vs. other cART disruptions vs. no disruptions) as 
a mediating factor was performed. The RRs for the associations between the 
covariates and virological non-suppression are displayed in Table 6.13. The first and 
second columns were equivalent to those in Table 6.2 for the main analysis of 
virological non-suppression at 12 months, but were included here for comparison. 
Additionally, a univariable model for the association between cART disruptions and 
virological non-suppression was assessed: cART switches and cART interruptions 
were associated with 1.5 times and 6.6 times the risk of virological non-suppression 
compared to no disruptions, respectively.  
Following adjustment for cART disruptions the adjusted RRs in column 2 of Table 6.13 
were attenuated towards one by 19% and 49% for MSW and women compared to 
 cART interruption cART disruption 
aRR a 95% CI P-
valueb 
aRR a 95% CI P-
valueb 
Relative 
change per 
calendar year 
of cART 
initiation 
MSM 0.86 0.83, 0.90 0.029 0.96 0.94, 0.98 0.078 
MSW 0.91 0.85, 0.98  0.98 0.94, 1.01  
Women  0.94 0.90, 0.98  0.99 0.97, 1.01  
a For age, baseline CD4 count and VL, and third drug in initial ART regimen; b likelihood 
ratio test for interaction term; aRR= adjusted risk ratio. 
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MSM, respectively, however, the risk of virological non-suppression at 12 months 
remained higher among MSW and women. There was also an attenuation of the 
association of calendar year of cART initiation, age, baseline VL, and baseline CD4 
count with virological non-suppression; however, associations with type of initial cART 
regimen were not reduced. cART interruptions and other cART disruptions remained 
very strongly associated with a greater risk of virological non-suppression compared to 
no treatment disruptions in this multivariable model. 
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Table 6.13: Associations of gender/sexual orientation, calendar year of cART initiation and other factors at baseline with virological non-suppression at 
12-18 months after cART initiation and additional adjustment for cART disruptions a b 
Factors Unadjusted c Adjusted d Adjusted additionally for 
cART disruptions e 
RR  95% CI P-
valuef 
aRR 95% CI P-valuef aRR  95% CI P-valuef 
Gender/ sexual orientation 
MSW vs. MSM 1.45 1.06, 1.96 <.0001 1.60  1.17, 2.20 <.0001 1.41 1.04, 1.91 0.019 
Women vs. MSM 1.93 1.51, 2.47  1.87  1.45, 2.43  1.38 1.07, 1.77  
Women vs. MSW 1.34 0.99, 1.80  1.17  0.86, 1.58  0.98 0.73, 1.31  
Calendar year of cART initiation  
Per year 0.93 0.90, 0.96 <.0001 0.92 0.89, 0.95 <.0001 0.96 0.92, 0.99 0.0070 
Age 
Per 10 years 0.77 0.67, 0.88 <.0001 0.84 0.74, 0.96 0.0095 0.88 0.77, 1.00 0.039 
Baseline VL (copies/ mL) 
<10000  1  0.0024 1  0.0028 1   0.013 
10000-99999  0.62 0.44, 0.86  0.67 0.48, 0.92  0.76 0.57, 1.02  
≥100000  0.90 0.67, 1.22  1.00 0.73, 1.37  1.09 0.81, 1.46  
Baseline CD4 count (cells/µL) 
≥350  1  0.96 1  0.093 1  0.52 
200-350  0.97 0.72, 1.29  0.83 0.63, 1.11  1.13 0.87, 1.46  
<200 1.00 0.76, 1.32  0.71 0.53, 0.96  0.99 0.74, 1.33  
Type of initial cART regimen 
NNRTI 1  0.0009 1  0.0005 1  0.0004 
PI 1.51 1.19, 1.91  1.52 1.21, 1.91  1.49  1.20, 1.85  
Other 1.80 1.13, 2.88  1.73 1.10, 2.73  1.73 1.12, 2.67  
cART disruptions within 12 months of cART initiation 
None 1  <.0001 - - - 1  <.0001 
Switched 1.54 1.16, 2.05  - - - 1.42 1.07, 1.88  
Interrupted 6.57 5.29, 8.17  - - - 5.33 4.19, 6.79  
 
 
a ART disruption: interrupted ART (stopping all ARVs for greater than seven consecutive days); switched ART (if not stopped then switched any ARV for 
reasons other than simplification); or no disruptions; b using analysis strategy B: missing VL at 12 months= excluded; c each factor considered in separate 
univariable models; d adjusted for all factors listed in the table except ART disruptions; e adjusted for all factors listed in the table including ART adherence; f 
likelihood ratio test; RR= Risk Ratio; aRR= adjusted Risk Ratio; NNRTI= Non-Nucleoside Reverse Transcriptase Inhibitors; PI= Protease Inhibitors. 
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Reasons for cART disruptions by gender/sexual orientation 
Of the 969 individuals who had disrupted their cART regimen within 12 months of 
cART initiation, 943 (97%) had a clinician-completed reason recorded for stopping at 
least one ARV. The reasons are summarised in Table 6.14. The frequencies sum to 
over 943 since 370 (39%) individuals had different reasons recorded when stopping 
more than one ARV (262 two ARVs; 81 three ARVs; 25 four ARVs; two had five 
ARVs), leading to 1450 ARV switches over the first 12 months of cART. 
Toxicity was the main reason for stopping an ARV (39%) followed by rationalisation 
(14%) and patient choice (12%). Rationalisation usually means simplification of an 
individual’s cART regimen, for example changing to a single tablet once a day 
regimen. 
There were differences in the reasons given for cART disruptions by gender/sexual 
orientation group. For example, of all the stopping reasons and treatment failure 
reasons were more prevalent for MSW and toxicity reasons were more prevalent 
among MSM. CNS effects and rash were in the top three toxicity reasons for treatment 
disruption for all three gender/sexual orientation groups; however, diarrhoea, renal 
problems, and nausea were more prevalent among MSM, MSW, and women, 
respectively. Among MSW and women “other reasons” and not having reasons 
recorded in their notes were more common than among MSM.
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Table 6.14: Reasons for disruption of cART regimen during the first 12 months of cART 
initiation by gender/sexual orientation 
Reason  Overall MSM MSW Women 
N % a N % a N % a N % a 
Treatment failure 82 5.7 30 4.4 24 9.1 28 5.5 
 Virological failure 58 4.0 23 3.4 16 6.1 19 3.7 
 CD4 count failure 2 0.1 1 0.1 1 0.4 0 0 
 Increased resistance 22 1.5 6 0.9 7 2.7 9 1.8 
Study end point or change 50 3.4 41 6.1 4 1.5 5 1.0 
Toxicity (any) 558 38.5 294 43.4 80 30.4 184 36.1 
 CNS effects / insomnia 147 10.1 90 13.3 24 9.1 33 6.5 
 Rash 71 4.9 34 5.0 14 5.3 23 4.5 
 Nausea / vomiting 58 4.0 25 3.7 5 1.9 28 5.5 
 Diarrhoea 56 3.9 42 6.2 3 1.1 11 2.2 
 Anaemia 52 3.6 24 3.5 8 3.0 20 3.9 
 Renal problem 40 2.8 17 2.5 10 3.8 13 2.5 
 Abnormal LFTs 31 2.1 13 1.9 4 1.5 14 2.7 
 Peripheral neuropathy 24 1.7 13 1.9 3 1.1 8 1.6 
 Allergic reaction 18 1.2 9 1.3 2 0.8 7 1.4 
 Gastrointestinal side effects 
/intolerance 
11 0.8 2 0.3 2 0.8 7 1.4 
 Malaise /fatigue 8 0.6 5 0.7 0 0.0 3 0.6 
 Skin problems 8 0.6 2 0.3 1 0.4 5 1.0 
 Lipid abnormality 7 0.5 7 1.0 0 0.0 0 0 
 Lipodystrophy 6 0.4 3 0.4 1 0.4 2 0.4 
 Abdominal pain 6 0.4 2 0.3 0 0.0 4 0.8 
 Other toxicity 15 1.0 6 0.9 3 1.1 6 1.2 
Pregnancy 42 2.9 0 0.0 0 0.0 42 8.2 
Rationalization 202 13.9 105 15.5 37 14.1 60 12.0 
Patient choice 180 12.4 86 12.9 32 12.2 62 12.2 
Death 17 1.2 4 0.6 10 3.8 3 0.6 
Other reasons 167 11.5 64 9.5 40 15.2 63 12.4 
 Other 123 8.5 47 6.9 29 11.0 47 9.2 
 Poor compliance 17 1.2 8 1.2 5 1.9 4 0.8 
 Drug interaction 24 1.7 8 1.2 6 2.3 10 2.0 
 Following a TDM result 3 0.2 1 0.1 0 0.0 2 0.4 
Not recorded 152 10.5 53 7.8 36 13.7 63 12.4 
 
 
 
 Treatment non-adherence at 12 months 
Prevalence of treatment non-adherence between three and 12 months 
after cART initiation 
Of the 2753 individuals initiating cART between January 2000 and March 2014 aged 
over 18 years with sexually acquired HIV, 2644 had any prescription data over follow-
up. Of these, 1351 (51%) had a prescription recorded within seven days of the date of 
cART initiation and at least one additional prescription between one and three months 
after cART initiation, and were therefore included: 716 (53%) MSM; 251 (19%) MSW; 
384 (28%) women. 
a Percentages may not sum to 100 due to rounding; other toxicity includes: intolerance, 
headache, pancreatitis, diabetes, myositis and raised amylases; CNS= central nervous 
system; LFTs= liver function tests; TDM= therapeutic drug monitoring. 
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The distribution of percentage cART coverage is displayed in Figure 6.6. There were 
257 (19%) individuals with 100% adherence, 486 (36%) with 90-99% prescription 
coverage, 211 (16%) with 80-89%, 225 (17%) with 60-79%, and the remaining 172 
(13%) had <60% adherence.  
Figure 6.6: Cumulative frequency distribution of the prescription based treatment 
adherence measure a 
 
 
 
Of the 1351 individuals, 808 (60%) and 397 (29%) had <95% and <80% prescription 
coverage between three and 12 months after cART initiation, respectively. 
Among individuals with <95% adherence, 16% had a VL >50 copies/mL at 12 months 
after cART initiation compared to 12% of individuals with ≥95% adherence (p=0.025). 
Likewise, of individuals with <80% adherence, 24% had VL >50 copies/mL compared 
to 11% of individuals with ≥80% adherence (p<0.0001).  
The prevalence of <95% cART adherence between three and 12 months after cART 
initiation fell from 2000/2001 to 2008/2009, but then rose again in the more recent 
periods. For <80% adherence, the prevalence tended to decrease over the whole 
period (Figure 6.7).  
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a N=1351 individuals who had a prescription for cART recorded within a week of the date 
recorded that they first initiated cART and who had at least one further cART prescription 
between one and three months after cART initiation.  
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Figure 6.7: Percentage with cART non-adherence between three and 12 months after 
cART initiation by calendar year of cART initiation 
 
 
Overall a lower percentage of MSM had <95% cART adherence compared to women 
and MSW in particular (Figure 6.8). Similarly, a lower percentage of MSM had <80% 
cART adherence compared to MSW and women. 
Figure 6.8: Percentage with cART non-adherence between three and 12 months after 
cART initiation by calendar year of cART initiation 
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a Cochran-Armitage test for trend; numbers on each bar represent the number of individuals 
in that category. 
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The association between gender-sexual orientation, calendar year of 
cART initiation and cART non-adherence between three and 12 months after 
cART initiation 
The RRs for the associations between the covariates and <95% adherence are shown 
in Table 6.15. In unadjusted analyses the factors associated with a higher risk of <95% 
adherence were: MSW compared to MSM or women; less recent calendar year of 
cART initiation; an “other-based” initial cART regimen compared to NNRTI-based. 
There were no significant differences between women and either MSM or MSM, by 
age, or by baseline VL or CD4 count. In the multivariable model the same factors 
remained associated with a higher risk of <95% adherence.  
Table 6.15 also shows the RRs for the associations between the covariates and <80% 
adherence. In contrast to the analysis of <95% as an endpoint, women had a higher 
unadjusted risk of non-adherence compared to MSM. Individuals who initiated cART in 
earlier years had a higher risk of non-adherence. In adjusted analyses, calendar year 
of cART initiation was the only factor which remained associated with <80% 
adherence: a 5% reduction in the adjusted risk of <80% cART adherence per year 
more recently that cART was initiated.
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Table 6.15: Associations of gender/sexual orientation, calendar year of cART initiation and other factors at baseline with cART non-adherence between 
three and 12 months after cART initiation 
Factors a <95% cART adherence <80% cART adherence 
RR (95% CI) P-valueb aRR (95% CI) c P-valueb RR (95% CI) P-valueb aRR (95% CI) c P-valueb 
Gender/ sexual orientation 
MSW vs. MSM 1.17 (1.05, 1.30) 0.023 1.16 (1.04, 1.30) 0.031 1.09 (0.87, 1.36) 0.086 1.06 (0.84, 1.33) 0.25 
Women vs. MSM 1.05 (0.94, 1.16)  1.03 (0.92, 1.15)  1.24 (1.03, 1.49)  1.18 (0.97, 1.44)  
Women vs. MSW 0.89 (0.79, 1.01)  0.88 (0.78, 1.00)  1.14 (0.90, 1.14)  1.12 (0.88, 1.42)  
Calendar year of cART initiation 
Per year 0.99 (0.98, 1.00) 0.022 0.99 (0.98, 1.00) 0.052 0.95 (0.93, 0.98) <.0001 0.95 (0.93, 0.98) <.0001 
Age 
Per 10 years 0.97 (0.93, 1.02) 0.25 0.97 (0.93, 1.02) 0.31 0.92 (0.84, 1.02) 0.093 0.95 (0.87, 1.05) 0.34 
Baseline VL (copies/mL) 
<10000  1 0.24 1  0.51 1 0.87 1  0.77 
10000-99999  0.94 (0.82, 1.06)  0.96 (0.84, 1.09)  0.94 (0.74, 1.19)  0.99 (0.78, 1.25)  
≥100000  1.02 (0.90, 1.15)  1.02 (0.90, 1.15)  0.95 (0.76, 1.19)  0.93 (0.74, 1.18)  
Baseline CD4 count (cells/µL) 
≥350  1 0.42 1 0.96 1 0.36 1 0.69 
200-350  1.01 (0.89, 1.14)  0.98 (0.87, 1.11)  1.01 (0.81, 1.28)  0.91 (0.72, 1.15)  
<200 1.07 (0.95, 1.19)  1.00 (0.88, 1.13)  1.14 (0.92, 1.41)  0.97 (0.77, 1.23)  
Type of initial cART regimen 
NNRTI 1 0.13 1 0.097 1 0.56 1 0.45 
PI 1.04 (0.96, 1.14)  1.05 (0.96, 1.15)  0.99 (0.83, 1.17)  1.00 (0.84, 1.18)  
Other 1.23 (1.02, 1.50)  1.26 (1.04, 1.53)  1.26 (0.85, 1.87)  1.34 (0.89, 2.03)  
a Each factor considered in separate univariable models then all factors in a single multivariable model;  b likelihood ratio test; c adjusted for all factors listed in 
the table; RR= risk ratio; aRR= adjusted risk ratio; NNRTI= Non-Nucleoside Reverse Transcriptase Inhibitors; PI= Protease Inhibitors. 
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 Test for interaction between gender/sexual orientation and calendar year 
of cART initiation 
Among MSM, the adjusted risk of <95% adherence decreased by 2% per year later 
that cART was initiated, and the risk of <80% adherence decreased by 7% per year. 
However, there was no evidence of an increasing trend in adherence over time among 
MSW or women (Table 6.16). Despite these differences there was no evidence that 
the reductions in risk of cART non-adherence by calendar year of cART initiation 
differed by gender/sexual orientation (p=0.26 and p=0.13). 
Table 6.16: Associations of the interaction between gender/sexual orientation and 
calendar year of cART initiation with cART non-adherence between three and 12 months 
after cART initiation 
 
Adherence as a mediating factor for the association between 
gender/sexual orientation and virological non-suppression at 12 months 
An analysis considering virological non-suppression at 12 months as the outcome and 
adherence as a mediating factor was performed. There were 1615 individuals that met 
the inclusion criteria for strategy B (missing VL at 12 months=excluded). Of these, 
1087 additionally had at least one prescription recorded within seven days of cART 
initiation and another recorded between one to three months after initiation. A total of 
592 (54%) were MSM, 195 (18%) were MSW, and 300 (28%) were women. 
The results of the unadjusted and adjusted modified Poisson regression models for 
virological non-suppression are displayed in Table 6.17. These results are similar to 
that in the main analysis. In addition, there was evidence of a 17% higher unadjusted 
risk of virological non-suppression at 12 months per 10% additional prescription 
coverage between three and 12 months after cART initiation. 
Additionally, adjustment for non-adherence attenuated the association between 
gender/sexual orientation and virological non-suppression by 9% and 19% for MSW 
and women compared to MSM, respectively (Table 6.17). This was likely a result of 
the increasing trend over time in adherence among MSM compared to the lack of 
evidence of a trend among MSW and women.
 <95% adherence <80% adherence 
aRR a 95% CI  P-
valueb 
aRR a 95% CI P-
valueb 
Relative 
change per 
calendar year 
of cART 
initiation 
MSM 0.98 0.96, 1.00 0.26 0.93 0.90, 0.96 0.13 
MSW 1.00 0.98, 1.02  0.97 0.92, 1.02  
Women  1.00 0.97, 1.02  0.98 0.94, 1.02  
a For age, baseline CD4 count and VL, and third drug in initial cART regimen; b likelihood 
ratio test; aRR= adjusted risk ratio. 
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Table 6.17: Associations of gender/sexual orientation, calendar year of cART initiation and other factors at baseline with virological non-suppression at 
12 months with additional adjustment for cART non-adherence 
Factors a Unadjusted Adjusted  Adjusted additionally for 
non-adherence 
RR  95% CI P-value 
b 
aRR 
c 
95% CI P-value 
b 
aRR 
d  
95% CI P-
value b 
Gender/ sexual orientation 
MSW vs. MSM 1.62 1.08, 2.43 0.0002 1.68  1.11, 2.55 0.0007 1.59 1.06, 2.40 0.0035 
Women vs. MSM 2.04 1.46, 2.85  1.98  1.39, 2.81  1.79 1.26, 2.53  
Women vs. MSM 1.26 0.85, 1.87  1.17 0.79, 1.75  1.12 0.76, 1.66  
Calendar year of cART initiation  
Per year 0.93 0.89, 0.97 0.0005 0.93 0.89, 0.97 0.0008 0.94 0.90, 0.99 0.013 
Age 
Per 10 years 0.85 0.71, 1.02 0.065 0.93 0.77, 1.10 0.38 0.94  0.80, 1.12 0.52 
Baseline VL (copies/mL) 
<10000  1  0.075 1  0.17 1   0.14 
10000-99999  0.68 0.43, 1.08  0.75 0.47, 1.19  0.80 0.51, 1.25  
≥100000  0.97 0.64, 1.48  1.02 0.66, 1.58  1.12 0.60, 1.34  
Baseline CD4 count (cells/µL) 
≥350  1  0.32 1  0.71 1  0.83 
200-350  1.02 0.67, 1.55  0.84 0.55, 1.27  0.90 0.60, 1.34  
<200 1.28 0.87, 1.89  0.86 0.57, 1.32  0.98 0.65, 1.47  
Type of initial cART regimen 
NNRTI 1  0.031 1  0.021 1  0.024 
PI 1.43 1.04, 1.95  1.45 1.07, 1.98  1.43 1.06, 1.93  
Other 2.14 1.11, 4.11  2.08 1.08, 4.00  1.99  1.10, 3.60  
Adherence 
Per additional 10% 0.83 0.80, 0.86 <.0001 -  - 0.85 0.81, 0.89 <.0001 
 
 
a Each factor considered in separate univariable models then all factors in a single multivariable model;  b likelihood ratio test; c adjusted for all factors listed in 
the table except cART adherence; d adjusted for all factors listed in the table including cART adherence; RR= risk ratio; aRR= adjusted risk ratio; NNRTI= Non-
Nucleoside Reverse Transcriptase Inhibitors; PI= Protease Inhibitors. 
 
244 
 
 Sensitivity analyses  
Virological non-suppression at 12 months 
Viral load cut-off changed to 200 copies/mL (instead of 50 copies/mL) 
There were 517/1971 (26%), 161/1615 (10%), and 91/1522 (6%) individuals with VL 
>200 copies/mL at 12 months under analysis strategies A, B, and C, respectively. 
Using this definition of virological non-suppression, the results were comparable to 
those in the main analysis (Table 6.18 and Table 6.19). 
Individuals not excluded if missing baseline VL and CD4 count (complete case 
analysis)  
In the main analysis, 754 (12%) individuals were excluded due to missing baseline VL 
or CD4 count. When these individuals were included, there were 1129/2710 (42%), 
355/1936 (18%), and 249/1801 (14%) individuals with virological non-suppression 
using analysis strategies A, B, and C, respectively. The prevalence of virological non-
suppression was substantially higher for analysis strategy A compared to the main 
analysis (42% vs 31%). However, the RRs found in these analyses were similar to 
those in the main analysis, which suggested that the exclusion of these individuals had 
not biased the results (Table 6.18 and Table 6.19). 
Virological non-suppression defined using a VL measurement between six and 
18 months after cART initiation 
There were 447/1971 (23%), 280/1804 (16%), and 204/1711 (12%) individuals with 
virological non-suppression at 12 months under strategies A, B, and C, respectively. 
The prevalence of virological non-suppression was substantially lower for analysis 
strategy A compared to the main analysis (23% vs 31%), but equivalent to the main 
analysis under the other two analysis strategies. Furthermore, the RRs in this 
sensitivity analysis were largely consistent with those of the main analysis (Table 6.18 
and Table 6.19). One exception to this was that, unlike in the main analysis, increasing 
calendar time was associated with lower risk of virological non-suppression under 
strategy A as well as the other strategies. Additionally, contrasting to the main 
analysis, for strategy C there was no evidence of a higher adjusted risk of virological 
non-suppression among women compared to MSM. 
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Table 6.18: Associations of gender/sexual orientation and calendar year of cART initiation with virological non-suppression 12-18 months after cART 
initiation – sensitivity analyses 
Factors Strategy A (missing=failure) Strategy B (missing=excluded) Strategy C (on cART) 
aRR a  95% CI P-valueb aRR a 95% CI P-valueb aRR a 95% CI P-valueb 
Viral load cut-off changed to 200 copies/mL (instead of 50 copies/mL) 
Gender/ sexual orientation MSW vs. MSM 1.53  1.26, 1.87 <.0001 2.90  1.88, 4.47 <.0001 3.95  2.23, 6.98 <.0001 
Women vs. MSW 1.55  1.30, 1.84  3.56  2.48, 5.11  3.74  2.18, 6.41  
Women vs. MSW 1.01 0.83, 1.22  1.23 0.85, 1.79  0.95 0.60, 1.49  
Calendar year of cART initiation  Per year 0.98 0.96, 1.00 0.030 0.86  0.82, 0.91 <.0001 0.89 0.83, 0.95 0.0005 
Individuals not excluded if missing baseline VL and CD4 count (complete case analysis) 
Gender/ sexual orientation MSW vs. MSM 1.31 1.11, 1.55 0.0002 1.56 1.15, 2.13 <.0001 1.57 1.12, 2.21 0.0052 
Women vs. MSW 1.32  1.14, 1.52  1.91 1.49, 2.45  1.57 1.15, 2.14  
Women vs. MSW 1.00 0.85, 1.19  1.22 0.91, 1.64  1.00 0.71, 1.40  
Calendar year of cART initiation  Per year 0.92 0.84, 1.00 0.045 0.93 0.90, 0.96 <.0001 0.96 0.92, 0.99 0.021 
Virological non-suppression defined using a VL measurement between six and 18 months after cART initiation 
Gender/ sexual orientation MSW vs. MSM 1.53  1.23, 1.90 <.0001 1.56 1.16, 2.11 0.0001 1.62  1.16, 2.25 0.025 
Women vs. MSW 1.44  1.19, 1.75  1.69 1.32, 2.18  1.28 0.93, 1.76  
Women vs. MSW 0.94 0.76, 1.17  1.08 0.81, 1.44  0.79 0.56, 1.10  
Calendar year of cART initiation  Per year 0.93 0.91, 0.96 <.0001 0.91 0.88, 0.94 <.0001 0.93  0.90, 0.97 0.0003 
a Multivariable model included gender/sexual orientation, year of cART initiation, age, baseline VL, baseline CD4 count, initial cART regimen; denominators 
are provided in Table 6.1; b likelihood ratio test; RR= risk ratio; aRR= adjusted risk ratio; NNRTI= Non-Nucleoside Reverse Transcriptase Inhibitors; PI= 
Protease Inhibitors. 
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Table 6.19: Associations of the interaction between gender/sexual orientation and calendar year of cART initiation with virological non-suppression 12-
18 months after cART initiation – sensitivity analyses 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Factors  Strategy A (missing=failure) Strategy B (missing=excluded) Strategy C (on cART) 
aRR a 95% CI P-valueb aRR a 95% CI P-valueb aRR a 95% CI P-valueb 
Viral load cut-off changed to 200 copies/mL (instead of 50 copies/mL) 
Relative change per 
calendar year of cART 
initiation 
MSM 1.00 1.02, 1.04 0.053 0.83 0.76, 0.90 0.36 0.87 0.76, 1.00 0.50 
MSW 0.95 0.91, 0.99  0.86 0.77, 0.97  0.85 0.75, 0.96  
Women  0.96 0.92, 0.99  0.89 0.84, 0.95  0.92 0.84, 1.02  
Individuals not excluded if missing baseline VL and CD4 count (complete case analysis) 
Relative change per 
calendar year of cART 
initiation 
MSM 1.00 0.98, 1.03 0.047 0.93 0.89, 0.98 0.75 0.98 0.93, 1.04 0.18 
MSW 0.96 0.93, 1.00  0.90 0.84, 0.98  0.90 0.83, 0.97  
Women  0.96 0.94, 0.99  0.93 0.89, 0.97  0.96 0.90, 1.02  
Virological non-suppression defined using a VL measurement between six and 18 months after cART initiation 
Relative change per 
calendar year of cART 
initiation 
MSM 0.95 0.91, 0.98 0.23 0.91 0.86, 0.95 0.99 0.94 0.89, 0.99 0.94 
MSW 0.95 0.90, 1.00  0.91 0.85, 0.98  0.93 0.86, 1.00  
Women  0.91 0.87, 0.94  0.91 0.86, 0.95  0.92 0.86, 0.99  
 
a Adjusted for age, baseline VL and CD4 count, initial ART regimen; b likelihood ratio test; aRR= adjusted risk ratio. 
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 Discussion 
 Summary of results 
 Overall, among people starting cART in the UK, the risk of virological non-
suppression at one year is now low. The results of this chapter have 
demonstrated that the risk of virological non-suppression at 12 or 24 months 
after starting cART has decreased over calendar year of cART initiation for all 
gender/sexual orientation groups.  
 However, even in the most recent years, women and MSW remained at a 
greater risk of virological non-suppression than MSM.  
 Overall there was no evidence that differences in the risk of having a VL >50 
copies/mL at 12 or 24 months after cART initiation between the gender/sexual 
orientation groups were narrowing.  
 The interaction term between gender/sexual orientation and calendar time was 
only found to be associated with virological non-suppression at 12 months 
when I considered those LTFU as having virological non-suppression (analysis 
strategy A), and not under the other two analysis strategies. Thus, the greater 
improvements over time in virological response among MSW and women 
(compared to MSM) reflected the lower percentage of individuals in these 
groups who were LTFU in more recent compared to earlier years. Furthermore, 
when those who initiated ART between 2012 and 2014 were removed there 
was no evidence that the interaction term was associated with virological non-
suppression. 
 For every calendar year of cART initiation later, the risk of interrupting 
treatment within 12 months of cART initiation decreased by 9% and the risk of 
<80% cART adherence decreased by 5% on average.  
 Women and MSW had a greater risk of both cART non-adherence and 
interruptions compared to MSM. Notably, women were at over twice the risk of 
cART interruption in the first 12 months compared to MSM, which puts them at 
a disadvantage for achieving virological suppression – a disadvantage that 
does not seem to have diminished over time.  
 The results of this chapter suggest that cART non-adherence and interruptions 
explain at least part of the differences in virological non-suppression at 12 
months by gender/sexual orientation. 
 
 
248 
 
 Interpretation of results 
The reductions in risk over calendar year of cART initiation were more substantial 
when individuals with a missing VL were excluded (strategy B) than when restricted to 
individuals on cART at the time of their VL measurement (strategy C). When I 
investigated whether cART disruptions were a mediator for the association between 
gender/sexual orientation and virological non-suppression, there was evidence that 
treatment disruptions somewhat attenuated this association, and the association 
between increasing calendar year of cART initiation and decreasing risk of virological 
non-suppression. It is likely, therefore, that the greater improvements over time seen in 
analysis strategy B compared to strategy C arose in part from reductions in cART 
interruptions for people starting cART in later calendar years.  
Adjustment for cART interruptions attenuated the differences in virological non-
suppression between MSW and MSM and between women and MSM to a greater 
extent than adjustment for cART prescription coverage, as a measure of adherence. 
This may have reflected the greater accuracy of the measurement of cART 
interruptions compared to adherence (see Section 6.5.3). However, it is also likely 
that, since cART interruptions are a more extreme form of non-adherence these 
behaviours are more able to account for poorer virological outcomes. On the other 
hand, the difference in the extent to which these factors explained the differences in 
virological non-suppression could also be a result of the measure of non-adherence 
failing to capture true adherence levels (see Section 6.5.3).  
The reductions in cART interruptions over time were likely in part related to the 
introduction of one tablet once a day regimens604, less toxic ARVs605 and better clinical 
management with regard to adherence. However, since there were not substantial 
differences in the cART regimens used by gender/sexual orientation in this chapter, 
these factors were unlikely to explain the greater prevalence of treatment interruptions 
found among women compared to MSM and MSW. Differences with by gender/sexual 
orientation respect to socio-economic status (SES), time in the UK, family 
circumstances, pregnancy, psychosocial factors and comorbidities may be related to 
gender/sexual orientation disparities in ART adherence and in turn virological 
outcomes. As shown in Section 2.5, several studies have found that lower SES is 
associated with poorer virological response126;342;359;363;400-405;408;415, but further study of 
the role of these factors in a UK setting is required. It was not possible to assess the 
impact of these factors in this chapter since they are unavailable in the Royal Free 
cohort study, as is the case with many cohorts that use routinely collected data; 
however, I look at SES and social circumstances in Chapters 7 and 8. 
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Other than gender/sexual orientation and calendar year of cART initiation, age at 
cART initiation and initial cART regimen were found to affect initial virological 
response. Younger age was associated with a greater prevalence of virological non-
suppression at 12 and 24 months after cART initiation, similarly to other recent cohort 
studies596;606;607. Adjustment for cART disruptions within 12 months of cART initiation 
attenuated the association between younger age and poorer virological response at 12 
months to some extent. A greater prevalence of treatment disruptions among younger 
individuals were also found in several other studies588;608;609. NNRTI-based initial cART 
regimens were also associated with a lower prevalence of virological non-suppression 
at 12 months compared to PI-based or other regimens under analysis strategies B and 
C. There was no evidence of an association between initial cART regimen and 
virological response at 24 months after cART initiation though, so it is likely that any 
effect of initial treatment is short-term. However, choice of initial regimen does have an 
effect in the long-term on what subsequent regimens may follow if drug-resistance 
develops610. Unlike gender/sexual orientation and age differences, the association 
between initial cART regimen and virological non-suppression was not substantially 
attenuated by adjustment for cART disruptions. Thus, its effect on initial virological 
response is likely through time until an initial period of viremia611.  
 Strengths and Limitations 
The variety of outcome measures under consideration are a major advantage to this 
chapter, in that it tests the robustness of any differences or associations found. Three 
analysis strategies were considered for the virological outcomes, including the use of a 
missing=failure analysis, in order to give a more complete picture of the trends. 
Additionally I considered two definitions of cART disruptions/interruptions and two 
more of cART adherence. Treatment disruption data came from patient notes recorded 
by HIV clinicians, which were 100% notes, reviewed annually, with attempts made to 
record treatment disruptions as short as two to three days; therefore, the data on 
ARVs stopped or switched for others should be highly accurate. However, it is possible 
that some treatment disruptions could have been missed, since the collection of this 
data requires the individual to report that they stopped taking their treatment. Thus 
treatment disruptions in this chapter may have been underestimated. 
An advantage of the data being from a single centre is that the patients should have 
received fairly homogenous care, e.g. similar resources available (and this would be 
difficult to capture in routinely collected data), and the data collection was 
homogenous. Furthermore, in a multicentre study, if there were differences in the 
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proportion of MSM at the different clinics, then it may be difficult to distinguish the role 
of gender/sexual orientation. A single centre study avoids this problem.  
One important limitation of this chapter was the amount of baseline missing VL data, 
which meant that it was not possible to include the whole population starting cART. 
However, I considered a sensitivity analysis addressing this issue, which gave similar 
results. Furthermore, 18% (356) of those included in strategy A were excluded under 
strategy B no VL measurement in the six-month window, 12-18 months after baseline. 
In a sensitivity analysis where the window was widened to between six and 18 months 
after cART initiation, only 8% (167) were excluded because they did not have a VL 
measurement within the period. There was also a large proportion of individuals 
without prescription-based adherence data who were excluded for the analyses 
including the cART non-adherence measure. However, there was not another 
measure of adherence available from the RFHCS and restrictions for a prescription-
based measure must be such that individuals can be reasonably assessed to be 
collecting prescriptions from the pharmacy.  
Prescription refill was the only measure currently available for measuring adherence in 
this cohort, and this measure was only available for about half of the patients for which 
it was relevant. The advantage of measuring adherence by using prescription refill 
data is that it does not suffer from the social desirability or self-reporting bias. 
Additionally, these data can be collected easily and cheaply in most healthcare 
settings. One disadvantage of prescription based adherence measures is that they can 
only be used in a closed pharmacy system. It is possible that individuals could have 
accessed treatment from another source, however, this was considered as unlikely to 
any large degree due to the inclusion criteria, since the HIV pharmacy is co-located at 
the HIV clinic, and the fact that only specialist pharmacies can dispense ARVs. 
Another drawback of the measure is that it considered individuals to be adherent on 
the basis that they had been prescribed enough treatment to enable complete 
adherence, but this does not mean that the treatment had actually been taken. 
Likewise, the measure that was used only recorded the issue of prescriptions and not 
whether those prescriptions had actually been collected. Prescription based measures 
cannot fully capture the number of doses missed; however, studies have found good 
agreement between these measures of adherence and electronic adherence 
monitors612.  
The method of adjusting for non-adherence or disruptions in order to assess whether 
they mediate the association between gender/sexual orientation and virological non-
suppression works through blocking the causal pathway, however, as a result it may 
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lead to intermediate confounding613. Furthermore, the effect of non-adherence or cART 
disruptions in attenuating gender/sexual orientation associations with virological non-
suppression would be underestimated when assessed by change in magnitude of 
estimates that were already adjusted for baseline factors, as the effect of adherence 
may have been partially captured by this initial adjustment. Adjustment for cART non-
adherence may not be expected to fully attenuate the association between 
gender/sexual orientation and virological non-suppression due to inadequacy of the 
prescription based measure as an accurate measure of non-adherence over the whole 
time-period. Furthermore, the overall measure would not necessarily capture non-
adherence at the most critical time in relation to the VL measurement on which the 
outcome was based. 
Other limitations of this chapter concern the measurement of the virological outcomes. 
Virological non-suppression may be underestimated because of its definition using a 
single VL measurement >50 copies/mL closest to 12 months after ART initiation, which 
could miss any VL >50 copies/mL before and after this measurement. However, such 
a strategy based on VL at a fixed time point is likely to be preferable to a ‘time to 
event’ type analysis which would be more likely to capture transient viremia and may 
also be more influenced by frequency of VL measurement. A recent study in the 
Australian HIV Cohort found that even a single VL between 50 and 199 copies/mL was 
predictive of over four times higher risk of subsequent virological failure (VL >200 
copies/mL)555. Furthermore, the results were consistent in the sensitivity analysis 
where virological non-suppression was defined by a VL >200 copies/mL. Since 
strategy A is a missing=failure analysis, the outcome of virological non-suppression at 
24 months is dominated by the number of individuals without a measurement in the 
six-month window considered. Even among individuals LTFU from the Royal Free HIV 
cohort, this does not mean that they are necessarily not engaged in care anymore. In 
fact, as people with HIV are free to transfer their care between the many HIV treatment 
centres in London as they wish, transfer of patients between centres is likely to be very 
common. Thus, assuming that all individuals without a VL measurement are 
virologically non-suppressed is likely to be an over-estimate. Therefore, it could be 
concluded that the ‘true’ proportion with virological non-suppression one year after 
starting cART is likely to lie between results for strategy A and strategy B. 
This analysis considered initial response to first cART. Therefore, the associations and 
trends over time found may not be generalisable to longer-term response or to second 
or third-line regimens. Moreover, data came solely from a single centre in a UK setting, 
and therefore the results may not be able to be extrapolated to the UK or to other 
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geographic settings with different healthcare systems. However, the characteristics of 
individuals attending the Royal Free HIV outpatient clinic are generally similar to the 
HIV positive population in the UK (discussed further in Section 10.2). 
In terms of the measure of reasons for cART disruptions, the reasons recorded were 
clinician-completed, so it is possible that they were not representative of the actual 
reasons that individuals had disrupted treatment614. Furthermore, categories such as 
toxicities as reasons for disrupting treatment does not necessarily capture the reason 
why an individual was having difficulties in coping with toxicities. Reasons such as 
“patient choice”, “poor compliance”, or “other” give even less insight into the cause of 
treatment disruption. A qualitative questionnaire study would likely be more able to 
collect this information. 
 
 Conclusions 
Over the study period, virological response to first-line cART at 12 and 24 months 
substantially improved among all three gender/sexual orientation groups and the 
prevalence of treatment non-response to first-line cART in recent years has been low. 
However, this chapter highlighted that even in a high-income setting with universal free 
access to healthcare, such as the UK, MSW and women are at higher risk of an initial 
virological non-response. These differences, albeit relatively small in absolute terms, 
persisted in the most recent years, and there was no evidence that differences were 
narrowing over time. Emphasis should be placed on tailoring support for MSW and 
women with HIV.  
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 Socio-economic factors and cross-sectional 
and longitudinal virological outcomes for HIV-
positive people on ART in the UK: results from the 
ASTRA study 
 
 Objectives 
 To investigate the association of socio-economic factors with ART non-
adherence and virological non-suppression in cross-sectional analyses, and 
virological rebound in longitudinal analyses, among HIV-positive people on 
ART in the ASTRA study, a multi-centre UK-based study.  
 To investigate the extent to which any socio-economic associations with 
virological outcomes were mediated by a self-reported measure of ART non-
adherence. 
 Introduction 
There is substantial evidence of socio-economic inequalities in the prognosis of a 
number of diseases, including cancer, diabetes, and cardiovascular disease305;315-
318;437-440;615;616. Further studies have found evidence that lower socio-economic status 
(SES), measured by education or income, is associated with poorer adherence to 
treatment, such as steroids for asthma617, insulin for diabetes618 and anti-
depressants619.  
HIV-positive populations in high-income settings comprise distinct demographic 
groups, with substantial variation in social circumstances620 and a high proportion of 
migrants269;327. As such, social inequalities may also impact on disparities in HIV health 
outcomes621. Although the literature review in Section 2.5 identified some evidence of 
an association between socio-economic deprivation and poorer ART response in US 
studies402;403;409;622, few studies had addressed this question in settings with universal 
access to healthcare. Two European studies found that lower level of education126;405 
was associated with poorer virological outcomes of ART, and a further study found an 
association between unemployment342 and poorer virological response to ART. It is 
likely that neither education nor employment status alone are able to adequately 
capture current socio-economic hardship. One further cross-sectional study in France 
used several markers of socio-economic disadvantage: lower education level, 
unemployment and material deprivation and found each to be inversely associated 
with sustained virological suppression (unadjusted odds ratio [OR]=0.5-0.6)359. There 
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have been no previous studies of socio-economic variations in virological outcomes in 
the UK. 
Socio-economic factors might have less impact on HIV prognosis in settings with 
universal access to HIV diagnosis and treatment, since this should considerably 
lessen financial barriers to accessing ART. Thus, one may expect that findings from 
countries such as the US may not be replicated in these settings. If socio-economic 
deprivation were associated with poorer treatment response in settings such as the 
UK, then this would imply that the effects of SES go beyond ability to pay for 
healthcare. Therefore, study of the association between lower SES and ART 
outcomes in these settings may help to shed light on the mechanisms by which it 
operates.  
As discussed in Section 2.6.2.1 , non-adherence to ART is the fundamental driver of 
virological response170;455. The correlation between measures of non-adherence and 
failure to achieve virological suppression is well documented455;623;624. Moreover, there 
is evidence that poorer SES (measured by education, employment, and social 
support) is associated with ART non-adherence from some European studies346;625-627. 
Thus, any impact of SES on virological outcome is likely to be mediated in part through 
differential patterns of adherence to ART.  
 
 Methods 
 Study design 
The Antiretrovirals, Sexual Transmission Risk and Attitudes (ASTRA) study is a cross-
sectional, questionnaire study of 3258 HIV-diagnosed individuals recruited from eight 
HIV outpatient clinics in the UK in 2011/2012 (64% response rate), which was 
described in detail in Section 4.3 and in a paper by Speakman et al.516. Participants 
self-completed a confidential questionnaire on socio-demographic, health and lifestyle 
issues. Study personnel recorded the most recent VL and CD4 count results available 
at the time of the questionnaire for all participants. Six of the eight study centres 
provided linkage to routine HIV clinical records (including serial VL measurements) for 
consenting participants (2983 [92%]) using a pseudo-anonymised study number. 
Thus, cross-sectional analyses were performed in order to assess associations 
between both non-adherence and with virological non-suppression at the time of the 
questionnaire with SES. Additionally, longitudinal analyses were performed to assess 
the association of subsequent virological rebound with SES, among people with 
virological suppression at the time of the questionnaire. 
255 
 
 Outcomes of interest 
ART non-adherence 
ART non-adherence was considered as a binary variable. A broad definition was used 
in order to capture any potential non-adherence. Thus, non-adherence was defined as 
either an affirmative response to the question: “In the past three months, have you 
ever missed your HIV treatment for two or more days at a time?” or reporting one or 
more missed doses in response to the question: “In the last two weeks, how many 
doses of HIV treatment have you missed?” 
Virological non-suppression 
Virological non-suppression was defined as a single VL >50 copies/mL at the time of 
the questionnaire. The VL was reported by the clinic (i.e. patient-reported VLs were 
not considered). This VL was either that recorded by the study team at the time of 
questionnaire completion, or that obtained from the linked clinical data provided by the 
participating site, depending on which was the latest VL value at the time of the 
questionnaire. 
Virological rebound 
Individuals were followed from baseline until virological rebound (defined as the first 
VL >200 copies/mL) or the last available VL (latest October 2015). Since continuous 
ART is recommended, follow-up was not censored at ART interruption162.  
 
 Inclusion criteria 
ART non-adherence 
All ASTRA study participants who met the following criteria were considered for 
inclusion: (i) on ART at the time of the questionnaire, (ii) a non-missing value for age, 
and (iii) a non-missing value for at least one of two ART-adherence questions. On ART 
was defined by an affirmative response to the question from the questionnaire: “Are 
you currently taking HIV treatment?” Thus unlike Chapters 5 and 6, individuals on a 
regimen of fewer than three ARVs were included. However, as the ASTRA study was 
conducted between 2011 and 2012, most individuals were likely on cART regimens. 
Virological non-suppression 
Analyses considering virological suppression additionally required: (i) a non-missing 
value for VL; (ii) a non-missing value for the date of ART initiation; (iii) started ART at 
least six months prior to the VL measurement being used for analysis (for the reasons 
described in Section 5.3.3367;556-560). Thus, these analyses took a missing=excluded 
approach. 
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Virological rebound 
Consenting ASTRA participants from the six centres for which linked longitudinal clinic 
data were available were considered. Baseline was defined as the date of 
questionnaire issue. Inclusion criteria were: (i) on ART with a VL ≤50 copies/mL at 
baseline (latest value at the time of the questionnaire); (ii) non-missing value for age at 
baseline; (iii) non-missing value for at least one ART-adherence question; (iv) started 
ART at least six months prior to the date of the “baseline VL measurement” (so that 
individuals had had a chance to have reached virological suppression); (v) at least one 
VL measurement subsequent to baseline. 
 Covariates of interest 
Four questions in the ASTRA study, discussed in Section 4.4.2.3 , were directly 
related to SES and thus form the primary covariates of interest in my analysis:  
 Ability to afford basic needs (financial hardship with four levels) 
 Employed (yes; no) 
 Housing status (homeowner; renting; unstable/other) 
 University education (yes; no).  
In addition, I considered five questions related to social circumstance in order to 
provide supportive evidence on the association between SES and virological 
outcomes to ART: 
 Time living in the UK (UK-born; >5 years; ≤5 years) 
 English reading ability (UK-born; fluent; not fluent) 
 Supportive network (most; medium; least) 
 Children (yes; no)  
 Current partner (yes; no). 
The demographic factors considered in this analysis were gender/sexual orientation 
(MSM; MSW; women), ethnicity (white; black African; other), and age (as a continuous 
variable). The gender/sexual orientation variable was based on self-reported sexual 
orientation, rather than the likely mode of HIV transmission, as it was in the previous 
two chapters. Therefore, individuals who acquired HIV through routes other than 
sexual intercourse were included in this chapter. Demographic factors were not the 
focus in this chapter but were explored in detail in Chapter 8.  
Information on how each of the variables were derived from the original ASTRA study 
questions is given in Section 4.4.2. 
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 Statistical analysis 
Cross-sectional analyses 
The prevalences of ART non-adherence and virological non-suppression were 
summarised according to the demographic, socio-economic, and social circumstance 
factors. The groups were compared using Chi-squared tests or Cochran-Armitage 
tests for trend for ordered categorical variables. Spearman correlation coefficients 
were calculated to measure the correlations between all of the covariates. This was 
used to check for collinearity, so that highly correlated variables were not included in 
the same model. Correlation tables are useful in understanding associations and 
providing supplementary information to assess the extent to which model choices are 
supported, but they were not the basis by which I decided what covariates to include. 
In order to investigate the association of socio-economic and social circumstance 
factors with ART non-adherence and virological non-suppression, unadjusted 
prevalence ratios (PRs) and adjusted prevalence ratios (aPRs) were generated using 
modified Poisson regression models526. Each socio-economic/social circumstance 
factor was considered in a separate model to avoid the negative effects of collinearity. 
Furthermore, this made it possible to evaluate how each different marker of SES may 
relate to ART response individually, rather than in addition to that explained by the 
other SES markers. As in previous chapters, multivariable models were adjusted for 
gender/sexual orientation and age, but not ethnicity. This was in part due to its high 
collinearity with gender/sexual orientation (see Section 4.4.1), but also because it was 
thought likely that any effect of ethnicity on ART outcomes would largely reflect the 
effect of social factors. Therefore, ethnicity would be acting as a marker of SES, and 
its inclusion as an independent variable would potentially weaken an association 
between a specific SES factor and virological outcome. 
The association between ART non-adherence and virological non-suppression was 
also assessed using modified Poisson regression, where ART non-adherence was 
considered as a covariate rather than an outcome. ART non-adherence was then 
added to each multivariable regression model in turn to investigate the extent to which 
the associations between SES markers and virological non-suppression were 
attenuated by this potential mediating factor (see Section 6.3.5 for the assumptions 
underlying this). 
Longitudinal analyses 
In order to check the validity of using time-to-event analyses, I considered the median 
number of VL measurements by each SES and social circumstance factor. The 
association of socio-economic/social circumstance factors with time to virological 
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rebound were assessed using Kaplan-Meier plots and Cox proportional hazards 
regression models, where each factor was considered in a separate model; firstly 
unadjusted and then adjusted for demographic factors (gender/sexual orientation and 
age). Additionally, the association between ART non-adherence and virological 
rebound was assessed using Cox proportional hazards regression. 
Analyses of the subgroups white MSM and black African heterosexuals 
All cross-sectional and longitudinal analyses were repeated, where the study 
population was restricted to the subgroups of: (i) MSM of white ethnicity; and (ii) MSW 
and women of black African ethnicity. The rationale for these subgroup analyses was 
to reduce confounding by race, gender, and sexual orientation.  
ART non-adherence as a mediator of the association between SES and 
virological response to ART 
Additional analyses assessed the extent to which the association between socio-
economic/social circumstance factors and virological response changed when ART 
non-adherence was also included as a covariate. Modified Poisson regression was 
used to assess whether ART non-adherence was a mediator of the association 
between SES and virological non-suppression. Cox proportional hazards regression 
was used to assess whether ART non-adherence attenuated associations between 
SES and virological rebound. 
 Sensitivity analyses 
Firstly, for the analysis with ART non-adherence as an outcome, a sensitivity analysis 
was conducted where individuals who had been on ART previously but were not on 
ART at the time of the questionnaire, were defined as non-adherent. Secondly, a 
cross-sectional sensitivity analysis for the virological suppression outcome was 
performed, considering a VL cut-off of 200 copies/mL instead of 50 copies/mL. Finally, 
two longitudinal sensitivity analyses were performed for the virological rebound 
outcome where: (i) the outcome was defined as two consecutive VL measurements 
>200 copies/mL to investigate an endpoint of sustained virological rebound628; and (ii) 
those who were lost to follow-up (LTFU) were considered as having experienced 
virological rebound six months after the date of the last available VL measurement, as 
lack of retention in HIV care has been found to be associated with poorer prognosis629. 
In the last analysis described, LTFU was defined as eligible for the analysis but date of 
last measurement was >18 months prior to administrative censoring date. 
 Missing data 
Complete-case analyses were performed throughout, as the proportion of participants 
with missing data did not exceed four percent for any variable used in the analysis. 
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Twelve percent of participants had missing data for at least one variable. However, 
only individuals with missing data for any of the demographic, SES, or social 
circumstances covariates included in a particular model were excluded from that 
model. Thus, the percentage of individuals excluded due to missing data in any model 
was always below 12%. 
 
 Results 
 Participant characteristics 
Of 3258 individuals (69% MSM, 11% MSW, 20% women) who participated in the 
ASTRA study, 2771 (85%) reported being on ART at the time of the questionnaire. 
The remaining 487 (15%) not on ART included: 366 (11%) ART naïve individuals; 65 
(2%) individuals who had stopped ART; 56 (2%) with missing ART information. Of the 
2771 participants currently on ART, 58 (2%) had missing age, and nine (<1%) had not 
responded to either adherence question, thus were excluded. This resulted in 2704 
individuals being included (1867 MSM, 321 MSW, 516 women), whose characteristics 
are shown in Table 7.1. The majority (80%) had been diagnosed with HIV for over five 
years. Participants reported having been on ART for a median of 6.9 years 
(interquartile range [IQR] = 2.8-12.4 years). Median clinic-recorded CD4 count was 
546 cells/µL (IQR = 393-732 cells/µL) and 2276 (87%) individuals had a VL ≤50 
copies/mL at the time of the questionnaire. Overall, 55% of participants were 
employed, 35% were homeowners, and 40% were university educated. Of note, over 
half of participants reported that they did not always have enough money to cover their 
basic needs.
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Table 7.1: Characteristics of questionnaire respondents included in cross-sectional and 
longitudinal analyses 
Factor Cross-
sectional: 
ART non-
adherence 
analysis a 
Cross-
sectional: 
virological 
non-
suppression 
analysis b 
Longitudinal: 
virological 
rebound 
analysis c 
 N %d N %d N %d 
Total 2704 100 2405 100 1740 100 
Gender/sexual 
orientation 
MSM 1867 69 1670 69 1267 73 
MSW 321 12 277 12 171 10 
Women 516 19 458 19 302 17 
Mode of HIV 
acquisition 
Sex between men 1748 65 1571 65 1195 69 
Heterosexual sex 536 20 472 20 314 18 
PWID 46 2 42 2 25 1 
Other  353 13 303 13 197 11 
Missing 21 1 17 1 9 1 
Ethnicity White 1875 69 1670 69 1259 72 
Black African 507 19 460 19 281 16 
Black Other 89 3 78 3 52 3 
Other 184 7 153 6 113 6 
Missing 49 2 44 2 35 2 
Age Median (IQR) 46 (40, 52) 46 (40, 52) 46 (41, 52) 
Afford basic 
needs (financial 
hardship) 
Always 1170 43 1038 43 814 47 
Mostly 701 26 627 26 454 26 
Sometimes 464 17 412 17 265 15 
No 326 12 290 12 176 10 
Missing 43 2 38 2 31 2 
Employment  Employed 1479 55 1302 54 985 57 
Unemployed 483 18 425 18 286 16 
Sick/ disabled 375 14 344 14 224 13 
Retired 180 7 165 7 129 7 
Other  127 5 115 5 79 5 
 Missing 49 2 54 2 37 2 
Housing  Homeowner 914 35 852 35 658 38 
Renting from council 840 31 763 32 522 30 
Renting privately 609 23 523 22 393 23 
Temporary/homeless 70 3 58 2 35 2 
Staying with family 191 7 162 7 97 6 
Other 10 <1 10 <1 6 <1 
 Missing 40 1 37 2 29 2 
Education 
(highest level) 
≥University degree 1094 40 977 41 759 44 
A-level or equivalent 536 20 484 20 338 19 
O-levels or 
equivalent 
601 22 529 22 364 21 
Other 108 4 97 4 70 4 
None 302 11 260 11 169 10 
Missing 63 2 58 2 40 2 
Time in UK Born in UK 1511 56 1329 55 983 56 
> 5 years 991 37 899 37 635 36 
≤ 5 years  116 4 98 4 68 4 
Missing 86 3 79 3 54 3 
English reading 
ability  
Born in UK 1511 56 1329 55 983 56 
Fluent 912 34 825 34 595 34 
Not fluent 208 8 182 8 114 7 
Missing 73 3 69 3 48 3 
Supportive 
network 
Most support 878 32 762 32 562 32 
Medium support 1414 52 1273 53 930 53 
Least support 377 14 342 14 227 13 
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Factor Cross-
sectional: 
ART non-
adherence 
analysis a 
Cross-
sectional: 
virological 
non-
suppression 
analysis b 
Longitudinal: 
virological 
rebound 
analysis c 
 N %d N %d N %d 
Missing 35 1 28 1 21 1 
Children Yes 733 27 661 27 426 24 
No 1954 72 1729 72 1305 75 
Missing 17 1 15 1 9 1 
Partner Yes 1530 57 1363 57 997 57 
No 1158 43 1026 43 731 42 
Missing 16 1 16 1 12 1 
Time since HIV 
diagnosis 
< 2 years 180 7 107 4 64 4 
2 – 5 years 361 13 304 13 222 13 
5 – 15 years 1345 50 1266 53 926 53 
> 15 years 755 28 723 30 528 30 
Missing 63 2 5 <1 0 0 
Number of times 
taking ART per 
day 
1 2159 80 1902 79 1419 81 
≥2 513 19 476 20 309 18 
Missing 32 1 27 1 21 1 
Self-reported ≥2 
consecutive 
missed days of 
ART in past 3 
months 
No/ don’t know 2236 83 1973 82 1461 84 
Yes  464 17 429 18 277 16 
Missing 4 <1 3 <1 2 <1 
Self-reported ≥1 
missed dose in 
the last 2 weeks 
No/ don’t know 2022 75 1777 74 1289 74 
Yes  676 25 624 26 447 26 
Missing 6 <1 4 <1 4 <1 
ART Non-
adherent e 
No/ don’t know 1831 68 1601 67 1174 67 
Yes  873 32 804 33 566 33 
Time on ART 
(years) f 
Median (IQR) 6.9 (2.8, 
12.4) 
7.7 (3.7, 12.9) 7.7 (3.7, 12.9) 
CD4 count 
(cells/µL) g 
Median (IQR) 546 (393, 
732) 
560 (410, 749) 590 (442, 780) 
VL at time of the 
questionnaire 
≤50 copies/mL 2276 87 2186 91 1740 100 
>50 copies/mL 329 13  219 9 0 0 
Missing 16 1 0 0 0 0 
 
 
 
 
 
a All participants who self-reported being on ART at the time of the questionnaire and had 
recorded age and non-adherence information; b all participants who self-reported being 
on ART at the time of the questionnaire, had recorded age and non-adherence 
information, recorded VL and date of ART initiation, and started ART >6 months prior to 
completion of the questionnaire; c all participants had linked clinical data, recorded age 
and non-adherence information, were on ART, had VL ≤50 copies/mL at the time of the 
questionnaire, started ART >6 months before the baseline VL measurement, and had ≥1 
subsequent VL measurement; d some column percentages do not sum to 100% due to 
rounding; e self-reported ART non-adherence: ≥2 consecutive missed days of ART in the 
past 3 months or ≥1 missed dose in the last 2 weeks; f missing time on ART: cross-
sectional (ART non-adherence) N=99, cross-sectional (virological non-suppression) N=0, 
and longitudinal N=0; g missing CD4 count: cross-sectional (ART non-adherence) N=17, 
cross-sectional (virological non-suppression) N=5, and longitudinal=2; PWID=people who 
inject drugs; IQR=interquartile range. 
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Figure 7.1 displays spearman’s rank correlation coefficients for the bivariate 
correlations between each of the covariates. There was a moderate correlation 
observed between gender and sexual orientation, which lent support to the decision to 
include these as a combined variable in the analyses. The associations observed 
between ethnicity and both time in the UK and English reading ability was one 
rationale in the decision not to adjust the models for ethnicity, since it was at least 
partially acting as a marker of social circumstances. Having children, gender, sexual 
orientation and ethnicity all had a moderate correlation with one another. 
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Figure 7.1: Spearman Correlation Coefficients between demographic, socio-economic and social circumstances factors630 
  
 
 Financial 
hardship 
Employ
ment Housing 
Educatio
n 
Time in 
UK 
Reading 
ability 
Social 
support Children Partner Gender 
Sexual 
orientati
on 
Ethnicity Age 
Financial 
hardship 1.00 0.39 0.41 0.23 0.20 0.24 0.26 0.25 -0.11 0.25 0.29 0.32 -0.07 
Employme
nt  
1.00 0.23 0.19 0.01 0.04 0.23 0.12 -0.15 0.08 0.11 0.10 0.18 
Housing  1.00 0.20 0.27 0.28 0.12 0.17 -0.12 0.21 0.26 0.30 -0.22 
Education 
 
 1.00 -0.07 -0.03 0.05 0.10 -0.08 0.07 0.07 0.03 0.02 
Time in UK 
 
1.00 0.97a 0.00 0.29 -0.00 0.35 0.43 0.56 -0.14 
Reading 
ability 
 1.00 0.01 0.33 -0.01 0.37 0.45 0.58 -0.13 
Social 
support 
 
 1.00 -0.02 -0.31 0.02 -0.01 0.00 0.04 
Children 
 
1.00 0.03 0.51 0.66 0.50 0.06 
Partner  1.00 -0.03 0.05 0.02 -0.04 
Gender 
 
1.00 0.69 0.52 -0.13 
Sexual 
orientation  1.00 0.64 -0.08 
Ethnicity 
 
1.00 -0.15 
Age  1.00 
a Time in the UK and English reading ability had one identical group for individuals born in the UK so inevitably have a very strong correlation; b this key denotes 
absolute values. 
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 SES and ART non-adherence 
Of the 2704 participants on ART, 873 (32%; 95% CI: 31%, 34%) reported ART non-
adherence. Individuals with poorer SES by any measure – increased financial 
hardship, non-employment, rented or unstable housing status, and non-university 
education – were more likely to have reported ART non-adherence (Figure 7.2). In 
terms of social circumstance factors, reporting ART non-adherence was associated 
with living in the UK for over five years but not being born in the UK (with lower levels 
of non-adherence among the two other groups); non-fluent English reading ability; 
lowest supportive network; having children; and not having a current partner. Women 
were most likely to report ART non-adherence, followed by MSW and then MSM. 
Black African and other ethnicity and lower age were also associated with reporting 
ART non-adherence compared to white ethnicity and older age respectively.  
Unadjusted associations of socio-economic factors and social circumstances with ART 
non-adherence are shown in terms of PRs in Table 7.2. After adjustment for 
demographic factors (gender/sexual orientation and age), all measures of poorer SES 
remained associated with a greater prevalence of ART non-adherence. These were 
attenuated by 1-14%, with the greatest attenuations for housing status. Likewise, 
associations of non-adherence with all social circumstance variables remained after 
adjustment for demographic factors. The association between being fluent or non-
fluent in English and greater prevalence of non-adherence compared to UK-born 
individuals was attenuated by 6% and 10%, respectively. However, adjustment for 
demographic factors actually increased the PR for the association between living in 
the UK for fewer than five years and non-adherence; this is likely a result of the 
correlation between time in the UK and sexual orientation (Figure 7.1).
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Figure 7.2: Prevalence of ART non-adherence by socio-economic and demographic factors a 
 
 
 
a Cross-sectional analysis among 2704 respondents who self-reported being on ART at the time of the questionnaire, self-reported ART non-adherence: ≥2 
consecutive missed days of ART in the past 3 months or ≥1 missed dose in the last 2 weeks; b Cochran-Armitage test for trend; c Chi square test. 
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Table 7.2: Cross-sectional associations of socio-economic factors and social 
circumstances with ART non-adherence a (N=2704) 
Factors b 
N 
Unadjusted Adjusted for gender/sexual 
orientation and age 
PR 95% CI P-valuec  aPR 95% CI P-valuec  
Enough money 
for basic 
needs? 
(Financial 
hardship) 
Always 1170 1  <.0001 d 1  <.0001 d 
Mostly 701 1.44 1.24, 1.66  1.43 1.23, 1.65  
Sometimes 464 1.88 1.62, 2.17  1.85 1.59, 2.15  
No  326 1.82 1.55, 2.14  1.78 1.50, 2.11  
Employed Yes 1479 1  0.0002 1  <.0001 No  1165 1.24 1.11, 1.38  1.29 1.16, 1.45  
Housing status 
Homeowner 944 1  <.0001 d 1  <.0001 d 
Renting  1449 1.44 1.27, 1.65  1.36 1.19, 1.56  
Unstable  271 1.76 1.47, 2.10  1.62 1.35, 1.95  
University Yes 1094 1  0.0041 1  0.0050 No  1547 1.18 1.05, 1.33  1.18 1.05, 1.32  
Time in UK 
Born in UK 1511 1  0.0010 1  0.018 
>5 years 991 1.24 1.11, 1.39  1.16 1.02, 1.32  
≤5 years  116 1.00 0.75, 1.34  0.86 0.63, 1.16  
English reading 
ability 
Born in UK 1511 1  <.0001 1  0.0007 
Fluent 912 1.13 1.00, 1.28  1.07 0.94, 1.22  
Not fluent  208 1.59 1.35, 1.88  1.49 1.24, 1.79  
Supportive 
network 
Most  878 1  <.0001 d 1  <.0001 d 
Medium  1414 1.39 1.22, 1.60  1.40 1.22, 1.60  
Least  377 1.63 1.38, 1.93  1.65 1.39, 1.95  
Children Yes 733 1  0.0030 1  0.022 No  1954 0.83 0.74, 0.94  0.83 0.70, 0.97  
Partner Yes 1530 1  0.0037 1  0.0014 No  1158 1.18 1.06, 1.31  1.20 1.07, 1.34  
a Self-reported ART non-adherence: ≥2 consecutive missed days of ART in the past 3 
months or ≥1 missed dose in the last 2 weeks; b each socio-economic factor considered in a 
separate model for all results but gender/sexual orientation and age are included in every 
model, individuals with missing values for explanatory variables were excluded; c Chi square 
test; d test for trend. PR=Prevalence Ratio; aPR=adjusted Prevalence Ratio. 
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 SES and virological non-suppression 
Of the 2704 participants included in the ART non-adherence analysis, 2605 had a 
recorded VL at the time of the questionnaire and date of first ART initiation, of whom 
2405 had started ART more than six months before the VL measurement. Therefore, 
the virological non-suppression analysis included 2405 (89%) participants. Of these, 
219 (9%; 95% CI: 8%, 10%) had virological non-suppression (VL>50 copies/mL; 
comprising 79 (36%) with >500 copies/mL, 68 (31%) with >1000 copies/mL, and 32 
(15%) with >10000 copies/mL). For each of the four indicators of SES, socio-economic 
disadvantage was strongly associated with virological non-suppression (Figure 7.3). In 
addition, individuals with non-fluent English reading ability and those who had children 
had a greater prevalence of virological non-suppression. There was also weak 
evidence of an increased prevalence of virological non-suppression among those 
living in the UK for over five years but not born in the UK, those with lowest supportive 
network and those without a current partner. The demographic factors associated with 
virological non-suppression were being an MSW or woman compared to MSM, black 
African or other compared to white ethnicity, and younger age.  
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Figure 7.3: Prevalence of virological non-suppression (VL >50 copies/mL) by socio-economic and demographic factors a 
a Cross-sectional analysis among 2405 respondents who had started antiretroviral therapy (ART) >6 months prior to completion of the questionnaire; b 
Cochran-Armitage test for trend; c Chi square test. 
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The markers of lower SES: financial hardship, non-employment, non-homeownership, 
and non-university education all remained strongly associated with virological non-
suppression after adjustment for demographic factors (Table 7.3). There was a 
marked trend between greater prevalence of virological non-suppression and 
increasing financial hardship and housing instability. In terms of the social 
circumstance factors, lowest supportive network and not having a current partner were 
associated with increased prevalence of virological non-suppression in the model 
adjusted for demographic factors. English reading ability and having children were not 
associated with virological non-suppression after accounting for demographic factors. 
Table 7.3: Cross-sectional associations of socio-economic factors and social 
circumstances with virological non-suppression a (N=2405) 
 
 
 
ART non-adherence and virological non-suppression 
ART non-adherence was associated with 2.37 times higher prevalence of virological 
non-suppression (95% CI: 1.84, 3.07; p<0.0001), adjusted for demographic factors.  
Factors b 
N 
Unadjusted Adjusted for gender/sexual 
orientation and age 
aPR 95% CI P-valuec aPR 95% CI P-valuec 
Enough 
money for 
basic needs? 
(Financial 
hardship) 
Always 1038 1  <.0001 d 1   <.0001 d 
Mostly 627 1.63 1.15, 2.30  1.57 1.11, 2.22  
Sometimes 412 2.06 1.44, 2.95  1.87 1.29, 2.72  
No  290 2.68 1.87, 3.86  2.42 1.67, 3.51  
Employed Yes 1302 1  <.0001 1   <.0001 No  1049 1.85 1.42, 2.41  1.98 1.51, 2.61  
Housing 
status 
Homeowner 852 1  <.0001 d 1   <.0001 d 
Renting  1286 2.39 1.69, 3.39  2.12 1.49, 3.02  
Unstable  230 3.70 2.42, 5.67  3.04 1.97, 4.68  
University Yes 977 1  0.0004 1   0.0005 No  1370 1.63 1.23, 2.16  1.62 1.22, 2.14  
Time in UK 
Born in UK 1329 1  0.083 1   0.076 
>5 years 899 1.30 1.00, 1.69  1.01 0.76, 1.35  
≤5 years  98 0.75 0.34, 1.67  0.51 0.23, 1.14  
English 
reading ability 
Born in UK 1329 1  0.036 1   0.11 
Fluent 825 1.09 0.82, 1.45  0.86 0.64, 1.17  
Not fluent  182 1.89 1.29, 2.78  1.40 0.91, 2.16  
Supportive 
network 
Most  762 1  0.071 d 1   0.049 d 
Medium  1273 1.07 0.80, 1.44  1.09  0.82, 1.46  
Least  342 1.49 1.03, 2.15  1.53 1.06, 2.20  
Children Yes 661 1  0.0053 1  0.14 No  1729 0.67 0.51, 0.87  0.74 0.49, 1.10  
Partner Yes 1363 1  0.094 1  0.023 No  1026 1.25 0.97, 1.61  1.35 1.05, 1.75  
a VL >50 copies/mL at the time of the questionnaire; b each socio-economic factor considered 
in a separate model for all results but gender/sexual orientation and age are included in every 
model, individuals with missing values for explanatory variables were excluded; c Chi square 
test; d test for trend. PR=Prevalence Ratio; aPR=adjusted Prevalence Ratio. 
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 Participant characteristics – longitudinal analyses 
The longitudinal association between socio-economic factors and virological rebound 
was considered in a subset of the 2186/2405 (91%) participants who had a VL ≤50 
copies/mL at the time of the questionnaire (baseline). Of these, 1740 (80%) had linked 
clinic data and at least one follow-up VL measurement. These individuals were 
followed for 3818 person-years with a median 2.4 (range: 0.01-3.31, IQR: 2.0-2.7) 
years of follow-up and a median six (range: 1-25, IQR: 5-8) VL measurements per 
person. During this period eight (<1%) individuals were known to have died. The 
characteristics at baseline of the 1740 participants are summarised in Table 7.1.  
 SES and virological rebound 
To justify the use of time-to-event analysis I considered whether the median number of 
VL measurements during follow-up differed according socio-economic and social 
circumstances factors (Table 7.4). For most factors, there were no differences in 
frequency of measurement, however, individuals who were not employed, reported a 
medium or least supportive network, did not have a partner at the time of the 
questionnaire, and who had children had a greater median number of VL 
measurements over follow-up. However, this is unlikely to have biased the results to 
any great extent since the maximum difference between the groups across all of the 
socio-economic factors was 0.2 VL measurements per year.
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Table 7.4: Median number of VL measurements during follow-up by socio-economic factor 
  
 
Over follow-up, 139 (8%) individuals experienced virological rebound, with a rate of 
3.6/100 person-years (95% CI 3.0, 4.2). By 12 and 24 months of follow-up the Kaplan 
Meier estimates (95% CI) of virological rebound were 3.9% (3.0, 4.8) and 7.0% (5.7, 
8.2), respectively (Figure 7.4).  
 
 
 
 
 
 
 
Factors Number of VL measurements over follow-
up 
Median IQR a P-valueb 
Enough money for 
basic needs? 
(Financial hardship) 
Always 2.73 2.17, 3.33 0.88 
Mostly 2.75 2.17, 3.47  
Sometimes 2.82 2.12, 3.45  
No  2.76 2.30, 3.52  
Employed Yes 2.68 2.11, 3.27 <.0001 
No 2.88 2.28, 3.55  
Housing status Homeowner 2.73 2.16, 3.30 0.53 
Renting 2.76 2.19, 3.48  
Unstable/ other 2.80 2.14, 3.53  
University education Yes 2.70 2.11, 3.35 0.12 
No 2.80 2.21, 3.46  
Time in UK Born in UK 2.79 2.22, 3.40 0.074 
In UK >5 years 2.69 2.08, 3.35  
In UK ≤5 years  2.85 2.33, 3.61  
English reading ability  Born in UK 2.79 2.22, 3.40 0.11 
Fluent 2.69 2.10, 3.34  
Not fluent 2.84 2.10, 3.56  
Supportive network Most support 2.68 2.12, 3.27 0.013 
Medium support 2.81 2.20, 3.43  
Least support 2.79 2.27, 3.60  
Children Yes 2.62 2.05, 3.34 0.0045 
No 2.78 2.21, 3.43  
Partner Yes 2.69 2.12, 3.33 0.0040 
No 2.84 2.26, 3.48  
a IQR = interquartile range; b Kruskal-Wallis test. 
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Figure 7.4: Kaplan-Meier plot of time until virological rebound (VL >200 copies/mL) a with 
95% confidence bands b 
       
 
 
 
a Longitudinal analysis among N=1740 respondents with VL <50 copies/mL at the time of 
the questionnaire; b confidence bands displayed by the shaded area. 
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Figure 7.5: Kaplan-Meier plot of time until virological rebound (VL >200 copies/mL) a  
 
 
 
 
 
 
 
 
 
a) By ability to afford basic needs (financial hardship) at baseline b) By employment status at baseline 
Sometimes 
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c) By housing status at baseline d) By university education at baseline 
a Longitudinal analysis among N=1740 respondents with VL <50 copies/mL at the time of the questionnaire. Individuals with missing values were 
excluded. Numbers provided indicate the number of individuals at risk. 
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In unadjusted Cox regression analyses, increased financial hardship, non-
employment, and rented or unstable housing status were strongly predictive of 
increased rate of virological rebound (Table 7.5). Although the effect size was not as 
large, non-university education was also associated with increased rebound rate. In 
addition, decreased supportive network, having children, and not having a partner 
were associated with a higher rate of virological rebound. However, there was no 
evidence that time in the UK and English reading ability were associated with rebound. 
The pattern of associations remained, with some attenuation for most factors, after 
adjustment for gender/sexual orientation and age. For employment, time in the UK, 
supportive network, and current partner the effect sizes increased after adjustment, 
indicating a possible interaction between these and the demographic factors.  
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Table 7.5: Longitudinal associations of socio-economic factors and social circumstances with virological rebound a (N=1740) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Factors b N Rate c Unadjusted Adjusted for gender/sexual 
orientation and age 
   HR 95% CI P-valued aHR 95% CI P-valued 
Enough 
money for 
basic needs? 
(Financial 
hardship) 
Always 814 2.49 1  <.0001 e 1   0.0005 e 
Mostly 454 3.64 1.47 0.95, 2.27  1.34 0.87, 2.09  
Sometimes 265 5.60 2.25 1.43, 3.55  1.83 1.14, 2.95  
No  176 6.95 2.78 1.71, 4.53  2.30 1.39, 3.81  
Employed Yes 985 2.26 1  <.0001 1   <.0001 
No 718 5.78 2.56 1.81, 3.62  2.87 2.00, 4.10  
Housing 
status 
Homeowner 658 1.70 1  <.0001 e 1   <.0001 e 
Renting 915 4.76 2.80 1.81, 4.32  2.33 1.49, 3.65  
Unstable/ other 138 6.95 4.11 2.27, 7.42  3.18 1.73, 5.85  
University 
education 
Yes 759 2.79 1  0.021 1   0.025 
No 941 4.24 1.52 1.07, 2.17  1.50 1.05, 2.15  
Time in UK Born in UK 983 3.09 1  0.11 1   0.55 
In UK >5 years 635 4.47 1.44 1.02, 2.04  1.03 0.70, 1.53  
In UK ≤5 years  68 2.96 0.95 0.35, 2.59  0.58 0.21, 1.63  
English 
reading 
ability  
Born in UK 983 3.09 1  0.14 1   0.94 
Fluent 595 4.35 1.40 0.98, 2.00  1.00 0.68, 1.48  
Not fluent 114 4.43 1.43 0.74, 2.78  0.89 0.44, 1.81  
Supportive 
network 
Most support 562 3.07 1  0.070 e 1   0.050 e 
Medium support 930 3.68 1.20 0.81, 1.77  1.19  0.81, 1.76  
Least support 227 5.04 1.63 0.98, 2.72  1.72 1.03, 2.87  
Children Yes 426 6.03 1  <.0001 1  0.015 
 No 1305 2.91 0.49 0.34, 0.68  0.54 0.33, 0.89  
Partner Yes 997 2.96 1  0.0081 1  0.0011 
 No 731 4.65 1.57 1.12, 2.19  1.75 1.25, 2.45  
a Self-reported ART non-adherence: ≥2 consecutive missed days of ART in the past 3 months or ≥1 missed dose in the last 2 weeks; b each socio-economic 
factor considered in a separate model for all results but gender/sexual orientation and age are included in every model, individuals with missing values for 
explanatory variables were excluded; c Chi square test; d test for trend. PR=Prevalence Ratio; aPR=adjusted Prevalence Ratio. 
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ART non-adherence and virological rebound 
Individuals who self-reported ART non-adherence at baseline had over three times the 
rate of virological rebound compared to individuals who did not (aHR=3.11, 95% CI: 
2.20, 4.38; p<0.0001, adjusted for demographic factors). 
 Association of SES factors with non-adherence and virological 
outcomes among subgroups white MSM and black African heterosexuals 
 SES and ART non-adherence - subgroup analyses 
In the subgroup of white MSM, 1665 individuals met the inclusion criteria for the ART 
non-adherence analyses, of whom 490 (29%) reported ART non-adherence. Similarly, 
to the main analysis, in this subgroup all four measures of poorer SES were 
associated a greater prevalence of ART non-adherence in unadjusted analyses and 
analyses adjusted for age (Table 7.6).  
In the subgroup of black African MSW and women, 195/493 (40%) reported ART non-
adherence. In this subgroup, there was a trend of greater prevalence of ART non-
adherence with increasing financial hardship and increasing housing instability (Table 
7.6). However, there was no association between the other two socio-economic 
factors and non-adherence. 
 
278 
 
Table 7.6: Cross-sectional associations of socio-economic factors and social circumstances with ART non-adherence – subgroup analyses a b 
 
Factors c White MSM only (N=1665) Black African men and women only (N=493) 
N 
Unadjusted Adjusted for age 
N 
Unadjusted Adjusted for age 
PR 95% CI P-value 
d 
aPR 95% CI P-value 
d 
PR 95% CI P-value 
d 
aPR 95% CI P-value 
d 
Enough 
money for 
basic needs? 
(Financial 
hardship) 
Always 899 1  <.0001 e 1  <.0001 e 86 1  0.030 e 1  0.030 e 
Mostly 450 1.48 1.24, 
1.76 
 1.47 1.23, 
1.75 
 102 1.20 0.80, 
1.81 
 1.20 0.79, 
1.80 
 
Sometimes 195 1.88 1.54, 
2.29 
 1.84 1.51, 
2.25 
 163 1.42 0.98, 
2.05 
 1.43 0.99, 
2.06 
 
No 120 1.47 1.12, 
1.94 
 1.45 1.10, 
1.90 
 136 1.44 0.99, 
2.09 
 1.43 0.98, 
2.08 
 
Employed Yes 999 1  0.0070 1  0.0003 229 1  0.42 1  0.38 
No 658 1.23 1.06, 
1.43 
 1.34 1.15, 
1.56 
 255 1.10 0.88, 
1.37 
 1.10 0.88, 
1.38 
 
Housing status Homeowner 743 1  0.0002 e 1  0.0018 e 37 1  0.0088 e 1  0.012 e 
Renting 814 1.27 1.09, 
1.49 
 1.23 1.04, 
1.45 
 351 1.81 0.96, 
3.38 
 1.79 0.95, 
3.35 
 
Unstable/ other  106 1.57 1.21, 
2.05 
 1.50 1.14, 
1.97 
 104 2.18 1.14, 
4,16 
 2.14 1.12, 
4.08 
 
University 
education  
Yes 722 1  0.0040 1  0.0027 185 1  0.36 1  0.34 
No 938 1.25 1.07, 
1.46 
 1.26 1.08, 
1.47 
 294 0.90 0.72, 
1.13 
 0.89 0.71, 
1.12 
 
a Cross-sectional analysis among respondents who self-reported being on ART at the time of the questionnaire; b ART non-adherence: self-reported ≥2 
consecutive missed days of ART in the past 3 months or ≥1 missed dose in the last 2 weeks; c each socio-economic factor considered in a separate model for 
all results, individuals with missing values for socio-economic factors were excluded; d Chi square test; e test for trend; PR=Prevalence Ratio; aPR=adjusted 
Prevalence Ratio. 
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 SES and virological non-suppression - subgroup analyses 
Of the 1498 white MSM participants, 112 (7%) had a VL >50 copies/mL at the time of 
the questionnaire. All four measures of poorer SES were associated with higher levels 
of virological non-suppression in unadjusted analyses and after adjustment for age 
(Table 7.7).  
Of the 452 black African MSW and women, 57 (13%) had a VL >50 copies/mL at the 
time of the questionnaire. None of the socio-economic factors had a strong association 
with virological non-suppression; however, there was some evidence that renting or 
unstable housing status were associated with a higher prevalence of virological non-
suppression (Table 7.7). 
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Table 7.7: Cross-sectional associations of socio-economic factors and social circumstances with virological non-suppression – subgroup analyses a b 
 Factors c White MSM only (N=1498) Black African men and women only (N=452) 
N 
Unadjusted Adjusted for age N Unadjusted Adjusted for age 
PR 95% 
CI 
P-
value d 
aPR 95% 
CI 
P-
value d 
 
PR 95% CI P-
value  
d 
aPR 95% CI P-
value  
d 
Enough 
money for 
basic needs? 
(Financial 
hardship) 
Always 813 1  0.0041 
e 
1  0.0055 
e 
81 1  0.25 e 1  0.19 e 
Mostly 407 1.48 0.96, 
2.26 
 1.45 0.95, 
2.23 
 94 1.29 0.56, 
3.01 
 1.27 0.55, 
2.94 
 
Sometimes 172 2.06 1.25, 
3.38 
 2.00 1.22, 
3.28 
 148 1.16 0.52, 
2.58 
 1.19 0.54, 
2.58 
 
No 105 2.02 1.11, 
3.69 
 1.95 1.07, 
3.56 
 125 1.62 0.75, 
3.50 
 1.67 0.79, 
3.50 
 
Employed Yes 887 1  0.0021 1  0.0002  212 1  0.28 1  0.21 
No 603 1.79 1.25, 
2.57 
 2.12 1.47, 
3.08 
 232 1.31 0.80, 
2.16 
 1.37 0.83, 
2.24 
 
Housing 
status 
Homeowner 677 1  <.0001 
e 
1  0.0001 
e 
36 1  0.059 e 1  0.081 e 
Renting 731 2.13 1.41, 
3.23 
 1.99 1.32, 
3.01 
 323 2.17 0.55, 
8.63 
 2.15 0.55, 
8.35 
 
Unstable/ other  88 3.33 1.81, 
6.15 
 3.06 1.67, 
5.62 
 92 3.13 0.76, 
12.93 
 2.87 0.72, 
11.52 
 
University 
education  
Yes 650 1  0.0008 1  0.0006 173 1  0.84 1  0.59 
No 844 1.90 1.28, 
2.83 
 1.93 1.30, 
2.88 
 266 1.05 0.63, 
1.75 
 1.14 0.69, 
1.89 
 
a Cross-sectional analysis among 1498 respondents who had started ART >6 months prior to completion of the questionnaire; b virological suppression: VL >50 
copies/mL at the time of the questionnaire; c each socio-economic factor considered in a separate model for all results, individuals with missing values for socio-
economic factors were excluded; d Chi square test; e test for trend; PR=Prevalence Ratio; aPR=adjusted Prevalence Ratio. 
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 SES and virological rebound - subgroup analyses 
There were 1131 white MSM with VL ≤50 copies/mL at the time of the questionnaire 
with at least one follow-up VL measurement, of whom 70 (6%) had virological rebound 
in 2561 person-years (rate 2.7/100 person-years; 95% CI 2.4, 2.9). In this subgroup, 
there was a 93% higher HR for virological rebound among individuals who reported 
that they only sometimes had enough money for their basic needs compared to 
individuals who reported that they always did (in model adjusted for age), however, 
there was not an increasing trend with financial hardship (Table 7.8). Not being 
employed, living in rented accommodation, and not having a university education were 
predictive of a greater rate of virological rebound. However, unstable housing status 
was not associated with virological rebound in this subgroup.  
In the subgroup of black African MSW and women, 34/276 (12%) individuals had 
virological rebound in 561 person-years (rate 6.1/100 person-years; 95% CI 5.3, 6.8). 
In this subgroup, individuals who could not always afford their basic needs, non-
employed individuals, and those with unstable housing had over twice the HR of 
rebound compared to those who could always afford basic needs, were employed, and 
homeowners, respectively, after adjustment for gender and age (Table 7.8). 
282 
 
Table 7.8: Longitudinal associations of socio-economic factors and social circumstances with virological rebound - subgroup analyses a b  
 
 
 
 
 
 
Factors c White MSM only (N=1131) Black African men and women only (N=276) 
Rate 
d 
Unadjusted Adjusted for age 
Rate 
d 
Unadjusted Adjusted for age 
HR 95% 
CI 
P-value e aHR 95% 
CI 
P-value e HR 95% 
CI 
P-value e aHR 95% 
CI 
P-value e 
Enough 
money for 
basic needs? 
(Financial 
hardship) 
Always 2.41 1  0.21 f 1   0.27 f 2.96 1  0.20 f 1   0.18 f 
Mostly 2.73 1.14 0.65, 
2.00 
 1.12 0.63, 
1.97 
 6.34 2.22 0.59, 
8.39 
 2.07 0.55, 
7.87 
 
Sometimes 4.83 2.00 1.04, 
3.85 
 1.93 1.00, 
3.71 
 7.02 2.45 0.70, 
8.61 
 2.38 0.67, 
8.39 
 
No 2.53 1.05 0.37, 
2.94 
 0.99 0.35, 
2.79 
 7.20 2.50 0.69, 
9.10 
 2.49 0.68, 
9.07 
 
Employed Yes 2.05 1  0.0074 1   0.0002 3.54 1  0.028 1   0.017 
No 3.91 1.90 1.19, 
3.04 
 2.55 1.56, 
4.15 
 8.51 2.36 1.10, 
5.05 
 2.55 1.18, 
5.47 
 
Housing 
status 
Homeowner 1.51 1  0.013 f 1   0.047 f 5.66 1  0.029f 1   0.039 f 
Renting 4.01 2.47 1.46, 
4.15 
 2.22 1.30, 
3.78 
 4.74 0.79 0.23, 
2.67 
 0.79 0.23, 
2.68 
 
 Unstable/ 
other  
1.56 0.97 0.23, 
4.15 
 0.87 0.20, 
3.73 
 13.23 2.28 0.64, 
8.19 
 2.17 0.60, 
7.80 
 
University 
education  
Yes 1.84 1  0.011 1   0.0079 7.57 1  0.22 1   0.31 
No 3.53 1.93 1.16, 
3.19 
 1.98 1.20, 
3.29 
 4.96 0.65 0.33, 
1.29 
 0.70 0.35, 
1.39 
 
a Longitudinal analysis among respondents with VL <50copies/mL at the time of the questionnaire; b virological rebound: a subsequent VL >200copies/mL; c 
each baseline socio-economic factor considered in a separate model for all results, individuals with missing values for socio-economic factors were excluded; d 
per 100 person-years; e Chi square test; f test for trend; HR= Hazard Ratio; aHR=adjusted Hazard Ratio. 
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 ART non-adherence as a mediator of the association between SES 
and virological response to ART 
In this analysis, non-adherence was added as an additional independent variable 
together with gender/sexual orientation and age, in the modified Poisson regression 
model for the main cross-sectional analysis of virological non-suppression. This was 
done in order to assess to what extent this measure could account for any 
associations of socio-economic factors with virological non-suppression. The results 
are displayed in the first column of Table 7.9. The association between each of the 
four markers of SES and virological non-suppression remained after adjustment for 
ART non-adherence; however, all associations were attenuated further (by 9-45% on 
top of the attenuation by adjusting for gender/sexual orientation and age).  
Similarly, the Cox Proportional hazards model for virological rebound was additionally 
adjusted for self-reported ART non-adherence at baseline (results shown in second 
column of Table 7.9). The adjustment for ART non-adherence did not fully explain the 
associations between virological rebound and the socio-economic factors, but 
associations were further attenuated in each case (by 8-48%).
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Table 7.9: Associations of socio-economic factors and social circumstances with virological non-suppression a (N=2405) and virological rebound b 
(N=1740) adjusted for gender/sexual orientation, age, and ART non-adherence c 
 
 
Factors d Virological non-suppression a Virological rebound b 
N 
Adjusted for 
demographic factors 
Additionally adjusted for 
ART non-adherence 
N 
Adjusted for demographic 
factors 
Additionally adjusted for 
ART non-adherence 
aPR 95% CI P-value e 
aPR 95% CI P-value e 
aHR 95% CI P-value e 
aHR 95% CI P-value e 
Enough 
money for 
basic 
needs? 
(Financial 
hardship) 
Always 1038 1   <.0001 d 1  <.0001 f 814 1   0.0005 e 1  0.018 f 
Mostly 627 1.57 1.11, 2.22  1.44 1.02, 2.04  454 1.34 0.87, 2.09  1.22 0.79, 1.90  
Sometimes 412 1.87 1.29, 2.72  1.56 1.08, 2.27  265 1.83 1.14, 2.95  1.44 0.89, 2.32  
No 290 2.42 1.67, 3.51  2.04 1.40, 2.98  176 2.30 1.39, 3.81  1.82 1.09, 3.04  
Employed Yes 1302 1   <.0001 1  <.0001 985 1   <.0001 1  <.0001 No 1049 1.98 1.51, 2.61  1.82 1.39, 2.37  718 2.87 2.00, 4.10  2.67 1.87, 3.82  
Housing 
status 
Homeowner 852 1   <.0001 d 1  <.0001 f 658 1   <.0001 e 1  0.0002 f 
Renting 1286 2.12 1.49, 3.02  1.95 1.37, 2.78  915 2.33 1.49, 3.65  2.18 1.39, 3.41  
Unstable 230 3.04 1.97, 4.68  2.59 1.67, 4.02  138 3.18 1.73, 5.85  2.74 1.49, 5.04  
University Yes 977 1   0.0005 1  0.0016 759 1   0.025 1  0.053 No 1370 1.62 1.22, 2.14  1.53 1.16, 2.03  941 1.50 1.05, 2.15  1.42 1.00, 2.03  
a Cross-sectional analysis, virological non-suppression= VL >50 copies/mL at the time of the questionnaire; b Longitudinal analysis, virological rebound= VL 
<50copies/mL at the time of the questionnaire followed by a subsequent VL >200copies/mL; c self-reported ≥2 consecutive missed days of ART in the past 3 
months or ≥1 missed dose in the last 2 weeks; d each socio-economic factor considered in a separate model for all results but gender/sexual orientation, age 
and ART non-adherence are included in every model, individuals with missing values for explanatory variables were excluded; e Chi square test; f test for trend. 
aPR=adjusted Prevalence Ratio; aHR=adjusted Hazard Ratio. 
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 Sensitivity analyses 
 SES and ART non-adherence - sensitivity analysis 
In a sensitivity analysis, the 65 individuals who had been on ART previously but were 
not on ART at the time of the questionnaire, were defined as non-adherent. After the 
inclusion of these individuals, 938/2769 (34%; 95% CI: 32%, 36%) were defined as 
non-adherent to ART. The results of this analysis showed associations between all 
four markers of lower SES and greater prevalence of ART non-adherence, similar to 
the main analysis (Table 7.10).  
Table 7.10: Sensitivity analysis: individuals previously on ART defined as non-adherent a 
 
 
 
 
 
 
 
 
 
 
 
Factors b 
N 
Unadjusted Adjusted for gender/sexual 
orientation and age 
PR 95% CI P-valuec aPR 95% CI P-valuec 
Enough 
money for 
basic needs? 
(Financial 
hardship) 
Always 1192 1  <.0001 d 1  <.0001 d 
Mostly 720 1.43 1.24, 1.64  1.41 1.22, 1.62  
Sometimes 477 1.83 1.59, 2.11  1.78 1.54, 2.05  
No  337 1.79 1.54, 2.09  1.72 1.47, 2.02  
Employed Yes 1506 1  <.0001 1  <.0001 No  1203 1.25 1.13, 1.39  1.31 1.18, 1.46  
Housing 
status 
Homeowner 954 1  <.0001 d 1  <.0001 d 
Renting  1493 1.48 1.30, 1.68  1.37 1.20, 1.57  
Unstable  282 1.79 1.51, 2.12  1.61 1.35, 1.93  
University Yes 1119 1  0.0037 1  0.0054 No  1587 1.17 1.05, 1.31  1.17 1.05, 1.30  
a ART non-adherence: (i) previously on ART but not at the time of the questionnaire, or (ii) 
self-reported ≥2 consecutive missed days of ART in the past 3 months or ≥1 missed dose in 
the last 2 weeks; b each socio-economic factor considered in a separate model for all results 
but gender/sexual orientation and age are included in every model, individuals with missing 
values for explanatory variables were excluded; c Chi square test; d test for trend. 
PR=Prevalence Ratio; aPR=adjusted Prevalence Ratio. 
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SES and virological non-suppression - sensitivity analysis 
The analysis of the association between virological non-suppression and socio-
economic factors was repeated using a VL >200 copies/mL at the time of the 
questionnaire as the definition of non-suppression rather than >50 copies/mL. Using 
this definition 115/2405 individuals (5%; 95% CI: 4%, 6%) were virologically non-
suppressed. The results were consistent with those of the main analysis (Table 7.11). 
All four markers of socio-economic disadvantage were strongly associated with a 
higher prevalence of VL >200 copies/mL, even after adjustment for gender/sexual 
orientation and age.  
Table 7.11: Sensitivity analysis: virological non-suppression defined as VL >200 
copies/mL (N= 2405) 
  
 
 
Factors a 
N 
Unadjusted Adjusted for 
gender/sexual orientation 
and age 
PR 95% CI P-valueb aPR 95% CI P-valueb 
Enough 
money for 
basic 
needs? 
(Financial 
hardship) 
Always 1038 1  <.0001 c 1  <.0001 c 
Mostly 627 1.34 0.80, 2.24  1.30 0.77, 2.19  
Sometimes 412 2.52 1.55, 4.09  2.34 1.39, 3.94  
No 290 3.12 1.89, 5.14  2.93 1.73, 4.94  
Employed Yes 1302 1  <.0001 1  <.0001 No 1049 2.35 1.60, 3.45  2.60 1.74, 3.91  
Housing 
status 
Homeowner 852 1  <.0001 c 1  0.0002 c 
Renting 1286 3.08 1.84, 5.16  2.70 1.60, 4.54  
 Unstable/ other 230 3.92 2.05, 7.49  3.08 1.58, 6.03  
University 
education 
Yes 977 1  0.0003 1  0.0003 
No 1370 2.00 1.33, 3.00  2.00 1.33, 3.00  
a Each socio-economic factor considered in a separate model for all results, individuals with 
missing values for socio-economic factors were excluded; b Chi square test; c test for trend; 
PR=Prevalence Ratio; aPR=adjusted Prevalence Ratio. 
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 SES and virological rebound - sensitivity analyses 
In the first longitudinal sensitivity analysis, virological rebound was redefined as a VL 
≤50 copies/mL at baseline followed by two consecutive VL measurements >200 
copies/mL among individuals with at least two VL measurements following the date of 
the questionnaire. Of 1717 individuals included in this analysis, 75 (4%) had virological 
rebound during follow-up. The associations between the socio-economic factors and 
virological rebound were consistent with those in the main analysis, although the effect 
sizes were generally larger (Table 7.12).  
In the second longitudinal sensitivity analysis, virological rebound was defined in the 
same way as in the main analysis (VL≤50 copies/mL at baseline and one subsequent 
VL>200 copies/mL), however, additionally individuals were considered to have 
experienced virological rebound six months after their last VL measurement if they 
were LTFU. Individuals were classified as LTFU if they had had at least one VL 
measurement after the date of the questionnaire but their latest VL measurement was 
over eighteen months prior to the administrative censoring date, which differed by 
clinical centre. These were April 2014 for Brighton, January 2015 for Eastbourne, 
March 2013 for Homerton, December 2013 for Mortimer Market, October 2015 for 
Newham, and May 2014 for the Royal Free. Of 1740 individuals, 226 (13%) had 
virological rebound during follow-up. Again, the results of this sensitivity analysis were 
consistent with the main analyses (Table 7.12).  
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Table 7.12: Sensitivity analyses where virological rebound was the outcome 
 
 
Factors a 
N 
Rate 
b 
Unadjusted Adjusted for gender/sexual 
orientation and age 
HR 95% CI P-valuec aHR 95% CI P-valuec 
Virological rebound defined as confirmed VL measurements >200 copies/mL (N=1717) 
Enough money for 
basic needs? 
(Financial hardship) 
Always 810 1.17 1  <.0001 d 1   0.0007 d 
Mostly 448 2.30 1.98 1.10, 3.54 1.80 1.00, 3.24 
Sometimes 258 1.92 1.64 0.79, 3.38 1.30 0.62, 2.75 
No  170 5.21 4.38 2.37, 8.10 3.60 1.90, 6.83 
Employed Yes 975 1.12 1  <.0001 1   <.0001 
No  705 3.20 2.86 1.77, 4.63  3.29 2.01, 5.40  
Housing status Homeowner 654 0.78 1  <.0001 d 1   0.0025 d 
Renting 899 2.71 3.50 1.87, 6.54 2.81 1.48, 5.33 
 Unstable/ other  135 3.19 4.17 1.76, 9.90 3.02 1.24, 7.32 
University education Yes 749 1.11 1  0.0016 1   0.0016 
No 928 2.59 2.33 1.38, 3.92  2.33 1.38, 3.94  
Individuals lost to follow-up considered as having virological rebound (N=1740) e 
Enough money for 
basic needs? 
(Financial hardship) 
Always 814 3.97 1  <.0001 d 1   <.0001 d 
Mostly 454 5.79 1.46 1.03, 2.06  1.35 0.95, 1.90  
Sometimes 265 8.36 2.11 1.46, 3.04  1.73 1.18, 2.53  
No  176 11.89 3.02 2.08, 4.39  2.49 1.69, 3.67  
Employed Yes 985 3.98 1  <.0001 1   <.0001 
No  718 8.66 2.18 1.67, 2.85  2.42 1.83, 3.19  
Housing status Homeowner 658 2.60 1  <.0001 d 1   <.0001 d 
Renting 915 7.61 2.92 2.06, 4.14  2.43 1.70, 3.48  
Unstable/ other  138 11.39 4.38 2.75, 6.97  3.41 2.11, 5.49  
University education Yes 759 4.87 1   0.037 1   0.047 
No  941 6.50 1.34 1.02, 1.76  1.32 1.00, 1.74  
a Each socio-economic factor considered in a separate model for all results, individuals with missing values for socio-economic factors were excluded; b per 
100 person-years; c Chi square test; d test for trend; e LTFU defined as consented longitudinal linkage and ≥1 VL measurement after questionnaire date but 
latest follow-up VL over eighteen months before administrative censoring date, date of rebound for these individuals is the date of but latest follow-up VL 
plus six months; HR= Hazard Ratio; aHR=adjusted Hazard Ratio. 
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 Discussion  
 Summary of results 
 The present study is the first to assess the impact of SES on virological 
outcomes among people treated for HIV in the UK. In this setting with universal 
free access to healthcare, and high levels of treatment success, all four 
markers of poorer SES considered (financial hardship, non-employment, 
rented/unstable housing status, and non-university education) were strongly 
associated with ART non-adherence and virological non-suppression. 
  Furthermore, each marker of poorer SES was predictive of subsequent 
virological rebound among those who had achieved virological suppression on 
ART at baseline. Additional social circumstance factors were also found to be 
associated with treatment adherence and response. Individuals living in the UK 
for over five years but not born in the UK, and individuals with non-fluent 
English reading ability had a greater prevalence of ART non-adherence 
compared to individuals born in the UK, and there was some evidence that 
they had a greater prevalence of virological non-suppression too. In addition, 
less supportive network, having children and not having a current partner were 
associated with a greater prevalence of ART non-adherence and virological 
non-suppression, and predictive of virological rebound.  
 There were strong associations between socio-economic factors and ART non-
adherence, and between non-adherence and poorer virological response. This 
suggests that, as might be expected, at least part of the observed associations 
between lower SES and virological non-suppression were mediated through 
ART non-adherence. The associations between socio-economic factors and 
virological outcomes were attenuated to some extent when adjusted for non-
adherence, which lends some support for non-adherence as a mechanism. 
 Interpretation of results 
These results from a setting of universal health care suggest that the implications of 
poorer SES on treatment outcomes go beyond inability to pay for treatment and 
associated healthcare costs, and operate strongly even amongst those who are 
accessing, and engaged with, clinical care. Socio-economic effects on outcome were 
also apparent after adjustment for demographic factors and specifically among the 
white MSM subgroup and the black African MSW and women subgroup. This showed 
that they were not solely a feature of the diverse demographic composition of the HIV-
positive population in the UK. 
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Overall, virological suppression rates are high among people on ART in the UK631. 
This was evident in the present study: 91% of respondents on ART for at least six 
months had a VL ≤50 copies/mL and 95% had a VL ≤200 copies/mL at the time of the 
questionnaire. Of those with VL ≤50 copies/mL and available follow-up, only 8% 
experienced virological rebound after a median 2.3 years. It is worth noting that this 
was a population with an average time on ART at the time of the questionnaire of eight 
years, and so one might have expected better virological outcomes compared to 
individuals who had all recently started treatment334. Though there was substantial 
variation in the prevalence of virological suppression by socio-economic factors, 
across all subgroups considered the proportion with VL >50 copies/mL never 
exceeded 20%, indicating that, even among those of lower SES, the majority were 
successfully treated. 
Associations were apparent both for education and for the other markers of SES, but 
there was some evidence that associations were stronger for markers of current 
financial status (money for basic needs, housing and employment) than for level of 
education. These results provide evidence of the importance of current socio-
economic disadvantage in determining virological outcomes of ART. 
It is important to appreciate the apparent impact of socio-economic factors on non-
adherence, even in the current era of simpler and more tolerable drugs, with the 
majority of participants on once a day regimens. There are a number of reasons why 
people with greater levels of social or financial disadvantage may have greater 
difficulties maintaining ART adherence, including: competing responsibilities, stress 
and/or worries about work632, housing, family or social situations633, unsettled living 
circumstances, food insecurity (particularly when the ART regimen requires food401), 
increased prevalence of depression and other mental health problems373;625;634;635, 
increased medication burden due to other comorbid conditions, stigma and low self-
esteem636, or less knowledge about the importance of adherence637. However, it is 
also worth noting that other studies suggest that part of the effect of SES on virological 
outcomes may be independent of non-adherence, for example related to: late 
diagnosis638;639, lower CD4 count or AIDS at ART initiation163, prescription/non-
prescription drug-drug interactions640-642, differences in quality of healthcare or 
experiences of healthcare643, pharmacokinetics through absence of food644, and 
possibly direct biological effects of psychosocial factors645-647. 
The self-reported measure of adherence used in the analyses in this chapter did not 
explain all of the effect, as with the ART non-adherence measure in Chapter 6 
(Section 6.4.4.4 ). This measurement may not fully capture adherence to treatment 
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since only a single time-point was considered and it may be subject to social 
desirability bias. Nonetheless, at least part of the observed associations between 
lower SES and virological non-suppression were explained by this crude binary 
measure of adherence.  
 Strengths and limitations 
Although these analyses provide evidence that SES disadvantage impacts on non-
adherence to ART, they do not help to elucidate the precise mechanisms by which this 
relationship occurs. Further analyses are required to investigate how exactly socio-
economic status effects an individual’s ability to adhere to treatment. 
There were some limitations in the data collected by the ASTRA questionnaire study. 
The response rate was 64% and non-responders may differ from responders with 
regard to socio-economic factors and association with virological outcomes. Thus, 
there may be a higher prevalence of poorer SES among non-responders and the 
associations between SES and VL outcomes may be under or overestimated. Several 
participants had missing data for some of the variables included in the analysis. The 
use of complete case analysis could have introduced bias if the missing data 
mechanism was not missing completely at random (MCAR). However, since the 
proportion of individuals with missing data was low, the bias introduced is likely to be 
minimal. The age of any children was only asked on the questionnaire for women, and 
even this had missing data, it was not possible to consider the ages of any children. 
Furthermore, the questionnaire did not collect data on whether the individual was 
currently looking after any children. I did not account for whether participants were on 
first-line or subsequent ART regimens, and the specific regimen used, because these 
data were not available from the questionnaire. Furthermore, in longitudinal analyses, 
it would have been useful to assess the effect of adjustment for previous history of 
ART exposure, previous virological failures, and duration of current virological 
suppression, however, complete treatment and virological history was not available for 
a substantial portion of ASTRA participants. Therefore, the analyses presented in this 
chapter cannot determine whether poorer outcomes among people with socio-
economic disadvantage were linked to use of different ART regimens. In the cross-
sectional analysis, only association can be studied648, and it is not possible to rule out 
the presence of reverse causality for some factors. However, the main findings were 
reinforced in the longitudinal analysis, which was unlikely to suffer from this bias as 
SES was measured at the time of the questionnaire, at which point all individuals had 
virological suppression.  
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There were also limitations concerning the analysis of ART adherence. The measures 
of adherence to ART were by self-report, and as such they may have been subject to 
response bias649 (refer to Section 1.3.3.3 ). The measures were also reported at a 
single point in time and were unlikely to fully capture adherence patterns for an 
individual. This was especially true in the longitudinal analysis, which required 
individuals to be virologically suppressed on ART at the time of reporting adherence. 
Individuals who had previously been on ART but were not on ART at the time of the 
questionnaire were not included in the main analysis. When these individuals were 
considered non-adherent in a sensitivity analysis, the prevalence of non-adherence 
and non-suppression was slightly higher, but socio-economic associations were 
unchanged. In Section 7.4.7, the method of adjusting for adherence in order to assess 
whether it mediates the associations between SES and VL outcomes may suffer from 
the same limitations discussed in Chapter 6 (Section 6.5.3) where a similar method 
was used. The fact that the socio-economic associations were not fully explained by 
non-adherence may be due to the inability of the two self-reported baseline measures 
to completely capture all aspects of recent and subsequent non-adherence, and the 
potential for both recall and social desirability bias in such measures650;651.  
Longitudinal ‘time-to-rebound’ analyses are potentially subject to bias if the frequency 
of VL monitoring differs according to explanatory variables. Although in Chapter 6 
time-to-event analyses were not appropriate, for the reasons given in Section 6.3.5, it 
was more appropriate in the present chapter since the median number of VL 
measurements during follow-up was reasonably similar across socio-economic 
subgroups. With more data, longitudinal analysis using fixed time-points analysis 
would be a useful additional analysis to minimise this particular bias. LTFU was 
considered as virological rebound in a sensitivity analysis in order to account for 
differences by SES. It may have been useful to look at a snapshot of LTFU652, 
however, there was insufficient follow-up data to conduct this analysis.  
The study population had a lower proportion of black African individuals, a lower 
proportion of individuals who acquired HIV through heterosexual sex, and a greater 
proportion of MSM than among PLWH in the UK in general210. Furthermore, as 
discussed earlier, the findings of the present analysis are not necessarily generalisable 
to other European settings including those which may have greater socio-economic 
disparities (for example Eastern Europe), or a greater proportion of people who inject 
drugs (PWID). Only 2% of the study population were PWID, however, this group make 
up a greater proportion of the HIV-positive population in other settings, for example in 
Eastern Europe and central Asia 51% of new diagnoses in 2014 were PWID. In 
settings with different healthcare systems to the UK, where HIV treatment may not be 
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free of charge and thus not as easily accessible to individuals with lower SES, it is 
conceivable that the association of socio-economic factors on treatment outcomes 
may be even stronger than that found in the present analysis. 
The analyses presented from the ASTRA study do not adjust for study centre. Such 
adjustment was not considered ideal, given the aims of the thesis, because study 
centre was confounded with gender/sexual orientation – since for some clinics, the 
vast majority of patients were MSM and for other clinics, patients were predominately 
heterosexual men and women. Furthermore, study centre was also confounded with 
SES; therefore adjusting for it would have removed some socio-economic effects that I 
wished to measure. Therefore, I took the decision not to adjust for clinic in the 
analyses for my thesis. Although it would be interesting to assess regional differences 
in treatment response, this ASTRA study is limited in this respect as 5 out of 8 clinics 
were in London, and all but one in the south of England. Furthermore, ASTRA policies 
prohibit publication of clinic-specific comparisons.  
  
 Conclusions 
In summary, even in a European setting with free access to treatment and overall high 
rates of treatment success, lower SES substantially influenced HIV treatment 
outcomes. Emphasis should be placed on supporting adherence of people in these 
higher risk groups. Socio-economic factors should be taken into account when 
designing clinical management strategies including linkage to the relevant social 
agencies. Further research is needed on specific interventions that may reduce socio-
economic inequalities in HIV-outcomes.
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 Can socio-economic disadvantage explain 
gender/sexual orientation disparities in ART 
adherence and virological response to ART in the 
UK? 
 Objectives 
 To assess the association of gender/sexual orientation with ART adherence 
and virological response to ART, using data from the ASTRA study. 
 To assess differences in socio-economic factors according to gender/sexual 
orientation. 
 To investigate whether any observed differences in socio-economic 
disadvantage between MSM, MSW and women were able to explain any 
observed differences in ART adherence and virological outcomes between the 
gender/sexual orientation groups. 
 Introduction 
Previous studies in high-income settings in HIV-positive populations have shown that 
the prevalence of socio-economic deprivation differs by gender/sexual orientation. In 
particular, women and MSW on average have poorer socio-economic status (SES) 
than MSM323;324;357;364;375. These differences could have therefore played a part in 
explaining the observed inequalities by gender/sexual orientation in ART response. In 
Chapter 7, gender/sexual orientation and socio-economic factors were considered in 
the same model for virological response, but the focus was on the marginal effect of 
SES alone. This chapter extended these analyses to explicitly examine the extent to 
which socio-economic factors differed across gender/sexual orientation groups, and to 
assess whether such variation in SES ‘explained’ differences in virological response 
by gender/sexual orientation. 
The issue has previously been addressed in a limited number of studies. Two 
European studies found some evidence that adjustment for socio-economic factors 
attenuated differences in virological suppression between gender/sexual orientation 
groups126;359 (these were discussed in detail in Section 2.6.1). However, both of these 
studies adjusted for multiple factors simultaneously, and one also included clinical 
factors and the other additionally included ART adherence. Therefore, it is difficult to 
make inferences from these studies regarding whether SES could act as a mediator 
for gender/sexual orientation and VL response associations. Furthermore, 
demographic and socio-economic effects on treatment outcomes may not be 
generalisable across different geographic settings. 
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In this chapter, I assessed the extent to which differences in ART adherence and 
virological response to ART between gender/sexual orientation groups were explained 
by SES and other factors. This was in order to provide insight into likely pathways 
through which gender/sexual orientation impacts on virological suppression, and thus 
suggest potential target areas for intervention to improve virological response to ART 
and reduce inequalities in response. 
 
 Methods 
 Study design 
This chapter used the same cross-sectional and longitudinal ASTRA study data as for 
the analyses in Chapter 7.  
 Outcomes of interest and inclusion criteria 
In this chapter, the three outcomes and respective entry criteria were identical to those 
described in Section 7.3.3: ART non-adherence, virological non-suppression and 
virological rebound.  
 Covariate of interest 
The main covariate of interest in this chapter was gender/sexual orientation, 
categorised as MSM, MSW, and women. As in Chapter 7, sexual orientation was 
derived from patient-reported sexual orientation (see Section 4.4.2).  
 Other covariates 
The same four indicators of SES considered in Chapter 7 were used again here in 
identical form (see Section 4.4.2 for definitions):  
SES factors: 
 Ability to afford basic needs (financial hardship with four levels), 
 Employed (yes; no), 
 Housing status (homeowner; renting; unstable/other), 
 University education (yes; no). 
Four social circumstance factors, English reading ability, time in the UK, social 
support, and current partner were considered as in the previous chapter. An additional 
variable was also derived based on country of birth, with people who were non-UK 
born categorised according to whether they were born in Europe, Africa or other 
region. Furthermore, whether or not participants had children was not used because 
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this measure was exceptionally closely linked to sexual orientation (7% MSM vs. 69% 
MSW and 74% women reported having children, Spearman’s rank coefficient = 0.66) 
and therefore would necessarily be expected to ‘explain’ much of the variation in 
outcomes across gender/sexual orientation groups. As discussed in Chapter 7, it was 
not possible to derive from the questionnaire the age of children or whether 
participants were currently looking after children. I also considered markers of mental 
health and lifestyle. Thus, the following covariates were also considered in this 
chapter: 
Social circumstances factors: 
 Country of birth (UK; European; African; other), 
 Time in UK (UK-born; >5 years; ≤5 years), 
 English reading ability (UK-born; fluent; not fluent), 
 Supportive network (most; medium; least), 
 Current partner (yes; no). 
Mental health factors: 
 Major depressive symptoms (yes; no), 
 Major or other depressive symptoms (yes; no). 
Lifestyle factors: 
 Recreational drug use in the last 3 months (yes; no), 
 Evidence of alcohol dependency (yes; no). 
 Statistical analysis 
 Cross-sectional analyses 
The characteristics of the individuals at the time of the questionnaire were summarised 
according to gender/sexual orientation and compared using Chi-squared tests. 
The prevalence of ART non-adherence and virological non-suppression by 
gender/sexual orientation and then by each of the other covariates were summarised 
and compared using the Chi-squared test, or Cochran-Armitage test for trend for 
ordered categorical variables. 
Other analysis methods were initially similar to those used in Chapter 7. Unadjusted 
and adjusted prevalence ratios (PR) were produced for the association of 
gender/sexual orientation with ART non-adherence and virological non-suppression 
using modified Poisson regression. I constructed linear contrasts in order to define 
pairwise comparisons for MSW vs. MSM, women vs. MSM, and women vs. MSW, but 
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all came from the same regression model. A number of models were considered to 
evaluate the effect of adjustment for different socio-economic factors on the 
association between gender/sexual orientation and non-adherence/virological non-
suppression. The first adjusted model included only gender/sexual orientation and age 
as covariates. Each subsequent model included gender/sexual orientation, age, and 
each additional socio-economic factor from those listed in Section 8.3.4 in turn. Two 
additional models included gender/sexual orientation, age, and multiple socio-
economic factors: (i) all four socio-economic factors; and (ii) a subset of socio-
economic factors selected using stepwise variable selection (with an entry and exit P-
value of 0.05). In the stepwise method, a sequence of log-likelihood tests were used to 
select a subset of the four socio-economic factors for each outcome. In addition, in 
order to put the results for SES factors into context, each of the social circumstance, 
mental health and lifestyle factors from Section 8.3.4 were included in a separate 
model alongside gender/sexual orientation and age. Age was adjusted for in all 
models to reduce confounding by age, as women attending for HIV care are generally 
younger than men, and age is a known predictor of ART-adherence and virological 
suppression on ART163;455;653-656. 
As previously discussed, ART adherence is likely to be on the causal pathway 
between gender/sexual orientation or SES and lack of treatment response. Thus, in 
Chapters 6 and 7 ART non-adherence was adjusted for in order to assess the extent 
to which poorer ART adherence could explain differences in ART response by 
gender/sexual orientation and SES, respectively. In contrast, adherence was not 
adjusted for in the present chapter since the aim was to assess how much socio-
economic disparities account for gender/sexual orientation differences in treatment 
response, most of which will likely act through non-adherence. 
If the addition of a particular covariate (or set of covariates), to the model that included 
only gender/sexual orientation and age as covariates, resulted in attenuation of the 
association between gender/sexual orientation and the outcome in question (i.e. the 
PR moved closer to one), then this suggested that this covariate (or set of covariates) 
was “explaining” part of the association. See Section 6.5.3 for the assumptions 
underlying this.  
Longitudinal analyses 
In longitudinal analyses, Cox proportional hazards regression models were used to 
generate unadjusted and adjusted hazard ratios (HR) for the association between 
gender/sexual orientation and time to virological rebound. The strategy of adjustment 
used in the models was identical to that described in Section 8.3.5.1 .  
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 Sensitivity analyses 
Two sensitivity analyses were performed: virological non-suppression was defined as 
VL >200 copies/mL; and individuals who were lost to follow-up (LTFU) were 
considered as having experienced virological rebound six months after the date of the 
last available VL measurement (missing=failure approach). See the methods of 
Chapter 7 for more details. 
 
 Results 
 Participant characteristics 
There were many differences between the gender/sexual orientation groups in terms 
of demographics, socio-economic factors, social circumstances, lifestyle, and HIV 
related factors. Table 8.1 shows the differences in these factors by gender/sexual 
orientation among individuals included in the ART non-adherence analysis. There 
were very similar distributions for the study populations for the virological non-
suppression and virological rebound analyses also. 
As one might expect, the most prevalent mode of HIV acquisition for MSM and women 
was sex with a man, and for MSW was sex with a woman. A greater percentage of 
MSW and women reported they likely acquired HIV from injection drug use (IDU), 
another non-sexual route, or an unknown route, compared to MSM. Most MSM were 
white, and only 1% were of black African ethnicity. In contrast, the most common 
ethnic group among MSW and women was black African. The median age of women 
was lower than for either of the male groups. 
MSW and women had poorer SES than MSM by all four markers: a much higher 
percentage reported being less able to afford basic needs, being unemployed, renting 
housing from the council or being in temporary housing or homeless. A higher 
proportion of MSW and women (compared to MSM) reported having no formal 
education or education below university level, although these differences in education 
were somewhat smaller than the differences by the other SES markers. In general, 
when comparing MSW with women, levels of socio-economic disadvantage tended to 
be somewhat poorer among women. 
Most MSW or women were born in a country other than the UK, with the majority born 
in an African country, whereas UK-birth was most common for MSM. The proportion of 
individuals living in the UK for fewer than five years was small for each group, but 
highest among women. Not being able to read English fluently was much more 
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common for MSW and women compared to MSM. Levels of reported supportive 
network were similar between the gender/sexual orientation groups, however, MSW 
were more likely to have a current partner compared to the other two groups.  
Prevalence of symptoms of major depression was similar between gender/sexual 
orientation groups; however, a greater percentage of women had depression 
symptoms under the “major or other depression” definition. MSM were much more 
likely to have used recreational drugs in the last three months, and both male groups 
were more likely to have evidence of alcohol dependency compared to women. 
MSM were more likely to have been diagnosed with HIV longer compared to MSW and 
women, and they had a greater median number of years on ART. The proportion 
taking once-a-day regimens was similar between the gender/sexual orientation 
groups.  
A greater percentage of MSW and women self-reported ≥2 consecutive missed days 
of ART in the past three months, compared to MSM. On the other hand similar 
percentages of MSM and MSW self-reported ≥1 missed dose in the last two weeks, 
compared to a higher proportion among women.  
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Table 8.1: Characteristics of questionnaire respondents included in cross-sectional ART 
non-adherence analysis by gender/sexual orientation a 
Factor MSM MSW Women  P-
valueb 
N  % c N  % c N  % c  
Total 1867 69% 321 12% 516 19% 
Likely mode of 
HIV acquisition 
Sex with a man 1742 93% 6 2% 347 67% <.0001 
Sex with a woman 8 <1% 189 59% 0 0%  
IDU 13 1% 18 6% 15 3%  
Unknown 76 4% 74 23% 103 20%  
Other  23 1% 33 10% 44 9%  
Missing 5 <1% 1 <1% 7 1%  
Ethnicity White 1665 89% 103 32% 107 21% <.0001 
Black African 14 1% 163 51% 330 64%  
Black Other 36 2% 21 7% 32 6%  
Other 125 7% 27 8% 32 6%  
Missing 27 1% 7 2% 15 3%  
Age Median (IQR d) 46 (40, 52) 47 (42, 
53) 
43 (37, 
49) 
<.0001 
Afford basic needs 
(financial 
hardship) 
Always 968 52% 89 28% 113 22% <.0001 
Mostly 502 27% 74 23% 125 24%  
Sometimes 230 12% 91 28% 143 28%  
No 147 8% 58 18% 121 23%  
Missing 20 1% 9 3% 14 3%  
Employment  Employed 1101 59% 144 45% 234 45% <.0001 
Unemployed 265 14% 85 26% 133 26%  
Sick/ disabled 286 15% 34 11% 55 11%  
Retired 142 8% 24 7% 14 3%  
Other 44 2% 23 7% 60 12%  
Missing 29 2% 11 3% 20 4%  
Housing  Homeowner 799 43% 68 21% 77 15% <.0001 
Renting from council 511 27% 113 35% 216 42%  
Renting privately 406 22% 75 23% 128 25%  
Temporary/homeless 18 1% 22 7% 30 6%  
Staying with 
family/other 
113 6% 35 11% 53 11%  
Missing 20 1% 8 2% 12 2%  
Education 
(highest level) 
University degree or 
higher 
811 43% 117 36% 166 32% <.0001 
A-level/equivalent 379 20% 55 17% 102 20% 
O-levels/equivalent 420 23% 77 24% 104 20% 
Other 50 3% 14 4% 44 9% 
None 183  10% 47 15% 72 14% 
Missing 24 1% 11 3% 28 5% 
Country of birth e UK 1329 71% 86 27% 96 19% <.0001 
Europe (non-UK) 216 12% 22 7% 23 4% 
Africa 71 4% 171 53% 324 63% 
North America 53 3% 6 2% 5 1% 
South America 65 3% 6 2% 6 1% 
Asia 42 2% 5 2% 3 1% 
Australia 30 2% 0 0% 1 <1% 
Unknown (non-UK) 40 2% 17 5% 37 7% 
Missing 21 1% 8 2% 21 4% 
Time in UK Born in UK 1329 71% 86 27% 96 19% <.0001 
>5 years 440 24% 206 64% 345 67% 
≤5 years 62 3% 16 5% 38 7% 
Missing 36 2% 13 4% 37 7% 
English reading 
ability 
Born in UK 1329 71% 86 27% 96 19% <.0001 
Fluent 454 24% 162 50% 296 57% 
Not fluent 54 3% 61 19% 93 18% 
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Factor MSM MSW Women  P-
valueb 
N  % c N  % c N  % c  
Total 1867 69% 321 12% 516 19% 
Missing 30 2% 12 4% 31 6% 
Supportive 
network 
Most support 600  32% 118 37% 160 31% 0.16 
Medium support 1001  54% 153 48% 260 50% 
Least support 259 14% 37 12% 81 16% 
Missing 7 <1% 13 4% 15 3% 
Children Yes 133  7% 220 69% 380 74% <.0001 
No 1725 92% 99 31% 130 25%  
Missing 9 <1% 2 1% 6 1%  
Partner Yes 1030  55% 223 69% 277 54% <.0001 
No 825 44% 97 30% 236 46%  
Missing 12 1% 1 <1% 3 1%  
Major depressive 
symptoms 
Yes 342 18% 60 19% 104 20% 0.64 
No 1525 82% 261 81% 412 80%  
Major or other 
depressive 
symptoms 
Yes 469 25% 90 28% 166 32% 0.0052 
No 1398 75% 231 72% 350 68%  
Reported 
recreational drug 
use in past 3 
months 
Yes 932 49% 50 15% 35 7% <.0001 
No 935 51% 271 85% 481 93%  
Alcohol 
dependency 
problem 
Yes 349 19% 57 18% 58 11% 0.0005 
No 1518 81% 262 82% 453 88%  
Missing 0 0% 2 1% 5 1%  
Time since HIV 
diagnosis 
<2 years 101 5% 35 11% 44 9% <.0001 
2-5 years 234 13% 52 16% 75 15%  
5-15 years 897 48% 157 49% 291 56%  
>15 years 596 32% 63 20% 96 19%  
Missing 39 2% 14 4% 10 2%  
Number of times 
taking ART per 
day 
1 1485 80% 259 81% 415 80% 0.34 
≥2  370  20% 55 17% 88 17%  
Missing 12 1% 7 2% 13 3%  
SR ≥2 consecutive 
missed days of 
ART in past 3 
months 
No/don’t know 1575 84% 262 80% 399 77% 0.0006 
Yes  289 15% 58 18% 117 23%  
Missing 3 <1% 1 <1% 0 0%  
SR ≥1 missed 
dose in the last 2 
weeks 
No/don’t know 1412 76% 239 74% 371 72% 0.27 
Yes  455 24% 78 24% 143 28%  
Missing 0 0% 4 1% 2 <1%  
Non-adherent to 
ART f 
No/don’t know 1298 70% 217 68% 316 61% 0.0018 
Yes  569 30% 104 32% 200 39%  
Time on ART 
(years) g h 
Median (IQR d) 7.6  
(3.2, 13.3) 
6.6  
(2.5, 10.8) 
6.5  
(2.6, 10.7) 
<.0001 
CD4 count i 
(cells/µL) 
Median (IQR d) 560  
(420, 740) 
447  
(300, 664) 
540  
(379, 740) 
<.0001 
VL at the time of 
the questionnaire 
≤50 copies/mL 1648 88% 261 81% 438 85% 0.0009 
>50 copies/mL 208 11% 58 18% 75 15%  
Missing 11 1% 2 1% 3 1%  
 
 
 
a 2704 participants included who self-reported being on ART at the time of the questionnaire 
and had recorded age and non-adherence data; b some column percentages do not sum to 
100% due to rounding; c Chi-squared test for categorical and Wilcoxon-Mann-Whitney test 
for continuous variables, after missing values excluded; d IQR= interquartile range; e grouped 
by continent except for UK; f self-reported ART non-adherence: ≥2 consecutive missed days 
of ART in the past 3 months or ≥1 missed dose in the last 2 weeks; g missing time on ART: 
MSM=65 (3%), MSW=16 (5%), women=18 (3%); h among those with known date started 
ART; i missing CD4 count: MSM=10 (1%), MSW=4 (1%), women=3 (1%); SR= self-reported. 
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 Cross-sectional self-reported ART non-adherence 
 The association between gender/sexual orientation and ART non-
adherence 
As noted above, there were differences according to gender/sexual orientation in the 
prevalence of ART non-adherence. Using my definition, among the 2704 individuals 
eligible for the non-adherence analysis, 569/1867 (31%) MSM, 104/321 (32%) MSW, 
and 200/516 (39%) women self-reported ART non-adherence at the time of the 
questionnaire (p=0.0018). This is displayed in Figure 8.1. 
Figure 8.1: Prevalence of ART non-adherence by gender/sexual orientation a 
 
 
 The association between the other covariates and ART non-adherence 
The associations of socio-economic factors with ART non-adherence have previously 
been displayed in Section 7.4.2 and Table 7.2. Poorer SES by any of the four markers 
considered was found to be associated with a greater prevalence of ART non-
adherence. 
In addition, younger age, African country of birth, not being UK-born but living in the 
UK for over five years, having non-fluent English reading ability, not having a current 
partner, major or other depressive symptoms, recreational drug use in the last three 
months, and evidence of alcohol dependency were all strongly associated with greater 
prevalence of ART non-adherence (Table 8.2). 
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a Cross-sectional analysis among 2704 respondents who self-reported being on ART at the 
time of the questionnaire, self-reported ART non-adherence: ≥2 consecutive missed days of 
ART in the past 3 months or ≥1 missed dose in the last 2 weeks; b Chi square test. 
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Table 8.2: Prevalence of ART non-adherence a by demographic, social circumstance, 
mental health and lifestyle factors 
Factor b Frequency (%) P-valuec 
Demographic factors    
Age 
<30 years 41/103 39.8% <0.0001 d 
30-49 years 613/1767 34.7%  
≥50 years 219/834 26.3%  
Social circumstance factors    
Country of birth 
Born in UK 443/1511 29.3% <0.0001 
Non-UK: European 79/261 30.3%  
Non-UK: African 230/566 40.6%  
Non-UK: other/unknown 99/316 31.3%  
Time in the UK 
Born in UK 443/1511 29.3% 0.0008 
>5 years 361/991 36.4%  
≤5 years 34/116 29.3%  
English reading ability 
Born in UK 443/1511 29.3% <0.0001 
Fluent  303/912 33.2%  
Non-fluent 97/208 46.6%  
Supportive network 
Most support 218/878 24.8% <0.0001 d 
Medium support 489/1414 34.6%  
Least support 153/377 40.6%  
Current partner Yes 459/1530 30.0% 0.0035 No 409/1158 35.3%  
Mental health factors    
Major Depression Yes 220/506 43.5% <0.0001 No 653/2198 29.7%  
Major or other 
depression 
Yes 305/725 42.1% <0.0001 
No 568/1979 28.7%  
Lifestyle factors    
Recreational drug use Yes 392/1017 38.5% <0.0001 No 481/1687 28.5%  
Alcohol dependency Yes 190/464 41.0% <0.0001 No 678/2233 30.4%  
 
 
Gender/sexual orientation and ART non-adherence: effect of adjustment 
for other covariates 
Table 8.3 shows the results from a number of modified Poisson regression models 
assessing the association of gender/sexual orientation with ART non-adherence using 
PRs. The first model was unadjusted, followed by models were adjusted sequentially 
for factors as described in Section 8.3.5.1 . In the unadjusted analysis, there was no 
evidence of a difference in ART non-adherence between the male groups, as the PR 
was close to one (1.06, p=0.49 for MSW vs. MSM). In contrast, women had a 27% and 
20% increased prevalence of ART non-adherence compared to MSM and MSW, 
respectively. Adjustment for age attenuated these associations by 5% and 7% (in 
relative terms), respectively, thus although the difference in non-adherence between 
women and MSW was partially explained by age differences, there remained evidence 
of greater non-adherence among women, even after accounting for age (Table 8.3).  
a Self-reported ART non-adherence: ≥1 missed dose in the past 3 months for ≥2 consecutive 
days or ≥1 missed dose in the last 2 weeks; b individuals with missing values for explanatory 
variables were excluded; c Chi square test; d Cochran-Armitage test for trend. 
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Since there was little difference in the prevalence of ART non-adherence observed 
between MSW and MSM in unadjusted analyses or analyses adjusted for age only, 
additional adjustment for any of the SES factors had little effect. In contrast, additional 
adjustment for any one of financial hardship, employment, or housing status, and to a 
lesser extent education, attenuated the PRs for women vs. MSM toward one. Using 
stepwise selection, financial hardship and housing status were chosen as the two most 
significant predictors, among SES factors, of ART non-adherence. As adjustment for 
financial hardship alone completely attenuated the differences between MSM and 
women, adjusting for this subset of two socio-economic factors, or for all four socio-
economic factors together was unable to attenuate the differences any further. With 
regard to the differences between women and MSW, adjustment for any single SES 
factor or multiple SES factors had little effect on attenuating the PRs for women vs. 
MSW over and above age. 
When considering social circumstance, lifestyle and mental health factors, adjustment 
for most of these factors made only minor differences to the age adjusted PRs for 
each pairwise comparison. Country of birth, time in the UK and English reading ability 
attenuated each of the pairwise differences to the greatest extent. In particular, 
adjustment for country of birth attenuated the differences in adherence between MSM 
and women substantially, perhaps indicating that differences were also related to 
migrant status. Recreational drug use accentuated the difference in prevalence of ART 
non-adherence between MSW and MSM and between women and MSM because 
recreational drug use was associated with non-adherence and the prevalence of drug 
use was substantially greater among MSM. 
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Table 8.3: Cross-sectional association between gender/sexual orientation and ART non-
adherence a following adjustment for SES, social circumstance, mental health, and 
lifestyle factors in separate models (N=2704) 
  
Adjusted for b: 
PR (95% CI) P-
valuec 
MSW vs. 
MSM 
Women vs. 
MSM 
Women vs. 
MSW 
 
Unadjusted 1.06 0.89, 1.26 1.27 1.11, 1.45 1.20 0.99, 1.45 0.0027 
Age  1.08 0.91, 1.29 1.21 1.06, 1.38 1.12 0.92, 1.35 0.019 
SES factors 
Adjusted for age and: 
           
Financial hardship 0.92 0.77, 1.10 1.01 0.88, 1.16 1.10 0.91, 1.34 0.58 
Employment 1.03 0.87, 1.23 1.13 0.99, 1.30 1.10 0.90, 1.34 0.22 
Housing status 1.00 0.84, 1.19 1.10 0.97, 1.26 1.11 0.91, 1.34 0.35 
Education 1.09 0.91, 1.29 1.17 1.02, 1.33 1.07 0.88, 1.31 0.084 
Multiple SES factors 
Adjusted for age and: 
           
All SES factors d 0.90 0.75, 1.08 0.97 0.85, 1.12 1.08 0.89, 1.32 0.48 
Stepwise selected 
subset of SES factors 
e 
0.90 0.75, 1.07 0.99 0.86, 1.13 1.10 0.91, 1.34 0.45 
Social circumstance 
factors 
Adjusted for age and: 
           
Country of birth 0.90 0.74, 1.10 0.97 0.81, 1.16 1.07 0.88, 1.30 0.60 
Time in the UK 1.03 0.86, 1.24 1.11 0.96, 1.29 1.07 0.88, 1.31 0.39 
English reading ability 0.99 0.82, 1.18 1.07 0.93, 1.25 1.09 0.89, 1.33 0.58 
Supportive network 1.11 0.94, 1.33 1.20 1.06, 1.37 1.08 0.89, 1.31 0.022 
Current stable partner 1.12 0.94, 1.33 1.21 1.06, 1.38 1.08 0.89, 1.31 0.016 
Mental health 
factors 
Adjusted for age and: 
           
Major depression 1.08 0.91, 1.28 1.21 1.06, 1.37 1.11 0.92, 1.35 0.022 
Major or other 
depression 
1.07 0.90, 1.27 1.18 1.04, 1.34 1.10 0.91, 1.33 0.048 
Lifestyle factors 
Adjusted for age and: 
       
Recreational drug use 1.26 1.06, 1.51 1.50 1.30, 1.73 1.19 0.98, 1.44 <.0001 
Alcohol dependency 1.08 0.91, 1.29 1.23 1.08, 1.40 1.14 0.94, 1.38 0.011 
 
 
 
a Self-reported ART non-adherence: ≥1 missed dose in the past 3 months for ≥2 consecutive 
days or ≥1 missed dose in the last 2 weeks; b individuals with missing values for explanatory 
variables were excluded; c Chi square test; d financial hardship, employment, housing status, 
and education; e financial hardship and housing status only. PR = Prevalence Ratio; SES = 
socio-economic status. 
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 Cross-sectional virological non-suppression 
The association between gender/sexual orientation and virological non-
suppression 
Among the 2405 individuals included in the analysis, virological non-suppression (>50 
copies/mL) was more prevalent among MSW and women compared to MSM (14% 
[39/277] and 11% [51/458] vs. 8% [129/1670] respectively, p=0.0007) shown in Figure 
8.2. 
Figure 8.2: Prevalence of virological non-suppression by gender/sexual orientation a 
 
 
The association between the other covariates and virological non-
suppression 
The associations of the SES factors with VL non-suppression among people on ART 
were previously shown in Section 7.4.3 and Table 7.3. Lower SES by any marker was 
associated with a higher prevalence of virological non-suppression.  
The association of demographic, social circumstance, mental health and lifestyle 
factors with virological non-suppression are shown in Table 8.4. Younger age, being 
born in Africa, non-fluent English reading ability, depression and alcohol dependency 
were each associated with a higher prevalence of virological non-suppression. There 
was also weak evidence that living in the UK for over five years but not being UK-born, 
least supportive network, and not having a current partner were associated with a 
higher prevalence of virological non-suppression. In contrast, there was no evidence 
that recreational drug use was associated with this outcome.
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a Cross-sectional analysis among 2405 respondents who had started ART >6 months prior 
to completion of the questionnaire; b Chi square test. 
 
p=0.0007 b 
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Table 8.4: Prevalence of virological non-suppression a by demographic, social 
circumstance, mental health and lifestyle factors 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gender/sexual orientation and virological non-suppression: effect of 
adjustment for other covariates 
Table 8.5 shows the unadjusted association between gender/sexual orientation and 
virological non-suppression, and the association following adjustment for SES and 
other factors. In unadjusted analyses, MSW and women had 82% and 44% greater 
prevalence of virological non-suppression compared to MSM, respectively, and there 
was weak evidence of 21% lower prevalence among women compared to MSW. 
Adjustment for age alone did not substantially alter the difference in prevalence 
between MSW and MSM. However, it attenuated the PR between women and MSM to 
some extent, such that there was only weak evidence of a difference in virological non-
suppression between these groups after controlling for age. Adjustment for age 
actually accentuated the differences between women and MSW, such that women had 
31% lower prevalence of virological non-suppression compared to MSW. 
Factor b Frequency (%) P-valuec 
Demographic factors    
Age 
<30 years 12/73 16.4% 0.0033 d 
30-49 years 153/1563 9.8%  
≥50 years 54/769 7.0%  
Social circumstance factors    
Country of birth 
Born in UK 108/1329 8.1% 0.035 
Non-UK: European 16/235 6.8%  
Non-UK: African 62/513 12.1%  
Non-UK: other/unknown 25/282 8.9%  
Time in the UK 
Born in UK 108/1329 8.1% 0.085 
>5 years 95/899 10.6%  
≤5 years 6/98 6.1%  
English reading ability 
Born in UK 108/1329 8.1% 0.0056 
Fluent  73/825 8.9%  
Non-fluent 28/182 15.4%  
Supportive network 
Most support 63/762 8.3% 0.059 d 
Medium support 113/1273 8.9%  
Least support 42/342 12.3%  
Current partner Yes 112/1363 8.2% 0.090 No 105/1026 10.2%  
Mental health factors    
Major Depression Yes 67/456 14.7% <0.0001 No 152/1949 7.8%  
Major or other 
depression 
Yes 93/652 14.3% <0.0001 
No 126/1753 7.2%  
Lifestyle factors    
Recreational drug use Yes 78/899 8.7% 0.57 No 141/1506 9.4%  
Alcohol dependency Yes 55/421 13.1% 0.0020 No 164/1979 8.3%  
a VL >50 copies/mL; b individuals with missing values for explanatory variables were 
excluded; c Chi square test; d Cochran-Armitage test for trend. 
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When considering MSW compared to MSM, while the difference in prevalence of 
virological non-suppression was attenuated to some extent by adjustment for any of 
the socio-economic factors, there remained a substantial difference between MSW 
and MSM. Adjustment for all SES factors or the stepwise selected subset of SES 
factors (in this case housing status and employment), attenuated the PR towards one, 
further than any single factor. However, the PR was still substantial at 1.43, suggesting 
a substantially higher prevalence of virological non-suppression for MSW compared to 
MSM, even when SES was accounted for. Similarly, for women versus MSM, 
additional adjustment for any socio-economic factor attenuated the PR for the 
difference between women and MSM further towards one. In particular, following 
adjustment for age and financial hardship there was no evidence of a difference 
between these groups (PR=0.99). Thus, additional adjustment multiple socio-
economic factors was unable to attenuate the differences any further. Finally, when 
comparing women to MSW, adjustment for age and financial hardship, employment, 
education or multiple SES factors together actually increased the effect size for the 
difference in virological non-suppression. This was likely because in this study women 
tended to have poorer SES than MSW. Thus, higher prevalence of virological non-
suppression in MSW compared to women could possibly be even larger than those 
found in analyses unadjusted for SES.  
For both MSW versus MSM and women versus MSM, adjustment for country of birth 
and English reading ability made the most substantial attenuations to PRs of the social 
circumstance, mental health, and lifestyle factors - to the extent that the PRs were 
similar to the models which adjusted for a single SES factor. Adjustment for any of the 
other factors made little difference to the PRs. None of the social circumstances, 
mental health, or lifestyle factors had a considerable effect on the differences in 
virological non-suppression between women and MSW above that of age.  
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Table 8.5: Cross-sectional association between gender/sexual orientation and virological 
non-suppression a following adjustment for SES, social circumstance, mental health, 
and lifestyle factors in separate models (N=2405) 
  
Adjusted for b: 
PR (95% CI) P-
valuec MSW vs. 
MSM 
Women vs. 
MSM 
Women vs. 
MSW 
Unadjusted 1.82 1.30, 2.55 1.44 1.06, 1.96 0.79 0.54, 1.17 0.0033 
Age  1.88 1.35, 2.63 1.30 0.95, 1.76 0.69 0.47, 1.02 0.0053 
SES factors 
Adjusted for age and: 
           
Financial hardship 1.50 1.05, 2.14 0.99 0.71, 1.37 0.66 0.44, 0.98 0.12 
Employment 1.63 1.15, 2.31 1.07 0.77, 1.48 0.65 0.43, 0.98 0.063 
Housing status 1.50 1.06, 2.12 1.05 0.76, 1.43 0.70 0.47, 1.04 0.13 
Education 1.83 1.30, 2.58 1.19 0.86, 1.63 0.65 0.43, 0.97 0.015 
Multiple SES factors 
Adjusted for age and: 
           
All SES factors d 1.39 0.96, 2.01 0.90 0.64, 1.25 0.64 0.43, 0.97 0.14 
Stepwise selected 
subset of SES factors 
e 
1.43 1.00, 2.04 0.96 0.70, 1.33 0.67 0.45, 1.01 0.17 
Social circumstance 
factors 
Adjusted for age and: 
           
Country of birth 1.66 1.14, 2.42 1.14 0.77, 1.68 0.69 0.45, 1.04 0.067 
Time in the UK 1.79 1.25, 2.56 1.23 0.87, 1.72 0.68 0.45, 1.03 0.021 
English reading ability 1.70 1.17, 2.49 1.21 0.86, 1.71 0.71 0.47, 1.08 0.051 
Supportive network 1.93 1.38, 2.69 1.31 0.96, 1.77 0.68 0.46, 1.00 0.0042 
Current stable partner 2.01 1.44, 2.82 1.32 0.97, 1.79 0.65 0.44, 0.97 0.0023 
Mental health factors 
Adjusted for age and: 
           
Major depression 1.88 1.35, 2.62 1.28 0.94, 1.74 0.68 0.46, 1.01 0.0059 
Major or other 
depression 
1.84 1.32, 2.56 1.23 0.90, 1.66 0.67 0.45, 0.98 0.0095 
Lifestyle factors 
Adjusted for age and: 
       
Recreational drug use 1.91 1.34, 2.71 1.32 0.94, 1.85 0.69 0.47, 1.02 0.0075 
Alcohol dependency 1.91 1.37, 2.66 1.36 1.00, 1.85 0.71 0.48, 1.05 0.0031 
 
 
 Longitudinal virological rebound 
The association between gender/sexual orientation and virological 
rebound 
Of the 1740 ASTRA participants included in the longitudinal analyses, 82 (6%) MSM, 
22 (13%) MSW, and 35 (12%) women experienced virological rebound (p=0.0006; log 
rank test), over 2851, 350, and 617 person-years, respectively. The median number of 
years of follow-up (median [IQR]: MSM: 2.4 [2.1, 2.7]; MSM: 2.3 [1.9, 2.7]; women: 2.3 
[1.7, 2.7]) and number of VL measurements (MSM: 6 [5, 8]; MSW: 6 [4, 8]; women: 5 
[4, 7]) were similar for the gender/sexual orientation groups.  
 
a VL >50 copies/mL; b individuals with missing values for explanatory variables were excluded; 
c Chi square test; d financial hardship, employment, housing status, and education; e 
employment and housing status only. PR = Prevalence Ratio; SES = socio-economic status. 
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At 1 year MSM, MSW and women had a Kaplan Meier probability of rebound (95% CI) 
of 2.6% (1.7%, 3.4%), 9.1% (4.7%, 13.5%) and 7.2% (4.2%, 10.2%), respectively, and 
at 2 years this was 5.5% (4.2%, 6.8%), 12.2% (7.0%, 17.4%), and 11.5% (7.6%, 
15.4%), respectively (Figure 8.3).  
Figure 8.3: Kaplan-Meier plot of time until virological rebound according to 
gender/sexual orientation a (N=1740) 
 
 
The association between the other covariates and virological rebound 
The rates of virological rebound in the different socio-economic groups are provided in 
Section 7.4.5 and Table 7.5. Higher rates of virological rebound were found among 
those with poorer SES by each of the four markers.  
Additionally, higher rates of virological rebound were found among younger 
individuals, individuals born in African countries, individuals without a current partner, 
and individuals with major or other depressive symptoms (Table 8.6). In contrast, 
virological rebound was not associated with time in the UK, English reading ability, 
supportive network, recreational drug use, and alcohol dependency. 
 
 
 
 
a VL ≤50copies/mL at the time of the questionnaire and one subsequent VL >200copies/mL. 
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Table 8.6: Rate of virological rebound a by mental health and lifestyle factors 
 
 
Gender/sexual orientation and virological rebound: effect of adjustment 
for other covariates 
Table 8.7 shows the HRs for the association between gender/sexual orientation and 
virological rebound from a Cox regression model. In an unadjusted analysis, MSW and 
women had 2.2 and 2.0 times the hazard rate of virological rebound compared to 
MSM, respectively. However, there was no difference between MSW and women, with 
a HR close to 1.00 (p=0.69 for MSW vs. women). Adjustment for age attenuated the 
HR comparing virological rebound between women and MSM somewhat. However, it 
actually led to a greater difference in the rate of rebound between MSW and MSM and 
between women and MSW; likely the result of the younger median age among women 
compared to both male groups.  
Additional adjustment for any of financial hardship, employment status, housing status, 
stepwise selected subset of SES factors (in this case employment and housing), or all 
four SES factors explained some of the differences in rate of virological rebound 
Factor b Rate  95% CI P-valuec 
Demographic factors    
Age 
<30 years 8.74 6.24, 11.24 0.0028 d 
30-49 years 4.06 3.82, 4.30  
≥50 years 2.51 2.31, 2.72  
Social circumstance factors    
Country of birth 
Born in UK 3.09  2.36, 3.82 0.0043 
Non-UK: European 3.17 1.38, 4.96  
Non-UK: African 6.17  4.30, 8.04  
Non-UK: other/unknown 2.84  1.30, 4.38  
Time in the UK 
Born in UK 3.09  2.36, 3.82 0.17 
>5 years 4.47 4.12, 4.82  
≤5 years 2.96 2.26, 3.66  
English reading ability 
Born in UK 3.09  2.36, 3.82 0.27 
Fluent  4.35 4.00, 4.70  
Non-fluent 4.43 3.61, 5.24  
Supportive network 
Most support 3.07 2.82, 3.33 0.078 d 
Medium support 3.68 3.45, 3.92  
Least support 5.04 4.38, 5.69  
Current partner Yes 2.96 2.77, 3.14 0.0065 No 4.65 4.31, 4.99  
Mental health factors    
Major Depression Yes 8.13  5.90, 10.36 <0.0001 No 2.76  2.19, 3.33  
Major or other 
depression 
Yes 6.96  5.23, 8.69 <0.0001 
No 2.63  2.04, 3.22  
Lifestyle factors    
Recreational drug use Yes 4.10  3.09, 5.11 0.16 No 3.33  2.58, 4.08  
Alcohol dependency Yes 4.54  2.89, 6.19 0.18 No 3.44  2.79, 4.09  
a VL≤50 copies/mL at the time of the questionnaire and one subsequent VL>200 copies/mL; 
b individuals with missing values for explanatory variables were excluded; c Chi square test. 
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between MSW and MSM. However, there remained substantial differences between 
the two groups of men even after adjustment for multiple SES factors. These were 
also the factors that most attenuated the differences between women and MSM, 
although there was some evidence that a difference between these groups remained. 
For women versus MSW, adjustment for employment in addition to age accentuated 
the HR for virological rebound further, though there was still not a statistically 
significant difference between these groups. Adjustment education made little 
difference to the HR. 
Adjustment for country of birth attenuated the differences in virological rebound 
between MSW and MSM and between women and MSM to a similar extent as when 
adjusted for one of the SES factors. Adjustment for depressive symptoms somewhat 
attenuated the PRs for MSW versus MSM and women versus MSM, but to a lesser 
extent than the markers of current SES. On the other hand, adjustment for major 
depression accentuated the PR for differences between women and MSW, such that 
women had 0.6 times the rate of virological rebound compared to MSW. Alcohol 
dependence was unable to attenuate differences in virological rebound between MSW 
and MSM or between women and MSM; however, adjustment for recreational drug 
use accentuated differences between these groups. There was little evidence of a 
difference between women and MSW when adjusted for age and any one lifestyle 
factor. 
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Table 8.7: Longitudinal association between gender/sexual orientation and virological 
rebound following adjustment for SES, social circumstance, mental health, and lifestyle 
factors in separate models a (N=1740) 
  
Adjusted for b: 
HR (95% CI) P-
valuec 
MSW vs. MSM Women vs. 
MSM 
Women vs. 
MSW 
 
Unadjusted 2.18 1.36, 3.49 1.96 1.32, 2.91 0.90 0.53, 1.53 0.0002 
Age  2.34 1.46, 3.76 1.79 1.20, 2.66 0.76 0.44, 1.31 0.0002 
SES factors 
Adjusted for age and: 
           
Financial hardship 1.98 1.21, 3.22 1.44 0.94, 2.19 0.73 0.42, 1.26 0.015 
Employment 2.09 1.30, 3.37 1.39 0.92, 2.11 0.67 0.38, 1.15 0.0065 
Housing status 1.98 1.22, 3.20 1.49 0.99, 2.24 0.75 0.43, 1.30 0.0095 
Education 2.32 1.43, 3.77 1.65 1.09, 2.50 0.71 0.41, 1.25 0.0007 
Multiple SES factors 
Adjusted for age and: 
           
All SES factors d 1.68 1.02, 2.77 1.32 0.86, 2.04 0.80 0.45, 1.37 0.10 
Stepwise selected 
subset of SES factors e 
1.73 1.07, 2.80 1.44 0.95, 2.16 0.83 0.48, 1.42 0.042 
Social circumstance 
factors 
Adjusted for age and: 
           
Country of birth 2.01 1.16, 3.47 1.37 0.81, 2.31 0.68 0.39, 1.19 0.044 
Time in the UK 2.28 1.37, 3.81 1.64 1.04, 2.60 0.72 0.41, 1.27 0.0034 
English reading ability 2.48 1.49, 4.12 1.66 1.05, 2.62 0.67 0.38, 1.17 0.0012 
Supportive network 2.49 1.55, 4.01 1.78 1.19, 2.67 0.72 0.41, 1.24 0.0001 
Current stable partner 2.53 1.57, 4.08 1.83 1.23, 2.72 0.72 0.42, 1.24 0.0011 
Mental health factors 
Adjusted for age and: 
           
Major depression 2.21 1.38, 3.55 1.71 1.15, 2.56 0.55 0.45, 1.33 0.0007 
Major or other 
depression 
2.24 1.39, 3.59 1.69 1.13, 2.52 0.75 0.44, 1.30 0.0007 
Lifestyle factors 
Adjusted for age and: 
       
Recreational drug use 2.78 1.70, 4.55 2.30 1.47, 3.61 0.83 0.48, 1.43 <.0001 
Alcohol dependency 2.30 1.42, 3.73 1.86 1.25, 2.79 0.81 0.47, 1.41 0.0002 
 
 
 
 
 
 
 
a VL ≤50 copies/mL at the time of the questionnaire and one subsequent VL >200 copies/mL; 
b individuals with missing values for explanatory variables were excluded; c Chi square test; d 
financial hardship, employment, housing status, and education; e employment and housing 
status only. HR = Hazard Ratio; SES = socio-economic status. 
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 Sensitivity analyses 
Virological non-suppression sensitivity analysis 
Virological non-suppression was redefined as a VL >200 copies/mL at the time of the 
questionnaire instead of >50 copies/mL as in the main analysis. As expected the 
prevalence of virological non-suppression was even lower: of the 2405 individuals 
included, 68/1670 (4%) MSM had a VL >200 copies/mL, compared to 25/277 (9%) 
MSW and 22/458 (5%) women (p=0.0017). 
The PRs for the association of gender/sexual orientation and VL >200 copies/mL are 
displayed in Table 8.8. Using this definition, there was still a large difference in the 
prevalence of virological non-suppression in favour of MSM versus MSW, which was, 
if anything, larger in magnitude compared to that seen when using a 50 copies/ml VL 
cut-off. However, there was little evidence of a difference between women and MSM. 
In addition, women had half the prevalence of virological non-suppression compared 
to MSW under this definition.  
Adjustment for age accentuated the differences between the groups observed in 
unadjusted analyses. Additional adjustment for financial hardship, employment, 
housing status, or multiple SES factors attenuated the differences between MSW and 
MSM to some extent. There remained no evidence of a statistically significant 
difference in the prevalence of virological non-suppression between women and MSM 
following adjustment for any of the SES, social circumstances, mental health, or 
lifestyle factors. There was also no evidence that any of these factors explained the 
differences in virological non-suppression between women and MSW; this was as 
expected since women generally have poorer SES than MSW.
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Table 8.8: Sensitivity analysis: virological non-suppression defined as VL >200 
copies/mL (N=2405) 
  
Adjusted for b: 
PR (95% CI) P-valuec 
MSW vs. MSM Women vs. MSM Women vs. MSW 
Unadjusted 2.22 1.43, 3.44 1.18 0.74, 1.89 0.53 0.31, 0.93 0.022 
Age  2.31 1.49, 3.59 1.03 0.64, 1.66 0.45 0.25, 0.78 0.017 
SES factors 
Adjusted for age 
and: 
           
Financial 
hardship 
1.77 1.10, 2.86 0.73 0.44, 1.20 0.41 0.23, 0.72 0.018 
Employment 2.00 1.26, 3.16 0.77 0.46, 1.30 0.39 0.21, 0.70 0.017 
Housing status 1.92 1.22, 3.02 0.83 0.51, 1.35 0.43 0.25, 0.76 0.030 
Education 2.31 1.49, 3.59 0.97 0.60, 1.56 0.42 0.24, 0.74 0.016 
Multiple SES 
factors 
Adjusted for age 
and: 
           
All SES factors d 1.70 1.03, 2.80 0.65 0.39, 1.09 0.38 0.22, 0.69 0.0088 
Stepwise selected 
subset of SES 
factors e 
1.81 1.13, 2.90 0.71 0.42, 1.19 0.39 0.22, 0.70 0.016 
Social 
circumstance 
factors 
Adjusted for age 
and: 
           
Country of birth 2.23 1.35, 3.68 0.99 0.55, 1.77 0.44 0.25, 0.79 0.024 
English reading 
ability 
2.36 1.43, 3.90 1.08 0.65, 1.81 0.46 0.25, 0.83 0.029 
Supportive 
network 
2.43 1.57, 3.76 1.03 0.64, 1.65 0.42 0.24, 0.74 0.012 
Current stable 
partner 
2.61 1.69, 4.05 1.05 0.66, 1.69 0.40 0.23, 0.71 0.0076 
Mental health 
factors 
Adjusted for age 
and: 
           
Major depression 2.29 1.48, 3.55 1.01 0.63, 1.63 0.44 0.25, 0.77 0.017 
Major or other 
depression 
2.22 1.43, 3.42 0.94 0.58, 1.51 0.42) 0.24, 0.74 0.017 
Lifestyle factors 
Adjusted for age 
and: 
       
Recreational drug 
use 
2.38 1.48, 3.84 1.07 0.63, 1.83 0.45 0.26, 0.79 0.017 
Alcohol 
dependency 
2.35 1.52, 3.64 1.09 0.67, 1.75 0.46 0.26, 0.81 0.015 
 a VL >200 copies/mL; b individuals with missing values for explanatory variables were 
excluded; c Chi square test; d financial hardship, employment, housing status, and education; e 
employment and housing status only. PR = Prevalence Ratio; SES = socio-economic status. 
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Virological rebound sensitivity analyses 
In a sensitivity analysis which additionally considered individuals who were LTFU as 
having experienced virological rebound, 133 (11%) MSM, 33 (19%) MSW and 60 
(17%) women experienced the outcome (p<0.0001; log rank test). The rate of rebound 
was 4.6 (3.8, 5.4) per 100 person years among MSM, compared to 9.3 (6.1, 12.4), and 
9.5 (7.1, 11.9) among MSW and women, respectively. This was a worst-case scenario 
since many of those LTFU may have simply transferred clinics; however, this data was 
not captured. 
The results of this analysis were similar to those of the main analysis (Table 8.9). The 
effect sizes for women compared to MSM were larger than in the main analysis and 
adjustment for the other risk factors were not as able to explain the associations 
between gender/sexual orientation and virological rebound. However, the greater rate 
of rebound among women and MSW compared to MSM were still much attenuated. In 
particular, the model adjusted for age and all four socio-economic factors attenuated 
the associations to the greatest extent: the rate of rebound was attenuated by 65% 
and 48% for MSW and women compared to MSM, respectively.  
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Table 8.9: Sensitivity analysis: individuals lost to follow-up a considered as virological 
rebound b (N=1740) 
  
Adjusted for c: 
HR (95% CI) P-valued 
MSW vs MSM Women vs. 
MSM 
Women vs. 
MSW 
Unadjusted 2.01 1.37, 2.94 2.06 1.52, 2.79 1.02 0.67, 1.57 <.0001 
Age  2.16 1.47, 3.17 1.86 1.37, 2.53 0.86 0.56, 1.33 <.0001 
SES factors 
Adjusted for age and: 
           
Financial hardship 1.78 1.20, 2.66 1.48 1.07, 2.04 0.83 0.53, 1.29 0.0047 
Employment 1.92 1.30, 2.83 1.50 1.09, 2.07 0.78 0.50, 1.22 0.0010 
Housing status 1.76 1.19, 2.61 1.53 1.12, 2.09 0.87 0.56, 1.35 0.0025 
Education 2.11 1.42, 3.13 1.74 1.26, 2.39 0.82 0.53, 1.29 <.0001 
Multiple SES factors 
Adjusted for age and: 
           
All SES factors e 1.51 1.00, 2.26 1.38 0.99, 1.92 0.92 0.59, 1.43 0.055 
Stepwise selected 
subset of SES factors 
f  
1.56 1.05, 2.31 1.51 1.10, 2.07 0.97 0.63, 1.49 0.011 
Social circumstance 
factors 
Adjusted for age and: 
           
Country of birth 1.83 1.18, 2.85 1.52 1.02, 2.26 0.83 0.53, 1.29 0.017 
English reading ability 1.96 1.29, 2.96 1.59 1.12, 2.25 0.81 0.52, 1.27 0.0016 
Supportive network 2.17 1.46, 3.21 1.85 1.35, 2.52 0.85 0.55, 1.33 <.0001 
Current stable partner 2.29 1.56, 3.37 1.86 1.37, 2.54 0.82 0.53, 1.26 <.0001 
Mental health 
factors 
Adjusted for age and: 
           
Major depression 2.09 1.42, 3.06 1.81 1.33, 2.47 0.87 0.56, 1.34 <.0001 
Major or other 
depression 
2.10 1.43, 3.08 1.79 1.32, 2.44 0.85 0.55, 1.32 <.0001 
Lifestyle factors 
Adjusted for age and: 
       
Recreational drug 
use 
2.40 1.61, 3.57 2.17 1.54, 3.06 0.90 0.59, 1.40 <.0001 
Alcohol dependency 2.15 1.46, 3.17 1.90 1.39, 2.59 0.88 0.57, 1.37 <.0001 
 
 
 
 
 
a LTFU defined as consented longitudinal linkage and ≥1 VL measurement after 
questionnaire date but latest follow-up VL over eighteen months before administrative 
censoring date, date of rebound for these individuals is the date of but latest follow-up VL 
plus six months; b VL ≤50copies/mL at the time of the questionnaire and one subsequent VL 
>200copies/mL or individuals LTFU; c individuals with missing values for explanatory 
variables were excluded; d Chi square test; e financial hardship, employment, housing status, 
and education; f employment and housing status only. HR = Hazard Ratio; SES = socio-
economic status. 
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 Discussion 
 Summary of results 
 The results presented in this chapter demonstrated that in the ASTRA study, 
MSW and women had poorer virological responses compared to MSM. MSW 
and women had 1.8 and 1.4 times greater prevalence of virological non-
suppression and 2.2 and 2.0 times greater rate of virological rebound 
compared to MSM, respectively. In addition, women had 1.3 times greater 
prevalence of ART non-adherence compared to MSM. Although women tended 
to have a lower prevalence of virological non-suppression and lower rate of 
virological rebound compared to MSW, these differences were not statistically 
significant. 
 Among the ASTRA participants, MSW and women were considerably more 
likely to have socio-economic disadvantage (by a range of markers) compared 
to MSM. This difference was most marked for current SES markers such as 
financial hardship and housing status compared to education.  
 This is the first study to specifically assess the role of socio-economic factors in 
explaining gender/sexual orientation disparities in ART response. Although a 
few previous studies have investigated gender/sexual orientation disparities in 
virological outcomes, they have presented results adjusted for several 
covariates simultaneously, from which it was difficult to assess the specific role 
of SES. In the ASTRA study the differences between MSM and women were 
substantially ‘explained’ by a greater prevalence of socio-economic 
disadvantage among women, though there remained a relatively large PR for 
virological rebound. Additionally, adjustments for socio-economic factors were 
less able to fully attenuate virological differences between MSM and MSW. The 
results of this chapter give some insight into the potential reasons for 
gender/sexual orientation disparities in virological response to ART, suggesting 
that socio-economic disadvantage is an important factor, particularly for 
women. 
 Interpretation of results 
The results of the present analysis showed considerable socio-economic disparities 
between the three gender/sexual orientation groups in the UK setting. By all markers 
of SES, MSM had the most favourable profile, consistent with the results of other 
European studies323;324;357;364;375. Furthermore, a greater percentage of MSW compared 
to women reported they were always able to afford their basic needs (28% vs. 22%), 
homeowners (21% vs. 15%), and university educated (36% vs. 32%). In the analyses, 
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disparities in socio-economic factors were more able to explain the differences in 
virological response to ART between women and MSM as opposed to between MSW 
and MSM. This could be due to the above observation that levels of socio-economic 
deprivation were lowest among MSM, greatest for women, and the levels for MSW 
were intermediate. Therefore, adjustment for socio-economic factors would tend to 
accentuate, rather than attenuate, poorer virological outcomes for MSW compared to 
women. It is also worth noting the relatively weaker role of education, compared to the 
other SES markers. Education tended to have less strong associations with virological 
outcomes (as seen in Chapter 7), show somewhat less variation between 
gender/sexual orientation groups, and was less effective in ‘explaining’ gender/sexual 
orientation differences in virological outcomes and non-adherence. This could provide 
some evidence that current financial disadvantage is a more pertinent factor than level 
of education. 
Socio-economic factors appeared to account for much of the difference in virological 
response of women compared to MSM. However, socio-economic factors were less 
able to explain the differences between MSW and MSM it terms of virological 
outcomes. It implies that there may be other important differences between MSW and 
MSM affecting adherence not being captured by the SES variables. For example, 
cultural factors affecting healthcare or support seeking behaviours, stigma, or 
differences in comorbidities. Alternatively, factors other than non-adherence may play 
a larger role in poor responses for MSW than they do for women. Giving some support 
to this was the observation that the prevalence of self-reported ART non-adherence 
was similar between MSW and MSM, while it was higher for women. Possibly 
differences in virological outcomes between MSW and MSM may be affected by 
factors independent of non-adherence, such as late diagnosis (a particular issue for 
MSW in the UK208) or a higher VL at ART initiation. It was not possible to investigate 
this in ASTRA, as data on CD4 count at diagnosis and VL at ART initiation were not 
available for most participants. Equally, it was not possible to assess the extent of bias 
in self-reported adherence, and that this may differ between gender/sexual orientation 
groups.  
One may expect MSW and women to have similar responses to ART because they 
are more comparable in terms of ethnicity, place of birth, and SES. Thus differences in 
observations were likely attributable to differences between genders (either biological 
or behavioural). In that context I found that, although self-reported ART adherence 
was similar among MSW and women, women had a decreased prevalence of 
virological non-suppression and there was some evidence of a lower rate of virological 
rebound among women compared to MSW. Smaller numbers of MSW and women 
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included in the ASTRA study mean that the comparisons of these groups were 
underpowered to some extent. The present chapter shows that the observed 
differences between these groups could not be explained by imbalances in SES, 
social circumstances, depression or lifestyle factors. Factors that it was not possible to 
measure using the ASTRA study data, such as late diagnosis or initiation of ART, may 
help to explain these differences. 
The results suggested that socio-economic factors were less able to account for 
differences in the longitudinal virological rebound analysis amongst those that have 
achieved virological suppression at some point, than in the cross-sectional virological 
non-suppression analysis including all of those on ART. As the socio-economic factors 
were measured at the time of the questionnaire (the same time as the cross-sectional 
virological outcome), it is possible that they are more reflective of circumstances at 
that time, rather than at the time of a future virological rebound. It is also possible that 
different socio-economic factors will affect the ability to achieve an undetectable VL at 
a single point in time versus sustaining this over time to prevent subsequent rebound. 
There may be changes over time in socio-economic circumstance. However, while it is 
possible for factors such as ability to afford basic needs and employment status to 
change over time, this is unlikely over such a short follow-up, and particularly for socio-
economic factors such as education. The differences between results for the 
longitudinal and cross-sectional analyses could also reflect differences in the way the 
analyses were conducted. For example, individuals in the cross-sectional analyses 
were among those who reported they were on ART at the time of the questionnaire, 
but these individuals could have subsequently interrupted ART over follow-up. 
Therefore, some of the virological rebounds may have been caused by both poorer 
adherence to treatment and complete treatment interruptions. In theory SES may be 
more able to explain poor adherence to ART than complete treatment interruptions, 
since there may be clinical reasons for longer treatment disruptions657. The cross-
sectional and longitudinal analyses also differed in that individuals included in the 
virological rebound analysis had already achieved a VL ≤50 copies/mL, thus were 
likely to have been adherent to treatment at least at this time. Since socio-economic 
difficulties did not stop these individuals from achieving a virological suppression 
initially, it is possible that these factors were less important in explaining differences in 
subsequent virological response by gender/sexual orientation. To address this in 
future work, a sensitivity analysis considering only virological rebounds occurring while 
individuals were on ART by gender/sexual orientation could be conducted. 
Besides SES, country of birth was the variable that most attenuated the differences in 
ART non-adherence and virological response both between MSW and MSM, and 
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between women and MSM. This finding, which is consistent with other European 
studies364;658, indicates that poorer adherence to ART and poorer virological response 
to ART compared to MSM might be particularly affected by issues related to migrant 
status among MSW and women. This would include SES659;660, but may also 
encompass factors such as language barriers659;661, stigma662;663, fear of 
deportation659;662;664, healthcare and medication beliefs659;665, and difficulties accessing 
healthcare269. 
 Strengths and limitations 
Although I have used the method of adjusting for socio-economic and other factors 
and assessing the attenuation of the gender/sexual orientation effect, other methods, 
such as structural equation modelling (SEMs), could have been used to address this 
question, and may better account for confounding and the inter-relationships between 
variables666-668. Future work could develop the use of such methods. 
It is feasible that differences in ART adherence between the gender/sexual orientation 
groups were resultant from the likelihood of individuals to correctly self-report sub-
optimal adherence669, including reporting of adherence based on knowledge of current 
virological status. Self-reported adherence is a subjective measure and certain groups 
may perceive their adherence to be worse or better than it is in reality. Social 
desirability bias may affect the gender/sexual orientation groups differently: in previous 
studies of dietary self-report, men were likely to overestimate energy and fat intake 
while women were more likely to underestimate these measures670;671. In a study of 
self-reported depressive symptoms, men were less likely to report symptoms when 
consent forms indicated that “more involved follow-up” may occur, but that this was not 
true of women670;672. As such, men may be less likely to report ART non-adherence if 
they believe this is undesirable, or perhaps will lead to additional healthcare 
attendance or interventions. Potential bias in reporting ART adherence was suggested 
in the present study, as self-reported non-adherence was similar for MSW and MSM, 
in contrast to virological outcomes, which were poorer among MSW compared to 
MSM. This might suggest some sort of social desirability bias in the more subjective 
outcome of non-adherence. This could have implications for interpreting the results of 
adherence studies and adds to the existing evidence that support around adherence 
should not be based solely on self-reported measures, since these tend to 
overestimate adherence591;673-676. Previous studies have not studied whether this 
overestimation is more prevalent in certain demographic groups. Further limitations of 
the self-reported ART adherence measure were discussed in Section 7.5.3. 
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The inclusion of multiple socio-economic factors in a single model may have induced 
collinearity as some of the socio-economic factors were correlated with one another 
(see Spearman’s rank correlation coefficients in Section 7.4.1). This could have 
reduced parameter variance estimates and affected the inferences made on whether 
there were differences between the gender/sexual orientation groups in this model. 
However, even in the models including gender/sexual orientation, age, and all four 
socio-economic factors, there was little evidence of multicollinearity.  
As explained in previous chapters, Cox proportional hazards models could be biased 
by differences in frequency of monitoring of VL by gender/sexual orientation. As there 
were not substantial differences between the gender/sexual orientation groups in 
terms of median number of VL measurements per patient year of follow-up (median 
(IQR): 2.8 (2.2, 3.5) vs. 2.7 (2.1, 3.5) and 2.6 (2.0, 3.2) for MSM vs. MSW and 
women), it is unlikely that the results have been influenced by differences in the 
frequency of VL monitoring.  
 
 Conclusions 
Poorer virological responses to ART were found among women and MSW compared 
to MSM in the ASTRA study, along with a greater prevalence of self-reported ART 
non-adherence among women. Gender/sexual orientation and socio-economic 
disparities in HIV treatment outcomes are intertwined. In particular, among people 
treated for HIV in the UK, socio-economic disadvantage appears to make a substantial 
contribution to explaining the poorer virological responses among women compared to 
MSM, and to explaining part of the difference for MSW compared to MSM. The results 
suggested that other factors might also be important for MSW: virological outcomes for 
this group were generally poorer than for women, even though markers of socio-
economic disadvantage were somewhat less prevalent. This study is the first to focus 
on the ability of SES to attenuate or “explain” gender/sexual orientation disparities in 
virological response to ART in high-income settings. More research in this area is 
required to understand the mechanisms by which socio-economic factors are related 
to ART adherence and VL response.  
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 Prevalence of late HIV diagnosis by 
gender/sexual orientation and socio-economic 
factors  
 Objectives 
 To present descriptive date on the trends in late and very late HIV diagnosis 
among individuals newly diagnosed with HIV between 2011 and 2015 
attending the Royal Free Hospital, using the RFHCS. 
 To assess whether demographic factors were associated with late and very 
late HIV diagnosis. 
 To assess whether socio-economic factors were associated with late and very 
late HIV diagnosis. 
 To evaluate HIV testing behaviours and healthcare provider missed 
opportunities for an earlier HIV diagnosis as potential mechanisms of any 
associations between demographic and socio-economic factors and late 
diagnosis. 
 Introduction  
Diagnosis of HIV at a late stage continues to be a major problem even in recent years. 
In the UK in 2015, 39% of people newly diagnosed with HIV were diagnosed with a 
CD4 count <350 cells/μL677, despite HIV testing being free and accessible to all in 
need. Individuals who are diagnosed with HIV at a higher CD4 count have the 
opportunity to initiate treatment earlier. Therefore, they are at an advantage in terms of 
slowing the progression of HIV91, and improved prognosis93;96;98. People diagnosed 
late have been found to have a 10-fold increased risk of death within one year of 
diagnosis compared to those with a timely diagnosis543. Caring for individuals who 
have been diagnosed late tends to be complex because they are more likely to need 
treatment for symptomatic infections, have poorer long-term prognosis even after 
starting treatment (the nadir CD4 count remains a long-term predictor of clinical 
outcome678;679), and have had extended exposure to viraemia and increased immune 
activation102;103. Furthermore, it is estimated that 82% of new HIV infections among 
MSM in the UK are sexual transmissions from people unaware of their HIV status213, 
meaning that late HIV diagnosis also contributes to ongoing transmission.  
As late diagnosis is generally more common among populations who do not perceive 
themselves to be at a high risk of HIV infection103;638;680-682, there are substantial 
variations in late diagnosis rates between demographic groups. For example in high-
income settings ,individuals with demographic characteristics considered to put them 
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at high risk of acquiring HIV, such as MSM and people who inject drugs (PWID), are 
often less likely to be diagnosed late compared to those infected through heterosexual 
sex111;245;543;639;683-691. Certain groups may be less likely to test due to differing 
knowledge of HIV, such as migrants692 and the elderly693. Additionally, migrants may 
be less likely to have a timely HIV diagnosis due to reduced access to healthcare 
services through language, stigma or cultural barriers694, or due to diagnosis and 
testing patterns in their country of origin, if they were infected with HIV prior to 
migration217. Groups which are more likely to have access to routine HIV testing, such 
as women through routine opt out antenatal testing, may be at a reduced risk of late 
diagnosis217;695.  
Differences in the frequency of late diagnosis by demographic factors may also reflect 
disparities by SES696. Some European studies, including one which used data from the 
COHERE cohort collaboration697, found an association between poorer SES and late 
diagnosis, using education level as a marker405;639;698;699. In contrast, the French ANRS 
study found that individuals on welfare benefits before HIV diagnosis had 72% lower 
odds of late diagnosis than those who were not, when adjusted for gender, age, year 
of diagnosis and other SES factors700. Other studies have found no evidence of an 
association between late diagnosis and educational attainment406, housing683 or 
employment status699. The association of socio-economic factors with late diagnosis 
may vary across geographic and healthcare settings, even within Europe, since the 
characteristics of the HIV-positive populations can be very different701. In order to 
better understand the relationship between SES and late diagnosis, and in turn to 
identify potential interventions, it may be useful to consider multiple SES markers in 
the same setting.  
As mentioned previously, factors such as risk perception may affect HIV testing 
behaviours. It is important to examine the contribution both of barriers to HIV testing at 
the patient-level, and of missed opportunities for an earlier diagnosis at the healthcare 
provider-level, to the prevalence of late diagnosis of HIV692;702. Healthcare 
professionals may perceive certain groups, such as MSM, as at higher risk of 
acquiring HIV, and so may be more likely to offer a test as a part of routine care. Thus, 
some groups may have an advantage over others in accessing a timely HIV diagnosis. 
Of 977 individuals newly-diagnosed in January-March 2003 in the UK, 17% had 
sought medical care in the previous year with symptoms potentially related to HIV but 
remained undiagnosed245. Furthermore, an audit of all UK adult HIV service providers 
known to the British HIV Association (BHIVA) found that 25% of new diagnoses in 
August-September 2010 had previously had symptoms/conditions indicative of HIV but 
had not been tested at that time703. It is pertinent to consider whether missed 
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opportunities for earlier diagnosis are still an issue in more recent years and whether 
they occur more often in specific groups. 
 
 Methods 
 Study population 
The study population included newly diagnosed individuals attending the Ian 
Charleson Day Centre (ICDC) at the Royal Free Hospital for their first visit between 
April 2011, when the new patient registration forms were introduced (see Appendix I.), 
and April 2015. Data were collected via the clinician-administered patient registration 
form, the details of which are described in Section 4.2.4.1 . Only individuals with 
completed patient registration forms were included. Data from the forms were linked to 
laboratory data, including CD4 counts. 
 Inclusion criteria 
Individuals were required to have a recorded HIV diagnosis date that was no more 
than one year prior to completion of the patient registration form, to exclude those who 
were new to the ICDC but were transferring from other treatment centres. In addition, 
included individuals were required to have had at least one of the following to 
definitively categorise their late diagnosis status: (i) a CD4 count within three months 
of the date of diagnosis (either recorded on the patient registration form or by linkage 
to the electronic CD4 count laboratory results); (ii) an ADE before the date of diagnosis 
or within one month after; (iii) symptoms of seroconversion at their first visit to the 
ICDC; (iv) a negative HIV test within 12 months of their first positive HIV test. 
 Outcomes 
Late and very late diagnosis 
The two primary outcomes of interest were late diagnosis and very late diagnosis. The 
definitions were chosen to largely agree with the European Late Presenter Consensus 
working group definitions704, but were modified so that individuals with missing CD4 
count data who were in the primary stage of infection were not classified as diagnosed 
late705. All those who had ether a CD4<350 cells/µL within three months of the date of 
diagnosis or an ADE before diagnosis or within one month after diagnosis, were 
classified as being diagnosed late. If individuals had missing data for CD4 count at 
diagnosis and they had either a seroconversion illness reported at presentation to the 
ICDC or a previous negative HIV test within a year of the date of diagnosis, then they 
were categorised as not diagnosed late. 
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Very late diagnosis was defined similarly, but using a CD4 count cut-off of <200 
cells/µL at diagnosis rather than <350 cells/µL. Therefore, the categories were not 
mutually exclusive (as in the European late presenter consensus definition), and ‘late 
diagnosis’ also included all individuals classified as ‘very late’ diagnosis. 
HIV testing behaviours and recent contact with health services 
In order to address the fourth objective of this chapter, to investigate the association 
between recent HIV testing behaviour and late diagnosis, three patient-level testing 
behaviour outcome variables were derived from responses to the following three 
questions on the patient registration form:  
 Has the patient ever had a previous negative HIV test? (yes; no) 
 Was the patient’s first positive HIV test self-prompted? (yes; no) 
 Was the patient’s first positive HIV test in a genitourinary (GU) clinic (i.e. a 
sexual health clinic)? (yes; no). 
The location of an individual’s HIV diagnosis was included as this was thought to be 
indicative of perception of need for sexual health care and perception of HIV risk706.  
Additionally, four variables on recent contact with health services were derived from 
the following four questions:  
 Has the patient been offered an HIV test in the 12 months prior to HIV 
diagnosis? (yes; no) 
 Has the patient visited a primary care (PC) clinic in the 12 months prior to HIV 
diagnosis? (yes; no) 
 Has the patient visited a GU clinic in the 12 months prior to HIV diagnosis? 
(yes; no) 
 Has the patient visited an emergency department (A&E) in the 12 months prior 
to HIV diagnosis? (yes; no) 
 Covariates of interest 
The following covariates of interest were considered as factors associated with late 
diagnosis, as defined in Section 4.4.3:  
Demographic factors: 
 Gender/sexual orientation (MSM; MSW; women) 
 Age at diagnosis (continuous derived from date of birth and date of diagnosis) 
 Ethnicity (white; black African; other) 
Socio-economic factors: 
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 Employed (yes; no) 
 Housing status (homeowner; renting; unstable/other) 
 University education (yes; no) 
Social circumstances: 
 Children (yes; no) 
 Current partner (yes; no)  
HIV risk factors: 
 Reported being sexually active in the last three months (yes; no) 
 Reported having ever injected drugs (yes; no) 
 Likely country of infection (UK; non-UK). 
In absence of an individual reporting sexual activity in the last three months or injection 
drug use (IDU) ever, the individual was assumed to have a negative response. In 
contrast to Chapters 5 and 6, sexual orientation was defined using self-identified 
sexual orientation rather than HIV acquisition risk, as this information was available 
from the registration form. The group MSM includes men reporting either homosexual 
or bisexual orientation, and MSW includes men reporting heterosexual orientation 
only. The group of women includes women reporting heterosexual, homosexual or 
bisexual orientation. Therefore, the analyses in this chapter do not exclude individuals 
who had a non-sexual route of transmission. 
 Statistical analysis 
Factors associated with late and very late HIV diagnosis 
The percentage with late and very late diagnosis was calculated for each of the 
covariates listed above. The groups were compared using Chi-squared tests or 
Cochran-Armitage tests for trend for ordered categorical variables. 
Modified Poisson regression models526 were used to generate prevalence ratios (PR) 
in order to assess the associations of each covariate with late and very late diagnosis. 
The association between each factor and late diagnosis was assessed in a separate 
model to avoid collinearity between the different markers of SES. In adjusted analyses, 
as in previous chapters, gender/sexual orientation and age were included in each 
model. 
In order to reduce confounding by sexual orientation, the modified Poisson regression 
models were repeated in the following two subgroups: (i) MSM, and (ii) MSW and 
women.  
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Sensitivity analysis/ missing data 
As the patient registration forms were completed during routine clinical care, time 
constraints meant that there were relatively high levels of missing data for some 
variables. It was necessary to select a method to handle the issue of missing data. 
The main analyses used a complete case (CC) approach. This means that individuals 
with complete data for a particular variable were included in analyses using that 
variable, therefore denominators varied between analyses. In a sensitivity analysis, the 
analyses described above were repeated using multiple imputation (MI). MI by chained 
equations536 was performed using the “mi” package in Stata version 12707, where the 
imputation-specific coefficients were combined in accordance with Rubin’s rules537. 
Due to perfect prediction, it was necessary to use augmented regression. To check the 
variation in analysis results due to using a finite number of imputations, Monte Carlo 
errors (MCE) were calculated. A detailed description of this method was provided in 
Section 4.5.7. Data on date of HIV diagnosis, previous negative HIV tests, whether 
testing for HIV was self-prompted, and whether diagnosis took place in a GU clinic, 
were included in the imputation model as auxiliary variables. The outcome variable, 
late diagnosis, was also included in the imputation model although only individuals 
with known (non-imputed) late diagnosis status were included in the analysis. The 
literature suggests that the number of imputed datasets should be at least equal to the 
proportion of incomplete cases536;538, thus 68 imputed datasets were created with 100 
burn-in imputations before the first data set. Individuals who could not be classified as 
having a timely or late diagnosis (see Section 9.3.3.1 ) were included in the imputation 
model in order to provide additional information to improve the quality of the imputed 
values. However, under the MAR assumption, the individuals with a missing outcome 
variable contribute no information to the regression of the outcome variable upon the 
covariates708, thus these individuals were excluded from the modified Poisson 
regression models. 
Prevalence of HIV testing behaviours and recent contact with health 
services by demographic and SES factors 
I decided to restrict analysis of these data to descriptive statistics. Thus, in order to 
address the secondary objective, firstly the prevalence of HIV testing behaviours and 
recent contact with health services were calculated and stratified by CD4 count at 
diagnosis (<200; 200-350; ≥350 cells/µL). Secondly, the percentage of individuals with 
each of the HIV testing behaviours and who had contacted health services in the year 
prior to diagnosis was calculated for each covariate.  
 
329 
 
 Results 
 Participant characteristics 
Of 888 first attendances at the ICDC between April 2011 and April 2015, 442 had been 
diagnosed in the previous year, were aged 18 years or older at their first visit, and 
were potentially eligible for inclusion in this analysis. Of these, 25 (6%) individuals 
were unable to be included as it was not possible to categorise their late diagnosis 
status definitively. Thus, 417 individuals were included.  
The characteristics of the individuals included are displayed in Table 9.1. As 
gender/sexual orientation was defined using self-identified sexual orientation rather 
than HIV acquisition risk, this analysis included those infected sexually (189 (45%) sex 
between men and 168 (40%) heterosexual sex) as well as by other routes (12 (3%) 
sharing syringes/needles; 17 (4%) vertical transmission; 31 (7%) other – none by 
blood transfusion).
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Table 9.1: Characteristics of individuals at the time of HIV diagnosis 2011-15 (N=417) 
 
 
 
Factors 
Complete 
case analysis  
Multiple imputation 
analysis 
%a N %a (95% CI) 
Year of diagnosis 
2011 24% 104 24% (21%, 29%) 
2012 24% 100 24% (20%, 28%) 
2013 24% 99 24% (20%, 28%) 
2014/2015 27% 114 27% (23%, 32%) 
Missing 0% 0   
Demographic factors  
Gender/sexual 
orientation 
MSM 50% 209 54%  (49%, 59%) 
MSW 18% 76 20%  (16%, 24%) 
Women 25% 105 27%  (22%, 31%) 
Missing 6% 27   
Age Median (IQR) 40 (32, 48) 40 (32, 48) Missing 0%   
Ethnicity 
White 56% 234 59%  (55%, 64%) 
Black African 23% 96 24%  (20%, 28%) 
Other 15% 64 16%  (13%, 20%) 
Missing 6% 23   
Socio-economic factors  
Employed 
Yes 63% 262 80%  (75%, 84%) 
No 16% 66 20%  (16%, 25%) 
Missing 21% 89   
Housing status 
Homeowner 18% 76 24%  (19%, 28%) 
Renting 46% 193 60%  (54%, 65%) 
Unstable/other 12% 52 16% (12%, 21%) 
Missing 23% 96   
University 
educated 
Yes 34% 140 51% (45%, 57%) 
No 29% 120 49% (43%, 55%) 
Missing 38% 157   
Social circumstance factors  
Children 
Yes 28% 117 35% (30%, 40%) 
No 51% 214 65% (60%, 70%) 
Missing 21% 86   
Partner 
Yes 46% 190 53% (47%, 58%) 
No 37% 155 47% (42%, 53%) 
Missing 17% 72   
HIV risk factors  
Reported recent 
sexual activity 
Yes 47% 197 47% (42%, 52%) 
No 53% 220 53% (48%, 58%) 
Missing c 0% 0   
Reported ever 
IDU 
Yes 6% 26 6% (4%, 9%) 
No 94% 391 94% (91%, 96%) 
Missing c 0% 0   
Likely infected 
outside the UK 
Yes 25% 105 37% (32%, 43%) 
No 48% 202 63% (57%, 68%) 
Missing 26% 110   
a Not all percentages add to 100% due to rounding; c individuals with missing values 
included in the “no” category; IDU= injection drug use; IQR=interquartile range. 
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 Late and very late diagnosis 
Prevalence of late and very late diagnosis 
Approximately half of newly diagnosed individuals were diagnosed late (206/417; 
49%); 187 as they had a CD4 count <350 cells/μL and 64 with a previous ADE (58 of 
whom had both an ADE and low CD4 count). In addition, 134/417 individuals (32%) 
were diagnosed very late; 121 with a CD4 count <200 cells/μL and 64 with a previous 
ADE. Among individuals with a recorded CD4 count within 3 months of diagnosis 
(N=402), the median was 353 cells/μL (interquartile range 133-574 cells/μL). 
Seroconversion illness was reported by 51/417 (12%) individuals and 93/417 (22%) 
had a negative HIV test within the last year. The percentages with late and very late 
diagnosis were 51% and 33%, respectively. 
The prevalence of late and very late diagnosis by calendar year of diagnosis are 
displayed in Figure 9.1. For both outcomes, there were improvements in the most 
recent years. In 2014/2015, the percentage with a late diagnoses fell from 55% in 
2013 to 38% in 2014/15 (p=0.014). Similarly 34% of diagnoses in 2013 were very late 
compared to 19% 2014/2015 (p=0.013).  
Figure 9.1: Percentage of individuals diagnosed late (CD4 <350 cells/μL a or with AIDS 
defining condition b) and diagnosed very late (CD4 <200 cells/μL a or with AIDS defining 
condition b) by calendar year of diagnosis c  
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The association of demographic, socio-economic, social circumstances, 
and HIV risk factors with late and very late diagnosis 
The prevalence of late diagnosis by each of the covariates is displayed in Figure 9.2. 
When considering demographic factors, late diagnosis was more common for MSW 
and women (compared to MSM), those of older age and those of black African 
ethnicity (compared to white/other ethnicity). I did not observe any clear differences 
according to markers of SES. For social circumstances, those with children were more 
likely to be diagnosed late, but there was no association with having a current partner. 
Considering HIV risk factors, individuals who did not report recent sexual activity and 
those with a likely source of HIV infection outside of the UK were more likely to be 
diagnosed late, whereas there was no statistically significant association with reporting 
IDU.  
The same factors were associated with a higher prevalence of very late diagnosis, but 
in addition, very late diagnosis was more common among individuals with rented or an 
unstable housing status compared to homeowners (Figure 9.3). 
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Figure 9.2: Percentage with late HIV diagnosis (CD4<350 cells/μL a or with AIDS defining condition b) by potential explanatory factors (N=417) c 
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p=0.0015d  p=0.64e p=0.76d  p<.0001d p=0.25d p=0.73d p<.0001d p<.0001d  p=0.0002e p=0.22d p<.0001d 
a Within 3 months of date of diagnosis; b before diagnosis or within one month after; c complete case analysis, for denominators refer to column one of Table 
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Figure 9.3: Percentage with very late HIV diagnosis (CD4<200 cells/μL a or with AIDS defining condition b) by potential explanatory factors (N=417) c 
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p=0.050d p=0.56d p<.0001d p=0.46d p=0.011e p=0.62d p<.0001d p=0.21d p<.0001e p=0.0003d p<.0001d 
a Within 3 months of the date of diagnosis; b before diagnosis or within one month after; c complete case analysis, for denominators refer to column one of Table 
9.1; d Chi-squared test; e Cochran-Armitage tests for trend; IDU= injection drug use. 
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The results of Figure 9.2 are also summarised in the unadjusted PRs displayed in 
Table 9.2. For example, MSW and women had over twice the prevalence of late 
diagnosis compared to MSM. After accounting for potential confounding due to 
gender/sexual orientation and age, most associations were attenuated. Heterosexual 
sexual orientation, older age, and not reporting recent sexual activity remained 
associated with a greater prevalence of late diagnosis in adjusted analyses and weak 
associations remained between late diagnosis and both likely being infected with HIV 
outside of the UK and being of black African ethnicity. In addition, an association with 
education level emerged – those who did not attend university had a 26% reduced 
prevalence of late diagnosis. 
The unadjusted and adjusted modified Poisson regression models for very late 
diagnosis are displayed in Table 9.3. For most factors, these were similar to the 
associations with late diagnosis. Of note, both of the heterosexual groups had around 
2.7 times the prevalence of very late diagnosis compared to MSM. In the analysis of 
very late diagnosis, there was evidence of an association with housing status, with 
increasing prevalence of very late diagnosis with greater housing instability: having an 
unstable housing situation was associated with twice the prevalence of very late 
diagnosis compared to homeowners. Following adjustment for gender/sexual 
orientation and age, similar attenuations were seen to those in the models for late 
diagnosis. Heterosexual orientation, older age, unstable housing situation, and not 
reporting recent sexual activity were associated with a greater prevalence of very late 
diagnosis.
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Table 9.2: Factors associated with late (CD4<350 cells/μL a or with AIDS defining 
condition b) HIV diagnosis (N=417) c  
 
 
 
Factors N d 
Unadjusted 
Adjusted for 
gender/sexual 
orientation and age 
PR 95% CI 
P-
valuee aPR 
95% 
CI 
P-
valuee 
Gender/sexual 
orientation 
MSW vs. MSM - 2.10  1.65, 2.68 <.0001 1.94  
1.52, 
2.49 <.0001 
Women vs. 
MSM - 2.01  
1.59, 
2.55  1.95  
1.54, 
2.47  
Women vs. 
MSW - 0.96 
0.78, 
1.17  1.00 
0.82, 
1.23  
Age Per 10 years 417 1.22  1.13, 1.32 
<.0001 
f 1.16  
1.07, 
1.27 0.0011
 f 
Ethnicity 
White 234 1  <.0001 1  0.11 
Black African 96 1.82  1.49, 2.21  1.29  
1.02, 
1.64  
Other 64 1.23  0.92, 1.65  1.12  
0.83, 
1.52  
Employed 
Yes 262 1  0.24 1  0.68 
No 66 1.18  0.91, 1.52  1.06  
0.82, 
1.36  
Housing status 
Homeowner 76 1  0.64f 1  0.62 f 
Renting 193 1.01  0.77, 1.34  1.04  
0.77, 
1.40  
Unstable/other 52 1.10  0.77, 1.56  1.09  
0.79, 
1.50  
University 
Yes 140 1  0.69 1  0.031 
No 120 0.95  0.73, 1.23  0.76  
0.59, 
0.98  
Children 
Yes 117 1  <.0001 1  0.35 
No 214 0.62  0.50, 0.77  1.14  
0.87, 
1.49  
Partner 
Yes 190 1  0.72 1  0.23 
No 155 1.04  0.83, 1.30  1.14  
0.92, 
1.41  
Reported recent 
sexual activity 
Yes 197 1  <.0001 1  <.0001 
No 220 1.79  1.43, 2.17  1.54  
1.25, 
1.92  
Reported ever 
IDU 
Yes 26 1  0.24 1  0.40 
No 391 1.30  0.79, 2.13  1.22  
0.75, 
1.96  
Likely infected 
outside the UK 
Yes 105 1  0.0019 1  0.092 
No 202 0.67  0.53, 0.85  0.81  
0.63, 
1.03  
a Within 3 months of diagnosis; b before diagnosis or within one month after; c using 
complete case analysis, for numbers missing for each variable refer to column one of Table 
9.1; d number included in each model is different; e likelihood ratio test; f Cochran-Armitage 
test for trend; PR= prevalence ratio; aPR= adjusted prevalence ratio; IDU= injection drug 
use. 
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Table 9.3: Factors associated with very late (CD4<200 cells/μL a or with AIDS defining 
condition b) HIV diagnosis (N=417) c 
 
 
 
 
 
 
 
 
Factors N d 
Unadjusted Adjusted for gender/sexual orientation and age 
PR 95% CI P-valuee aPR 95% CI 
P-
valuee 
Gender/s
exual 
orientatio
n 
MSW vs. 
MSM - 2.67 1.83, 3.89 <.0001 2.39  1.63, 3.50 <.0001 
Women vs. 
MSM - 2.68  1.88, 3.83  2.57  1.81, 3.67  
Women vs. 
MSW - 1.01 0.74, 1.37  1.08 0.79, 1.47  
Age Per 10 years 417 1.33  1.20, 1.49 
<.0001 
f 1.24  1.10, 1.39 
0.0011 
f 
Ethnicity 
White 234 1  0.0007 1  0.62 
Black 
African 96 1.87  1.40, 2.51  1.15  0.81, 1.64  
Other 64 1.16  0.76, 1.77  0.96  0.62, 1.51  
Employed Yes 262 1  0.24 1  0.70 No 66 1.18  0.91, 1.52  1.08  0.73, 1.60  
Housing 
status 
Homeowne
r 76 1  0.012
 f 1  0.021 f 
Renting 193 1.50  0.91, 2.48  1.69  0.99, 2.88  
Unstable/ot
her 52 2.05  1.17, 3.59  2.19  1.25, 3.83  
University Yes 140 1  0.64 1  0.21 No 120 1.10  0.74, 1.63  0.78  0.53, 1.15  
Children Yes 117 1  0.0001 1  0.42 No 214 0.51  0.36, 0.70  1.20  0.77, 1.85  
Partner Yes 190 1  0.45 1  0.12 No 155 1.14  0.82, 1.59  1.32  0.93, 1.85  
Reported 
recent 
sexual 
activity 
Yes 197 1  <.0001 1  0.0001 
No 220 2.27 1.64, 3.13  1.82  1.32, 2.56  
Reported 
ever IDU 
Yes 26 1  0.54 1  0.85 
No 391 1.20  0.63, 2.33  1.06  0.55, 2.04  
Likely 
infected 
outside 
the UK 
Yes 105 1  0.060 1  0.52 
No 202 0.69  0.48, 1.00  0.88  0.61, 1.28  
a Within 3 months of diagnosis; b before diagnosis or within one month after; c using 
complete case analysis, for numbers missing for each variable refer to column one of Table 
9.1; d number included in each model is different; e likelihood ratio test; f Cochran-Armitage 
test for trend; PR= prevalence ratio; aPR= adjusted prevalence ratio; IDU= injection drug 
use. 
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Gender/sexual orientation subgroup analyses 
Table 9.4 presents the factors associated with late diagnosis in the subgroups of MSM 
and of MSW and women. In the subgroup of MSM, late diagnosis was more prevalent 
among individuals who were older, but the only other factor with evidence of an 
association was recent sexual activity. In the heterosexual subgroup, there was 
evidence of an association of late diagnosis with older age, unstable housing status, 
university education, having no current partner, and recent sexual activity. 
Table 9.4 also presents the factors associated with very late diagnosis in the 
subgroups of MSM and of MSW and women. For both subgroups, the results were 
very similar as those seen for late diagnosis. Of note, unstable housing status was 
strongly associated with a higher prevalence of very late diagnosis among 
heterosexual individuals.
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Table 9.4: Gender/sexual orientation subgroup analysis: factors associated with prevalence of late (CD4<350 cells/μL a or with AIDS defining condition 
b) and very late (CD4<200 cells/μL a or with AIDS defining condition b) HIV diagnosis c 
 
MSM (N=209) MSW and women (N=181) 
N 
Late diagnosis Very late diagnosis 
N 
Late diagnosis Very late diagnosis 
aPRd 95% CI P-valuee aPR
d 95% CI P-valuee aPR
f 95% CI P-valuee aPR
f 95% CI P-valuee 
Age Per 10 years 209 1.28  1.10, 1.49 
0.0040 
g 1.37  1.10, 1.69 0.016
 g 181 1.09 0.99, 1.20 0.087 g 1.17 1.02, 1.35 0.027 g 
Employed Yes 145 1  0.56 1  0.64 109 1  0.90 1  0.94 No 31 1.17  0.70, 1.95  1.23  0.55, 2.72  32 0.98 0.74, 1.30  1.02 0.65, 1.58  
Housing 
status 
Homeown
er 48 1  0.50
 g 1  0.14 g 25 1  0.059 g 1  0.0095 g 
Renting 101 1.04  0.63, 1.71  2.29  0.85, 6.21  84 1.09 0.77, 1.53  1.46 0.79, 2.71  
Unstable/
other 24 0.62  0.23, 1.71  2.15  0.52, 8.99  28 1.35 0.96, 1.89  2.15 1.15, 4.00  
University Yes 97 1  0.22 1  0.86 41 1  0.059 1  0.074 No 61 0.76  0.48, 1.20  1.07  0.50, 2.29  55 0.77 0.59, 1.01  0.69 0.45, 1.03  
Children Yes 15 1  0.73 1  0.16 95 1  0.30 1  0.066 No 158 0.88  0.45, 1.75  0.45 0.19, 1.03  52 1.15 0.88, 1.52  1.49 0.99, 2.27  
Partner Yes 91 1  0.56 1  0.23 92 1  0.0062 1  0.0021 No 93 0.88  0.58, 1.35  0.65 0.33, 1.32  57 1.35 1.10, 1.67  1.82 1.27, 2.63  
Reported 
recent 
sexual 
activity 
Yes 119 1  0.030 1  0.21 75 1  0.0001 1  <.0001 
No 90 1.54  1.04, 2.27  1.45 0.81, 2.63  106 1.59 1.23, 2.00  2.13 1.43, 3.23  
Reported 
ever IDU 
Yes 17 1  0.68 1  0.56 9 1  0.41 1  0.36 
No 192 1.15 0.56, 2.38  0.75  0.32, 1.75  172 1.27 0.69, 2.33  1.49 0.57, 3.85  
Likely 
infected 
outside 
the UK 
Yes 43 1  0.48 1  0.48 61 1  0.11 1  0.85 
No 138 0.83  0.51, 1.35  0.76  0.37, 1.56  57 0.81 0.62, 1.05  1.04 0.69, 1.56  
a Within 3 months of the date of diagnosis; b before diagnosis or within one month after; c complete case analysis so number included in each model is different 
due to different levels of missing data; d adjusted for age; e likelihood ratio test; f adjusted for age and gender; g Cochran-Armitage test for trend; aPR= 
adjusted prevalence ratio; IDU= injection drug use. 
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Multiple imputation sensitivity analysis  
Data on gender, sexual orientation, ethnicity, employment status, housing status, 
education, children, current partner, and likely country of infection were missing for 
between 6% and 38% of individuals (Table 9.1). Of the 417 individuals included in the 
analysis, 220 (53%) were missing information on at least one explanatory variable and 
276 (66%) were missing information on at least one variable included in the imputation 
model. The criteria on the MC errors specified in Section 9.3.5 were met. In addition, 
the MC errors of the p values were sufficiently low that additional imputations would be 
unlikely to change the results of the tests.  
As the outcome variable was not imputed, the proportions diagnosed late, (206/417 
[49%]; 95% CI: 45%, 54%), and very late (134/417 [32%]; 95% CI: 28%, 37%) were 
identical to the complete case analyses. The characteristics of the individuals included 
in the analysis following multiple imputation are shown in the last column of Table 9.1.  
Figure 9.4 shows the proportion diagnosed late by each covariate. These results were 
comparable to those when complete case analysis was used. Similarly, the results of 
the analysis for very late diagnosis were consistent with complete case analysis 
(Figure 9.5). 
The PRs calculated from modified Poisson regression models of the multiply imputed 
data are consistent with those seen in the complete case analysis for both late and 
very late diagnosis (Table 9.5 and Table 9.6). 
341 
 
  
Figure 9.4: Multiple imputation analysis: percentage with late HIV diagnosis (CD4<350 cells/μLa or with AIDS defining conditionb) by potential 
explanatory factors (N=417) 
a Within 3 months of diagnosis; b before diagnosis or within one month after; IDU= injection drug use. 
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Figure 9.5: Multiple imputation analysis: percentage with very late HIV diagnosis (CD4<200 cells/μLa or with AIDS defining conditionb) by potential 
explanatory factors (N=417) 
a Within 3 months of diagnosis; b before diagnosis or within one month after; IDU= injection drug use. 
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Table 9.5: Multiple imputation analysis: factors associated with late (CD4<350 cells/μL a 
or with AIDS defining condition b) HIV diagnosis (N=417) 
 
 
 
Factors Unadjusted 
Adjusted for gender/sexual 
orientation and age 
PR 95% CI P-valuec aPR 95% CI P-valuec 
Gender/s
exual 
orientatio
n 
MSW vs. MSM 2.11  1.66, 2.67 <0.0001 1.93  1.52, 2.45 <0.0001 
Women vs. 
MSM 
2.00  1.58, 2.52  1.93  1.53, 2.43  
Women vs. 
MSW 
0.95 0.78, 1.16  1.00 0.82, 1.22  
Age Per 10 years 1.22  1.13, 1.32 <0.0001
 d 1.17  1.08, 1.27 <0.0001 
d 
Ethnicity 
White 1  <0.0001 1  0.12 
Black African 1.77  1.45, 2.17  1.27  1.01, 1.61  
Other 1.24  0.92, 1.65  1.09  0.81, 1.47  
Employed Yes 1  0.21 1  0.57 No 1.18  0.91, 1.51  1.07  0.84, 1.36  
Housing 
status 
Homeowner 1  0.70 d 1  0.51 d 
Renting 1.00  0.77, 1.30  1.06  0.81, 1.39  
Unstable/other 1.07  0.76, 1.51  1.12  0.80, 1.55  
University Yes 1  0.86 1  0.062 No 0.98  0.76, 1.25  0.79  0.62, 1.01  
Children Yes 1  <0.0001 1  0.60 No 0.63 0.52, 0.77  1.08  0.83, 1.37  
Partner Yes 1  0.75 1  0.19 No 1.04  0.83, 1.28  1.15  0.93, 1.41  
Reported 
recent 
sexual 
activity 
Yes 1  <0.0001 1  0.0001 
No 
1.79  1.43, 2.22  1.56  1.25, 1.92  
Reported 
ever IDU 
Yes 1  0.30 1  0.43 
No 1.30  0.79, 2.13  1.22  0.75, 1.96  
Likely 
infected 
outside 
the UK 
Yes 1  0.0013 1  0.15 
No 
0.69  0.55, 0.86  0.85  0.68, 1.06  
a Within 3 months of diagnosis; b before diagnosis or within one month after; c Chi-squared 
test; d test for trend; PR= prevalence ratio; aPR= adjusted prevalence ratio; IDU= injection 
drug use. 
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Table 9.6: Multiple imputation analysis: factors associated with very late (CD4<200 
cells/μL a or with AIDS defining condition b) HIV diagnosis (N=417) 
 
Factors Unadjusted 
Adjusted for gender/sexual 
orientation and age 
PR 95% CI P-valuec aPR 95% CI P-valuec 
Gender/s
exual 
orientatio
n 
MSW vs. MSM 2.67  1.85, 3.86 <0.0001 2.34  1.62, 3.39 <0.0001 
Women vs. 
MSM 
2.63  1.86, 3.73  2.50  1.76, 3.53  
Women vs. 
MSW 
0.99 0.73, 1.33  1.07 0.79, 1.44  
Age Per 10 years 1.34  1.20, 1.49 <0.0001
 d 1.27  1.14, 1.42 <0.0001 
d 
Ethnicity 
White 1  0.0002 1  0.66 
Black African 1.86  1.38, 2.50  1.13  0.80, 1.58  
Other 1.16  0.75, 1.77  0.95  0.61, 1.46  
Employed Yes 1  0.18 1  0.49 No 1.28  0.89, 1.83  1.13  0.80, 1.57  
Housing 
status 
Homeowner 1  0.029 d 1  0.0061 d 
Renting 1.35  0.87, 2.10  1.54  1.00, 2.37  
Unstable/other 1.74  1.05, 2.89  1.95  1.18, 3.21  
University Yes 1  0.39 1  0.53 No 1.17  0.81, 1.69  0.89  0.61, 1.29  
Children Yes 1  <0.0001 1  0.78 No 0.52 0.39, 0.70  1.06 0.71, 1.56  
Partner Yes 1  0.41 1  0.10 No 1.15  0.83, 1.59  0.77  0.95, 1.79  
Reported 
recent 
sexual 
activity 
Yes 1  <0.0001 1  0.0002 
No 
2.27  1.64, 3.13  0.54  1.35, 2.56  
Reported 
ever IDU 
Yes 1  0.57 1  0.81 
No 1.20  0.63, 2.33  0.92  0.56, 2.08  
Likely 
infected 
outside 
the UK 
Yes 1  0.029 1  0.59 
No 
0.69  0.49, 0.96  1.09  0.66, 1.27  
a Within 3 months of diagnosis; b before diagnosis or within one month after; c Chi-squared 
test; d test for trend; PR= prevalence ratio; aPR= adjusted prevalence ratio; IDU= injection 
drug use. 
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 HIV testing behaviours and recent contact with health services 
This section focussed on the prevalence of HIV testing behaviours and recent contact 
with health services by demographic, socio-economic, social circumstances, and HIV 
risk factors with the aim of gaining understanding of why late diagnosis is more 
prevalent in certain groups.  
Missing data 
Table 9.7 shows the percentage of individuals without a response recorded for the 
seven indicators of HIV testing behaviours and recent contact with health services. 
The testing factors were relatively well completed, with between 66% and 79% having 
a completed response. In contrast, the health services questions were not well 
completed – between 35% and 45% had a response recorded.  
 
Table 9.7: Percentage missing for each HIV testing behaviour and recent contact with 
health services variable  
 
  
 
 
 
 
 
 
 
 
 
In addition, individuals with a missing response to whether they had had a previous 
HIV test were more likely to have been diagnosed with a CD4 count <350 cells/µL 
(67% vs. 45%; p=0.0001). Also, individuals with a missing response to the question on 
who had prompted their first positive HIV test tended to have been diagnosed with a 
CD4 count <350 cells/µL (59% vs. 47%; p=0.053).  
 
 % a N 
HIV testing behaviour factors  
Ever negative HIV test Yes 56% 234 
No 23% 94 
Missing 21% 89 
HIV test self-prompted Yes 45% 188 
No 34% 142 
Missing 21% 87 
Diagnosed in a GU clinic Yes 27% 114 
No 39% 162 
Missing 34% 141 
Contact with health services in the last year  
Offered an HIV test Yes 9% 36 
No 26% 109 
Missing  65% 272 
Attended a PC clinic Yes 27% 112 
No 17% 72 
Missing 56% 233 
Attended a GU clinic Yes 10% 42 
No 29% 122 
Missing 60% 253 
Attended A&E Yes 10% 43 
No 31% 129 
Missing 59% 245 
a Not all percentages add to 100% due to rounding; PC= primary care; GU= genitourinary; 
A&E= accident and emergency department. 
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HIV testing behaviours  
Of those with a recorded response, 94/328 (29%) reported that they had not previously 
been tested for HIV. In addition, 142/330 (43%) reported that their HIV test was 
recommended by a healthcare professional or other source rather than self-prompted. 
Finally, 114/276 (41%) reported that they had been diagnosed in a GU clinic. Other 
locations of diagnoses included: 44 (16%) at PC centres; 22 (8%) in A&E; eight (3%) 
in antenatal care or a fertility clinic; seven (3%) in a chest or Tuberculosis clinic; two 
(1%) in a Hepatology clinic; nine (3%) in an infectious disease clinic; 27 (10%) in other 
hospital clinics; and 43 (16%) reported other locations.  
A wide range of other factors were also associated with not previously testing for HIV 
and not self-prompting for an HIV test (Table 9.8). Those without a previous test and 
those who did not self-prompt were more likely to be: a heterosexual man or woman, 
over the age of 30 and particularly over 50 years old, of black African ethnicity 
compared to white ethnicity, not be employed, have an unstable housing situation 
compared to being a homeowner, not have a university education, have children, not 
report recent sexual activity, and likely infected outside the UK. Individuals of other 
ethnicity and individuals in rented accommodation were also less likely to self-prompt 
their HIV test than individuals of white ethnicity and homeowners, respectively. Being 
tested for HIV in a location other than a GU clinic was associated with: being a 
heterosexual man or woman, older age, black African ethnicity compared to white 
ethnicity, not being employed, having children, not reporting recent sexual activity, not 
reporting a history of IDU, and likely infected outside the UK. 
CD4 cell count at diagnosis was strongly associated with all three markers of test 
seeking behaviour (Table 9.8); lower CD4 counts were associated with a much higher 
prevalence of not having had a previous HIV test not self-prompting an HIV test and 
not being diagnosed in a GU clinic. 
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Recent contact with health services 
In the 12 months before their HIV diagnosis, 109/145 (75%) reported that they had not 
been offered an HIV test, 112/184 (61%) individuals reported that they attended a PC 
clinic, 42/164 (26%) individuals reported attendance to a GU clinic, and 43/172 (25%) 
individuals reported attendance at A&E.  
A number of demographic factors were associated with having been in contact with 
health services in the year prior to diagnosis, with associations consistent with those 
for HIV testing behaviours (Table 9.9). Three of the outcome markers used (not being 
offered a test, attending a PC clinic and attending A&E in the previous 12 months) 
displayed similar associations. These were more common among: MSW and women 
compared to MSM, individuals over 50 years old compared to younger than 30 years, 
individuals renting or with an unstable housing situation compared to homeowners, 
non-university educated individuals, and individuals with children. In addition, 
individuals reporting recent sexual activity and those born in the UK were more likely 
to have been offered an HIV test. Attending primary care or A&E was associated with 
non-white ethnicity. 
In contrast, the associations between potential predictive factors and being seen in a 
GU clinic were very different. Attendance in the previous 12 months were more 
common amongst: MSM, those of white or other ethnicity, individuals <30 years old, 
homeowners and unstably housed individuals, individuals with a university education, 
individuals without children, individuals without a current partner, individuals who 
reported recent sexual activity, individuals who reported a history of IDU, and 
individuals likely infected in the UK.  
Ninety-four percent of those diagnosed with HIV with a CD4 count <200 cells/µL had 
not been offered an HIV test in the last 12 months (Table 9.9). A very high proportion 
of those with low CD4 counts at diagnosis had interactions with healthcare in the year 
prior to diagnosis; 75%, 13%, and 32% of individuals with a CD4 count <200 cells/µL 
had attended a PC clinic, GU clinic or A&E in the 12 months before diagnosis, 
respectively. For PC this percentage was significantly higher than that seen for 
individuals with higher CD4 counts at diagnosis.
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Table 9.8: Factors associated with HIV testing behaviours a 
 
 
Factor No previous negative HIV test HIV test not self-prompted Not diagnosed in GU clinic 
N b % c P-valued N b % c P-valued N b % c P-valued 
Gender/sexual orientation 
MSM 19/183 10% <.0001 45/179 25% <.0001 62/140 44% <.0001 
MSW 32/57 56%  45/65 69%  44/57 77%  
Women 41/77 53%  47/76 62%   51/64 80%  
Age 
<30 years 10/72 14% <.0001 e 16/66 24% 0.0003 e 25/55 45% 0.019 e 
30-50 years 52/194 27%  87/196 44%  94/158 59%  
≥50 years 32/62 52%  39/68 57%   43/63 68%  
Ethnicity 
White 40/192 21% <.0001 67/192 35% 0.0004 80/153 52% 0.015 
Black African 34/68 50%  44/72 61%  47/64 73%  
Other 15/48 31%  25/50  50%   24/43 56%  
Employed Yes 62/238 26% 0.10 99/245 40% 0.017 114/196 58% 0.087 No 22/60 37%  36/63 57%   39/55 71%  
Housing status 
Homeowner 15/69 22% 0.019 e 26/72 36% 0.078 e 32/56 57% 0.35 e 
Renting 49/172 28%  79/178 44%  90/148 61%  
Unstable/other 21/50 42%  26/50 52%   28/42 67%  
University Yes 21/128 16% 0.0001 41/137 30% 0.0007 56/103 54% 0.32 No 43/111 39%  58/114 51%   63/103 61%  
Children Yes 52/93 56% <.0001 64/103 62%  <.0001 66/91 73% 0.0041 No 39/206 19%  69/206 34%  86/159 54%  
Partner Yes 48/166 29% 0.96 74/173  43%  0.93 84/137 61% 0.79 No 42/144 29%  64/148 43%  74/124 60%  
Reported recent sexual activity Yes 43/180 24% 0.035 71/183 39%  0.083 76/144 53% 0.037 No 51/148 34%  71/147 48%  86/132 65%  
Reported ever IDU Yes 8/22 36% 0.41 9/23  39%  0.70 10/22 45% 0.19 No 86/306 28%  133/307 43%  152/254 60%  
Likely infected outside the UK Yes 35/91 38% 0.0024 52/99 53%  0.0045 58/77 75% 0.0010 No 39/184 21%  65/185 35%  79/150 53%  
CD4 count at diagnosis <200 42/82 51% <.0001
 e 66/89 74% <.0001 e 65/82 79% <.0001 e 
200-349 21/60 35%  25/63 40%  32/52 62%  
 ≥350 30/173 17%  51/166 31%  62/135 46%  
a Individuals with missing values for each HIV testing behaviour factor and explanatory variable were excluded for their cross-tabulation; b number included in 
each model is different due to different levels of missing data; c percentages do not necessarily add to 100% due to rounding; d Chi-squared test; e Cochran-
Armitage test for trend; GU= genitourinary; IDU= injection drug use. 
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Table 9.9: Factors associated with contact with health services in the last year a 
Factors Not offered an HIV test Seen at a PC setting Seen at a GU clinic Seen at A&E 
N b % c P-valued N b % c P-valued N b % c P-valued N b % c P-valued 
Gender/sexual 
orientation 
MSM 43/69 62% 0.0044 50/95 53% 0.011 36/84 43% <.0001 18/90 20% 0.26 
MSW 29/35 83%  27/41 66%  1/36 3%  13/39 33%  
Women 33/37 89%   34/43 79%  5/39 13%  10/39 26%  
Age 
<30 years 19/29 66% 0.023 e 22/40 55% 0.045 e 17/37 46% 0.0082 e 12/38 32% 0.41 e 
30-50 years 63/86 73%  64/110 58%  20/94 21%  19/101 19%  
≥50 years 27/30 90%   26/34 76%  5/33 15%  12/33 36%   
Ethnicity 
White 56/78 72% 0.79 60/105 57% 0.25 31/95 33% 0.021 21/101 21% 0.32 
Black African 28/36 78%  31/44 70%  3/35 9%  12/37 32%  
Other 15/20  75%   17/25 68%  6/24 25%  7/24 29%   
Employed Yes 87/117 74% 0.40 87/146 60% 0.40 34/132 26% 0.99 35/139 25% 0.63 No 19/23 82%   21/31 68%  7/27 26%  8/27 30%   
Housing status 
Homeowner 21/33 64% 0.17 e 23/38 61% 0.29 e 13/38 34% 0.71 e 5/37 14% 0.0078 e 
Renting 63/81 78%  60/105 57%  17/92 18%  24/99 24%  
Unstable/other 18/23 78%   23/31 74%  9/27 33%  12/28 43%   
University Yes 38/57 67% 0.099 41/74 55% 0.082 27/67 40% 0.0013 14/70 20% 0.12 No 45/56 80%   46/66 70%  9/61 15%  20/63 32%   
Children Yes 41/49 84%  0.070 43/59 73% 0.043 4/54 7% 0.0004 19/55 35%  0.049 No 62/89 70%  67/117 57%  34/103 33%  22/108 20%  
Partner Yes 62/82  76%  0.76 58/96 60% 0.87 15/89 17% 0.0063 24/93 26%  0.71 No 44/60 73%  53/86 62%  26/73 36%  18/77 23%  
Reported recent 
sexual activity 
Yes 55/83  66%  0.0041 64/107 60% 0.73 35/99 35% 0.0004 26/105 25%  0.93 
No 54/62 87%  48/77 62%  7/65 11%  17/67 25%  
Reported ever 
IDU 
Yes 7/9  78%  0.85 7/11 64% 0.85 5/10 50% 0.068 2/10 20%  0.71 
No 102/136 75%  105/173 61%  37/154 24%  41/162 25%  
Likely infected 
outside the UK 
Yes 35/40 88%  0.0082 30/49 61% 0.83 7/44 16% 0.027 12/47 26%  0.84 
No 53/82 65%  68/108 63%  33/97 34%  24/100 24%  
CD4 count at 
diagnosis 
<200 49/52 94% 0.0001 e 44/59 75% 0.032 e 7/54 13% 0.0019 e 17/53 32% 0.43 e 
200-349 19/27 70%  17/35 49%  5/28 18%  4/32 13%  
≥350 41/65 63%  49/88 56%  29/80 36%  21/85 25%  
a Individuals with missing values for each missed opportunities factor and explanatory variable were excluded for their cross-tabulation; b number included in 
each model is different due to different levels of missing data; c percentages do not necessarily add to 100% due to rounding; d Chi-squared test; e Cochran-
Armitage test for trend; PC= primary care; GU= genitourinary; A&E= accident and emergency department; IDU= injection drug use. 
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 Discussion 
 Summary of results 
 Despite reductions in the proportion diagnosed late over time, late diagnosis of 
HIV continues to be a major problem in the UK543. In our cohort, CD4 count at 
diagnosis was improved in 2014-15 compared to 2011-2013; however, the 
prevalence of late and very late diagnosis remained high.  
 There were substantial differences in the prevalence of late diagnosis between 
demographic groups, in particular, MSW and women had over twice the 
prevalence of late and very late diagnosis compared to MSM.  
 As socio-economic factors are infrequently collected in a routine clinic setting, 
to my knowledge this is the first UK-study to look at the association of socio-
economic disadvantage with late HIV diagnosis. Unlike the considerable socio-
economic disparities in virological response to treatment across all markers 
considered in Chapter 6, late and very late diagnosis were not consistently 
associated with SES across all three markers. Individuals with unstable 
housing status had over two times the prevalence of very late diagnosis 
compared to homeowners and individuals without a university level education 
had 0.76 times the prevalence of late diagnosis compared to those with 
university level education. However, the inconsistency between findings from 
various SES markers and between the two late diagnosis definitions mean that 
these results should be interpreted with caution. It is possible that housing 
status will affect late diagnosis due to practical barriers, such as not being 
registered with a GP, rather than because of poorer SES. 
 MSW and women were less likely to have had a previous HIV test, to self-
prompt their first positive HIV test and to be diagnosed at a GU clinic than 
MSM. These are indications of HIV-related health-seeking behaviour and/or 
greater awareness of risk of HIV acquisition699;700, and risk of STI acquisition 
generally709, among MSM. Additionally, despite being more likely to have been 
seen in a primary care setting, MSW and women were less likely to have been 
offered an HIV test. This is indicative of greater missed opportunities for an 
earlier HIV diagnosis, among heterosexual individuals. Lower SES was 
associated with being less likely to have had a previous HIV test and less likely 
to self-prompt a HIV test.  
 Interpretation of results 
The overall percentage with late diagnosis in the study population was high, which has 
clinical implications at the individual-level. In particular, the high percentage with CD4 
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count <200 cells/µL is likely to lead to significant morbidity since AIDS events are more 
likely once CD4 count has fallen below 200 cells/µL710-712. Furthermore, it is now 
recommended that ART be initiated as soon as possible rather than waiting for CD4 
counts to fall below a certain threshold136-138, so individuals diagnosed late will be at a 
greater disadvantage in terms of starting ART as their infection is at a more advanced 
stage.  
The similar prevalence of late diagnosis among MSW and women could suggest the 
observed gender/sexual orientation disparities in late diagnosis were more of a cultural 
or demographic issue rather than a gender effect. In the UK there is a much lower 
overall prevalence of HIV in heterosexual population (even among black African 
heterosexuals) than in MSM population208 (see Section 1.4.2.1 , so there may be less 
awareness of the risks of HIV in the heterosexual population. Other factors which may 
go some way to explaining some of the observed differences include increased health 
literacy among white MSM compared to black African heterosexuals713, and a larger 
percentage of migrants in the heterosexual group, which in turn is associated with a 
number of barriers to HIV diagnosis217;692;694.  
The patterns of use of healthcare services in the year prior to diagnosis were different 
for MSM and heterosexual groups. MSM were much more likely to have engaged with 
GU clinics than heterosexual groups, who in turn were more likely to have engaged 
with primary care and accident and emergency care. This lends further support that 
the differences in timing of diagnoses observed are likely due to cultural differences 
between gender/sexual orientation groups rather than gender differences. 
Furthermore, these findings indicate that primary care and accident and emergency 
departments may be the most appropriate places to try to increase testing among 
heterosexual groups.  
When assessing the association between late diagnosis and the three markers of SES 
in this study, there were mixed results in different directions between the measures. In 
addition, increasing housing instability was associated with very late HIV diagnosis but 
not late diagnosis. Thus, it is difficult to interpret the relationship between SES and 
timing of HIV diagnosis. It is possible that the markers are measuring different things, 
for example, educational level may affect late diagnosis through perceived risk 
whereas housing status may operate through access to healthcare714;715. It is possible 
that there is an association between housing status and late diagnosis as well as very 
late diagnosis, but that this was not detected due to lack of statistical power. 
Furthermore, there was evidence in the gender/sexual orientation subgroup analyses 
that housing status was an important factor among heterosexuals but not MSM. There 
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seemed to be some effect modification by sexual orientation for university education, 
with a borderline statistically significant association between having university-level 
education and a greater prevalence of late diagnosis among the heterosexual 
subgroup and not among MSM. Potentially this could be related to a greater 
prevalence of migrants among the heterosexual individuals, who despite university-
level education may not have a “university-level” job once a migrant. This corresponds 
with our results in Chapter 8, where socio-economic factors were more able to explain 
poorer virological response to ART among women compared to MSM. An interaction 
between gender/sexual orientation and socio-economic factors with respect to late 
diagnosis may have masked the importance of SES among the heterosexual 
subgroup. 
Lower SES (by all three markers) was associated with being less likely to have had a 
previous HIV test or self-prompt the first positive HIV test. Furthermore, each lower 
SES group had a lower percentage of individuals offered an HIV test in the year prior 
to diagnosis, although there was not a statistically significant association. There was 
no difference in usage of various healthcare settings in the year prior to diagnosis by 
employment status. However, unstably housed individuals were more likely to have 
attended accident and emergency departments, and individuals without a university 
level education were less likely to have attended a GU clinic and more likely to have 
attended a primary care setting. These observed differences in engagement with 
healthcare services indicate that interventions to target HIV testing among socio-
economically disadvantaged individuals would be best placed at emergency 
departments or primary care settings.  
Very high percentages of individuals who were diagnosed with a CD4 count <200 
cells/µL had never previously tested for HIV (51%) and had not self-presented for their 
positive test result (74%), which suggests that individual-level factors are important 
drivers of late diagnosis. Possible reasons for lack of self-prompting an HIV test may 
include lack of perceived risk of HIV infection716;717, fear of stigma or the consequences 
of a positive result716-718, or lack of awareness of the need for regular HIV testing. 
Although 94% of individuals diagnosed with a CD4 count <200 cells/µL had not been 
offered an HIV test in the year prior to diagnosis, a large percentage reported having 
had interactions with primary care in the year prior to HIV diagnosis (75%). This could 
indicate that many instances of late diagnosis were due to missed opportunities in 
primary care settings, meaning that efforts to increase routine testing in this setting 
may be most effective.  
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Other than heterosexual sexual orientation, factors strongly associated with a greater 
prevalence of late or very late diagnosis were not being sexually active in the previous 
three months and likely acquiring HIV outside of the UK. The former suggests that 
lower perceived risk of HIV infection is likely a key barrier to achieving a timely 
diagnosis, while the latter may reflect testing in the respective country of HIV 
acquisition. 
 Strengths and limitations 
In London in 2014, 33% of new diagnoses were with a CD4 count <350 cells/µL543. 
This was consistent with the present analysis, which found that 36% of people 
diagnosed in 2014 were diagnosed late (or 38% of individuals diagnosed in 2014/2015 
as shown in Figure 9.1). Late and very late diagnoses in our cohort were reduced in 
the most recent years; similarly to the HIV-positive population across the UK. This was 
likely a result of increased testing, among MSM in particular210. In our cohort the 
proportions of individuals newly diagnosed with HIV by gender/sexual orientation, 
ethnicity and age were comparable to those found among the general population in the 
UK in 2014210. Thus, the data used in these analyses are, overall, a representative 
sample of the UK HIV positive population, so the conclusions made are likely 
applicable to the wider setting.  
Although there was a large proportion of missing data in this chapter, there was data 
on each socio-economic factor available for at least 62% of individuals. Since 
information is not routinely available on SES, then there is still value in the results of 
an analysis that has any data on socio-economic factors in a routine care setting. It is 
particularly useful with regard to conclusions around associations with SES since, as 
mentioned in the previous paragraph, the study population is generally a 
representative sample of the UK HIV positive population. 
Date of infection was not recorded, so CD4 count may be considered a proxy for time 
since infection for defining late diagnosis in this chapter. This is generally standard 
practice and it is defined in this way by the Consensus Working Group definition704. 
Furthermore, there was not a better marker available in this study. However, due to 
the variable nature of the decline in CD4 count in the absence of treatment, individuals 
in the “not late” group may actually have been infected a considerable time ago. Thus, 
they may have been exposed to viraemia and increased immune activation for long 
periods of time, which could have adverse clinical implications. This may also have 
issues from a public health point of view with respect to onwards transmission. 
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Since the recommendation is now to start ART as soon as the individual is ready, 
rather than when CD4 count has fallen to <350 cells/μL138;139, considering anyone with 
a CD4 count above this level without an ADE as not diagnosed late may no longer be 
intuitive. The Consensus Working Group definition was defined before these new 
treatment recommendations, but it is possible that it is no longer relevant. However, 
one would need to collect data on seroconversion in order to define late diagnosis 
without using CD4 count as a marker, and such data was not available in the present 
study. 
Prior to 2010, late diagnosis had been defined inconsistently in terms of different CD4 
count cut-offs and clinical criteria. Since the European Late Presenter Consensus 
working group proposed in 2010 that “late diagnosis” be defined as a CD4 count <350 
cells/μL at diagnosis, and “diagnosis at an advanced stage” to be a diagnosis with a 
CD4 count <200 cells/μL or with an AIDS defining event (ADE)704, many studies have 
used these definitions111;688-690;719;720. Late diagnosis was defined in this way as it was 
based upon the CD4 count at which guidelines at the time stated that cART should be 
initiated. However, since 2015, guidelines recommend that cART be started as soon 
after diagnosis that an individual is ready to start136-138, thus the current definition is 
now perhaps more arbitrary. In addition, an important limitation of the above definitions 
is that as the very early stages of HIV infection are often associated with sizable 
temporary declines in CD4 count6, so individuals diagnosed during primary HIV 
infection may be subject to misclassification when using CD4 count alone to define 
late diagnosis705. In future studies it may be pertinent to consider individuals in primary 
infection (as defined by seroconversion symptoms or a recent negative HIV test) as 
not diagnosed late regardless of CD4 count. 
It is possible that some individuals attending the Royal Free Hospital for HIV care 
between April 2011 and April 2015 will not have been included in the study population. 
If an individual did not have a completed Patient Registration Form, or it was not 
entered into the electronic system, then I did not have any data on them to include 
them in the study. However, I believe that this is unlikely to be an issue because it is a 
requirement for this form to be completed for national surveillance purposes. 
Individuals attending the Royal Free Hospital as an outpatient who either died shortly 
after HIV diagnosis or who died before attaining a diagnosis could have been missed 
from this analysis. It is not possible to estimate the extent to which this may affect my 
results.  
Another limitation of this analysis was the proportion of missing data, although 
complete case (CC) analysis and multiple imputation (MI) analyses both provided 
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consistent results. The covariates were assumed missing at random (MAR) as it is not 
possible to rule out that they were in fact missing not at random (MNAR). Since the 
forms were clinician-completed, it is unlikely that an individual’s characteristics and 
testing behaviours themselves were related to why they were not completed. Thus, 
although it was not possible to rule out that the missing data mechanism was MNAR, 
this was unlikely to be the case. Being diagnosed with a CD4 count <200 cells/μL was 
associated with having missing values for the explanatory variables. Thus, it is likely 
that one reason the patient registration forms were not fully completed was that the 
individual was ill or in need of treatment, so clinician’s had other clinical priorities.  
There was missing data for 54-65% of the four recent contact with health services 
variables therefore any imputed values for these variables would have been subject to 
greater uncertainty. The larger the proportion of missing data, the less likely it 
becomes that the data are MAR, and more likely that they are MNAR. In order to 
analyse MNAR data it would have been necessary to have knowledge of the reasons 
that the data were missing. Without this information, it was not possible to conduct CC 
or MI analyses for these variables, and instead only raw percentages of the individuals 
with recorded information could be considered.  
The power to detect associations was limited in this chapter by the relatively few 
events in the data (206 late diagnoses and 134 very late diagnoses), particularly when 
considering the relatively low proportion of MSW in the study. This was demonstrated 
by some reasonably wide confidence intervals. Completing forms with detailed 
questions on SES and other factors is time consuming which could lead to a loss of 
data, however, gaining this detailed information is vital to understanding the reasons 
for delays in, and missed opportunities for, HIV diagnosis.  
The gender/sexual orientation category of MSM included men who self-identified as 
homosexual and bisexual, and the category of women included women of any sexual 
orientation, which may have led to bias. Some studies have indicated that individuals 
who identify as bisexual may be at increased risk of late diagnosis compared to 
MSM721;722. In our study, 23 (11%) of MSM reported bisexual sexual orientation and 
five (5%) of women reported homosexual or bisexual sexual orientation. However, 
there was no evidence of a difference in the proportions diagnosed late. For other 
variables, there may have been misclassification of individuals. In some cases, it may 
be difficult to differentiate between first diagnosis and first diagnosis in the UK if the 
individual does not want to report previous knowledge of the condition. This could 
have led to over-estimation of late diagnosis due to HIV progression between these 
tests. Social desirability bias may also affect the accuracy of the HIV testing behaviour 
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variables, for example, individuals may report having previously tested for HIV 
because they believe that this is the answer expected of them. Some of those defined 
as diagnosed late might not have been HIV infected at the time of the previous 
healthcare encounters, and therefore factors considered, for example visit to A&E in 
the last 12 months, may not represent missed opportunities for diagnosis. However, 
the natural history of the CD4 count trajectory suggests this is unlikely to be the case 
for most individuals. 
 
 Conclusions 
The results of this chapter add to the findings of the previous results chapters in this 
thesis to show that gender/sexual orientation, and perhaps socio-economic, disparities 
in HIV operate at the stage of diagnosis as well as treatment adherence and virological 
response. Moreover, a considerably higher prevalence of late and very late HIV 
diagnosis was found for both MSW and women in comparison to MSM. Both a lower 
probability of HIV test seeking (self-prompting an HIV test and having had a previous 
HIV-test) and a lower probability of having an HIV test offered by healthcare providers 
were apparent among heterosexual individuals compared to MSM. There was also 
some evidence of socio-economic inequalities in late diagnosis, but the inconsistency 
between measures means further work is needed to understand how different aspects 
of SES affect the timing of HIV diagnosis. Implementation of routine HIV testing would 
likely reduce the rates of late diagnoses in all groups, but is likely to have the biggest 
impact in groups that do not present themselves for testing or who are less frequently 
offered HIV tests.  
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 Summary and conclusions 
 Summary of main findings 
The four aims of this thesis were:  
1. To build an understanding of the existence of inequalities in virological 
response to ART by gender/sexual orientation and SES in the UK;  
2. To evaluate whether these gender/sexual orientation differences have 
narrowed in more recent years; 
3. To observe whether SES disparities contribute to any gender/sexual orientation 
differences in virological response; 
4. To identify the relationship of gender/sexual orientation and SES with late HIV 
diagnosis in the UK. 
The findings of my thesis against these aims were as follows: 
1. Chapters 5 and 6 used data from the Royal Free HIV Cohort Study (RFHCS) 
and found that there was a greater prevalence of virological non-suppression 
among MSW and women compared to MSM. This finding was consistent in the 
two analysis approaches: assessing the association between gender/sexual 
orientation and virological non-suppression in the entire clinic population who 
had ever received ART, from 2000 to 2014 and assessing the association 
among the subset of individuals starting cART since 2000. In concordance with 
these results, in Chapter 8, which used data from the Antiretrovirals Sexual 
Transmission Risk (ASTRA) questionnaire study (2011-12), MSW and women 
on ART had a greater prevalence of virological non-suppression and a higher 
rate of virological rebound compared to MSM. In Chapter 7, I found that, in the 
ASTRA study, poorer SES by any of four markers considered – financial 
hardship, non-employment, renting or unstable housing status, or non-
university education – was strongly associated with a higher prevalence of 
virological non-suppression, independently of demographic factors. 
Additionally, I found that socio-economic factors were strongly predictive of a 
higher rate of virological rebound among those who were virologically 
suppressed at the time of the questionnaire. Hence substantial inequalities in 
VL response by both gender/sexual orientation and SES was found in this 
thesis. 
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2. In the analyses of Chapter 5, substantial declines in the prevalence of 
virological non-suppression occurred from 2000 to 2006 among HIV-positive 
individuals on cART attending the Royal Free Hospital. There was no evidence 
of further reductions in the prevalence of virological non-suppression over time 
from 2006 onwards among individuals currently receiving cART. However, 
when inclusion criteria were extended to all those who ever started cART (i.e. 
also including those on treatment interruptions), virological response was found 
to be improving among MSM and women but not MSW. Although the absolute 
levels of non-suppression were low in recent years, there was evidence that 
differences between the gender/sexual orientation groups were widening over 
time, in relative terms. Similarly in Chapter 6, the risk of initial virological non-
suppression in the first two years of ART declined over calendar year of cART 
initiation for all gender/sexual orientation groups. There was no evidence that 
the differences between MSM, MSW and women in the risk of virological non-
suppression narrowed or widened with increasing calendar year of cART 
initiation. Therefore neither analysis provided evidence that disparities in 
virological response were narrowing between women, MSW and MSM and 
inequalities in achieving or sustaining virological suppression by gender/sexual 
orientation are likely to remain an important issue. 
 
3. The analyses in Chapter 8 showed that a higher percentage of women and 
MSW reported being unable to afford their basic needs, being unemployed, 
being in temporary housing or homeless, and having no education compared to 
MSM. Socio-economic factors and country of birth largely explained differences 
between women and MSM in terms of virological response to ART, but 
attenuated the differences between MSW and MSM to a lesser extent. 
Therefore socio-economic disadvantage appeared to play an important role in 
explaining observed differences in virological response across gender/sexual 
orientation groups. 
 
4. In Chapter 9 I considered whether gender/sexual orientation and SES 
disparities were also apparent for the outcome of late diagnosis, using patient 
registration data from the RFHCS. Among individuals newly diagnosed with 
HIV between 2011 and 2015, I found that MSW and women had a substantially 
higher prevalence of diagnosis with a CD4 count of <350 cells/µL or <200 
cells/µL compared to MSM, but there was a similar prevalence of late diagnosis 
among MSW and women. Poorer SES using the markers of non-university 
education and unstable housing was associated with late diagnosis and very 
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late diagnosis respectively; however the associations were not consistent 
across the three markers of SES or two definitions of late diagnosis 
considered. Therefore, at the first stage in the care continuum, HIV diagnosis, 
MSW and women compared to MSM, and to some extent individuals with lower 
SES, were at a disadvantage, which could impact on the achievement of the 
subsequent stages of the care continuum. 
 
 Results in context of other studies 
As I identified in Chapter 2, previous cohort studies of ART-treated individuals in 
France and the UK359;364;365, and two large US-based studies of the National HIV 
Surveillance System355;356, reported a greater prevalence of virological non-
suppression among MSW and women compared to MSM. This is in accordance with 
my findings in Chapters 5, and 8. Also, a number of studies have found improved 
short-term virological response to ART among MSM starting ART for the first time 
compared to MSW and women357-362;364, which is consistent with my findings in 
Chapter 6. Several previous studies comparing virological response to ART between 
MSW and women have found no statistically significant difference between these 
groups, or at least no differences after accounting for differences in characteristics at 
baseline 126;355;361;367;368. This is broadly consistent with my analyses, as small and 
mainly non-significant differences between MSW and women were apparent in 
analyses of virological response in RHCS and ASTRA; in some analyses outcomes 
were slightly better for MSW compared to women, and in other analyses the reverse 
was the case. Furthermore, the results of the existing literature were largely consistent 
with the results of Chapters 5 and 6 in the RFHCS and of Chapter 8 using data from 
the ASTRA study. 
Several studies using data from earlier calendar periods have found improved 
virological response to ART over calendar time in the HIV-positive population as a 
whole in high-income settings548-550. In a study conducted between 1999 and 2004 
over the whole HIV clinic population at the Royal Free Hospital looked at the 
prevalence of raised VL was lowest in MSM compared to MSW and women365. A test 
for interaction in this study found no evidence of differences between black African 
MSW, other ethnicity MSW and MSM in trends over calendar time in raised VL365. In a 
previous study of individuals initiating ART, a test for interaction between 
gender/sexual orientation and calendar year of treatment initiation was considered. 
This study conducted on four observational databases, including the Royal Free HIV 
Cohort, but which took place several years ago, and therefore included only individuals 
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who initiated ART between 1996 and 2002457. In this study, the downward trend in 
virological non-suppression at six months among people starting ART was more rapid 
among MSM than heterosexuals, therefore there was evidence of widening disparities 
over time. The analyses in Chapters 5 and 6 were the first to consider trends in 
virological response to cART within gender/sexual orientation groups in recent years, 
when it might be expected that experience with and success of treatment had closed 
the gap. However, the results of these chapters showed that it is still the case that 
disparities between these groups are not narrowing over time. In fact, in Chapter 5 
there was evidence of the differences in initial virological suppression between MSM 
and MSW were widening slightly over time among those who ever started cART. The 
analysis in this thesis extends upon previous studies in that it includes data from the 
last 14 years, showing that virological non-suppression continues to be a greater risk 
for MSW and women compared to MSM. Furthermore, in my thesis it was possible to 
look additionally at the moderating effect of adherence and treatment disruptions on 
virological response to treatment. 
In concordance with the results of Chapter 6 of this thesis, women have been found to 
be more likely to discontinue treatment in other large European, Canadian and US-
based cohort studies126;367;571;588;609;723. Studies which only assessed individuals 
initiating ART until 2002 or 2005 found either modest457 or no evidence of584 reductions 
in ART discontinuations over calendar time. In contrast, a study of 7901 individuals in 
Canada, found those starting ART in 2006-10 had around half the rate of treatment 
discontinuation or switches within three years of ART initiation compared to those 
starting in 1996-2000571. Similarly, the present analysis, which considered individuals 
initiating ART between 2000 and 2014, also found reductions in treatment interruptions 
over calendar year of ART initiation. 
Chapter 2 showed that previous research focusing on the association of SES with 
virological response among people on ART has mainly been carried out in the US, a 
setting with a different system of health care to that in the UK. These studies provided 
considerable evidence for the importance of socio-economic disadvantage as a factor 
having a negative impact of ART success. In these previous studies based in the US, 
lower education level has been found to be strongly associated with greater odds of 
virological non-suppression (aOR=2.23-5.00402;403 and aOR=1.12 for every year less 
education401). Some of these studies also found that unemployment and/or 
homelessness were associated with greater odds of virological non-suppression401, at 
least in unadjusted analyses400;402. Most prior European studies of SES and virological 
response to ART have exclusively considered education level126;405;406 or employment 
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status342. In these, lower education was associated with a 44% lower aOR of initial 
virological suppression in the Spanish CoRIS study405, 20% lower OR in the Swiss HIV 
Cohort126, and no association in the Danish HIV cohort study406. In the Italian ICoNA 
cohort, unemployment was associated with over two fold the adjusted risk of 
virological failure342. Unemployment was also found to be associated with 40% lower 
aOR of sustained virological suppression in the French VESPA study359, when 
adjusted for factors including demographics, other socio-economic factors and ART 
adherence. The other markers of lower SES considered by the VESPA study, lower 
education and material deprivation, were associated with 40% lower OR of sustained 
virological suppression, however, the association with deprivation was attenuated to 
one in multivariable analyses359. Therefore most of these results from European 
studies, also suggest an important role of SES in virological response to ART. The 
results of the analyses in Chapter 7 extend upon existing literature showing strong 
associations of current markers of poverty and hardship, as well as lower education 
level, with both virological non-suppression and risk of subsequent virological rebound 
among people with HIV in the UK. It is interesting that, in terms of European studies, 
the results from the Danish HIV cohort study (based on 1178 participants) are an 
exception to the others, giving little evidence of an association of education with 
treatment outcomes in that setting406. There is some evidence from both Chapters 7 
and 8, that education may have weaker associations with virological outcomes than 
markers of current poverty, and this in part may explain a lack of association in the 
Danish study, although the Swiss study which did find an association also only 
considered education. However, it is also possible that the effect of SES on ART 
outcomes differ across settings, even among settings of free health care. Factors such 
as absolute levels of poverty, the extent of social inequalities, and specifics of the 
health and social care systems may influence the effect of socio-economic hardship on 
health outcomes. Importantly, this thesis provides evidence of socio-economic 
disparities in adherence and virological response to ART in a UK setting, which was 
previously unstudied. 
There is little in the existing literature about whether SES may explain gender/sexual 
orientation differences in virological response to ART. Thus, my results in Chapter 8 
are among the first on this issue. Two European studies considered gender/sexual 
orientation differences in virological suppression adjusted for socio-economic factors. 
In a recent study of the French VESPA cohort, MSW and women on ART from sub-
Saharan Africa had lower unadjusted odds of sustained virological suppression 
compared to MSM359. However, these were attenuated following adjustment for socio-
economic factors, social circumstances, ART adherence and other factors. As no 
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results were presented unadjusted for adherence, it is not possible to isolate the effect 
of socio-economic factors in this study. In Chapter 8 of this thesis, adjustment for age, 
and four socio-economic factors attenuated the higher PR for virological non-
suppression among MSW and women compared to MSM by a greater magnitude to 
the previous study. In a recent analysis of the Swiss HIV cohort, women had higher 
odds of virological suppression compared to MSW126. However, adjustment for 
education, along with a number of demographic and other factors, only led to a 5% 
relative attenuation in the OR of virological suppression. In contrast, women in the 
ASTRA study had a lower prevalence of non-suppression compared to MSW, and 
adjustment for education and age alone led to a relative increase in this difference by 
22%. Switzerland and the UK are both settings with universal free healthcare, so one 
may expect similar results concerning how SES affects treatment outcomes. However, 
the Swiss cohort study did not include markers of current poverty additional to 
education. Neither of these studies, had the extent of confounding due to SES as their 
focus, as such they adjusted for SES and other factors simultaneously. Thus it was not 
possible in those studies to distinguish the effect of adjusting for education. Therefore 
the analysis in this thesis provides important additional insight into the underlying 
reasons for gender/sexual orientation differences in VL response, suggesting the 
critical importance of SES, particularly for women.  
The analyses in Chapter 9 suggested strong disparities in the prevalence of late 
diagnosis by gender/sexual orientation, with considerably higher prevalence of late 
and very late HIV diagnosis among MSW and women compared to MSM. This was 
consistent with the findings from previous studies in the UK and Europe245;683-685;689-691. 
In four studies in Spain, a setting which also has a national health service, 
heterosexual individuals had approximately twice the odds of late diagnosis compared 
to MSM111;639;686;687. Additionally, a German study of national surveillance data among 
22925 newly diagnosed individuals, found HIV acquisition through heterosexual sex 
was associated with 51% increased adjusted odds of late diagnosis compared to 
MSM688. With regards to the socio-economic factors, other European studies have 
found little evidence of an association between housing or employment status and late 
diagnosis683;699. In contrast to the findings of my thesis, several studies found that 
lower education was associated with a greater probability of late diagnosis405;639;697;698. 
However, in one study, welfare benefits were associated with a lower prevalence of 
late diagnosis700. Similarly, in Chapter 9, lower levels of education as a marker of 
poorer SES was associated with a lower prevalence of late diagnosis. The majority of 
previous studies looking at late diagnosis and SES only considered one marker of 
SES, whereas in this thesis I was able to consider three. Overall, the results of 
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previous studies and those in my thesis suggested a more mixed picture with regard to 
the association between SES and late diagnosis than is the case for the association 
between SES and virological response. 
 Strengths and limitations 
 Generalisability 
All data were either from the ASTRA study or the RFHCS. Both are studies of HIV-
diagnosed individuals accessing care and therefore they do not represent individuals 
who do not access care, however, in the UK this proportion is very low677. ASTRA is 
the largest multi-centre questionnaire based study on HIV-diagnosed individuals in the 
UK to date and the RFHCS is based on data from the first, and currently one of the 
largest, open-access HIV clinics in the UK. In terms of generalisability, the groups 
most affected by HIV, MSM and black African men and women, were well represented 
in the ASTRA study and the RFHCS543. However, 74% of ASTRA participants were 
from London clinics, and the RFHCS is based on a single centre in London. This 
compares to 40% of PLWH in the UK and living in London208. Therefore, the data may 
not necessarily be representative of the UK HIV-diagnosed population outside of 
London. Possibly, disparities in VL response across demographic and socio-economic 
factors may differ in less urban settings or smaller clinics. Inclusion in ASTRA was 
dependent on people agreeing to participate in a research study, so the ASTRA 
sample is necessarily a select sample. It is conceivable that socio-economic variation 
and differences in VL response across SES groups may be underestimated in ASTRA 
analysis, if socio-economic disadvantage was a barrier to participation. On the other 
hand, a major strength of the RFHCS is that it includes routine data from a complete 
clinic population making it more likely to be representative of all individuals accessing 
care, including those with less frequent clinic attendance, lower engagement in care, 
and severe socio-economic hardship. Repeating analyses of the gender/sexual 
orientation differences in response among two different cohorts and finding similar 
results suggests that the results may be generalisable. 
For analysis of VL outcomes, I largely chose to use analysis techniques that are less 
affected by frequency of monitoring, meaning that those with good attendance were 
not preferentially included. I also assessed the potential impact of loss to follow-up. In 
Chapter 5 I found that there were similar proportions of loss to follow-up in the RFHCS 
among all three gender/sexual orientation groups so this was unlikely to have affected 
my results. Similarly, in Chapters 7 and 8 the results were consistent after considering 
individuals who were lost to follow-up as having had virological rebound. 
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Since the findings of demographic and SES variation in VL response presented in this 
thesis were likely to have been driven by differences in non-adherence (i.e. 
behavioural factors) rather than by biological differences, the results may not 
necessarily be generalisable across countries. The demographics of the HIV-
diagnosed population varies even across other European settings. For example, in 
Southern Europe a significant proportion of PLWH are people who inject drugs 
(PWID), whereas this proportion is very low in the UK, and therefore my finings cannot 
necessarily be applied to this group. Systems of health care and social support may 
determine the extent to which demographic and SES factors impact on health 
outcomes. In addition, the extent of economic inequalities may vary across settings. 
My literature review identified studies in the US, Canada, France, Switzerland, Italy 
and Spain where there was evidence of consistent associations of gender/sexual 
orientation126;355-357;359-361;363;364 and SES126;342;359;363;400-405;408;415 with virological 
response to ART. However, such differences in virological response by SES were not 
apparent in the Danish HIV cohort study406, though this study only considered 
education as a marker for SES, which was the measure with the least strong 
association with virological response in my thesis (see Section 7.5.1). 
 Study design 
One limitation of assessing associations within observational studies is the possibility 
of unmeasured confounding, which it is not possible to control for. In other words 
demographic and SES groups may differ with respect to factors that were not 
measured in the database. However, there is a wealth of data collected and included 
in the Royal Free HIV database, so this is unlikely to be as big an issue as it would be 
for smaller cohort studies or multi-centre studies. It would have been interesting to 
consider the association of socio-economic factors with virological response to ART in 
the RFHCS in addition to the ASTRA study; however, these factors were not collected 
in the routine clinic database, except for individuals with completed patient registration 
forms from 2011 onwards; such an analysis may be possible using these data in the 
future. Even though factors such as ART adherence were not routinely collected in the 
RFHCS, it was possible to derive a measure from prescription data. Cohort studies 
also have their advantages such as the ability to consider temporal analyses and the 
incidence of an outcome. As it would not be possible to conduct an RCT, the gold 
standard, as one cannot randomise individuals to different genders or SES, cohort 
studies are the strongest evidence we have to establish causality. 
Both the ASTRA questionnaire study and the patient registration form was that the 
socio-economic factors were self-reported thus they may be subject to several biases, 
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including social desirability bias724, recall bias, and subjectivity570. However, the use of 
self-reported responses enables the collection of a range of individual-level socio-
economic factors, which it may otherwise not be possible to obtain, for example 
financial hardship and housing status. Furthermore, use of alternative measures, such 
as the neighbourhood-based index of multiple deprivation (IMD), also have their 
disadvantages, such as making assumptions about individual-level SES based on 
group-level data285;414. Self-report is also one of the easiest and cheapest ways to 
collect adherence data570. 
 Missing data  
The RFHCS patient registration form hosted a wealth of questions which covered 
presentation details, risk behaviours, a detailed medical history, demographic factors, 
social circumstance factors, socio-economic factors, lifestyle factors, and encounters 
with UK healthcare professionals in the year before diagnosis. As such, responses 
recorded on this form should give a great insight into the patient at the time of 
registration to the Royal Free. However, this large number of questions made the form 
quite lengthy, at 12 pages long. Therefore analysis of this data was limited by the 
amount of incomplete forms, particularly with regard to the section on opportunities for 
an earlier diagnosis. Thus in Chapter 9 there was limited power to assess associations 
of demographic and socio-economic factors with the prevalence of late diagnosis. I 
used both complete case analyses and multiple imputation as methods to handle the 
missing data and the results were consistent with each method, thus were unlikely to 
have been biased by missing data. I could only reasonably perform descriptive 
analyses of individual-level and healthcare provider-level barriers to an earlier HIV 
diagnosis because there was a larger proportion of missing data for these variables. 
There were also issues with missing data in Chapter 6, where a relatively large 
proportion of individuals had missing VLs and CD4 counts at ART initiation and were 
thus excluded (12%). I would anticipate that a large number of these individuals had 
transferred clinic since there are a large number of HIV clinics in London between 
which transfer of care is common. Nevertheless, I additionally conducted a complete 
case sensitivity analysis, for which the results were consistent with the main analyses. 
Therefore, the missing data was unlikely to have affected the results of my thesis to 
any large degree.  
 Outcome measures considered 
Virological response measures 
In this thesis, I considered VL-based outcome measures in four of the five results 
chapters. I also considered the crude incidence rates for AIDS events and mortality by 
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gender/sexual orientation in Chapter 5. With a cure for HIV unavailable at present, 
preventing HIV from progressing to AIDS and then on to death are the main aims of 
HIV treatment. Virological response is a surrogate endpoint for these clinical 
outcomes. While evidence of considerable differences in VL outcomes by 
gender/sexual orientation or SES may not necessarily indicate large differences in 
clinical outcomes725;726, identifying VL increases acts as an early indicator before drug 
resistance and clinical disease can develop. For instance, although, minor virological 
rebounds, such as a single VL >50 copies/mL or >200 copies/mL, may not necessarily 
be of clinical importance564, low level viraemia is a very strong predictor of subsequent 
virological failure334. With the decreases in frequency of monitoring603, some high VLs 
may be missed and therefore not be as accurate a measure of treatment response. 
However, sustained virological suppression has been found to be strongly associated 
with a lower risk of progression to AIDS or mortality727-731. In addition, identifying even 
small increases in VL may be enough to motivate another VL test may enable support 
to be provided to prevent the problem becoming of clinical importance. Virological 
response is one of the primary markers used in the clinical setting in order to evaluate 
success of ART. CD4 count is another primary marker of the success of treatment, 
however, this was only considered in the first analysis chapter of this thesis. As CD4 
count may lag behind changes in VL among individuals on treatment, VL is preferred 
for detecting treatment failure in a timely manner in the clinic. Furthermore, virological 
outcomes are important not only in the context of individual-level health, but also 
potentially for risk of onward HIV transmission, which, in the absence of condom use, 
is highly dependent on VL level13;732. Thus, VL is used in this thesis as the most 
appropriate measure of current response to treatment.  
ART adherence measures 
The ART adherence measure considered in Chapter 6 was a prescription coverage 
measure based on prescription refill data. Chapters 7 and 8 used self-reported 
responses to two questions in the ASTRA questionnaire. Both of these methods have 
their strengths and weaknesses. In particular, self-report can suffer from social 
desirability bias and the prescription based measure only evaluated the prescriptions 
dispensed and not that they were collected or taken. Additionally, it is possible that 
prescriptions could have been collected elsewhere, and therefore non-adherence may 
have been overestimated. However, this is unlikely as the pharmacy is within the ICDC 
itself and there are few specialist HIV pharmacies in London. It was only possible to 
assess dose adherence in this thesis; however, the results of previous UK-based 
studies suggest that the associations of gender/sexual orientation and SES with 
adherence may differ when instruction and schedule adherence is also 
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considered164;374. Despite the limitations of the adherence measures considered, 
poorer adherence was strongly associated with a higher risk/prevalence of virological 
non-suppression, which suggests that they had reasonable predictive ability of 
difficulties with taking ART, even if not precise measures of compliance. 
 Covariates 
Gender/sexual orientation measures 
Gender/sexual orientation was defined in two ways throughout this thesis: using 
gender and mode of acquisition of HIV, and using gender and sexual orientation. In 
the former, I used reported likely sexual acquisition as a marker for sexual orientation, 
however, this could have led to misclassification of individuals, e.g. men who acquired 
HIV through sex with other men would not necessarily self-identify as gay. 
Furthermore, when I used self-reported sexual orientation I included bisexual men in 
the MSM group and women of any sexual orientation in a single group rather than 
separate groups. This could have led to bias of the results, however, there were very 
few individuals who self-reported bisexual sexual orientation.  
SES measures 
The interpretation of the socio-economic factors is an important consideration. The 
analyses in this thesis do not evaluate whether an individual’s education or 
employment status, for example, are directly causally associated with virological 
outcomes, and they do not elucidate the precise mechanism of the association. Thus 
they do not suggest that providing an individual with additional education or if an not 
employed individual became employed that this would affect their virological response 
to ART. Instead the socio-economic factors are used as markers of an individual’s 
circumstances, i.e. lower levels of education and unemployment are indicators that an 
individual may currently have less access to resources and/or be exposed to greater 
social or economic difficulties. As this thesis considers relative SES and not absolute, 
the results need to be interpreted in this context. For example, the results suggest that 
individuals with unstable housing are at a greater risk of poorer virological response to 
ART than homeowners.  
Though several socio-economic factors were considered in this thesis, income or 
neighbourhood-level SES factors were not collected. Collecting income data by self-
report may be considered a sensitive issue, so self-reported financial hardship was 
collected in ASTRA instead. Gathering neighbourhood-level SES data would require 
postcodes to be collected which is identifiable data. Furthermore, there is mixed 
evidence on the use of these factors as a proxy for individual SES 285;414.  
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The ASTRA study only collected data on SES at a single time point. This means that 
an individual’s socio-economic circumstances may have changed over the study 
period, and in particular, may not necessarily be the same at the time of the VL used 
to define virological rebound subsequent to the questionnaire. However, the time span 
was relatively short and so one may expect the markers to have remained quite 
constant over this time span for most participants. Therefore, the association between 
virological rebound and SES may have been under-estimated, as prior studies suggest 
that living with HIV can be associated with a decline in socio-economic resources324;733-
735. 
 
 Implications of findings 
 Implications for HIV clinical care 
Gender/sexual orientation differences in initial response to first-line cART were 
apparent in Chapter 6 despite the UK being a setting with universal free access to 
care. It is important to appreciate that, although significant differences in risk of 
virological non-suppression across gender/sexual orientation groups remained for 
people starting cART in recent calendar years, the absolute differences were relatively 
small, with all gender/sexual orientation groups having good initial outcomes. 
However, as there was no evidence that the relative gender/sexual orientation 
disparities in treatment outcomes were lessening over time, then I would suggest that 
further intervention is required to minimise these differences in future. In particular, the 
Royal Free Hospital HIV Services have a dedicated women’s clinic, which has been 
established for over 20 years, in which counselling and adherence support is 
available508. However, women still had poorer responses to treatment compared to 
MSM and had a greater prevalence of treatment disruptions and MSM and MSW. This 
indicates that even more needs to be done to improve HIV outcomes for women. As 
the women’s HIV clinic already exists, one potential intervention would be to ensure 
women are regularly encouraged or invited to attend this clinic. Furthermore, 
questionnaires to ask women what could improve the service for them may be 
beneficial to understand what more can be done. Since peer support is currently 
available on the day after the women’s clinic, it would be worth investigating whether 
having it available on the day of the women’s clinic itself could positively affect the 
adherence of women attending the Royal Free hospital. Further study is required into 
the reasons for gender/sexual orientation disparities in virological response, but the 
results presented in this thesis suggest that such interventions should include a focus 
on ameliorating the impact of socio-economic disadvantage. 
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Interventions to reduce inequalities across socio-economic groups in treatment 
response and HIV diagnoses are needed. Interventions operating at a healthcare level 
are likely to have a limited impact on an individual’s SES, as potential for impact lies 
predominantly with political and economic policy. However, it may be possible to 
mitigate the impact of socio-economic disadvantage on HIV-related outcomes. When 
designing clinical management strategies, the individual’s personal and social 
circumstances should be taken into account. The results advocate a holistic approach 
to HIV care with linkage between clinical services and relevant social agencies to 
address issues related to employment, finance and benefits, immigration and 
housing736. Socio-economic interventions are particularly important since the results of 
Chapter 8 suggest that socio-economic disparities may go a long way to explaining 
differences in treatment response by gender/sexual orientation. Making HIV services 
more equitable may therefore help to reduce both SES and gender/sexual orientation 
disparities in virological outcomes. One intervention could be to provide subsidies for 
travel to and from HIV clinics for individuals on lower incomes737. 
Emphasis should be placed on supporting adherence of women and MSW and socio-
economically disadvantaged individuals, who were identified as groups at risk of 
poorer adherence. At least some of the associations of gender/sexual orientation and 
SES with virological outcomes acted through adherence or treatment interruptions. 
Increasing the time before an individual switches or stops their initial treatment 
regimen is likely to play an important role in improving treatment adherence, lessening 
treatment disruptions, and in turn improving virological response to cART among 
individuals with poorer adherence across all gender/sexual orientation and SES 
groups. Although further work is still required in order to understand the drivers of 
poorer adherence in these groups (see Section 10.5), possible interventions to 
improve adherence among groups most at risk could include: prescription of less 
complex regimens604 (in particular choosing antiretroviral drugs (ARVs) without food 
requirements/dietary restrictions644;738-740, such as kivexa, triumeq and raltegravir- or 
dolutegravir-based regimens); choosing ART regimens with fewer toxicities605; 
provision of adherence support services741, including peer support742; and providing 
additional education on the importance of adherence and consequences of non-
adherence741. Remembering to take treatment may be another barrier to treatment 
adherence743, for which pill-boxes744;745 or text reminders745-747 could be effective 
interventions. MSW, women, and socio-economically disadvantaged individuals may 
require closer monitoring of ART adherence, for example using MEMs caps748;749. 
Many of these are already in place, so it will be interesting to further study this issue in 
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the coming years to investigate its impact on response rates in the different 
gender/sexual orientation groups. 
The results of this thesis also have implications for reducing the prevalence of late 
diagnosis in the UK and for reducing the gender/sexual orientation and SES 
inequalities in accessing a timely HIV diagnosis. Among those diagnosed with a CD4 
count <200 cells/µL, 75% had visited a primary care clinic in the year prior to diagnosis 
and 32% had visited an emergency department, which suggests that additional 
allocation of resources to these settings may have an impact on reducing late 
diagnosis in the UK750-752. Opt-out HIV testing in emergency departments has been 
found to be acceptable and cost-effective753. However, in a study following the 
implementation of large-scale testing programs in emergency departments, lack of 
time and resources, as well as concerns with loss to follow-up were identified as 
barriers to this option754. Since MSW and woman compared to MSM, and individuals 
with poorer SES were more likely to have accessed primary care in the last year, then 
routine testing as a part of primary care appointments may reduce the prevalence of 
late diagnoses in these groups755-759. Prior studies have found that routine HIV testing 
decreased the delay from HIV infection to diagnosis717;760-762. Additionally, those who 
accessed healthcare in a setting where HIV is routinely tested for generally had a 
more timely diagnosis763. In particular, opt-out antenatal testing has led to increased 
diagnoses among women who may have otherwise been diagnosed at a much later 
stage. Routine HIV testing has been shown to be cost-effective in healthcare settings 
with a local HIV prevalence of >0.2%756, and in these settings it has been 
recommended by BHIVA757. There has already been progress in this area: the Royal 
Free Hospital now provides opt-out HIV tests in the medical admissions unit, and the 
Elton John foundation has provided funding for routine HIV testing for emergency 
department attendees at King’s College Hospital764. 
Public health campaigns to encourage regular testing are ongoing765-767. However, the 
large percentage of individuals in this study who had not had a previous HIV test 
(29%) suggests that further efforts to improve education and increase HIV awareness 
would be beneficial, particularly among those who perceive themselves at lower risk of 
HIV infection762;768. The majority of European studies have focused on barriers to HIV 
testing at the patient-level717. However, my analyses in this thesis found evidence of 
additional barriers to testing at the healthcare provider-level for MSW and women 
compared to MSM and among socio-economically disadvantaged individuals. This is 
likely to also be a result of cultural differences, since there is a high awareness of the 
importance of HIV testing among MSM. Women were much less likely to have been 
offered an HIV test than MSM in the year before HIV diagnosis, which indicates that 
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there may be missed opportunities to diagnose women at an earlier stage in their HIV 
infection. Previous studies have found that healthcare practitioners reported being 
anxious to suggest an HIV test717;762;769. To address this it may be beneficial to provide 
additional training for primary care staff, particularly in high incidence areas, in order to 
increase confidence in asking about sexual health. This was corroborated by the 
results of the Sexual Health in Practice (SHIP) study, which found substantially higher 
positivity rates following the educational intervention, in general practice770.  
As discussed in Section 10.3.3, the patient registration form for the ICDC collects 
much valuable data, however, in its current format takes time to complete. One way to 
improve completion rates would be to shorten the form; however, this would lead to 
loss of information. Alternatively, to speed up the process of completing the form, it 
could be re-designed to have two sections – one clinician completed and one 
completed by the patient. While the clinician could still complete the more clinical 
questions with the patient in the appointment, demographic, social circumstance, 
socio-economic and lifestyle questions could be self-completed in the waiting room. 
 Implications for HIV research studies 
The results of my thesis advocate the collection of socio-economic data, both to 
enable future studies to examine the impact of interventions to reduce inequalities in 
health and as an indicator to clinicians of individuals, which may require additional 
support in order to achieve optimal health outcomes. This is a major implication of this 
thesis since previous studies in the UK have not considered the associations between 
SES and virological response. 
While gender disparities in ART adherence and treatment response have been 
explored in several studies, many consider men versus women as opposed to MSM 
versus MSW versus women. This distinction is important since I observed substantially 
poorer virological response among women compared to MSM, but some evidence of 
improved virological response among women compared to MSW. Thus, any 
gender/sexual orientation differences may be masked by considering MSW and MSM 
as a single group. In the UK setting, evaluation of treatment responses and their 
predictors in these three distinct demographic groups appears a preferable strategy to 
use of gender and sexual orientation as two separate variables, and should facilitate 
the design of interventions to suit the individual needs of each group. 
The issue of the correct population to consider in analyses aiming to quantify levels of 
virological (non-)suppression in the continuum of care is critical771. In different 
countries, the number “on ART” in the continuum of care is defined in different ways. 
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Within Europe, several countries consider the number who had ever started ART, (e.g. 
Spain; Greece; Iceland; Croatia), other countries consider those on ART when last 
seen (e.g. UK), and some consider individuals who had received ART at least once in 
a year (e.g. Italy)771. One of the UNAIDS “90-90-90” targets, is that by 2020 90% of 
individuals receiving ART should have virological suppression221. The results of 
Chapter 5 suggested that the inconsistent definition of “on ART” used by different 
countries for the care continuum will affect the comparability of their estimates of the 
prevalence of virological suppression772. Furthermore, these results add to the existing 
evidence210 that the UK is approaching or exceeding this UNAIDS target: 89% of 
individuals who ever started ART and 91% of individuals on ART at the VL 
measurement had virological suppression in 2014. This is particularly the case since 
UNAIDS defines VL suppression as <1000 copies/mL rather than <50 copies/mL as 
used in the analyses in Chapter 5. 
 Wider implications 
In this era of persistent economic recession, financial support for the NHS has been 
cut in real terms and social support services in particular have been an area 
specifically targeted for cost savings773. The results of this thesis suggest that the 
opposite response is needed – since socio-economic difficulties were associated with 
poorer adherence to treatment and poorer outcomes, greater funding for social 
support services could be a route to diminishing this association. This is consistent 
with the results of the King’s Fund review, which recommended co-ordination between 
HIV care and social support services and that there needs to be a focus on providing 
access to social support services for PLWH774. 
The results of this thesis also raise the agenda of socio-economic inequalities in health 
in a wider context, adding to existing evidence of the adverse impact of socio-
economic disadvantage on a range of health outcomes444-446. Socio-economic factors 
have not previously been incorporated in large UK clinical research studies of HIV, 
however, the results demonstrate that such factors may be among the most profound 
determinates of HIV outcomes. Reducing socio-economic inequalities in health is a 
priority for the National Health Service (NHS) in the UK775, but despite this it is 
uncommon for socio-economic factors to be collected in routine clinical care 
settings776. 
In terms of routine healthcare settings in the UK, migration variables are not generally 
collected, thus there is a lack of information in order to understand barriers to care for 
migrants777. The associations found between country of birth and poorer health 
outcomes and their ability to attenuate gender/sexual orientation disparities in a HIV 
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setting in this thesis should raise the agenda for the collection of data on migrant 
status across other areas of healthcare.  
Adherence to treatment is the strongest determinant of virological response to ART199. 
In contrast, for clinical outcomes such as mortality there are other factors to consider, 
for example the concurrent opportunistic infections778-780, severe 
immunosuppression781-783, drug-resistance784;785, and lifestyle factors786-793. Thus an 
advantage of considering virological as opposed to clinical outcomes is that there are 
likely to be fewer confounders. Focussing on the narrow biomarker based-endpoint 
enabled me to concentrate on the behavioural differences between gender/sexual 
orientation and SES groups. Therefore, this thesis has implications beyond HIV, for 
other areas of health, which require long-term adherence to treatment to achieve 
improved disease prognosis.  
 
 Further research 
The results of this thesis indicate that MSW and women (compared to MSM), and 
individuals with poorer SES (compared to those with higher SES) are at a 
disadvantage in terms of achieving specific steps of the continuum of care necessary 
for optimal health among PLWH: HIV diagnosis and virological suppression. However, 
one should not assume that these inequalities would affect each step of the care 
continuum in the same way. Initiation of treatment and retention in care are also 
extremely important stages for achieving optimal health among PLWH, but these were 
not the focus of this thesis. In terms of retention in care, I touched on this by 
performing loss to follow-up analyses and “missing=failure” analyses, however, a 
specific analysis focussing on this would add further insight. The recommendations of 
when to start ART have changed a number of times in recent years making it difficult 
to assess disparities in timing of ART initiation50;133;134;136;137;142. Furthermore, gender 
comparisons may be complicated by ART use during pregnancy. However, the results 
of the START trial460 and subsequent change in recommendations such that all HIV 
diagnosed individuals should initiate ART regardless of CD4 count138;139, mean that 
factors associated with the time between HIV diagnosis and ART initiation will be of 
increasing importance in the coming years. Future research should consider 
inequalities at these points of the care continuum. 
Evaluating why women and individuals of poorer SES are less adherent to ART is key 
to understanding the barriers to virological suppression in these groups. A qualitative 
study may be best able to capture in depth behavioural information on the 
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mechanisms by which gender/sexual orientation and SES affect adherence in order to 
drive further quantitative work. It is possible that the reasons for inequalities in 
adherence to ART, a lifelong treatment, are similar to those for other long-term 
treatments, so such analyses could have wide implications.  
In this thesis, women were more likely to have cART disruptions during the first 12 
months of cART, thus understanding the drivers to this is key to ensuring virological 
response improves in this group. The most frequent reason recorded for cART 
disruption in Chapter 6 of this thesis was toxicity for all gender/sexual orientation 
groups. This was similarly the case in several other studies189;362;794. Of the reasons 
given by women for treatment disruptions in Chapter 6, 8.2% were pregnancy related. 
To gain more detailed information on the causes of disparities in adherence and 
treatment disruptions, qualitative studies of the reasons for these behaviours and 
targeted studies to assess the effectiveness of the aforementioned interventions by 
gender/sexual orientation group723 would be required. 
Women account for about a third of those infected in the UK105 but they are often 
underrepresented in HIV research339;795;796. This is true in clinical trials in all areas of 
medicine797-801, and in particular, black women have been shown to have even greater 
barriers to entering RCTs802. Often it is not possible to draw gender-based conclusions 
from clinical trials since the numbers of women included are too small. This situation 
does not appear to be improving in more recent years803 and is unlikely to improve in 
the future, unless the reasons for non-participation in these groups are explored. I 
wanted to address this as a part of this thesis. I considered a qualitative, interview-
based study and designed questions for this and for a survey. I discussed the potential 
for this analysis with physicians at the King’s College Hospital and the Royal Free 
Hospital as they were planning to conduct a study (BESTT trial). However, the period 
for the trial exceeded the period for completing my thesis. An insight of why women do 
not participate in HIV clinical trials would likely translate into reasons that women do 
not participate in RCTs more generally. This could have a long-term impact of 
ensuring that RCTs can be more representative of the population and more able to 
detect gender differences in efficacy and safety of new drugs. Thus, I recommend that 
a study of reasons for non-participation among women be conducted. 
The introduction of strategies such treatment as prevention (TasP) to prevent sexual 
acquisition of HIV has led to reductions in HIV transmission and fewer clinical 
events149. Since there is evidence of greater awareness of such strategies among 
MSM compared to heterosexuals804, it is possible that if TasP is successful, then HIV 
diagnoses would fall more rapidly among MSM compared to MSW and women. 
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Awareness or uptake of such methods would likely increase HIV awareness generally, 
thus studies should consider the effect TasP might have on disparities in prevalence of 
HIV diagnosis and late diagnosis.  
Women have lower mortality than men in the general population and one would expect 
to find a similar pattern in HIV studies. While some previous studies have found no 
difference in clinical outcomes by gender330;335;805;806, others have found evidence of 
higher standardised807;808 or unstandardised809 mortality rates among women 
compared to men. In the modern cART era, life expectancy is increasing for 
PLWH93;98, with individuals experiencing fewer AIDS events and more non-AIDS 
events810;811. A recent European study of the ART Cohort Collaboration (ART-CC) 
found that gender differences in mortality increasingly resemble those in the general 
population, as a result of this increasing importance of non-AIDS events for which 
there are greater gender differences812. In Chapter 5, I found that MSW had a higher 
rate of AIDS and mortality than MSM and women in most calendar years, however, I 
was unable to assess whether there were differences between the groups in trends 
over time due to lack of clinical events. Using a larger dataset, it would be of interest to 
assess whether the gender/sexual orientation inequalities I observed in virological 
outcomes are also apparent for clinical outcomes, with particular emphasis on 
assessing trends over time in AIDS and mortality by gender/sexual orientation. 
The results for MSW were more uncertain than for the other groups since there were 
smaller numbers in this group. Given that throughout this thesis MSW have poorer 
outcomes than MSM, and at times poorer outcomes compared to women, further 
study of this currently understudied group would be warranted. There are certain 
barriers that may be more of an issue for MSW than in the other gender/sexual 
orientation groups, for example there is anecdotal evidence of greater stigma among 
MSW813-815. Since differences in ART response between MSW and the other 
gender/sexual orientation groups remained after adjustment for socio-economic, social 
circumstances, or lifestyle factors in this thesis, future research should consider the 
role of other factors, such as stigma, in predicting treatment response among MSW. 
Additionally, adherence was not found to be poorer among MSW compared to MSM in 
the self-reported measures from the ASTRA study, despite the consistent finding that 
MSW had poorer responses to treatment than MSM throughout this thesis. Therefore, 
it is essential to assess whether there are other important factors influencing 
virological response among MSW or whether the measures of adherence used are not 
accurately capturing adherence for this group.  
376 
 
There are measures of socio-economic difficulties or difficult circumstances that it may 
be useful to consider in future studies. In this thesis, I found that several markers of 
SES were strongly associated with treatment adherence and response, thus having a 
number of these socio-economic issues concurrently may affect treatment adherence 
and response over and above any of the single markers of SES. Therefore, it may be 
of interest for a future study to consider composing a measure which incorporates the 
extent of socio-economic difficulties by combining several SES markers816;817. One of 
the SES markers considered in this thesis was education, however, the results of 
Chapters 7 and 8 in this thesis suggested that education may not be as representative 
of SES as markers of current poverty, such as financial hardship and housing status 
and may also reflect levels of health literacy. Evaluation of the association of education 
with virological response to treatment over and above the more current measures 
would help to understand the mechanism by which SES affects treatment outcomes. 
Stress has been shown to be associated with poorer SES818;819, and as such future 
studies may consider whether poorer responses to ART were due to greater levels of 
stress among socio-economically deprived individuals. US-based studies have found 
that the incidence of stressful life events is associated with poorer treatment 
adherence820-823. Furthermore, cumulative stressful life events were associated with 
increased odds of virological non-suppression820 and increases in VL824, though 
another study found no association between interventions to improve stress and VL825. 
Therefore, the effect of stressful life events should be considered in a UK setting. 
Another area that may warrant further attention is repeated measures of SES. SES is 
not fixed over time and some socio-economic factors, such as employment status, can 
change over a relatively short period. Multiple measurements of SES over time could 
not be studied as a part of my thesis since there was not a follow-up questionnaire for 
ASTRA and socio-economic factors are not currently collected as a part of routine care 
appointments. An analysis of repeated measures of socio-economic factors, ART 
adherence, and VL would reduce confounding and help to assess whether there is a 
true causal relationship between SES and adherence, and in turn with virological ART 
response826. 
In the HIV-positive population, it can be difficult to disentangle the effects of gender, 
sexual orientation, ethnicity, culture, and SES. Nonetheless, I studied this issue in 
Chapter 8 of this thesis, and found evidence suggesting that SES was a stronger 
predictor of virological response to ART compared to gender/sexual orientation. It 
would be of interest to conduct a case-control study, using RFHCS data, to investigate 
the association between specific socio-economic circumstances and virological 
rebound among those on ART for six months. A group of cases would be selected who 
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were experiencing VL rebound and compared to a similar group of controls who were 
virologically suppressed. In particular, such a study could assess the role of socio-
economic circumstances and life events occurring around the time of virological 
failure. The study could also consider whether the SES factors associated with 
improved VL response were different for each gender/sexual orientation group.  
With better understanding of the mechanisms that mediate the effect of lower SES on 
non-adherence and VL outcomes, interventions could be developed. Subsequently, an 
RCT could be designed to assess whether and which socio-economic interventions 
would reduce SES and gender/sexual orientation disparities in virological response to 
ART, or whether other interventions are needed over and above this, for example 
adherence-based interventions. Besides studies of the efficacy of these interventions, 
a cost effectiveness analysis of the allocation of resources should be conducted in 
order to assess which areas should be targeted to make the most impact on reducing 
inequalities in HIV outcomes. 
With the introduction of self-testing, the rise in rapid point-of-care testing in recent 
years, and the interventions from the London HIV Prevention Programme, one may 
expect a fall in late diagnoses, as HIV tests are increasingly accessible and 
convenient827. It is possible that this will affect some gender/sexual orientation or SES 
groups more than others though. For example, individuals without stable housing will 
be unlikely to benefit as much from the availability of self-testing from home. On the 
other hand, those finding it difficult to test for HIV may benefit most from strategies 
which make HIV testing more convenient, therefore they may reduce gender/sexual 
orientation or SES disparities in late diagnosis. Future studies should look at changes 
over time in late diagnosis by gender/sexual orientation and SES. Specifically one 
should consider the disparities in late diagnosis in a subset of individuals who were 
diagnosed with HIV by self-testing or rapid point-of-care testing. 
Since the number of individuals included in the analyses in Chapter 9 was quite small, 
additional years of accumulated data would allow a more in-depth analysis of factors 
associated with missed opportunities for an earlier HIV diagnosis. Moreover, due to 
the small absolute number of late diagnosis events in the present analysis, it would be 
interesting to repeat all analyses with the additional data collected in this time. At this 
point, it may be possible to make further inferences about the relationship between 
late diagnosis and socio-economic factors. 
There is evidence that individuals diagnosed during community-based point of care 
testing are less likely to be diagnosed late than those diagnosed at a GU clinic828. 
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Previous studies have indicated that there has been a shift from HIV being diagnosed 
in GU clinics towards community-based centres and primary care829. Since the results 
of this thesis show more women and MSW were seen in primary care in the year prior 
to diagnosis compared to MSM, it would be interesting in future to assess whether 
increased testing in this area leads to reductions in the gender/sexual orientation 
disparities in late diagnosis. This may also apply to socio-economic disparities, since 
non-university educated individuals were more likely to have attended primary care 
services in the year before HIV diagnosis. 
 
 Concluding remarks 
I have shown that, in the UK, HIV treatment outcomes are generally excellent and 
improving over calendar time. However, in both the RFHCS and the ASTRA study 
there were considerable relative differences by gender/sexual orientation and SES. 
Demographic and socio-economic risk factors for poorer treatment adherence could 
be screened for at ART initiation so that clinicians can try to link these individuals with 
the services to address these problems830. SES explains at least part of gender/sexual 
orientation inequalities in treatment outcomes; therefore, it is all the more important to 
collect this information as a part of routine care and, in turn, to provide personalised 
HIV care plans. In terms of wider dissemination of results from my thesis, some of the 
results have already been included as a part of regular parliamentary briefings on the 
current situation of PLWH in the UK and published in peer-reviewed journals with 
further publications planned. I hope that the results from this thesis may have some 
influence on government policy with regards to allocation of resources/funding to 
integrate social and financial support services into HIV care831, particularly in the 
current climate of the UK with increasing and competing demands on health and 
support service resources832;833. In addition, the evidence provided in this thesis may 
help to prioritise a focus on socio-economic factors in clinical research of HIV and 
other chronic conditions. 
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Appendix I. Patient registration form at the Royal Free Hospital 
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Appendix II. Routine clinic follow-up form at the Royal Free 
Hospital 
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Appendix III. ASTRA questionnaire information sheet 
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Appendix IV. ASTRA questionnaire consent form 
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Appendix VIII. Risk, rate and odds 
Risk, rate and odds are all used to describe how often an event occurs. In a population 
with 𝑁 individuals, 𝑛 is the number of people who have the outcome over a follow-up 
time of length 𝑡, thus 𝑁 − 𝑛 is the number of people who do not have the outcome. The 
probability of an outcome is 𝑝, hence 1 − 𝑝 is the probability of not having the 
outcome. Using this notation, risk is defined as: 
(𝐼𝑛𝑐𝑖𝑑𝑒𝑛𝑐𝑒)𝑅𝑖𝑠𝑘 =  
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑒𝑜𝑝𝑙𝑒 𝑤𝑖𝑡ℎ 𝑡ℎ𝑒 𝑒𝑣𝑒𝑛𝑡 𝑑𝑢𝑟𝑖𝑛𝑔 𝑓𝑜𝑙𝑙𝑜𝑤 − 𝑢𝑝
𝑇ℎ𝑒 𝑡𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑒𝑜𝑝𝑙𝑒 𝑖𝑛 𝑡ℎ𝑒 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛
=
𝑛
𝑁
= 𝑝 
rates are defined as: 
(𝐼𝑛𝑐𝑖𝑑𝑒𝑛𝑐𝑒)𝑅𝑎𝑡𝑒 =
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑒𝑜𝑝𝑙𝑒 𝑤𝑖𝑡ℎ 𝑡ℎ𝑒 𝑒𝑣𝑒𝑛𝑡 𝑑𝑢𝑟𝑖𝑛𝑔 𝑓𝑜𝑙𝑙𝑜𝑤 − 𝑢𝑝
𝑇𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑒𝑟𝑠𝑜𝑛 − 𝑦𝑒𝑎𝑟𝑠 𝑎𝑡 𝑟𝑖𝑠𝑘 𝑑𝑢𝑟𝑖𝑛𝑔 𝑓𝑜𝑙𝑙𝑜𝑤 − 𝑢𝑝
=
𝑛
𝑡
 
And odds are defined as:  
𝑂𝑑𝑑𝑠 =
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑒𝑜𝑝𝑙𝑒 𝑤𝑖𝑡ℎ 𝑡ℎ𝑒 𝑜𝑢𝑡𝑐𝑜𝑚𝑒 𝑑𝑢𝑟𝑖𝑛𝑔 𝑓𝑜𝑙𝑙𝑜𝑤 − 𝑢𝑝
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑒𝑜𝑝𝑙𝑒 𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝑡ℎ𝑒 𝑜𝑢𝑡𝑐𝑜𝑚𝑒 𝑑𝑢𝑟𝑖𝑛𝑔 𝑓𝑜𝑙𝑙𝑜𝑤 − 𝑢𝑝
=
𝑛
𝑁 − 𝑛
=  
𝑁𝑝
𝑁(1 − 𝑝)
=
𝑝
1 − 𝑝
. 
It is possible to convert from odds to risk: 
𝑂𝑑𝑑𝑠 =  
𝑝
1 − 𝑝
=  
𝑅𝑖𝑠𝑘
1 − 𝑅𝑖𝑠𝑘
. 
Effect measures are defined using these concepts. These enable comparisons 
between groups in order to understand associations. Common measures are the risk 
ratio/relative risk (RR), odds ratio (OR) and rate ratio, which are defined below. These 
definitions use the following notation: 𝑛ଵ is the number of individuals with a certain 
outcome of interest, if a member of group one and likewise 𝑛ଶ if a member of group 
two; 𝑝ଵ is the probability of an outcome if a member of group one and 𝑝ଶ if a member 
of group two; 𝑡ଵ is the total follow-up time for group one and 𝑡ଶ for group two.  
The risk ratio (RR) is defined as: 
𝑅𝑅 =
𝑅𝑖𝑠𝑘ଵ
𝑅𝑖𝑠𝑘ଶ
=
𝑝ଵ
𝑝ଶ
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the rate ratio as: 
𝑅𝑎𝑡𝑒 𝑟𝑎𝑡𝑖𝑜 =
𝑅𝑎𝑡𝑒ଵ
𝑅𝑎𝑡𝑒ଶ
=
𝑛ଵ
𝑡ଵ
𝑛ଶ
𝑡ଶ
  
And the odds ratio (OR) is defined as: 
𝑂𝑅 =
𝑂𝑑𝑑𝑠ଵ
𝑂𝑑𝑑𝑠ଶ
=
𝑝ଵ
(1 − 𝑝ଵ)
𝑝ଶ
(1 − 𝑝ଶ)
. 
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Appendix IX. Generalised linear model (GLM) 
GLM are models where the dependent variable is assumed to follow an exponential 
family distribution with its mean 𝜇 equal to some linear function of the independent 
variables 𝑥ଵ −  𝑥௡:  
𝑔(μ) =  𝛽଴ + 𝛽ଵ𝑥ଵ  + 𝛽ଶ𝑥ଶ + ⋯ + 𝛽௡𝑥௡. 
There are three components to a GLM, the random component (or error model), 
systematic component and link function. The random component is the probability 
distribution of the dependent variable. The systematic component specifies the linear 
combination of the independent variables. The link function states the link between the 
random and systematic components. Examples of GLMs include linear, logistic, log-
linear, and Poisson regression: 
Model (GLM) Random component distribution of 𝒚 Link function 
Linear Normal Identity 𝜇 
Logistic Binomial Logit log
𝜇
1 − 𝜇
 
Log-linear Poisson Log ln 𝜇 
Poisson Poisson Log ln 𝜇 
 
There are four assumptions that must hold for GLMs:  
1. Independence of each data points, 
2. Correct distribution of the residuals, 
3. Correct specification of the variance structure, 
4. Linear relationship between the response and the linear predictor. 
The definition of the GLM is a way of unifying the various statistical models, a number 
of which are used throughout this thesis and are therefore defined in the proceeding 
appendices. 
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Appendix X. Linear regression 
Linear regression is the simplest example of a GLM. A simple linear regression model 
contains only one covariate, whereas a multiple linear regression model contains two 
or more covariates:  
𝑦 =  𝛽଴ +  𝛽ଵ𝑥 +  𝜀 
𝑦 =  𝛽଴ +  𝛽ଵ𝑥ଵ +  𝛽ଶ𝑥ଶ + ⋯ +  𝛽௡𝑥௡ +  𝜀. 
In these equations, 𝑦 is the dependent variable, 𝑥ଵ to 𝑥௡ are the independent variables, 
𝛽଴ to 𝛽௡ are the coefficients determined in the analysis, and 𝜖 is the residual error term. 
The intercept term is denoted by 𝛽଴ and is expected value of the dependent variable 𝑦 
when all of the 𝑥௜ = 0.  
There are five main assumptions for the multiple linear regression model. Firstly, the 
association between dependent and independent variables is assumed to be linear 
and additive. This can be tested by scatter plots of the response against each 
covariate where the points should roughly have a straight-line relationship. Secondly, 
all residuals are assumed to be normally distributed. This can be tested with histogram 
plots. Thirdly there is assumed to be little multicollinearity between the independent 
variables and they must be uncorrelated with the error terms (i.e. the mean of the 
dependent variable must be uncorrelated with the independent variables). This can be 
checked with a correlation matrix. Additionally, there is assumed to be little or no 
autocorrelation in the data, i.e. the error terms must be independently distributed 
across the observations. Finally, there is assumed to be constant variance of the 
residual error terms across all values of the dependent variable (homoscedasticity). 
Again, the last two assumptions can be checked with scatter plots of the residual error. 
In order to estimate the regression line which best fits the data, two methods are 
generally used – least squares or maximum likelihood estimation (MLE). The least 
squares method estimates the unknown coefficients 𝛽଴ − 𝛽௡ by minimising the sum of 
the squared differences between the model and the data. The maximum likelihood 
method estimates the unknown parameters by maximising the known likelihood 
distribution (the likelihood of a set of parameter values given the observed data). In 
other words, MLE aims to find the parameter values that make the observed data most 
likely. 
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Appendix XI. Logistic regression 
For logistic regression the independent variables may be continuous, categorical or 
binary. Instead of classifying an observation into either the 𝑦 = 0 or 𝑦 = 1 group, 
logistic regression predicts the probability 𝑝 that an indicator variable is equal to 1. 
Since probabilities are restricted to the range (0,1) the logit link function or log odds 
function, log ఓ
ଵିఓ
, is used in order to transform this so that the independent variables 
can take any value from minus to plus infinity. The logistic regression model is defined 
as: 
log 
𝑝
1 − 𝑝
=  𝛽଴ + 𝛽ଵ𝑥ଵ  + 𝛽ଶ𝑥ଶ + ⋯ + 𝛽௡𝑥௡ 
where 𝒑 is the probability that the dependent variable 𝒚 = 𝟏. The odds is given by 
exponentiation834: 
𝑒୪୭୥ ቀ
௣
ଵି௣ቁ =  𝑒(ఉబା ఉభ௫భ ା ఉమ௫మା⋯ା ఉ೙௫೙) 
𝑝
1 − 𝑝
= 𝑜𝑑𝑑𝑠 =  𝑒ఉబ × 𝑒ఉభ௫భ × 𝑒ఉమ௫మ × … × 𝑒ఉ೙௫೙ 
In a logistic regression model with two independent variables 𝑥ଵ and 𝑥ଶ, if the value of 
𝑥ଶ was fixed (adjusted for), then the coefficient 𝑒ఉభ can be interpreted as an estimate 
of the additional effect of having the covariate of interest 𝑥ଵ on a multiplicative scale. 
Hence logistic regression produces ORs in order to assess associations. ORs from a 
model which contains more than one independent variable are generally known as 
adjusted odds ratios (aORs):  
For 𝑥ଵ = 0: 
𝑜𝑑𝑑𝑠 =  𝑒ఉబ × 𝑒଴ × 𝑒ఉమ௫మ =  𝑒ఉబ × 𝑒ఉమ௫మ , 
and for 𝑥ଵ = 1: 
𝑜𝑑𝑑𝑠 =  𝑒ఉబ × 𝑒ఉభ × 𝑒ఉమ௫మ . 
Thus the odds ratio is 
𝑂𝑅 =
𝑜𝑑𝑑𝑠 𝑤ℎ𝑒𝑛 𝑥ଵ = 1 
𝑜𝑑𝑑𝑠 𝑤ℎ𝑒𝑛 𝑥ଵ = 0
=  
𝑒ఉబ × 𝑒ఉభ × 𝑒ఉమ௫మ
𝑒ఉబ × 𝑒ఉమ௫మ
=  𝑒ఉభ . 
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Appendix XII. Poisson regression 
Poisson regression is generally used for data where the response variable is a count. 
It is best for rare events, which tend to follow a Poisson distribution, whereas common 
events tend to follow a normal distribution. The Poisson regression model is defined 
as: 
log 𝜇 =  𝛽଴ + 𝛽ଵ𝑥ଵ +  𝛽ଶ𝑥ଶ + ⋯ + 𝛽௡𝑥௡ 
𝜇 =  𝑒ఉబାఉభ௫భା ఉమ௫మା⋯ା ఉ೙௫೙ . 
Poisson regression can also be used to model a rate, ௬
௧
, where 𝑡 is an interval of time. 
The length of time can vary from observation to observation so the model needs to 
consider time; this is described below, where log 𝑡 is known as the offset term. 
log
𝜇
𝑡
=  𝛽଴ + 𝛽ଵ𝑥ଵ +  𝛽ଶ𝑥ଶ + ⋯ + 𝛽௡𝑥௡ +  𝜀 
log 𝜇 −  log 𝑡 =  𝛽଴ + 𝛽ଵ𝑥ଵ +  𝛽ଶ𝑥ଶ + ⋯ + 𝛽௡𝑥௡ +  𝜀 
log 𝜇 =  𝛽଴ + 𝛽ଵ𝑥ଵ +  𝛽ଶ𝑥ଶ + ⋯ + 𝛽௡𝑥௡ +  𝜀 + log 𝑡 
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Appendix XIII. Modified Poisson regression 
Poisson regression may be used to estimate binomial distributed data rather than 
logistic regression. However, when using this method the error for the estimated 
relative risk will be overestimated835. This problem can be remedied by using sandwich 
estimation to robustly estimate error variance, which is commonly referred to as 
modified Poisson regression. This method is outlined below. 
In a situation where 𝑥௜ is a binary exposure, with 𝑥௜ = 0 if unexposed and 𝑥௜ = 1 if 
exposed, then data can be summarised as displayed in the following table: 
 Y=1 (event) Y=0 (no event) Total 
X=1 (exposed) A B n1 = a + b 
X=0 (unexposed) C D n2 = c + d 
   N = n1 + n2 
The exponent of the intercept is the risk of an event in the unexposed group: 
exp൫𝛽଴෢൯ =
𝑐
𝑛଴
. 
In the case of the binary outcome the exponent of the coefficient 𝛽௜is a risk ratio (RR): 
exp൫𝛽መ௝൯ =
𝑎𝑛଴
𝑐𝑛ଵ
=  𝑅𝑅෢  
With the estimated variance for the RR of:  
𝑉𝑎𝑟൫𝑅𝑅෢ ൯ =
1
𝑎
+
1
𝑐
. 
Sandwich estimation is then used to obtain a more robust error variance526. The 
Corrected variance is: 
𝑉𝑎𝑟൫𝑅𝑅෢ ൯ =
1
𝑎ଶ
෍(𝑦௜ − exp[𝛽଴ + 𝛽ଵ + ⋯ + 𝛽௡])ଶ
௡భ
௜ୀଵ
+
1
𝑐ଶ
෍(𝑦௜ − exp[𝛽଴ + 𝛽ଵ + ⋯ + 𝛽௡])ଶ
௡బ
௜ୀଵ
 
and is consistently estimated as: 
𝑉𝑎𝑟൫𝑅𝑅෢ ൯ =
1
𝑎
−
1
𝑛ଵ
+
1
𝑐
−
1
𝑛଴
.
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Appendix XIV. Cox proportional hazards model 
In order to define the Cox proportion hazards model, one must first consider the 
survivor and hazard functions. The survivor function denotes the probability of survival 
at time t as shown below, with the opposite being F(t), the cumulative probability of 
failure at time 𝑡: 
𝑆(𝑡) = 1 − 𝐹(𝑡). 
In the definition of the hazard function below, 𝑡 are the survival times, f(t) is the 
density function (or probability distribution for the dependent variable) and S(t) is the 
survivor function defined above:  
ℎ(𝑡) =  
𝑓(𝑡)
𝑆(𝑡)
. 
The Cox proportional hazards model is defined below and is of the same form as all 
other GLM, where the coefficients are the estimated regression coefficients and the 𝒙𝒏 
are the independent variables. 
𝐿𝑜𝑔൫ℎ(𝑡)൯ = log൫ℎ଴(𝑡)൯ +  𝛽ଵ𝑥ଵ + 𝛽ଶ𝑥ଶ +  𝛽ଷ𝑥ଷ + ⋯ + 𝛽௡𝑥௡ 
ℎ(𝑡) = 𝑒୪୭୥൫௛బ(௧)൯ା ఉభ௫భାఉమ௫మା ఉయ௫యା⋯ା ఉ೙௫೙   
The intercept term here is analogous to the baseline hazard log൫ℎ଴(𝑡)൯, that is the 
hazard of an event occurring when all levels of the independent variables are set to 0. 
Cox proportional hazards models are semi-parametric since there is no functional form 
assumed for the baseline hazard function. Two key assumptions need to be met for 
the Cox proportional hazards model to be applicable. Firstly, non-informative 
censoring – the censoring of individuals should not be associated with the probability 
of an event occurring. Secondly, the proportional hazards assumption – survival 
curves for two strata must have constant relative hazard functions over time.  
Below is an outline of how the hazard ratios relate directly to the variable coefficients 
in an example with two independent variables 𝑥ଵ and 𝑥ଶ, where the value of 𝑥ଶ is held 
fixed. 
Group a are individuals for whom 𝑥ଵ = 𝑎, and group b are individuals for whom 𝑥ଵ = 𝑏 
𝐻𝑎𝑧𝑎𝑟𝑑𝑠 𝑓𝑜𝑟 𝑔𝑟𝑜𝑢𝑝 𝑎 =  ℎ௔(𝑡) =  𝑒୪୭୥൫௛బ(௧)൯ × 𝑒ఉభ௔ × 𝑒ఉమ௫మ =  ℎ଴(𝑡) × 𝑒ఉభ௔ × 𝑒ఉమ௫మ , 
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𝐻𝑎𝑧𝑎𝑟𝑑𝑠 𝑓𝑜𝑟 𝑔𝑟𝑜𝑢𝑝 𝑏 =  ℎ௕(𝑡) =  𝑒୪୭୥൫௛బ(௧)൯ × 𝑒ఉభ௕ × 𝑒ఉమ௫మ =  ℎ଴(𝑡) × 𝑒ఉభ௕ × 𝑒ఉమ௫మ . 
Thus the hazard ratio is 
𝐻𝑅 =
ℎ𝑎𝑧𝑎𝑟𝑑𝑠 𝑓𝑜𝑟 𝑔𝑟𝑜𝑢𝑝 𝑎 
ℎ𝑎𝑧𝑎𝑟𝑑𝑠 𝑓𝑜𝑟 𝑔𝑟𝑜𝑢𝑝 𝑏
=  
ℎ଴(𝑡) × 𝑒ఉభ௔ × 𝑒ఉమ௫మ
ℎ଴(𝑡) × 𝑒ఉభ௕ × 𝑒ఉమ௫మ
=
𝑒ఉభ௔
𝑒ఉభ௕
=  𝑒ఉభ(௔ି௕). 
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Appendix XV. Generalised estimating equations 
A model using GEEs extends the GLMs described in Appendix IX. so that the 
distribution does not need to be fully specified; therefore, the outcome is modelled 
using the same link function and systematic component as if the observations were 
independent. The random component must additionally specify the correlation (or 
covariance) structure for the responses as the error terms are no longer independent 
as assumed previously. GEEs use quasi-likelihood estimation rather than maximum 
likelihood estimation or ordinary least squares. 
One of four correlation structures is generally assumed: 
 Independence ൥
1 0 0
0 1 0
0 0 1
൩ 
 Exchangeable ൥
1 𝜌 𝜌
𝜌 1 𝜌
𝜌 𝜌 1
൩ 
 Autoregressive ቎
1 𝜌 𝜌ଶ
𝜌 1 𝜌
𝜌ଶ 𝜌 1
቏ 
 Unstructured ൥
1 𝜌ଵଶ 𝜌ଵଷ
𝜌ଵଶ 1 𝜌ଶଷ
𝜌ଵଷ 𝜌ଶଷ 1
൩ 
Where 𝜌 is the correlation parameter and 𝜌௜௝ = 𝑐𝑜𝑟𝑟𝑒𝑙𝑎𝑡𝑖𝑜𝑛(𝑦௜௝ , 𝑦௜௞) for the 𝑖th 
individual/hospital at times 𝑗 and 𝑘. The independent correlation structure assumes 
that responses within each cluster are independent. The exchangeable correlation 
structure indicates that the responses within each cluster are equally correlated. The 
autoregressive structure denotes that the further apart (e.g. in time) the responses are, 
the weaker their correlation with each other. This is generally a reasonable assumption 
for data where the response is repeated measures for each participant studied. The 
unstructured correlation structure is flexible and does not make any assumptions 
about the correlations within clusters. However, this usually requires estimation of a 
large number of additional parameters (𝜌ଵଶ, 𝜌ଵଶ, 𝜌ଵଶ, …) in comparison to the standard 
GLM and when an exchangeable or autoregressive correlation structure is assumed. 
This could cause poor estimation of the parameters when there are large clusters or 
clusters of varying sizes. 
Advantages of GEEs include that no assumptions about the distribution of the 
correlated response variable are required, and only the mean and variance must be 
specified. Additionally, even if the choice of the correlation matrix is false, the solution 
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to the GEE is consistent (tends towards the true value as the size of the dataset 
increases) and approximately normally distributed. However, correctly specifying of the 
correlation matrix can increase the accuracy of the estimates and decrease their 
standard errors.  
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Appendix XVI. Publications and presentations arising from this 
work  
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difference in virological response to ART declining over time? 5th International 
Workshop on HIV & Women, February 21-22 2015, Seattle, Washington. Oral abstract 
14.  
[Chapter 6] Burch L, Smith C, Lampe F, et al. Is the gender difference in viral load 
response to ART narrowing over time? 15th European AIDS Conference; Oct 21-24 
2015; Barcelona, Spain; Oral abstract PS6/3. 
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and Opportunistic Infections; Feb 23-26 2017; Seattle, Washington; Abstract 560. 
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